



EAACI 2026

12-15 JUNE
ISTANBUL
TURKIYE

www.eaaci.org
#EAACICongress2026



Final Programme



Welcome to the EAACI Annual Congress 2026!

We are delighted to welcome you to the EAACI Annual Congress 2026 in Istanbul, Türkiye, from 12 to 15 June 2026. Under the inspiring theme **“Vision Zero: A Future Free from Allergy and Asthma Burden,”** this year’s Congress brings together the global allergy and clinical immunology community to advance our shared vision of reducing the burden of allergic and respiratory diseases worldwide.

As you explore the scientific programme, you will discover a diverse range of sessions, including keynote lectures, symposia, oral abstract presentations, educational sessions, and interactive discussions. Covering the latest developments in allergy, asthma, clinical immunology, immunotherapy, prevention, precision medicine, and digital health, the programme reflects the breadth and innovation of our field.

Our distinguished faculty, researchers, and healthcare professionals will share cutting-edge scientific findings, clinical expertise, and forward-looking perspectives that will inspire meaningful discussions and foster new collaborations. The Congress serves as a unique platform for knowledge exchange, professional development, and international networking, bringing together experts from across the world who are committed to improving patient care and advancing science.

Beyond the scientific sessions, Istanbul offers an exceptional setting for cultural exchange and connection. Bridging Europe and Asia, the city provides a vibrant backdrop for an unforgettable Congress experience.

We hope you enjoy every moment of your journey with us at EAACI Annual Congress 2026, and we thank you for being part of this important gathering as we work together to turn Vision Zero into reality.

In order to match this format, we have split our Scientific Programme into 3 parts:

Live Scientific Programme

A selection of the most exceptional sessions, to be delivered to you from 12 to 15 June 2026. You will find the details of this programme from pages 30 to 244.

Industry Programme

All the valuable content brought to you by our sponsors and exhibitors.

On Demand Scientific Programme

The sessions streamed live will be available to all congress delegates in the on-demand section, to be fully replayed. Sessions will be available around an hour after the live session has ended.

A selection of the content will be available for 6 months after the Congress depending on author consent.

Contents



Welcome messages	4	Programme Description • Thursday, 11 June	30
EAACI Committees	6	Programme Description • Friday, 12 June.....	34
General information	8	Programme Description • Saturday, 13 June	109
EAACI Congress 2026 App	14	Programme Description • Sunday, 14 June	168
Ceremonies	15	Programme Description • Monday 15 June	234
EAACI Fellows	18	National Society Village.....	245
EAACI Awards 2026	16	Sponsorship & Exhibition	247
Description of Session Types	24	Founder Sponsors	249
EAACI Activity Challenge	26	Company Sponsored Symposia	251
Sessions Guide	29	Exhibition Floor Plan	273
		List of Exhibitors & Sponsors	274
		NAS Village Floor Plan	275
		Industry Profiles	277

Contacts

EAACI Headquarters

Hagenholzstrasse 111
3rd Floor
8050 Zurich
Switzerland
Tel: +41 44 205 55 33
email: info@eaaci.org
website: www.eaaci.org

Congress Venue

Harbiye Mahallesi,
Darülbeyaz Caddesi No:3, 34367
Sisli / Istanbul, Türkiye

Congress Registration

registration@eaaci.org

Abstract Handling

abstract@eaaci.org

Press & Media Contact Information

communications@eaaci.org
Tel: +41 44 205 55 33

The EAACI Media and Embargo
Policy is available [HERE](#).

EAACI Technical Support

support@eaaci.org

Exhibition and Sponsorship

sponsors@eaaci.org

EAACI Hybrid Congress 2022

Online Platform

<https://virtual.eaaci.org/>

General Enquiries

congress@eaaci.org

Hotels Requests

hotels@eaaci.org



Welcome messages



Dear Distinguished Colleagues,

It is with immense pleasure that I invite you to the EAACI Annual Congress 2026, taking place in the magnificent city of Istanbul, Türkiye, from 12 to 15 June 2026. This year, we unite under the bold and forward-looking theme “Vision Zero: A Future Free from Allergy and Asthma Burden”

This congress embodies our shared aspiration to reduce, and ultimately eliminate, the global impact of allergic and respiratory diseases. It’s a vision grounded in science, strengthened by collaboration, and guided by compassion. Together, we will explore how innovation, prevention, and policy can converge to turn this vision into reality.

Our scientific programme will feature the latest breakthroughs in immunotherapy, environmental and genetic research, digital health, and preventive strategies. From early detection to global health equity, the sessions will inspire us to look beyond today’s challenges and toward a world where allergic and asthmatic diseases no longer define the lives of millions.

But beyond the lectures and symposia, the EAACI Congress remains a celebration of our community, an extraordinary network of professionals committed to improving patient care. Istanbul, with its unique blend of history, culture, and warmth, will offer the perfect stage for scientific discovery and human connection.

Join us as we move one step closer to a future free from allergy and asthma. Let’s make Vision Zero more than a theme, let’s make it our mission.

I look forward to welcoming you to Istanbul!

Yours sincerely,



María Torres
EAACI President
European Academy of Allergy
and Clinical Immunology

Welcome messages



Dear Esteemed Colleagues,

It is a true honour to welcome you to the EAACI Annual Congress 2026, which will take place in the vibrant and historic city of Istanbul, Türkiye, from 12 to 15 June 2026. Under the inspiring motto “Vision Zero: A Future Free from Allergy and Asthma Burden,” this year’s congress invites us to look beyond boundaries and focus on a shared goal, a healthier, more sustainable future for all.

The 2026 scientific programme promises a journey through the most transformative areas of our field, featuring cutting-edge research, practical clinical insights, and multidisciplinary dialogue. Expect thought-provoking sessions that highlight innovation in diagnosis, prevention, treatment, and patient-centred care, all contributing to our common pursuit of “zero burden.”

At the heart of this event is our thriving EAACI community. The Congress is not only a forum for knowledge exchange, it is a catalyst for collaboration, mentorship, and inspiration. Istanbul, bridging Europe and Asia, stands as a fitting symbol of connection and progress, offering an unforgettable setting for scientific and cultural exchange.

Join us in shaping the next chapter of allergy and asthma care.

Together, let’s transform Vision Zero into a tangible reality, one discovery, one conversation, and one connection at a time.

Welcome to Istanbul!

Warm regards,



André Moreira
EAACI Vice President of Congresses
European Academy of Allergy
and Clinical Immunology

EAACI Executive Committee

EAACI Board of Officers

María Torres, *President*

Mohamed Shamji, *Secretary General*

Patrizia Bonadonna, *Treasurer*

André Moreira, *VP Congresses*

Jolanta Walusiak-Skorupa, *VP Education & Specialty*

Oliver Pfaar, *VP Communications*

Oscar Palomares, *VP Science*

Stefano Del Giacco, *Past President*

EAACI Section Chairpersons

Ian Adcock, *Asthma Section Chair*

Annick Barbaud, *Dermatology Section Chair*

Adam Chaker, *ENT Section Chair*

Alexandra Santos, *Basic & Clinical Immunology Section Chair*

Sophia Tsaouri, *Pediatrics Section Chair*

Cevdet Ozdemir, *Allied Health and Primary Care Section Chair*

Aspasia Karavelia, *JM Assembly Chair*

EAACI Interest and Working Group Representatives

Constantinos Pitsios

Arantza Vega Castro

Members at Large

Milena Sokolowska

Carmen Panaitescu

Ingrid Terreehorst

Isabella Annesi-Maesano

Gülfem Elif Çelik

María Escribese

Scientific Programme Committee (SPC)

Maria Jose Torres, *EAACI President*

Mohamed Shamji, *EAACI Secretary General*

André Moreira, *EAACI Vice-President Congresses*

Oscar Palomares, *EAACI Vice-President Science*

Jolanta Walusiak-Skorupa, *EAACI Vice-President Education*

Oliver Pfaar, *EAACI Vice-President Communication*

Stefano Del Giacco, *EAACI Past President*

Mübecce Akdis, *Scientific Programme Committee Co-Chair*

Ibon Eguiluz, *Scientific Programme Committee Co-Chair*

Section Secretaries 2024-2026

Jasper Kappen, *Section Secretary Asthma*

Emilia Vassilopoulou, *Section Secretary Allied Health and Primary Care*

Teresa Caballero, *Section Secretary Dermatology*

Sietze Reitsma, *Section Secretary ENT*

Andrzej Eljaszewicz, *Section Secretary Basic & Clinical Immunology*

Wojciech Feleszko, *Section Secretary Pediatrics*

Rubén Fernández-Santamaría, *JM Assembly Secretary*

Interest Group Chairs 2024-2026

Carmen Milagros Rondon, *IG Chair Allergen Immunotherapy*

Alma Villasenor Solis, *IG Chair Allergy Diagnosis & Systems Medicine*

Lene Heise Garvey, *IG Chair Drug Allergy*

Isabel Skypala, *IG Chair Food Allergy*

Paola Mason, *IG Chair Environmental and Occupational Allergy*

Working Group Chairs 2024-2026

Célia Antunes, *WG Chair Aerobiology & Air Pollution*

Ines Paciencia, *WG Chair One Health*

Oliver Price, *WG Chair Allergy, Asthma & Sport*

Carina Venter, *WG Chair Immunomodulation & Nutrition*

Sophia Karagiannis, *WG Chair AllergoOncology*

Alessandra Vultaggio, *WG Chair Biological*

To be elected WG Chair Comparative Veterinary Allergology

Arzu Bakirtas, *WG Chair Eosinophilic Eosinophagitis*

Thulja Trikamjee, *WG Chair Epidemiology*

Cagatay Karaaslan, *WG Chair Genomics & Proteomics*

Francesco Cinetto, *WG Chair Immunodeficiencies*

Joana Vitte, *WG Chair Infections*

Elisa Boni, *WG Chair Insect Venom Hypersensitivity*

Diana Silva, *WG Chair Ocular Allergy*

Ismail Ogulur, *WG Epithelial Cell Biology*

Patients Organisations Committee

Ozlem Ceylan, *Committee Chair*

General information A - W

A

About EAACI

The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organisation active in the field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug allergy and anaphylaxis. EAACI was founded in 1956 in Florence and has become the largest medical association in Europe in the field of allergy and clinical immunology. It includes over 13'000 members from 125 countries, as well as over 75 National Allergy Societies.

→ Visit <http://www.eaaci.org> for more information.

Abstracts

Abstracts will be displayed on the congress platform as of Friday, 12 June 2026. Presented abstracts will be published in the official EAACI Allergy Journal after the Congress and on EAACI content platforms (subject to consent).

B

Badges

Your badge will be available in the myEAACI portal from 2 June 2026. A confirmation email will be sent to you.

To avoid queues, please print your badge in colour ahead of the event. Badge holders can be collected from the registration area.

Please note:

Digital versions on mobile phones or tablets will not be accepted.

Badges are personal, individual, and non-transferable.

Entry may be refused without valid photo ID (Passport / ID Card / Driving Licence).

Lost badges can be reprinted at the Registration Desk (a fee may apply).

Your badge will be scanned at the entrance to session rooms for CME accreditation and internal EAACI statistics.

Bank / ATM Machines

ATMs are available within the congress venue and in nearby shopping areas such as Nisantasi and Taksim.

C

Certificate of Attendance

A Certificate of Attendance can be downloaded from the myEAACI portal after completing the delegate survey.

Cloakroom

A cloakroom will be located in the Registration area and is free of charge for congress attendees.

Cloakroom opening hours:



Friday, 12 June 2026	07:00 – 23:00
Saturday, 13 June 2026	06:30 – 19:15
Sunday, 14 June 2026	07:00 – 19:15
Monday, 15 June 2026	08:30 – 15:00

Important: Due to venue security regulations, suitcases should be left at hotels. All bags will be subject to inspection.

Currency

The local currency is the Turkish Lira (TRY). Onsite registration payments must be made using cashless methods (card or contactless payments).

CME Credits

The EAACI Congress 2026, Istanbul, Türkiye (12–15 June 2026), will be submitted for accreditation by the European Accreditation Council for Continuing Medical Education (EACCME®).

Once confirmed, CME details and credit allocation per day will be announced on the EAACI Congress website.

Congress Scholarship

EAACI Congress 2026 will award scholarships to EAACI Junior Members. Applications are made in connection with abstract submission and must be completed by the presenting author.

Each scholarship includes complimentary registration and a EUR 500 grant issued two weeks after the Congress.

D

Disclaimer

EAACI will not be held liable for personal injuries or loss/damage to property during EAACI Congress 2026. Participants are advised to obtain insurance for medical expenses, cancellations, or loss of belongings.

EAACI cannot be held responsible for disruptions caused by natural, political, or social events beyond its control (force majeure). Registration implies acceptance of these terms.

E

EAACI Campus

Located within the exhibition area, the EAACI Campus provides information on membership, publications, the EAACI Knowledge Hub, and future events.

Opening hours of the EAACI Campus:

Friday, 12 June 2026	08:30 – 18:00
Saturday, 13 June 2026	08:30 – 18:00
Sunday, 14 June 2026	08:30 – 18:00



General information A - W

EAACI Events app and Digital Congress Platform

The EAACI Events App allows delegates to:
Browse and personalise the Congress programme
Search and locate exhibitors
Access abstracts and session recordings
Provide session feedback and vote in live polls
Sync events with your calendar
A portion of the EAACI Congress 2026 Scientific Programme will be live-streamed via the Digital Congress Platform and app.

Exhibition

The exhibition area offers opportunities to engage with key industry leaders and explore the latest innovations in allergy and immunology.

Opening hours:

12–14 June 2026 | 09:00 – 17:30

Advertising of medicinal products must comply with Turkish and EU regulations.

F

Food and Beverage

A variety of sustainable and inclusive food options will be available throughout the Congress, including vegetarian, vegan, and gluten-free meals.
Please note that food and beverages are not included in the registration fee.

G

General Assembly

EAACI's General Assembly will be held on Monday, 15 June 2026 (07:45–08:45) in Room London. Access is restricted to members with valid 2026 membership status.

L

Language

The official language of EAACI Congress 2026 is English.

M

Membership

Visit the EAACI Campus to sign up, renew, or learn more about EAACI membership.

Mobile Phone Policy

Please switch mobile phones to silent mode in all meeting rooms.

N

National Society Village

Located in the exhibition area, the National Society Village is open from 12–14 June 2026 (09:00 – 17:30). Visit to connect with national societies in allergy, asthma, and clinical immunology.

P

Personal wheeled Vehicles

Hoverboards, scooters, segways, skateboards, and bicycles are not permitted within the venue.

Photography, filming and video recording

Photography or recording in scientific sessions is prohibited. Official EAACI photographers will capture the event, and images may be used for future promotional purposes.

R

Registration

Registration will take place at the main entrance of the congress venue.

Self-service badge print stations will be available.

Included in your registration:

Admission to Congress sessions and exhibition

Pocket Programme

Opening & Closing Ceremonies and Receptions

The opening hours are:

Friday, 12 June 2026	07:00 – 18:00
Saturday, 13 June 2026	07:30 – 18:00
Sunday, 14 June 2026	07:00 – 19:00
Monday, 15 June 2026	08:00 – 15:00

S

Safety, welfare and behaviour

Istanbul is a vibrant and generally safe city. Please take standard precautions and remain alert to personal belongings.

Follow venue security instructions and use only marked exits in case of emergency.

Access is restricted to participants 18 years or older. EAACI maintains a zero-tolerance policy toward harassment, discrimination, or disruptive behaviour.



General information A - W

Session Attendance

Please arrive early to sessions as room capacity may be limited. Entry may be restricted once maximum occupancy is reached.

Smoking Policy

Smoking, vaping, or e-cigarette use is prohibited inside the venue. Designated outdoor smoking areas are available.

Speaker Service Centre

The Speaker Service Centre will be located near the Registration area.

Opening hours:

Thursday, 11 June 2026	15:00 – 18:30
Friday to Sunday	07:00 – 18:30
Monday, 15 June 2026	07:30 – 15:00

T

Telephone and Emergency

The international dialling code for Türkiye is +90.
Emergency number: 112

V

Venue

Istanbul Congress Center, The Heart of EAACI Congress 2026

We are delighted to welcome you to the EAACI Congress 2026, taking place at the Istanbul Congress Center (ICC), one of Turkey's most prestigious and modern convention venues, located in the vibrant heart of Istanbul's European side.

About the Venue

The Istanbul Congress Center offers state-of-the-art facilities, impressive architecture, and versatile spaces designed to host large international events. Situated in the Harbiye district, it is surrounded by hotels, restaurants, and cultural landmarks, all within walking distance. The ICC provides a seamless congress experience, combining innovation, comfort, and the unmistakable charm of Istanbul.



How to Get There

Address: Harbiye Mahallesi, Darülbeyaz Caddesi No:3, 34367 Sisli / Istanbul, Türkiye

By Air:

Istanbul Airport (IST) – approximately 40 km from the venue (around 45 minutes by car).

Sabiha Gökçen International Airport (SAW) – approximately 45 km from the venue (around 60 minutes by car).

Airport shuttles, taxis, and private transfer options are available from both airports.

By Metro:

Take Metro Line M2 (Yenikapi – Haciosman) and exit at Osmanbey or Taksim Station. The ICC is a short walk from both stations.

By Taxi or Car:

You can reach the ICC easily via the main city arteries. Parking is available on site and nearby.

By Bus:

Multiple public bus lines connect the Harbiye area to key districts including Taksim, Besiktas, and Levent.

Explore Istanbul

Make the most of your stay! The venue is only minutes away from Taksim Square, Dolmabahçe Palace, and Nisantasi, one of Istanbul's most elegant neighborhoods for shopping and dining.

Visa, ETA & visiting the United Kingdom

Participants are responsible for arranging their own travel and visa documentation.

To check visa requirements, visit the official Republic of Türkiye e-Visa portal: <https://www.eviza.gov.tr>

If you need an invitation letter, please log into your myEAACI portal and select "Generate Visa Letter". Apply well in advance of travel.

W

WiFi Access

Complimentary Wi-Fi will be available throughout the congress venue.



EAACI Allergy School 2026

Mastocytosis and Insect Venom Hypersensitivity



10-12
September
Bologna, Italy

BECOME AN EAACI MEMBER

Over 20.000 professionals are already members of the largest medical association in Europe in the field of Allergy and Clinical Immunology.

Benefits applied to all categories

- ✓ Free access to online Allergy, PAI and CTA journals
- ✓ Possibility to join Task Forces
- ✓ Full voting rights & eligibility for election
- ✓ 50% Discount EAACI Knowledge Exam

Full Membership

150€*

- ✓ EAACI Annual Congress
Up to 25% discount
- ✓ EAACI Focused Meetings
25% discount
- ✓ EAACI Schools & Master Classes
Up to 40% discount

**For members from countries with a GNP of less than USD 10,000: Full Membership is 75€ and EAACI Allied Health Interest Group Membership is 40€.*

Junior Membership (under 41 years old)

Complimentary

- ✓ EAACI Annual Congress
Up to 55% discount
- ✓ EAACI Focused Meetings
Up to 70% discount
- ✓ EAACI Schools & Master Classes
Up to 50% discount
- ✓ Eligibility for EAACI fellowships & Scholarships
- ✓ Eligibility for EAACI events travel grants

EAACI / NAS Dual Membership

30€

- ✓ EAACI Focused Meetings
25% discount
- ✓ EAACI Schools & Master Classes
Up to 40% discount
- ✓ EAACI Annual Congress member rate discount

This membership only applies to members of National Societies who have signed the EAACI NAS Dual Membership Agreement. Check our National Societies Agreements list at www.eaaci.org/membership

FAAM 2026

FOOD ALLERGY & ANAPHYLAXIS MEETING

Joint meeting with **EUROBAT & ISMA**

EUROPEAN CONSORTIUM ON APPLICATION OF FLOW CYTOMETRY IN ALLERGY &
INTERNATIONAL SYMPOSIUM ON MOLECULAR ALLERGOLOGY



EUROBAT



19-21 NOVEMBER
UTRECHT, THE NETHERLANDS



#FAAMEUROBATISMA2026

EAACI.org



EAACI
EUROPEAN ACADEMY OF ALLERGY
AND CLINICAL IMMUNOLOGY

Download the Official EAACI 2026 Mobile App

All information at your fingertips during the Congress

- ◆ Access to the full scientific programme and available abstracts
- ◆ Overview of the industry exhibition and programme
- ◆ Real time updates on the programmes
- ◆ Connect to the **congress Wi-Fi** to download the EAACI Events app



Free Wi-Fi
Network: **eaaci_congress**



ANDROID DEVICES



iOS DEVICES



Description of Session Types



E

EAACI Journals Highlights (JH)

Organised with Allergy, Pediatric Allergy and Clinical Immunology, and Clinical and Translational Allergy Journals of EAACI, the traditional “Best of EAACI Journals” session provides the audience with an opportunity to review the best papers published throughout the year.

F

Flash Talks (FT)

Moderators will lead discussions featuring approximately 15 related posters per session, encouraging both the audience and presenters to place the work in context and highlight key themes and conclusions. These sessions will be conducted in electronic format across four designated PDS Zones in the Exhibition Hall. Additionally, a Poster Help Desk will be available in each e-Poster area. Please note: Sessions will be presented on-site only and will not be live streamed. Recordings will be available on the EAACI Congress Digital Platform after the congress.

I

Interactive Workshops (IWS)

Interactive Workshops (IWS) are sessions in which speakers share and discuss evidence and experience, clinical, translational, and/or basic, within a specific field. In line with the current pandemic situation, this year's IWS will take place in a hybrid format (combining in-person and online participation). The session room will be arranged in a more informal way to encourage interactive discussions with participants. Live interaction with the audience is encouraged, both on-site and remotely via live webcasting. Sessions will be held on-site, live streamed on the EAACI Congress Digital Platform, and available On-Demand after the congress.

J

JMA Sessions (JMA)

A programme designed by and for the JMA, with the support of internationally renowned experts across a wide range of topics. Gain accredited knowledge and valuable education while exploring the latest technologies, approaches, and solutions for your future professional pathway. Sessions will be held on-site, live streamed on the EAACI Congress Digital Platform, and available On-Demand after the congress.

M

Meet the Expert (MET)

Pre-registration is required. A separate registration fee applies. Meet the Expert sessions allow delegates to engage in small-group discussions with outstanding researchers and clinicians. The format is designed to foster informal conversations, enabling participants to ask questions and gain new insights. No formal presentations will be given; instead, participants will have ample time to interact with the faculty member and their peers. Sessions are for on-site participants only.

O

Oral Sessions (OAS)

The most outstanding work from abstracts submitted to the congress will be featured in these sessions, which begin with a brief introductory talk by one of the chairs. Each presenter will highlight their research and respond to questions from attendees. Sessions will be presented on-site only and not live streamed. Recordings will be available on the EAACI Congress Digital Platform after the congress.

P

Plenary Symposia (PL)

Plenary Symposia are at the core of the congress activities. These sessions provide comprehensive reviews of major topics within the specialty and are open to all congress participants. Plenary Symposia are scheduled during prime times in the programme, with no overlap with other activities, ensuring maximum attendance. Two parallel symposia will be held — one primarily clinical and the other focused on basic science. Leading international speakers have been invited to conduct these sessions. Due to their large scale, Plenary Symposia do not include time for questions or discussions. Sessions will be held on-site, live streamed on the EAACI Congress Digital Platform, and available On-Demand after the congress.

Pro & Con Sessions (P&C)

Pro & Con Sessions allow speakers to debate controversial topics in an engaging format that provides valuable “food for thought.” These lunchtime sessions take place in the Exhibition Hall. Sessions will be held on-site, live streamed on the EAACI Congress Digital Platform, and available On-Demand after the congress.



Description of Session Types



S

Satellite Symposia (SAT)

Satellite Symposia take place after the conclusion of the main scientific programme each day. These sessions are independently organised by sponsoring companies, which also select the topics and speakers, subject to approval by the Scientific Programme Committee.

Sister Society Symposia (SSS)

Joint EAACI-Sister Society Symposia have been developed in collaboration with several sister societies to highlight regional and scientific areas of shared interest. These sessions provide an excellent opportunity to broaden your knowledge beyond traditional boundaries.

Symposia (SYM)

Symposia are state-of-the-art educational sessions in which speakers critically review different aspects of a specific topic. These sessions are designed for delegates who are particularly interested in the subject or wish to update their knowledge in the field.

T

Thematic Symposia (TS)

Thematic Symposia are theme-based, cutting-edge educational sessions in which speakers critically highlight novel breakthroughs related to a specific theme. These sessions are intended for delegates who are particularly interested in the topic and wish to update their knowledge in the field.

Thematic Poster Session (TPS)

Poster Discussion Sessions feature abstracts grouped thematically into blocks of 15–20 posters, which are displayed throughout the day. During lunchtime, presenters are available at their posters to discuss their work and answer questions from delegates and moderators.

E-Thematic Poster Session (E-TPS)

Abstracts in this category will be available on the digital platform only.

Y

Year in Review (YIR)

Year in Review Sessions provide comprehensive and authoritative overviews of the most significant highlights published over the past year on a specific topic. Sessions will be held on-site, live streamed on the EAACI Congress Digital Platform, and available On-Demand after the congress.



Saturday 13 June 2026
Istanbul, Türkiye



EAACI Congress 2026

Beat Allergy Walk & Run



The EAACI Beat Allergy Walk & Run is a long-standing and much-loved tradition held during the EAACI Annual Congress. This event brings participants together in an informal and active setting, offering a chance to connect beyond the scientific programme while enjoying the atmosphere of the host city.

Open to all fitness levels, participants can choose to walk or run distances of 2.5K, 5K, or 10K. Whether you prefer a relaxed stroll or a more energetic run, the event provides an enjoyable opportunity to engage with colleagues, friends, and family in a fun and healthy environment.

The EAACI Beat Allergy Walk & Run 2026 will take place **on Saturday, 13 June 2026 at 07:00 AM** and is open exclusively to **EAACI Congress 2026 attendees**.

In addition to promoting health and wellbeing, the Beat Allergy Walk & Run supports charitable causes, with proceeds going towards organisations that make a meaningful impact in healthcare and patient support.

Running pack collection will take place at the Istanbul Congress Center on:

- Friday, 12 June from 08:00-18:30

We warmly encourage all congress participants and their companions to take part in this inclusive and community-focused event and create memorable moments during EAACI Congress 2026.

Beat Allergy Walk & Run

Jun 13, 2026
7:00 to 8:30

Running pack collection

Jun 12, 2026
8:00 to 18:30

→ Registration information is available online, please scan or click on the QR code.



Proudly sponsored by:



PHARVARIS



Vinyasa Flow Yoga Class

Find your **balance** with a grounding Vinyasa Flow yoga session on Friday, 13 June. This energising practice is open to all levels and offers a **mindful start to your day** with zero carbon footprint and maximum inner peace.

This energising session is the perfect way to start your Congress day with **movement, mindfulness, and community**. Whether you are a seasoned yogi or a complete beginner, this class is open to all levels. **Spaces are limited**, so we encourage you to register early to secure your spot.



For more information, please scan or click on the QR code.

- Friday, 13 June
 - 7:30 - 8:30 am
 - Congress Venue (Level B1)
 - Mats provided
- 25 spots only per class



SAM 2027

SKIN ALLERGY MEETING

11-13 MARCH • PARIS, FRANCE



#SAM2027

EAACI.org



SCIENTIFIC PROGRAMME

-  Symposia (SY)
-  Interactive Workshops (IWS)
-  Innovation Hub (IH)
-  Meet the Expert (MTE)
-  Ground Breaking Discoveries (GBD)
-  EAACI Enlightening Talk (ET)
-  EAACI Special Session (ESS)
-  POC (POC)
-  Sponsored Sessions (SAT)
-  Thematic Symposium (TSY)
-  Sister Society Symposia (SSS)
-  Flash Talks (FT)
-  JMA Sessions (JMA)
-  Oral Abstract Sessions (OAS)
-  Plenary Symposia (PL)
-  Pro & Con Sessions (P&C)
-  Thematic Poster Sessions (TPS)
-  Year in Review Sessions (YIR)
-  Oral Abstract Sessions on Clinical Trials (OAS-CT)
-  Pitch Session (PiS)
-  e-Thematic Poster Session (E-TPS)
-  Challenges in anaphylaxis (NAIS)
-  EAACI Journals (EAJ)

INDUSTRY

-  Satellite Symposia (SAT)
-  Mini Satellite Symposia (MSAT)

14:00 - 18:00 EC7 - EAACI Course 7 - Update and new concepts in basic and translation immunology (HALL 7, EAACI Course)

- 14:00** **Introduction to Immune system**
A. Abbas (San Francisco, United States of America)

- 14:30** **Innate immunity**
A. Abbas (San Francisco, United States of America)

- 15:00** **Antigen presentation, T cell activation and costimulation**
A. Abbas (San Francisco, United States of America)

- 15:30** **Networking Break**

- 16:00** **CD4 T cell subsets, cytokines**
A. Abbas (San Francisco, United States of America)

- 16:30** **B cells and antibodies**
A. Abbas (San Francisco, United States of America)

- 17:00** **Allergic inflammation, cytokines and chemokines**
A. Abbas (San Francisco, United States of America)

- 17:30** **Mechanisms of immune tolerance and immune regulation**
A. Abbas (San Francisco, United States of America)

14:00 - 18:00 PGC1 - Postgraduate Course 1 - Allergen Immunotherapy (HALL 1, PG Course)

Chair: **O. Pfaar (Marburg, Germany), C. M. Rondon (Málaga, Spain)**

- 14:00** **Mechanisms of Action, Patient Selection, Indications and Contraindications**
C. Riggioni-Viquez (Toronto, Canada)

- 14:30** **Interpretation of Molecular Allergy Testing Before Immunotherapy: Case-Based Approach**
M. Giovannini (Florence, Italy)

- 15:00** **The Role of Component-Resolved Diagnostics (CRD) in Polysensitized Patients**
N. N. Bahçeciler (Cyprus)

- 15:30** **Networking Break**

- 16:00** **Allergen Immunotherapy Protocols: Conventional, Cluster, Rush, and Pre-/Coseasonal Approaches**
O. Keskin (Gaziantep, Türkiye)

- 16:30** **Adverse Reactions and Their Management: Dose Adjustment and Premedication Strategies**
D. Antolin-Amerigo (Madrid, Spain)

- 17:00** **Allergen Immunotherapy in the Era of Precision Medicine: Biomarkers, Monitoring, and Future Perspectives**
S. Dramburg (Berlin, Germany)

- 17:30** **Discussion / Q&A**

14:00 - 18:00 PGC2 - Postgraduate Course 2 - Beta-Lactam Allergy in Children (HALL 2, PG Course)

Chair: *S. Kuyucu (Mersin, Türkiye), M. Kacar (Golnik, Slovenia)*

- 14:00** Overview of Beta-Lactam Allergy in Children: Epidemiology and Clinical Spectrum
E. Vezir (Ankara, Türkiye)

- 14:30** Immediate (Early) Reactions: Mechanisms, Clinical Features, and Diagnostic Approach
M. Atanaskovic-Markovic (Beograd, Serbia)

- 15:00** Non-Immediate (Delayed) Reactions: Mechanisms, Clinical Features, and Diagnostic Approach
L. Moral (Alicante, Spain)

- 15:30** Networking Break

- 16:00** Cross-Reactivity and Safe Alternative Selection in the Acute Setting
T. Arıkoğlu (Mersin, Türkiye)

- 16:30** Desensitization Protocols in Beta-Lactam Allergy
Ö. Cavkaytar (İstanbul, Türkiye)

- 17:00** Delabeling Strategies, Antimicrobial Stewardship, and Quality of Life
J.-C. Caubet (Geneva, Switzerland)

- 17:30** Discussion / Q&A

14:00 - 18:00 PGC3 - Postgraduate Course 3 - Skin Allergies (HALL 3, PG Course)

Chair: *O. Su Kucuk (Istanbul, Türkiye), D. Can (İzmir, Türkiye)*

- 14:00** Diagnosis and differential diagnosis of AD
P. Pyatilova (Berlin, Germany)

- 14:30** Moisturization and new-generation moisturizers in AD
P. Uysal (Aydın, Türkiye)

- 15:00** Topical treatments in AD
A. Bingöl (Antalya, Türkiye)

- 15:30** Networking Break

- 16:00** Systemic therapy and new biologicals in the treatment of AD
M. Deleuran (Aarhus, Denmark)

- 16:30** Diagnostic Approach to Chronic Urticaria
E. Damadoğlu (Ankara, Türkiye)

- 17:00** Practical application: Provocation tests (Fric, Temptest, etc.) in chronic inducible urticaria.
Practical application: Disease activity, control, and quality of life measurements in chronic urticaria.
M. Türk (Kayseri, Türkiye)

14:00 - 18:00 PGC4 - Postgraduate Course 4 - Environmental exposure science and clinical implications: towards planetary health (HALL 4, PG Course)

Chair: *O. Goksel (Izmir, Türkiye), C. Galan (Córdoba, Spain)*

- 14:00** Emerging, altering, and underestimated aeroallergens on a changing Planet: Impacts on allergic diseases.
A. Damialis (Thessaloniki, Greece)

- 14:30** Sensitisation rates to pollen across the globe: past, present and future.
S. Gilles (Augsburg, Germany)

- 15:00** A European information health service for allergic individuals.
J. Oteros (Córdoba, Spain)

- 15:30** Networking Break

- 16:00** Re-defining the atmospheric microbiome using novel eDNA
C. Antunes (Évora, Portugal)

- 16:30** From pollen calendars to sophisticated AI-based forecasting models: a new era to allergic patients?
M. P. Plaza (Augsburg, Germany)

- 17:00** Towards a plant selection tool for urban green planning: creating allergy-free cities.
A. Charalampopoulos (Thessaloniki, Greece)

14:00 - 18:00 PGC5 - Postgraduate Course 5 - Oral Food Immunotherapy (OIT) (HALL 5, PG Course)

Chair: *H. Brough (London, United Kingdom), M. Alvaro Lozano (Barcelona, Spain)*

- 14:00** What Is Oral Food Immunotherapy (OIT)? Indications, Contraindications, and Decision-Making in Clinical Practice
M. Alvaro Lozano (Barcelona, Spain)

- 14:30** Immunological Mechanisms of Oral Food Immunotherapy
H. Brough (London, United Kingdom)

- 15:00** OIT Protocols: Practical Approaches and Real-Life Implementation
C. Sackesen (İstanbul, Türkiye)

- 15:30** Networking Break

- 16:00** Adverse Reactions in OIT: Can We Reduce Risks? Role of Omalizumab and Management Strategies
K. Beyer (Berlin, Germany)

- 16:30** Eosinophilic Esophagitis (EoE) as a Delayed Complication of OIT: Prevention, Monitoring, and Management
S. Arasi (Rome, Italy)

- 17:00** Life After OIT: Sustained Unresponsiveness, Follow-Up, and Quality of Life
A. Fiocchi (, Italy)

- 17:30** Discussion / Q & A

14:00 - 18:00 PGC6 - Postgraduate Course 6 - Drug Allergy (HALL 6, PG Course)

Chair: *S. Bavbek (Ankara, Türkiye), S. Alvarez Arango (Dallas, United States of America)*

14:00 Opening Remarks

14:10 Topic 1: Perioperative Anaphylaxis

J. J. Laguna Martinez (Madrid, Spain), M. Serbes (Adana, Türkiye)

14:55 Topic2: Penicillin Allergy

A. Romano (Rome, Italy), J. A. Trubiano (Parkville, Australia)

15:40 Networking Break

15:55 Topic 3: Non-IgE-Mediated Immediate Reactions

S. Alvarez Arango (Dallas, United States of America), V. Sabato (Antwerp, Belgium)

16:40 Topic 4: Delayed Reactions

E. Phillips (Nashville, United States of America), K. Scherer Hofmeier (Pratteln, Switzerland)

17:25 Closing Remarks

07:45 - 08:30 MTE 1 - Allergy prevention in your clinic (Room Gothenburg, Meet The Expert)

07:45 Allergy prevention in your clinic
J. Hourihane (Dublin , Ireland)

07:45 - 08:30 MTE 2 - Combination of biologicals and AIT for airway allergy (Room Munich, Meet The Expert)

07:45 Combination of biologicals and AIT for airway allergy
A. Bozek (Katowice, Poland)

07:45 - 08:30 MTE 3 - Cross-protection through AIT (Room Athens, Meet The Expert)

07:45 Cross-protection through AIT
B. Bohle (Vienna, Austria)

07:45 - 08:30 MTE 4 - Conjunctival allergen challenge: methodology and indications (Room Glasgow, Meet The Expert)

07:45 Conjunctival allergen challenge: methodology and indications
D. Silva (Porto, Portugal)

08:00 - 08:00 e-Thematic Poster Session (E-TPS Display Only Digital section, e-Thematic Poster Session)

000036 Pembrolizumab induced Stevens-johnson syndrome in non-small cell carcinoma of lung
J. Lee (Bucheon, Korea, Republic of)

000065 Does the teicoplanin skin test predict IgE-mediated hypersensitivity?
K. Aksu (Ankara, Türkiye)

000096 Clinical Improvement of Recurrent or Treatment-Resistant Scabies Following SLIT for House Dust Mite Sensitization: A Three-Year Clinical Observation from Afghanistan
M. H. Arian (Kabul, Afghanistan)

000137 Fig allergy
T. De Aramburu Mera (Sevilla, Spain)

000138 Multiple fixed drug eruption attributable to oxaliplatin
T. De Aramburu Mera (Sevilla, Spain)

000139 Allergic contact dermatitis due to acrylates in catheter fixation devices
T. De Aramburu Mera (Sevilla, Spain)

000140 Amiodarone allergy
T. De Aramburu Mera (sevil, Spain)

000141 Perioperative Kounis syndrome
T. De Aramburu Mera (Sevilla, Spain)

08:00 - 08:00 e-Thematic Poster Session

(E-TPS Display Only Digital section, e-Thematic Poster Session)

- 000145 **Title (New): “Fight Against Air Pollution: A Strategy to Reduce Allergic Respiratory Diseases — Urgent for Afghanistan and Third World Countries”**
M. H. Arian (Kabul, Afghanistan)
- 000187 **Identification of a 25 kDa allergen in Orange**
T. Galán Díez (Alcalá de Henares, Spain)
- 000204 **Exploring the Impact of Emollient Therapy on Sleep Quality and Quality of Life in Patients with Atopic Dermatitis and Concurrent Sleep Disorders**
N. Teovska Mitrevska (Skopje, North Macedonia)
- 000250 **The impact of concomitant pathology on the clinical course of hereditary angioedema**
L. Sizyakina (Rostov-on-Don, Russia)
- 000255 **Hymenoptera venom-induced anaphylaxis with double sensitization to Polistes and Vespula**
C. Lemes Mendoza (El Palmar, Spain)
- 000258 **Childhood linear iga bullous dermatosis likely induced by amoxicillin–clavulanate: a single case report**
N. Gulieva (küçəsi, Azerbaijan)
- 000334 **Catalase as a Potential Novel Allergen in Avocado: Proteomic Characterization in a Case of Immediate Digestive Reaction**
E. Menéndez-Rivero (Seville, Spain)
- 000336 **Cutaneous Reaction After Persimmon Ingestion: Implication of a PR-10 Protein as a Possible Allergen in Diospyros kaki**
E. Menéndez-Rivero (Seville, Spain)
- 000370 **Desensitization to Acetylsalicylic Acid (ASA): a case report**
F. Kapsouli (Athens, Greece)
- 000389 **Environmental Pollutant Exposure and Risk of Respiratory Allergic Diseases in 36-Months-Old Children: The Korean Children’s ENvironmental health Study (Ko-CHENS)**
C. Kang (Seoul, Korea, Republic of)
- 000463 **Not All Cutaneous Mastocytosis Is Severe: A Pediatric Case Report**
L. Morejon (Madrid, Spain)
- 000478 **Multi-Omics Evidence Links Asthma to Lung Cancer and Enables an Asthma-Related Prognostic Gene Signature**
Y. Chen (guangzhou, China)
- 000486 **Public Awareness Activities for World Asthma Day in Japan**
N. Saito (Moriyama, Japan)
- 000491 **Cross-reactivity Analysis of 24 Pollen Allergens in Tomato Allergy: Identification of β -Expansin as a Novel Causative Allergen in Pollen–Food Allergy Syndrome**
N. Shimojo (Nagakute, Japan)
- 000516 **A Case Report of Quincke’s Edema in a Hospitalized Patient**
R. Sorokhan (Chernivtsi, Ukraine)
- 000519 **Real-world experience with dupilumab in severe chronic hand eczema**
G. U. Viquez Burboa (Ciudad de México, Mexico)
- 000540 **Amyloidosis in patients with Familial Mediterranean fever in Slovakia**
A. Markocsy (Martin, Slovakia)

08:00 - 08:00 e-Thematic Poster Session

(E-TPS Display Only Digital section, e-Thematic Poster Session)

- 000560** Rhinologic Manifestations of Eosinophilic Granulomatosis with Polyangiitis (EGPA): Two Cases of Systemic Flare-ups Following Localized Presentation
W. Y. Bae (Busan, Korea, Republic of)
- 000577** Survey of food allergy management in elementary school cooking classes
N. Hayashi (Niiza, Japan)
- 000630** Severe Drug-Induced Anaphylaxis After Naproxen Sodium Administration: A Case Report
C. Porr (Sibiu, Romania)
- 000634** Campylobacter Enteritis with Bloody Stools in a Child with Cow's Milk Protein Allergy and House Dust Mite Sensitization
C. Porr (Sibiu, Romania)
- 000669** Market-Access Determinants of Biologic Therapies for Respiratory and Allergic Diseases in Europe: A Systematic Literature Review
S. Yi (Incheon, Korea, Republic of)
- 000681** Severe anaphylactic shock triggered by gadolinium-based contrast agent during skin testing in a high-risk patient
C. Porr (Sibiu, Romania)
- 000706** Severe Anaphylaxis During Gabapentin Drug Provocation Testing in a Patient with Multiple Drug Hypersensitivity
C. Porr (Sibiu, Romania)
- 000710** Severe Immediate Hypersensitivity Reaction to Oxybuprocaine During Preoperative Skin Testing in a High-Risk Patient
C. Porr (Sibiu, Romania)
- 000719** Artificial Intelligence in Pediatric Allergy: Clinical Applications and Emerging Perspectives
A. A. Senatore (Pavia, Italy)
- 000722** Eosinophilic Esophagitis in children : a case study analysis and literature review
I. Grigalionytė (Kaunas, Lithuania)
- 000804** Anaphylaxis during honeybee venom immunotherapy despite proven sting tolerance: the impact of cold-chain breach
M. Reverter Morales (Castelló de la Plana, Spain)
- 000855** A Comprehensive Multicenter Evaluation of Pediatric Angioedema: Clinical Manifestations, Atopic Comorbidities, and Laboratory Profiles
K. Jeong (Suwon, Korea, Republic of)
- 000869** Severe Anaphylaxis in France nEtnetwork (SAFE): a new registry dedicated to severe anaphylaxis
G. Pouessel (Roubaix, France)
- 000876** Pustular Eruption Following Oral Iron Supplementation: A Drug Eruption Confirmed by Lymphocyte Transformation Test
Ö. ARGİN (Istanbul, Türkiye)
- 000884** From Drug Hypersensitivity–Associated Ulcerative Lesions to Systemic Lupus Erythematosus: A Case Report
Ö. ARGİN (Istanbul, Türkiye)
- 000902** Anaphylaxis Following Hymenoptera Sting in the Presence of Elevated Baseline Tryptasemia
L. P. De Djob Bell (Montluçon, France)
- 000913** Maternal anxiety regarding group settings and quality of life in mothers of children with food allergy
K. Sasaki (Hino, Japan)
- 000942** Surveys on Real-World Practice Patterns in the Pharmacological Treatment of Allergic Rhinitis
M.-A. Kim (Seongnam, Korea, Republic of)

08:00 - 08:00 e-Thematic Poster Session

(E-TPS Display Only Digital section, e-Thematic Poster Session)

- 000953** Successful Oral Desensitization to Pomalidomide in a Patient with Multiple Myeloma and Maculopapular Exanthema
G. Jimenez (Badajoz, Spain)
- 000968** Efficacy of Tofacitinib in Refractory Prurigo Nodularis: A Prospective Case Series from India
A. Singh (KOLKATA, India)
- 000974** Correlation assessment of serum LRG with activity indices and immunological markers in inflammatory bowel disease in children
O. Krasnova (Ivanovo, Russia)
- 000993** An allergist dealing with public health: my experience at the Italian Ministry of Health's helpline (1500) during the SARS-CoV-2 pandemic
G. Di Muzio (Rieti, Italy)
- 001033** Allergic Contact Dermatitis Presenting as Angioedema Following Mesotherapy with Dutasteride
L. De Dulanto García (Granada, Spain)
- 001125** Clinical Characteristics and Puberty-Related Changes in Pediatric Hereditary Angioedema
R. Uysal (Ankara, Türkiye)
- 001137** IgE Reactivity to Passiflora Lipid Transfer Protein in a Patient With Eosinophilic Esophagitis After Herbal Supplement Intake
A. E. Fernandez Fernandez (Alcalá de Henares, Spain)
- 001163** Biomarker study to determine the therapeutic efficacy of SCIT in Korean allergic rhinitis children sensitized with house dust mite
D. H. Lim (Incheon, Korea, Republic of)
- 001223** What Are the Essential Strategies for Early Prevention and Synergistic Improvement of ASD-Allergic Disease Comorbidity? Insights From Mechanisms to Multidisciplinary Care
D. Zeng (Chongqing, China)
- 001232** Short-term Clinical and Immunologic Outcomes of House Dust Mite Sublingual Immunotherapy
J.-W. KIM (Seoul, Korea, Republic of), J. Oh (Seoul, Korea, Republic of)
- 001359** Assessment of Knowledge, Skills, and Habits Regarding Label Reading and Meal Ingredient Review Among Parents and/or Caregivers of Children Aged 0-5 Years with Cow's Milk Protein Allergy
B. C. Colak (Istanbul, Türkiye)
- 001369** Sublingual immunotherapy in allergic conjunctivitis
S. Kumar (Panchkula, India)
- 001390** Acquired Angioedema due to C1-Inhibitor Deficiency – A Case Report
C. Porr (Sibiu, Romania)
- 001399** Can Mepolizumab at asthma doses prevent the development of vasculitis in patients with EGPA?
A. J. Albarracin Contreras (Santander, Spain)
- 001410** A Rare Case: Anaphylaxis Induced by Melon Seed
E. Solakoğlu Küçükdoğan (Ankara, Türkiye)
- 001414** Recognition of a Heat-Resistant Beef Allergen: Molecular Analysis in a Patient with Multiple Meat and Fish Allergy
F. Pineda de la Losa (Alcalá de Henares, Spain)
- 001426** Clinical and Genetic Characterization of Hereditary Alpha-Trypsinemia: A Case Series
J. Correa-Estáñ Cachorro (Granada, Spain)

08:00 - 08:00 e-Thematic Poster Session

(E-TPS Display Only Digital section, e-Thematic Poster Session)

- 001458** Multisensitization to Chicken, Turkey, Rooster and Whey Proteins: Molecular Allergen Characterization by IgE–Western Blot
T. Galán Díez (Alcalá de Henares, Spain)
- 001471** A Hidden Allergen in the Etiology of Anaphylaxis: Sumac
M. B. Öztürk (Ankara, Türkiye)
- 001490** Comparison of skin prick tests with allergen extracts and molecular allergy diagnostics for allergen-specific immunotherapy decision-making in pollen allergy
T. Nurpeissov (Almaty, Kazakhstan)
- 001498** Clinical heterogeneity of Eosinophilic Esophagitis in children
R. Rodrigues Cocco (São Paulo, Brazil)
- 001542** Immediate Hypersensitivity to Systemic Corticosteroids: Two Case Reports with Safe Alternative Identification
M.-J. Sanchez-Gonzalez (Alcalá de Henares (Madrid), Spain)
- 001611** PBMC activation via the ERK and STAT signaling pathways enhances the anti-tumor activity of Staphylococcal Enterotoxin A
S. Wu (Guangzhou, China)
- 001614** Biological Sensitization Patterns in Suspected Egg Allergy in Tunisia : A Real-Life Laboratory-Based Study
S. Samoud (Tunis, Tunisia)
- 001679** Alpha-gal sensitization as a cause of allergy to heparins and collagen
C. De Peña Avila (Vitoria-Gasteiz, Spain)
- 001757** Suspected Beta-Lactam Allergy in Young Children: A Delabeling Approach
P. A. Ortiz Aljaro (Santander, Spain)
- 001768** Reproductive phenotypes in ichthyosis vulgaris and X-linked ichthyosis: pleiotropy beyond skin disease
I. Sadovnychenko (Kharkiv, Ukraine)
- 001789** De-labeling of Beta-lactam Allergy: A One-Year Retrospective Study in a Tertiary Hospital
M. Muñoz Ramirez (El Palmar, Spain)
- 001828** DRESS syndrome or Bullous pemphigoid? A losartan-induced severe exanthema beyond limits
L. González-bravo (Alcalá de Henares, Spain)
- 001856** Eosinophilic esophagitis (EoE). A case report
R. Mira Fayos (Albacete, Spain)
- 001867** Excipients under suspicion: A diagnosis challenge in adverse reactions to drugs and vaccines. A case report
M. D. L. A. VARGAS DIAS (Santiago de Compostela, Spain)
- 001899** Efficacy of Omalizumab in Isolated Angioedema as An Uncommon Phenotype of Chronic Spontaneous Urticaria (one-centre experience)
O. Petrovicova (Martin, Slovakia)
- 001971** Omalizumab-Assisted Accelerated Oral Immunotherapy In Alpha-Gal Syndrome: A Case Report
G. Atakul (Eskişehir, Türkiye)
- 002001** Comparative analysis of psoriasis and cancer frequency in patients and their families
N. Rohr-Udilova (Wien, Austria)
- 002007** Quercus pollen as the primary sensitizer in patients with PR-10 sensitization in Salamanca
E. Mazoteras-Martínez (Salamanca, Spain)

08:00 - 08:00 e-Thematic Poster Session

(E-TPS Display Only Digital section, e-Thematic Poster Session)

- 002038** Exercise-Associated Anaphylaxis Complicated by Type II Kounis Syndrome in a Patient With Chronic Coronary Artery Disease
G. Cortellini (Rimini, Italy)
- 002096** The role of microbiota in cancer
E. Hatem (Conroe, United States of America)
- 002112** Heterozygous IL6ST Mutation–Associated Rare Primary Immunodeficiency: A Case Report
Ö. Ünsal (Ankara, Türkiye)
- 001069** Artificial Intelligence Mentorship (AIM) in Immunology Education
H. M. Ashour (St. Petersburg, United States of America)
- 100024** Eczema herpeticum triggered by acute solar burn in a patient with atopic dermatitis: a case report
K. Rushiti Mehmeti (Skopje, North Macedonia)
- 100063** Nasal ST2⁺ regulatory T cells restrain Tc1-Neutrophil axis in 1 chronic rhinosinusitis
K. Ji Heui (Seoul, Korea, Republic of)
- 100109** Toxic epidermal necrolysis due to fosfomycin
C. Bermúdez Hormigo (Algeciras, Spain)
- 100110** Perioperatives reaction to morphine
C. Bermúdez Hormigo (Algeciras, Spain)
- 100138** Diagnostic Value of Mixed Iodinated Contrast Media Skin Testing in Patients with Radiocontrast Media Hypersensitivity
J. Kim (Seoul, Korea, Republic of)
- 100141** Assessing the Safety, Effectiveness, and Impact of Community Pharmacy Penicillin Allergy Delabelling Service in Hong Kong: A Pilot Study
P. Li (Hong Kong, Hong Kong)
- 100162** Cutaneous Memory Due to Drug Sensitization: A Case of Fixed Drug Eruption
E. Erat Çelik (Konya, Türkiye)
- 100163** Comparison Of Clinical Features In Primary Immunodeficiency Patients With And Without Autoimmunity Or Autoinflammation
S. KOLAK (Konya, Türkiye)
- 100186** Something Fishy: Recurrent Angioedema Triggered by Environmental Exposure to Fish Allergens
A. Krejner-Bienias (Warsaw, Poland)
- 100197** Upper and Lower Airway Diseases: Current Phenotypes and Integrated Treatment Approaches
F. Manole (Oradea, Romania)
- 100199** Availability of skin-friendly personal protective equipment for healthcare workers with atopic dermatitis: a hospital-wide audit
A. Karavelia (Kalamata, Greece)
- 100206** Advancements and Challenges in the Management of Chronic Inducible Urticaria
M. Zhang (Beijing, China)
- 100228** Soluble CD25 as a marker of immune activation in pediatric asthma: a prospective case-control study
I. Allam (Algiers, Algeria)
- 100230** Lack of association between plasma interleukin-6 levels and pediatric asthma severity
I. Allam (Algiers, Algeria)

08:00 - 08:00 e-Thematic Poster Session

(E-TPS Display Only Digital section, e-Thematic Poster Session)

- 100243** Liver Transplantation in a Patient with Primary Immunodeficiency and Cirrhosis: A Clinical Evaluation
F. Sağun (Konya, Türkiye)

- 100252** Particulate Matter Co-Exposure with Indoor Airborne Bacteria Synergistically Exacerbates Allergic Rhinitis and Pulmonary Toxicity in Mice
W. Yoon (Seoul, Korea, Republic of)

- 100260** Inflammatory Bowel Disease in Inborn Errors of Immunity: NLRC4 Mutation
Ş. Arslan (Konya, Türkiye)

- 100276** Allergic Bronchopulmonary Aspergillosis Masked by Asthma and Recurrent Pneumonia
F. Çölkesen (Konya, Türkiye)

- 100284** Tolerance to iodixanol after anaphylaxis due to iohexol, guided by Basophil Activation Test
S. Serrano de Pablo (Ciudad Real, Spain)

- 100290** Method of the severity of asthma exacerbation evaluation by the Integral indicator
K. Pavlova (Moscow, Russia)

- 100302** Improvement in Atopic Dermatitis Signs and Symptoms With Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.15% or 0.05%: 52-Week Phase 3 INTEGUMENT-OLE Trial Outcomes in Patients Aged ≥2 Years
H. C.-H. Hong (Vancouver, Canada)

- 100332** Algorithm of the choice of nutritional therapy in infants with food allergy
T. Sentsova (Moscow, Russia)

- 100336** Vitamins sufficiency in bottle-feeding children with gastrointestinal form of food allergy
T. Sentsova (Moscow, Russia), L. Ilyenko (Moscow, Russia)

- 100373** "Refractory Chronic Spontaneous Urticaria to Conventional Treatment: Challenges and Therapeutic Strategies"
G. Yánez Lema (Barcelona, Spain)

- 100383** When the sun is not the only culprit: Persistent Th2-driven hydrochlorothiazide-induced photoallergic dermatitis responding to dupilumab
E. INIESTA TEJERA (Ciudad Real, Spain)

- 100384** Altered CD4⁺ T Helper cell subsets in children with Severe Asthma: A focus on Th1, Th2, and Th17 Cells
I. Allam (Algiers, Algeria)

- 100393** TSLP Blockade in Severe Refractory Chronic Rhinosinusitis with Nasal Polyps: A Case Report
G. Tussupbekova (Astana, Kazakhstan)

- 100406** Low-dose dupilumab as an effective alternative for eosinophilic esophagitis patients with recurrent esophageal candidiasis
L. Bas Bellver (Ciudad Real, Spain)

- 100440** Oxycodone/naloxone-induced anaphylactic shock with naloxone as the most likely culprit: diagnostic contribution of the basophil activation test
S. Bracamonte Odreman (Ciudad Real, Spain)

- 100492** Anaphylaxis from wheat
T. De Aramburu Mera (sev, Spain)

- 100496** Multiple fixed medicamentous rash attributable to Oxaliplatin
T. De Aramburu Mera (Sevilla, Spain)

- 100498** Perioperative Kounis syndrome
T. De Aramburu Mera (Sevilla, Spain)

08:00 - 08:00 e-Thematic Poster Session

(E-TPS Display Only Digital section, e-Thematic Poster Session)

- 100501 Amiodarone allergy**
T. De Aramburu Mera (Sevilla, Spain)
- 100505 Fig allergy**
L. Moreno Lozano (Algeciras, Spain)
- 100532 Phenotype-guided dupilumab therapy in multisegmental eosinophilic gastroenteropathy with systemic atopic disease**
C. Boggio Marzet (Buenos Aires, Argentina)
- 100560 Atypical Presentation of AGEP Highlighting the Overlapping Spectrum of Severe Cutaneous Adverse Reactions**
S. Sumayli (Riyadh, Saudi Arabia)
- 100586 Acral Recurrent Swelling in Chronic Urticaria: When Should We Suspect Autoinflammatory Disease? A 10-Year Diagnostic Challenge**
C. Guerra Auyanet (San Sebastián de los Reyes, Spain)
- 100629 Severe IgE-Mediated Anaphylactic Shock to Rabbit-Derived Anti-Thymocyte Globulin (Grafalon®) During Kidney Transplantation in a Patient with Rabbit Allergy**
C. Guillet (Zürich, Switzerland)
- 100651 VISTA overexpression and impaired IgE signaling in lung cancer patients with allergic phenotype: implications for anti-PD-L1 response**
I. Dávila (Salamanca, Spain)
- 100665 Omalizumab Enables Safe Honeybee Venom Immunotherapy in a Patient with Systemic Reactions to Immunotherapy**
E. Penalver de la Puente (Murcia, Spain)
- 100683 Applicability Of The Asthma Predictive Index In The Evaluation Of Children Under 5 Years With Recurrent Wheezing**
A. Calistru (Chişinău, Moldova)
- 100692 Effect of Mepolizumab on Tissue and Blood Eosinophils in Patients with Chronic Rhinosinusitis With Nasal Polyps**
M. Colque-Bayona (Tolosa, Spain)
- 100710 Breast Cancer Screening Knowledge, Attitudes, and Practices Among Hospital Staff During the Pink October Campaign: A Cross-Sectional Study**
C. Sridi (sousse, Tunisia)
- 100720 Occupational blood and body Fluid exposure among hospital staff: epidemiological profile, mechanisms and psychological impact**
C. Sridi (sousse, Tunisia)
- 100731 Multiple Beta-Lactam Allergy in a High-Risk Infant: Management Challenges**
F. LAMRANI (Algiers, Algeria)
- 100752 From IgE-Mediated Cow's Milk Protein Allergy to Steroid-Sensitive Idiopathic Nephrotic Syndrome**
F. LAMRANI (Algiers, Algeria)
- 100447 Feasibility and Impact of an Integrated Allergy-Oncology Clinical Service for Drug Allergy Management**
P. Li (Hong Kong, Hong Kong)
- 08:00 Respiratory Pathogen Profiles in Children with and without Allergic Respiratory Disease: A Prospective Cohort Study**
000294
L. Hu (Sanya, China)
- 08:07 The Role of Cord Blood DNA Methylation in Mediating the Effect of Prenatal Air Pollution Exposure on the Development of Allergic Diseases in Offspring**
000308
L. Hu (Sanya, China)

08:30 - 10:00 IH 1 - Artificial intelligence and machine learning in predicting AIT outcomes (Innovation Hub, Innovation Hub)

Chair: **M. Giovannini (Florence, Italy), R. J. Vieira (Porto, Portugal)**

08:30 The role of AI and machine learning
S. Fontanella (London, United Kingdom)

09:00 Reprogramming AIT through multiomic analysis
J. A. Layhadi (London, United Kingdom)

09:30 AI in pediatric allergy and immunotherapy: From concept to clinical practice
T. Eiwegger (St. Poelten, Austria)

08:30 - 10:00 IWS1 - When suspect inborn errors of immunity (Room Florence, Room Florence, 3- Florence, Interactive Workshop)

Chair: **F. Cinetto (Treviso, Italy), E. Karakoç Aydinler (İstanbul, Türkiye)**

08:30 How I approach to recurrent fever
E. Yucel (Istanbul, Türkiye)

09:00 How I approach to hypogammaglobulinemia
F. Pulvirenti (Rome, Italy)

09:30 How I approach to suspected primary atopic disorder
R. Castagnoli (Pavia, Italy)

08:30 - 10:00 IWS2 - Exercise and allergy – trigger or treatment? (Room Utrecht, Room Utrecht, 4- Utrecht, Interactive Workshop)

Chair: **L. Brussino (Torino, Italy), B. Brugnoli (Treviso, Italy)**

08:30 Diagnosis and management of exercise-induced bronchoconstriction
J. Dickinson (Canterbury, United Kingdom)

09:00 Epithelial barrier theory in the context of nutrition and environmental exposure in athletes
W. Kistler (Davos, Switzerland)

09:30 Practical approach to exercise prescription for adults with asthma
M. Kurowski (Łódź, Poland)

08:30 - 10:00 IWS3 - Updated management of atopic dermatitis (Room Zurich, Room Zurich, 5- Zurich, Interactive Workshop)

Chair: **D. Azkur (Kırıkkale, Türkiye), M.-C. Brüggen (Zürich, Switzerland)**

08:30 Targeted therapy in pediatric vs. adult AD: Similarities, challenges, and opportunities
M. Deleuran (Aarhus, Denmark)

09:00 From clinical scoring to precision diagnosis: Evolving tools in AD assessment
M. De Graaf (Utrecht, Netherlands)

09:30 Therapeutic education in atopic dermatitis
H. Brough (London, United Kingdom)

08:30 - 10:00 JMA1 - Basophils and mast cells diagnostic tools: How far are they from being applied in routine clinical practice?
(Room Krakow, JMA)

Chair: *R. Fernandez Santamaria (Madrid, Spain), C. Aranda Clemente (Málaga, Spain)*

08:30 Mast cell activation test in the diagnosis of allergic disease and anaphylaxis
R. Bahri (Manchester, United Kingdom)

09:00 New insights and standardization of BAT
M. Pascal-Capdevila (Barcelona, Spain)

09:30 Multiplex CytoBas in asthma and rhinitis
M. van Zelm (Melbourne, Australia)

08:30 - 10:00 SYM1 - Cellular metabolism in inflammation and resolution
(Room Istanbul, Room Istanbul, 1- Istanbul, Symposium)

Chair: *U. Radzikowska (Davos, Switzerland), M. Escribese (Madrid, Spain)*

08:30 Metabolic signaling in barrier immunity
M. Moniuszko (Białystok, Poland)

09:00 Myeloid cell plasticity in inflammation
M. Netea (Nijmegen, Netherlands)

09:30 Metabolic checkpoints in T cell function
M. Sokolowska (Davos, Switzerland)

08:30 - 10:00 SYM2 - Current understanding of nonsteroidal anti-inflammatory drug hypersensitivity
(Room Paris, Room Paris, 2- Paris, Symposium)

Chair: *S. Bavbek (Ankara, Türkiye), A. Romano (Rome, Italy)*

08:30 Nonsteroidal anti-inflammatory drug hypersensitivity: A reappraisal of current clinical phenotypes classification is needed
G. Celik (Ankara, Türkiye)

09:00 Deciphering the underlying mechanisms of NSAIDs-hypersensitivity: current knowledge and future perspectives.
M. Sanak (Krakow, Poland)

09:30 Genetic Biomarkers in NSAID Hypersensitivity: Still a Long Way to Go
J. A. Cornejo-Garcia (Málaga, Spain)

08:45 - 09:45 L-FT01 - Molecular Allergology

(Room Athens, Flash Talks)

- 08:45** **Complexes of allergen and specific IgG antibodies activate human neutrophils**
100043 B. Bohle (Austria)
-
- 08:52** **A diverse symptomatology reflects complex molecular sensitization profiles in an adult population with furry animal allergy – Findings of the RespAll Study**
100236 R. Klapp (Esch-sur-Alzette, Luxembourg)
-
- 08:59** **Natural history of Alternaria sensitisation and association with asthma and rhinitis from childhood to adulthood**
100277 M. Leily (Southampton, United Kingdom)
-
- 09:06** **Identification of IgE-reactive 11S globulin (cupin family) proteins in quinoa**
100449 C. Moreno Lopez (Sevilla, Spain)
-
- 09:13** **Analytical concordance of Euroline® and ImmunoCAP® for peanut component-specific IgE**
100482 M. Michel (Nîmes, France)
-
- 09:20** **Non-monovalent cross-reactive IgE-reactive carbohydrates as ubiquitous environmental sensitizers can elicit effector cell activation**
100517 P. Gattinger (Wien, Austria)
-
- 09:27** **Clinical and molecular cross-sensitization phenotypes of non-specific lipid transfer proteins (nsLTP) in a Portuguese pediatric cohort**
100630 M. I. Garcia (Funchal, Portugal)
-

08:45 - 09:45 L-FT02 - Molecular Allergology

(Room Glasgow, Flash Talks)

- 08:45** **Precision Medicine and Artificial Intelligence in Allergology: Perception and Clinical Application among Young Italian Allergologists**
100043 F. Frati (Milano, Italy)
-
- 08:52** **First-in-human evaluation of a recombinant Art v 1 vaccine formulated with an oil-based adjuvant for mugwort pollen allergy: a randomized, double-blind, placebo-controlled phase I trial**
100236 K. Tabynov (Almaty, Kazakhstan)
-
- 08:59** **Treatment effect of 300IR birch liquid sublingual immunotherapy translated into clinically meaningful benefits for the patient: results of the YOB1 trial**
100277 O. Pfaar (Marburg, Germany)
-
- 09:06** **Analysis of the Efficacy of Allergen Immunotherapy on Asthmatic Children Sensitized to House Dust Mite Allergens Der p 5 and/or 21: A Multicenter Study Design**
100449 L. Tang (Hangzhou, China)
-
- 09:13** **AIT prescription drivers in children: a subgroup analysis from the CHOICE survey**
100324 D. Caimmi (Montpellier, France)
-
- 09:20** **Home up-dosing Oral ImmunoTherapy for Treenuts, Other allergens and Peanuts In Children - HOT TOPIC Study**
100433 A. O'Neill (Cork, Ireland)
-
- 09:27** **Does Asymptomatic EE Predict EoE During OIT?**
100718 H. Duman Senol (İzmir, Türkiye)
-

08:45 - 09:45 L-OAS01 - Asthma

(EAACI Global Stage, Oral Abstract Sessions)

Chair: **Z. Arsovski** (Macedonia, North Macedonia)

08:45 Cross-compartment multi-modal analyses identify differences in IL2-STAT5 signalling associated with asthma
100041 in different self-reported racial groups

D. Ni (Camperdown, Australia)

08:57 Comprehensive multi-omics profiling reveals airway microbiome dynamics and immune restoration patterns
100240 under mepolizumab treatment in patients with nasal polyps and comorbid asthma

H. Loutrari (Athens, Greece)

09:09 Trajectories of respiratory symptoms in childhood and their associations with lung function in early adulthood:
100250 a population-based study

D. Lisik (Umeå, Sweden)

09:21 Unified airway profiling reveals shared and distinct features in T2-high asthma and nasal polyposis by mass cytometry

100289 F. A. Kidane (Vienna, Austria)

09:33 Protein signature of childhood airway obstruction

100453 C.-E. T. Pedersen (Copenhagen, Denmark)

08:45 - 09:45 L-OAS02 - Immune deficiencies and autoimmunity

(Room Gothenburg, Oral Abstract Sessions)

08:45 Lung Magnetic Resonance Imaging in Patients with Common Variable Immunodeficiency: Preliminary Results
100137

08:57 Toward Safer Imaging in CVID: Preliminary Results of Low-Dose Chest CT with Visual and Automated Evaluation
100280

09:09 Consensus in treatment switching of long-term prophylaxis in hereditary angioedema: results from a European modified
100285

09:21 Long-term prophylaxis with kallikrein and prekallikrein inhibitors in hereditary angioedema due to C1 inhibitor
100289 deficiency (HAE-C1INH)

09:33 Evaluation of Gastrointestinal Findings in Patients with Primary Antibody Deficiency
100535

08:45 - 09:45 OAS01 - Predicting anaphylaxis: risk, severity and cofactors (Room Munich, Oral Abstract Sessions)

Chair: *S. Arandjelovic (Belgrade, Serbia)*

- 08:45** High specificity of sIgE to α -/ β -gliadin and limited reactivity to non-gluten proteins in wheat allergy dependent on augmentation factors (WALDA)
000167 V. Faihs (Munich, Germany)
-
- 08:57** Neutrophil-to-Lymphocyte Ratio as a Marker of Cardiovascular Compromise in Pediatric Anaphylaxis: Beyond Severity Stratification
000281 A. Kuzu Kuşaklı (Ankara, Türkiye)
-
- 09:09** Nut Allergy Modulated by Cofactors: Immunochemical Characterization in a Patient With Subclinical Sensitization and Severe Anaphylaxis
000020 M. D. Rodríguez Bote (Sevilla, Spain)
-
- 09:21** The Relationship Between Inflammatory Markers and Anaphylaxis Severity in Patients Presenting to the Emergency Department
001231 M. Taş (Kırıkkale, Türkiye)
-
- 09:33** Pediatric Risk Evaluation for Predicting Anaphylaxis Recurrence in Emergency Department (PREPARED) Score: Derivation and Validation
000339 W. Alqurashi (Ottawa, Canada)
-

08:45 - 09:45 SSS1 - EAACI AAAAI Sister Society Symposium : Novel Developments in Food Allergy 2025: Pathophysiology, Diagnosis and Treatment (Room London, Room London, 6- London, Sister Society Symposium)

Chair: *C. Davis (Washington, United States of America)*

- 08:45** Recent Novel Mechanistic Cellular Insights in Food Allergy
S. Patil (Boston, United States of America)
-
- 09:05** Using Multi-omics to Identify Endotypes in Food Allergy for Diagnostic and Treatment Decision Making
S. Bunyavanich (New York, United States of America)
-
- 09:25** Novel Treatment with Epinephrine in Emergencies: World Expert Consensus and Best Practices
H. Sampson (New York, United States of America)
-

10:15 - 11:45 PL1 - Airway immunity and asthma (Room Istanbul, 1- Istanbul, Plenary Lectures)

Chair: *M. Shamji (London, United Kingdom), M. Escribese (Madrid, Spain)*

- 10:15** Gut microbiota and airway immune homeostasis
A. Mortha (Toronto, Canada)
-
- 10:45** Airway wall ecosystems and asthma risk
C. M. Lloyd (London, United Kingdom)
-
- 11:15** Cannabinoid receptors and regulation of Th2 airway inflammation
O. Palomares (Madrid, Spain)
-

10:15 - 11:45 PL2 - Practical management of biologicals (Room Paris, 2- Paris, Plenary Lectures)

Chair: **S. Del Giacco** (Cagliari, Italy), **A. Moreira** (Porto, Portugal)

10:15 Advances in biological therapies for chronic rhinosinusitis with nasal polyps
L. Zhang (Beijing, China)

10:45 Anti-IgE in food allergy: lessons from translational and clinical trials
S. Sindher (Stanford, United States of America)

11:15 How and why to switch biologicals in severe asthma
J. Kappen (The Hague, Netherlands)

10:15 - 11:45 PL3 - Presidential Symposium 2 - Drug allergy for the practicing clinician (Room Florence, 3- Florence, Plenary Lectures)

Chair: **P. Bonadonna** (Vicenza, Italy), **A. Barbaud** (Paris, France)

10:15 Nomenclature and risk stratification in drug allergy: towards a global common language
M. Torres (Malaga, Spain)

10:45 Cross-Reactivity in beta-lactam allergy: clinical implications
I. Terreehorst (Rotterdam, Netherlands)

11:15 Updates in pediatric drug allergy
M. Atanaskovic-Markovic (Beograd, Serbia)

12:00 - 12:45 P & C 1 - PRO CON 1: Can we prevent anaphylaxis in Hereditary alpha Trypsinemia (HaT) (EAACI Global Stage, Pro Con)

12:00 Pro
P. Kopac (Golnik, Slovenia)

12:23 Con
S. Broesby-Olsen (Odense, Denmark)

12:00 - 13:00 FT01 - Infections

(Room Athens, Flash Talks)

Chair: N. Papadopoulos (Athens, Greece), E. Yucel (Istanbul, Türkiye)

12:00 Single-cell multi-omic landscape reveals specific immune features in M.pneumoniae pneumonia with plastic bronchitis
000291 W. Jiang (suzhou, China)

12:07 Long-term Analysis of B and T cell response after SARS-CoV-2 vaccination or infection is not affected by the
001691 treatment with monoclonal antibodies for Severe Asthma
M. Bullita (Monserato, Italy)

12:14 Long-term real-world effectiveness of allergen immunotherapy on respiratory infections in children and adults
000748 with allergic rhinitis and asthma
C. Woehlke (Hørsholm, Denmark)

12:21 Coughing and Wheezing in Early Life Define Distinct Asthma and Lung Function Trajectories
001416 T. Sultan (Gentofte, Denmark)

12:28 Neonatal airway hyperreactivity and obstruction associates with lung function deficits in adulthood
001459 independent of early-life respiratory infections
S. K. Jensen (Gentofte, Denmark)

12:35 Off-label dupilumab as a steroid-sparing therapy in refractory allergic fungal rhinosinusitis: a real-world case
000791 A. Gorlat García (Majadahonda, Spain)

12:42 A Complex Case of PSTPIP1-Related Disorder: Pyogenic Sterile Arthritis, Pyoderma Gangrenosum, and Acne
001271 (PAPA) Syndrome Presenting with Recurrent Cutaneous Infections, Cytopenias, and Gastrointestinal Inflammation
R. F. Bantug (Manila, Philippines)

12:00 - 13:00 FT02 - Delayed hypersensitivity and desensitization

(Room Glasgow, Flash Talks)

Chair: M. Atanaskovic-Markovic (Beograd, Serbia)

12:00 "PROTECT-TEN/SJS: a novel prognostic tool for assessing disease severity and outcomes in Stevens-Johnson
001877 Syndrome and Toxic Epidermal Necrolysis"
E. Nikitina (Moscow, Russia)

12:07 Microbiological profiles and infectious complications in Stevens-Johnson syndrome and toxic epidermal necrolysis
001825 E. Nikitina (Moscow, Russia)

12:14 Proportion of Stevens-Johnson syndrome and toxic epidermal necrolysis cases associated with antiepileptic
000635 drugs: a systematic review and meta-analysis
E. Lee (Toronto, Canada)

12:21 Delayed hypersensitivity reaction to amoxicillin-clavulanic acid following carbamazepine-induced rash in a
002110 pediatric patient with focal epilepsy: a case report
R. L. Valluzzi (Rome, Italy)

12:28 The important role of affinity, drug dose and therapy duration in p-i-mediated delayed drug hypersensitivity
001921 O. Hausmann (Bern & Lucerne, Switzerland)

12:35 Platinum Hypersensitivity Reactions: Phenotyping of Initial and Breakthrough Reactions and Their Impact on
000461 Desensitization Success
A. Yildirim (Ankara, Türkiye)

12:42 Chemotherapy Hypersensitivity and Desensitization in Pediatric Patients, Particularly Asparaginase
001963 R. Selen (Ankara, Türkiye)

12:49 Can Repeated Enzyme Desensitizations Lead To The Development Of Transient Tolerance?
000632 M. Sezgin (Istanbul, Türkiye)

12:00 - 13:00 L-OAS03 - Skin Allergy (Room Gothenburg, Oral Abstract Sessions)

Chair: A. Bingol (Antalya, Türkiye), M. Pereira (Berlin, Germany)

12:00 The phenotype-genotype association in a cohort of 106 HAE-C1INH patients of Southern Spain

100610 K. Baynova (Seville, Spain)

12:12 Amlitelimab Reduces Atopic Dermatitis (AD)-Associated Biomarkers in Patients With Moderate-to-Severe AD:
100073 Results From an Exploratory Pooled Analysis of the Pivotal Phase 3 COAST1 and COAST2 Trials

B. Geng (San Diego, United States of America)

12:24 Tissue-dependent sexual dimorphism in chronic spontaneous urticaria revealed by integrative clinical and
100363 transcriptomic profiling

Z. Wang (Xi'an, China)

12:36 Remibrutinib demonstrated superior efficacy vs placebo and favorable safety in patients with chronic inducible
100213 urticaria in the phase 3 REMIND study

M. Metz (Berlin, Germany)

12:48 Remibrutinib demonstrated continuous efficacy and favorable safety in patients with chronic spontaneous
100662 urticaria in the randomized withdrawal period of the phase 3b REMIXED extension study

M. Metz (Berlin, Germany)

12:00 - 13:00 POC - PD1 - Panel Discussion: From Pipeline to Patient: Accelerating Access to Break-through Therapies (EAACI Global Stage, POC)

Chair: O. Ceylan (Istanbul, Türkiye)

Panel Discussion: From Pipeline to Patient: Accelerating Access to Breakthrough Therapies

C. Öztürk (Istanbul, Türkiye), K. Illy (Amersfoort, Netherlands)

12:00 - 13:00 TPS - Poster Sessions (Poster Area, Poster Walk)

12:00 - 13:00 Product Theatre Session 1 (Innovation Hub, Product Theatre)

12:00 - 13:00 SSS2 - EAACI JSA Sister Society symposium: Asthma Pathophysiology and Related Topics: Mechanisms, Targets, and Clinical Perspectives (Room Florence, 3- Florence, Sister Society Symposium)

Chair: M. Ebisawa (Sagamihara, Japan), M. Torres (Malaga, Spain)

12:00 Mechanisms and Management of Cough in Asthma

Y. Kanemitsu (Nagoya, Japan)

12:20 Molecular Targets in Asthma: Basic Insights into Biologic Therapies

H. Tashiro (Saga, Japan)

12:40 Clinical Remission in Asthma: Current Status and Future Perspectives

H. Nagase (Tokyo, Japan)

12:00 - 13:00 **Satellite Symposium**
(Room Paris, Sponsored Sessions)

12:00 - 13:00 **Satellite Symposium**
(Room Utrecht, Sponsored Sessions)

12:00 - 13:00 **Satellite Symposium**
(Room Zurich, Sponsored Sessions)

12:00 - 13:00 **Satellite Symposium**
(Room London, Sponsored Sessions)

12:00 - 13:00 **Satellite Symposium**
(Room Krakow, Sponsored Sessions)

12:00 - 13:00 L-TPS01 - Allergy diagnosis 17

(Poster Zone, Thematic Poster Session)

- D1.76** **Contact dermatitis in diabetic patients with wearable devices: A single-centre study**
P. Del Barba (Milan, Italy)

- D1.77** **Hereditary Angioedema in Real Life: Unmet Needs from the Patient Perspective**
Ç. Tüccar (Ankara, Türkiye)

- D1.78** **Non-Allergic Dermatologic Diagnoses Among Patients Presenting to an Allergy Immunology Outpatient Clinic: A Prospective Clinical Study**
A. Ekinçi (Ankara, Türkiye)

- D1.79** **Heterogeneity of Non-Allergic Non-Eosinophilic Asthma: Clinical Subphenotypes and Allergy Belief Patterns**
A. Ekinçi (Ankara, Türkiye)

- D1.80** **Comparison of Cupressaceae sensitization allergens in a large Spanish cohort**
Á. López (Alcobendas, Spain)

- D1.81** **Dermoscopy in the Reaction Interpretation of Patch Test with Pigmentation**
A. Li (Beijing, China)

- D1.82** **Pancake Syndrome: Molecular and Diagnostic Heterogeneity of Mite Sensitization**
M. Bernardo (Ponta Delgada, Portugal)

- D1.83** **Cannabis-related severe anaphylaxis without cutaneous manifestations: atypical sensitization profile and mast cell disorder differential diagnosis in a case report**
A. M. Aguirre Echeverry (Badalona, Spain)

- D1.84** **Invasion Meets Allergy: Cortaderia selloana as an Emerging Grass Aeroallergen**
A. J. Albarracín Contreras (Santander, Spain)

- D1.85** **Baseline lung function and clinical outcomes in Allergic Bronchopulmonary Mycosis: A real-world cohort from a Severe Asthma Multidisciplinary Unit**
N. Abdurrahid (Lisboa, Portugal)

- D1.86** **Age-Related Features of Sensitization to Timothy Grass in Children According to Component-Resolved Diagnostics**
M. Vafokulova (Tashkent, Uzbekistan)

- D1.87** **Kiwi allergy: A Comparative Analysis of Adult and Pediatric patients**
L. Gonçalves (Lisboa, Portugal)

- D1.88** **An unusual diagnostic aid for Hymenoptera venom genuine versus cross sensitization: the field sting**
J. Vitte (Reims, France)

- D1.89** **Qualitative comparison between Euroline Respiratory Profile and Phadiatop for the screening of airborne allergies**
J. Goret (Bordeaux, France)

12:00 - 13:00 L-TPS02 - Allergy diagnosis 18
(Poster Zone, Thematic Poster Session)

Chair: **Ö. Cavkaytar (İstanbul, Türkiye)**

- D1.90** **Soft Tissue Loss Due to Allergic Reaction to Adhesive System during Orthodontic Treatment: A Case Report**
S. Zubchenko (L'viv, Ukraine)

- D1.91** **Characterization of Bet v1 Sensitized Patients in Madrid: A Real Life Study**
A. González Jáimez (Madrid, Spain)

- D1.92** **Optimizing Aspirin Oral Provocation Testing in Suspected NSAID Hypersensitivity: A Real-World Protocol Analysis**
N. Piedade (Porto, Portugal)

- D1.93** **Isolated Generalized Pruritus Associated with SGLT2 Inhibitors: A Case Series with Negative Allergy Work-up**
C. Juárez Rodríguez (Aranjuez, Madrid, Spain)

- D1.94** **Vancomycin- and Meropenem-Induced DRESS Confirmed by the Lymphocyte Transformation Test: A Synergistic Effect in Severe Drug Reactions**
G. Kabadayı (İzmir, Türkiye)

- D1.95** **Utility and safety of Patch Testing in anti-epileptic Induced DRESS: Diagnostic sensitivity and cross-reactivity profiling**
N. Fathallah (Sousse, Tunisia)

- D1.96** **Assessment of sensitivity to Lipid Transfer Proteins in allergic patients in the Republic of Moldova**
V. Brocovschii (Chişinău, Moldova),

- D1.97** **To FeNO or Not to FeNO: Is It a Practical Tool in Daily Management of Chronic Cough?**
K. Xhelilaj (Tiranë, Albania)

- D1.98** **Comparative Evaluation of Basal Serum Tryptase Determinants: Differential Impact of KIT D816V Allelic Load and HaT Gene Copy Number**
M. Martinou (Athens, Greece)

- D1.99** **Allergic contact dermatitis caused by Trofoblastin**
C. Flores Infante (Madrid, Spain)

- D1.100** **Deciphering Multiple Drug Allergy syndrome: True Allergy or Pro-inflammatory Response?**
N. Fathallah (Sousse, Tunisia)

- D1.101** **Colchicine-induced hepatitis: a case of drug interaction involving rivaroxaban**
N. Fathallah (Sousse, Tunisia)

- D1.102** **Furosemide-induced erythroderma: a diagnosis to consider**
N. Fathallah (Sousse, Tunisia)

- D1.103** **Successful Class Switching of SGLT2 Inhibitors Following Empagliflozin-Induced Maculopapular Exanthema: A Case Report**
N. Fathallah (Sousse, Tunisia)

12:00 - 13:00 L-TPS04 - Allergen immunotherapy 08

(Poster Zone, Thematic Poster Session)

Chair: B. Pessina (Milano, Italy)

- D1.218** Effects of butyrylated high amylose maize starch (HAMSB) as an adjuvant for oral immunotherapy
D. Ni (Camperdown, Australia)

- D1.219** Efficacy and Safety of 300 IR Liquid Sublingual Immunotherapy in Allergic Asthma: A Systematic Review and Meta-analysis of Randomised Controlled Trials
D. Di Bona (Foggia, Italy)

- D1.220** Clinical profile and correlation of endoscopic disease severity with selected lifestyle risk factors in a cohort with chronic rhinosinusitis in Sri Lanka
T. Hewapathirana (Nugegoda, Sri Lanka)

- D1.221** Identification of IgE epitopes of major ragweed pollen allergens (Amb a 1 and Amb a 11)
M. Popova (Moscow, Russia)

- D1.222** Production of Bet v 1-specific IgG antibodies in mice immunized with the recombinant vaccine ABP-Vax
P. Strueva (Moscow, Russia)

- D1.223** TNFR2 regulates early PD-L1/PD-L2 induction and Th1-associated cytokine responses during the early events of Allergen-Specific Immunotherapy (AIT) in a preclinical model
M. L. Bazon (Esch-sur-Alzette, Luxembourg)

- D1.224** Rational Design of a T-Cell Epitope-Based Chimeric Allergen from Dermatophagoides pteronyssinus Toward Precision Immunotherapy
F. Adami (São Paulo, State of São Paulo, Brazil, Brazil)

- D1.225** Long-term adherence to seasonal allergen immunotherapy: a 3-year (22/23-24/25) retrospective study on 174 patients
G. Manzotti (Bergamo, Italy)

- D1.226** Allergen Immunotherapy Preferences by Patient in Some Arabic countries: The CHOICE-Middle East Study
A. Bulkhi (Makkah, Saudi Arabia)

- D1.227** Nanobody-based anti-FcεRI antibodies for therapeutic targeting of the IgE-FcεRI complex
G. Odabas (Aarhus, Denmark)

- D1.228** Mitochondrial Epigenetic Programming: A Unifying Mechanism Linking Environmental Stress, Epithelial Barrier Dysfunction, and Allergy
G. NAMASIVAYAM (Kyoto, Japan)

- D1.229** Real-life observational study on allergen-specific Immunotherapy with double-polymerized allergoids (Modigoid Cup a1) in patients allergic to Cupressus Arizonica pollen
A. Cinquantasei (Bari, Italy)

- D1.230** Efficacy and Safety of Hymenoptera Venom Immunotherapy in a Patient with Systemic Mastocytosis
A. Grilo Mendes (Vila Nova de Gaia, Portugal)

- D1.231** Endotype-Guided Management of Allergic Asthma in a Pediatric Athlete: Impact of Sublingual Immunotherapy
A. Alexandru (Târgu Mureș, Romania)

12:00 - 13:00 L-TPS05 - Immune deficiencies and autoimmunity 07

(Poster Zone, Thematic Poster Session)

Chair: **M. Serbes (Adana, Türkiye)**

- D1.348** Retrospective Evaluation of Laboratory and Clinical Characteristics of Pediatric Patients Diagnosed with IgG Subclass Deficiency and Receiving Intravenous Immunoglobulin Replacement Therapy
L. KILINÇKAYA (Sakarya, Türkiye)

- D1.349** Early Diagnosis of WHIM Syndrome in Infancy: A Case with a De Novo CXCR4 Mutation
H. Alkaya (İstanbul, Türkiye)

- D1.350** Selective IgA deficiency and its association with allergic and autoimmune diseases
I. Mrkić Kobal (Zagreb, Croatia)

- D1.351** Chronic urticaria and autoimmunity: clinical, laboratory and molecular associations
A. Dimitriou (Athens, Greece)

- D1.352** A retrospective study for IgG3 subclass deficiency in one primary clinic
Y. Jung (Seongnam-si, Korea, Republic of)

- D1.353** M.-J. Kim (Yongin-si, Korea, Republic of), M.-H. Park (Yongin-si, Korea, Republic of), Y. Jung (Seongnam-si, Korea, Republic of)
N. O. Sapci (Eskişehir, Türkiye)

- D1.354** Possible Association of a MYOF Loss-of-Function Variant With Recurrent Angioedema: Overlap Between Chronic Spontaneous Urticaria and Normal-C1 Hereditary Angioedema? A Case Report
S. Trainotti (Munich, Germany)

- D1.355** Familial Recurrent Angioedema with Normal C1-Inhibitor: A Clinical Case Series Suggestive of HAE with Normal C1-INH
C. Aznabakiyeva (Almaty, Kazakhstan)

- D1.356** Atypical association of anti-EJ and anti-RNA polymerase III antibodies in a patient referred for interstitial lung disease
J. Vitte (Reims, France)

- D1.357** Atypical case of common variable immune deficiency with granulomatous lymphocytic interstitial lung disease
S. Zivkovic (Novi Sad, Serbia)

- D1.360** Common Variable Immune Deficiency in Pregnancy: Multidisciplinary Approach to Improving Obstetrical Outcome
F. AlYaqout (Kuwait, Kuwait)

- D1.361** Real-world outpatient characterization and management of post-rituximab hypogammaglobulinemia in a multidisciplinary ambulatory center cohort in Bogota, Colombia
C. Gomez Parada (Bogotá, Colombia)

- D1.362** Autoimmunity Following Hematopoietic Stem Cell Transplant in a Patient with RAG2 Deficiency
A. Nasser Eldin (Jerusalem, Israel)

- D1.363** Long-Acting Prophylactic Injection BW-20805: Remarkable and Sustained HAE Attack Reduction — Updated Analysis from an Ongoing Phase 2 Study
Y. Zhi (Beijing, China)

12:00 - 13:00 L-TPS06 - Drug Allergy 05

(Poster Zone, Thematic Poster Session)

Chair: **T. Arıkoğlu (Mersin, Türkiye), J. A. Cornejo-Garcia (Málaga, Spain)**

- D1.394** Functional AOC1 variants associated with reduced diamine oxidase activity mimicking multiple drug hypersensitivity and mast cell disorders
E. Hernández Lerma (Ciudad de México, Mexico)

- D1.395** Mortality Risk Stratification in Antibiotic-Induced Severe Cutaneous Adverse Reactions: A Nationwide Multicenter Cohort Study
J.-W. Jung (Seoul, Korea, Republic of)

- D1.396** Drug hypersensitivity reactions in paediatric patients pre and post-liver transplant: a single-center study
E. Efstathiou (London, United Kingdom)

- D1.397** Successful rapid drug desensitization to cemiplimab in a patient with lung squamous cell carcinoma
D. Preziosi (Como, Italy)

- D1.398** Safety Outcomes and Predictors of Clinically Significant Reactions in Positive Drug Provocation Tests: A 10-Year Tertiary-Center Cohort
B. Çelik Eroğlu (Ankara, Türkiye)

- D1.399** Selective IgE Mediated Anaphylaxis to Gadobutrol and type I Kounis with tolerance to Gadoxetate Disodium
A. A. Vázquez Bautista (Madrid, Spain)

- D1.400** Omalizumab premedication improves ferric carboxymaltose desensitization outcomes: A Case Report
G. T. Vural Solak (Ankara, Türkiye)

- D1.401** Progression from Immediate to Delayed Hypersensitivity: A Rare Case of Iodixanol-Induced Acute Generalised Exanthematous Pustulosis
S. Flores Regalo (Coimbra, Portugal)

- D1.402** Angiotensin-Converting Enzyme Inhibitor-Induced Bradykinin-Mediated Angioedema: Three Cases of Sustained Remission Following Definitive Discontinuation and the Critical Role of the Prescribing Physician
P. Bērziņš (Rīga, Latvia)

12:00 - 13:00 L-TPS07 - Basic immunology 05
(Poster Zone, Thematic Poster Session)

- D1.421** Hydrolysable Tannins Synergize with JAK Inhibition in STAT1-Driven Inflammation Identified Using a Patient-Derived Reporter Platform
E. Y. Wang (Hong Kong, Hong Kong)
- D1.422** Characterization of provocation-induced changes in transcription factors in the nasal mucosa of birch pollen-allergic and non-allergic individuals
G. Lamorte (Vienna, Austria)
- D1.423** Immunological mechanisms underlying pulmonary manifestations in pediatric long COVID patients
T. TUNG (Taipei, Taiwan)
- D1.424** Single-cell transcriptomic profiling of allergen-restimulated PBMCs reveals innate immune activation in equine insect bite hypersensitivity
E. Marti Schalch (Bern, Switzerland)
- D1.425** Impact of Early Postnatal Administration of Escherichia coli O83:K24:H31 on Immune System Maturation and Gut Barrier Function
L. Zahradníčková (Prague, Czech Republic)
- D1.426** An in vitro model of human primary skin-derived mast cells for functional assessment of degranulation and inflammatory mediator release
A. Brulefert (Gençay, France)
- D1.427** Exploring the role of lipids on initiation of allergenic response in innate lymphoid cells
D. Schnögl (Krems an der Donau, Austria)
- D1.428** Immunomodulation of human PBMCs by peptide amphiphiles
H. Babayev (Davos, Switzerland)
- D1.429** The major birch pollen allergen activates the NLRP3 inflammasome in THP1-ASC-GFP reporter cells
C. ROHNER (St. Pölten, Austria)
- D1.430** Extracellular vesicles isolated after cholinergic urticaria challenge carry MRGPRX2 and induce pro-inflammatory mast cell responses
P. L. Quan-López (Pamplona, Spain)
- D1.431** Distinct Immunophenotypic Signatures in Pediatric Allergic Disease: Clinical Utility of Methylation qPCR-Based Epigenetic TBNK Profiling
F. Kırbıyık (Istanbul, Türkiye)
- D1.432** Association Between Autoimmunity and Endocrinopathy in Patients with Common Variable Immunodeficiency
F. Sağun (Konya, Türkiye)
- D1.433** DNA Ligase I Deficiency Masquerading as CVID-Like Phenotype: Implications for Long-Term Surveillance
G. Martins (Lisbon, Portugal)
- D1.434** Phenotyping Common Variable Immunodeficiency by Immune Dysregulation at Diagnosis: A Descriptive Comparison of Baseline Clinical and Laboratory Findings
U. Yılmaz Ergün (Konya, Türkiye)
- D1.436** Transfusion-Related Acute Lung Injury (TRALI) following plasma transfusion: A case report
C. Toma (Chişinău, Moldova)
- D1.435** A TSLP Tuft Cell-Treg Cell Circuit promotes Food Allergy
M. Martínez Blanco (Madrid, Spain)

12:00 - 13:00 L-TPS08 - Biologicals 05

(Poster Zone, Thematic Poster Session)

Chair: **H. Al Bahri (Bahrain)**

- D1.450** Real-world comparative effectiveness of dupilumab, JAK inhibitors, and azathioprine in severe adult atopic dermatitis: a 24-month longitudinal cohort
V. Gonzalez-Urbe (Ciudad de México, Mexico)

- D1.451** Adherence and persistence to biological treatments in patients with CRSwNP and comorbid asthma
M. Lundberg (Helsinki, Finland)

- D1.452** Remission as a therapeutic goal in chronic rhinosinusitis with nasal polyps treated with Dupilumab: a multicenter real-world study
E. Cavaglia (Milan, Italy)

- D1.453** Pregnancy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): a case report and literature review
S. Sartorio (Milan, Italy)

- D1.454** A Preliminary Comparative Study of Efficacy and Safety of Different Dosing Regimens in Patients with Type 2 Chronic Rhinosinusitis with Nasal Polyps Based on Real-World Data
Z. Ma (Hangzhou, China)

- D1.455** Dupilumab Efficacy in Unified Airways Disease: Pooled Analysis of Patients With Chronic Rhinosinusitis With Nasal Polyps/Allergic Fungal Rhinosinusitis With Coexisting Asthma in Ph3/4 Clinical Trials
P. Gevaert (Ghent, Belgium)

- D1.456** Integrated Analysis of Nemolizumab Immunogenicity Indicates No Effect on the Overall Benefit-Risk Profile of Nemolizumab in Patients with Atopic Dermatitis or with Prurigo Nodularis
L. Loprete (Zug, Switzerland)

- D1.457** Clinical and immune profile of newborns born to mothers with inflammatory diseases exposed to biological drugs during pregnancy
G. Yáñez Lema (Barcelona, Spain)

- D1.460** Diagnostic Opportunities in Type 2 Inflammations - A Machine-Learning Approach: EAACI Task Force Update
F. Ryser (Bern, Switzerland)

- D1.461** Dupilumab as a Steroid-Sparing Treatment Option for Pemphigus Vulgaris: A Case Series from a Tertiary Centre
S. Elkhaila (Abu Dhabi, United Arab Emirates)

- D1.462** Efficacy of Upadacitinib in Atopic Keratoconjunctivitis During four years Treatment for Atopic Dermatitis: A Case Report
M. Maia (Milano, Italy)

- D1.463** Real-World Transition from Reference Omalizumab to Biosimilar Omlyclo in Patients with Chronic Urticaria: A Single-Center Descriptive Study
E. Menéndez-Rivero (Seville, Spain)

- D1.464** Dupilumab in pediatric patients with severe atopic dermatitis
A. Ostojić (Belgrade, Serbia)

12:00 - 13:00 TPS01 - Allergy diagnosis 01

(Poster Zone, Thematic Poster Session)

Chair: J. Jagers (Cleveland, United States of America), A. Villaseñor Solís (Madrid, Spain)

- D1.01** Anaphylaxis After Crayfish Consumption with Strong *Anisakis simplex* Sensitization
S. San Roman Sirvent (Villajoyosa, Spain)

- D1.02** Sensitization to Sesame Proteins Despite Negative Conventional Testing
T. Galán Díez (Alcalá de Henares, Spain)

- D1.03** Identification of a Thaumatin-Like Protein as a Shared Allergen in Kiwi and Persimmon: Molecular Analysis in a Case of Anaphylaxis
M. Polo López (Segovia, Spain)

- D1.04** Cat-Cow Milk Syndrome in a Case of Anaphylaxis to Whey Protein
V. García Paz (A Coruña, Spain)

- D1.05** IgE-Mediated Rice Allergy: The Role of Immunoblotting in Allergen Identification
T. Freitas (Coimbra, Portugal)

- D1.06** When an allergic reaction turns into a cardiac event: clinical characterization of Kounis Syndrome
B. Cuevas Cantero (Seville, Spain)

- D1.07** Risk Stratification Tools in Suspected Beta-Lactam Allergy: A RealLife Delabeling Study
E. Cavaglia (Milan, Italy)

- D1.08** Clinical relevance of troponin C (Crp c 6) sensitization in crustacean allergy
L. Frattini Llorens (València, Spain)

- D1.09** Mast cell disorders in children with food-induced anaphylaxis
T. Pungertnik (Ljubljana, Slovenia)

- D1.10** Underrecognition of Anaphylaxis in Children: Gaps in Diagnosis and Management
A. Hadžimuratović (Sarajevo, Bosnia and Herzegovina)

- D1.11** Determinants of allergen sensitization and wheal size variability in skin prick testing in a large outpatient cohort
D. Hervas (Palma, Spain)

- D1.12** Cross-Reactivity Between Peach Juice and Cupressaceae Pollen
R. Pérez Durban (Majadahonda, Spain)

- D1.13** A rare case of isolated histaminergic angioedema
P. Paskalev (Plovdiv, Bulgaria)

- D1.14** Biphasic, Refractory, and Persistent Anaphylaxis in Children
G. Koken (Ankara, Türkiye)

- D1.15** True Mugwort Sensitization Presenting as Severe Atopic Dermatitis: A Diagnostic Challenge
A. Kovchun (Sumy, Ukraine)

12:00 - 13:00 TPS02 - Allergy diagnosis 02

(Poster Zone, Thematic Poster Session)

Chair: **S. Dramburg (Berlin, Germany), A. Karavelia (Kalamata, Greece)**

- D1.16** Challenging antibiotic resistance through beta-lactam delabeling. Less is more?
M. Curci (Roma, Italy)

- D1.17** Service Evaluation of patients with Suspected Allergic Reactions presenting to the Emergency Department of a tertiary Irish teaching hospital
T. Heffernan (Dublin, Ireland)

- D1.18** Not Just for Kids: A Rare Case of Adult-Onset IgE-Mediated Cow's Milk Allergy Masquerading as Drug Hypersensitivity
M. R. Vintila (Bucharest, Romania)

- D1.19** Etoricoxib-Induced Fixed Drug Eruption: A Case Series and Assessment of Tolerance to Alternative NSAIDs
D. De Zubiria (Cali, Colombia)

- D1.20** Challenges in Safe Alternative Selection in a Case of Amoxicillin-Induced Anaphylaxis
A. Chera (Bucharest, Romania)

- D1.21** Three cases of Food induced Anaphylaxis - Role of Cofactors
K. Sooriyakumar (Newcastle upon Tyne, United Kingdom)

- D1.25** Cannabis-Fruit-Veggie Syndrome: From Respiratory Symptoms to Life-Threatening Anaphylaxis
C. Burtescu (Bucharest, Romania)

- D1.26** Egg Allergy Persistence Beyond 8 Years of Age
Y. TEPE (istanbul, Türkiye)

- D1.27** Delayed Hypersensitivity Reactions to Iodinated Contrast Media: Diagnostic Outcomes and Alternative Selection
M.-L. Toader (Bucharest, Romania)

- D1.28** Clinical Follow-up in Radiocontrast Media-Induced Hypersensitivity Reactions: Beyond the Reaction
M. I. Toksoy Senturk (izmir, Türkiye)

- D1.29** When Anaphylaxis Is Not Anaphylaxis: A Rare Differential Diagnosis in Perioperative Shock
C. Maçães (Vila Nova de Gaia, Portugal)

- D1.30** Allergy Care in Adult Cystic Fibrosis Patients with Drug Hypersensitivity: A Service Evaluation at St Bartholomew's Hospital
L. Barbero Igualada (London, United Kingdom)

- D1.31** Identification of Process-Modified Allergens in Tiger Nut Milk (Horchata) as the Cause of IgE-Mediated Anaphylaxis: Molecular Evidence of Aldolase and α/β -Hydrolase Proteins
L. Barbero Igualada (Alicante, Spain)

- D1.32** When Anaphylaxis Presents as Syncope: Wasp Venom Allergy in the Setting of Significantly Elevated Basal Tryptase
P. Ibrishimov (Sofia, Bulgaria)

12:00 - 13:00 TPS03 - Allergy diagnosis 03
(Poster Zone, Thematic Poster Session)

Chair: **R. Castagnoli (Pavia, Italy), M. Martini (Ancona, Italy)**

- D1.33** Patient-reported outcomes following beta-lactam antibiotic allergy delabeling work-up
M. Powietrzyński (Gdańsk, Poland)

- D1.34** Guideline adherence and safety of AI chatbots in allergology
J. Glińska (Gdańsk, Poland)

- D1.35** Dysregulation of the MALAT1/TGF- β signaling pathway in CD103+ cells of patients with allergic rhinitis
M. Rajabinejad (Hamedan, Iran, Islamic Republic of),

- D1.36** Lactation-associated urticaria triggered by direct breast milk contact: a rare postpartum hypersensitivity reaction
M. Alotaibi (Riyadh, Saudi Arabia)

- D1.37** Which Came First? Atopic Dermatitis or occupational Allergic Contact Dermatitis in a Surgeon with Tropomyosin-Driven IgE Cross-Reactivity
M. Coman-Stanemir (Bucharest, Romania)

- D1.38** A Generalizable High-Throughput Nanobody Discovery Platform for Airborne Allergens
X. Li (Hong Kong, Hong Kong)

- D1.39** Oral Lichenoid Lesions Secondary to Contact Allergy to L-Carvone from Toothpaste: A Case Report
J. M. García Menaya (Bada, Spain)

- D1.40** Independent Sensitization to poultry meat and tuna in a food allergic young girl
C. Ferreira (Guilhufe, Portugal)

- D1.41** B cell responses to alarmins in type 2 inflammation
H. Du (Davos, Switzerland)

- D1.42** Unusual Delayed Hypersensitivity Reaction to Different Antibiotic Families
M. J. Calvo Delgado (Albacete, Spain)

- D1.43** Hypereosinophilic Dermatitis with Hyper-IgE and Breakthrough Urticaria Under Immunosuppression: A case of Probable Lymphocytic-HES
H. Aksoy (Manisa, Türkiye)

- D1.44** Primary care allergy and clinical immunology fellowship: A Delphi study of core competencies
A. O'Neill (Cork, Ireland, Ireland)

- D1.45** Selective Anaphylaxis to Salmonids with Tolerance to Other Fish
C. Ferreira (Guilhufe, Portugal)

12:00 - 13:00 TPS04 - Allergy diagnosis 04

(Poster Zone, Thematic Poster Session)

Chair: P. Alves (Coimbra, Portugal), M. Ollert (Esch-sur-Alzette, Luxembourg)

- D1.46** Molecular patterns of fungal sensitization in patients with asthma and allergic rhinitis: evidence from real-life clinical practice
O. Mirzaev (Samarqand, Uzbekistan)

- D1.47** Assessment of Asthma Control in Elderly Patients Using Forced Oscillation Technique, Spirometry, and Asthma Control Test in Relation to GINA Classification
M. Miodonska (Katowice, Poland)

- D1.48** Early-Onset Multiorgan Allergic Phenotype with Transformation into Controlled Asthma in a 2-Year-Old Child: The Role of Molecular Diagnostics (ALEX²) in Risk Stratification
A. Kuznetzova (Saint Petersburg, Russia)

- D1.49** Component-Resolved Pet Allergen Sensitization Identifies Adolescents With Airway Inflammation and Bronchial Hyperresponsiveness
F. Skov (Gentofte, Denmark)

- D1.50** Allergic Bronchopulmonary Aspergillosis in a Tertiary Allergy Center: Clinical Characteristics, Radiologic Subtypes, and Biologic Use
H. K. Oh (Seoul, Korea, Republic of)

- D1.51** Evaluation of the Correlation Between Skin Prick Test, Specific Immunoglobulin E Levels and Clinical Findings in Children with Cat Allergen Sensitization
Ç. Torun Özel (Ankara, Türkiye)

- D1.52** The Borg Fallacy in Olympic Athletes: Symptom Perception Fails to Identify Airway Hyperresponsiveness
I. Rosmaninho (Porto, Portugal)

- D1.53** Prevalence of Cat and Dog Allergen Sensitization in Pediatric Asthma in Morocco
B. ElGharbaoui (Rabat, Morocco)

- D1.54** Latex-Induced Occupational Asthma: An Underrecognized Hazard in the Electronics and Cable Industry
E. Baraketi (Tunis, Tunisia)

- D1.55** Monosensitization to Der p 23 in house dust mite allergy in daily clinical practice in a county of Gipuzkoa, Basque Country, Spain: a retrospective and descriptive analysis
M. S. Giraldo-Tugores (Tolosa, Spain)

- D1.56** Multiple H1 antihistamine hypersensitivity in a polysensitized patient with allergic rhinoconjunctivitis and asthma
G. M. Valentini (Milan, Italy)

- D1.57** New allergens registered in the WHO/IUIS Allergen Database in 2025: new and old foes
A. Jacquet (Bangkok, Thailand)

- D1.58** "Evaluation of Chronic Cough in Patients with Allergic Disease, GERD, and Chronic Rhinosinusitis"
L. Bugadze (T'bilisi, Georgia)

- D1.59** Species-Specific IgE Sensitisation to Seafood in Malaysian Adults: Clinical Implications for Risk-Stratified Diagnosis and Dietary Counselling
K. Reginald (Petaling Jaya, Malaysia)

- D1.60** Clinical Characteristics of Children with Patch Test-Positive Allergic Contact Dermatitis: Effects of Treatment on Quality of Life
M. S. Ensari (Ankara, Türkiye)

12:00 - 13:00 TPS05 - Allergy diagnosis 05
(Poster Zone, Thematic Poster Session)

Chair: **T. Trikamjee** (CAPE TOWN, South Africa), **S. Halken** (Odense, Denmark)

- D1.61** **Shrimp Tropomyosin as a Selective Allergen in a Case of Food Allergy: The Value of Individualized Molecular Analysis**
F. Pineda de la Losa (Alcalá de Henares, Spain)

- D1.62** **Thermal stress alters the allergen and proteome profile of the redclaw crayfish (Cherax quadricarinatus)**
S. Heidari (Douglas, Australia)

- D1.63** **Suspected Hypersensitivity to Non-Nutritive Sweeteners With Recurrent Respiratory Manifestations in a Pediatric Patient**
D. I. Suh (Seoul, Korea, Republic of)

- D1.64** **Distinct and Overlapping Sensitization Patterns to Crustacean and House Dust Mite Allergens in Tropical Allergy**
S. Heidari (Townsville, Australia)

- D1.65** **Selective Allergy to Large Prawn: Identification of a Projectin-Derived IgE-Binding Protein**
P. Mur Gimeno (Puertollano, Spain)

- D1.66** **Allergy profiling in selective goat and sheep milk allergy**
L. Rodríguez Calderón (Guadalajara, Spain)

- D1.67** **Comparison of machine learning models for grass carp allergy diagnosis**
C. Y. Y. Wai (Shatin, Hong Kong)

- D1.70** **IgE-sensitization to allergens in plant-based drinks in children with cow's milk allergy**
J. Ruppel (Berlin, Germany)

- D1.71** **Can an allergist predict the development of allergies? A Clinical case of dizygotic twins with divergent outcomes**
S. Dvorkina (Moscow, Russia)

- D1.72** **Assessing potential influencing factors on allergic reaction to the cumulative dose given on an extra day within oral food challenge in food-allergic children**
A. W. Szubert (Frankfurt am Main, Germany)

- D1.73** **Date Palm or Grass pollen rhinoconjunctivitis in a patient with watermelon allergy?**
D. QERIMI (Durrës, Albania)

- D1.74** **Sunflower Seed-Induced Anaphylaxis: Allergenic Characterization and Evidence of Cross-Reactivity with Niger Seeds**
F. Pineda de la Losa (Alcalá de Henares, Spain)

- D1.75** **Association of SCORAD Values with Skin Barrier Function Indicators in Patients with Atopic Dermatitis**
S. Seo (Seoul, Korea, Republic of)

12:00 - 13:00 TPS06 - Asthma 01

(Poster Zone, Thematic Poster Session)

Chair: **T. Chivato** (Alcorcon, Spain)

- D1.105** Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma
A. Alberto (porto, Portugal)

- D1.106** Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report
B. Hijazi (Riyadh, Saudi Arabia)

- D1.107** Real-world impact of mepolizumab in patients with severe asthma at a district hospital
E. J. Soto Hurtado (Vélez-Málaga, Spain)

- D1.108** Optimization of phenotyping in severe T2-bronchial asthma
V. Naumova (Ekaterinburg, Russia)

- D1.109** Biologics selection algorithm for severe T2-bronchial asthma targeted therapy
V. Naumova (Ekaterinburg, Russia)

- D1.110** Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients
P. Poza-Guedes (La Laguna, Spain)

- D1.111** Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study
K. C. Bergmann (Berlin, Germany)

- D1.112** ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study
J.-S. Shim (Seoul, Korea, Republic of)

- D1.113** Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study
G. Castro (Madrid, Spain)

- D1.114** Efficacy of Radical Endoscopic Surgery Combined with Mepolizumab in Chronic Rhinosinusitis with Nasal Polyps Complicated with Bronchial Asthma: A Real-World research
H. Zhong (Guangzhou, China), M. Yun (Guangzhou, China)

- D1.115** Real World Assessment of Uncontrolled Severe Asthma in Canada - A Multi-Site Qualitative Survey of Type 2 Inflammatory Biomarkers and Clinical Outcomes
J. K. Lee (Toronto, Canada)

- D1.119** Care pathways and systemic steroid (over)use in chronic rhinosinusitis with nasal polyps (CRSwNP) in Germany
A. Chaker (München, Germany)

- D1.120** Genetic Associations with Asthma in the Kazakh Population: A Case–Control Study
R. Bekmagambetova (Almaty, Kazakhstan)

- D1.121** Association of Serum Club Cell Secretory Protein 16 (CC16) with House Dust Mite Sensitization in Children with Asthma
T. Umanets (Kyiv, Ukraine)

- D1.122** Inspiratory and expiratory airway resistance and expiratory flow limitation in patients with asthma and in response to biological treatment in asthma
A. Nasr (Lund, Sweden)

12:00 - 13:00 TPS07 - Asthma 02

(Poster Zone, Thematic Poster Session)

Chair: **B. Kilic (Ankara, Türkiye), C. Zeyneloglu (Davos, Switzerland)**

- D1.123** Visualization of neutrophil extracellular traps (NETs) and autoantibodies targeting myeloperoxidase (MPO) and neutrophil elastase (NE) in sputum by confocal microscopy
S. Beyatli (London, United Kingdom)

- D1.124** Changes in respiratory infections patterns in Patients with Severe Asthma and a High burden of comorbidities treated with tezepelumab: interim analysis results of the T-ROSS II study
J. Dominguez-Ortega (Madrid, Spain)

- D1.125** Smartphone-Based Asthma Monitoring Using an Audio-Assisted Mouthpiece and STFT-VGG19 Deep Learning Model
I.-J. Wang (Taipei Hospital Ministry of Health and Welfare, Taiwan)

- D1.126** Therapeutic Splenic Ultrasound Insonation as a Modulator of Pro-atherogenic and Pro-asthmatic Immune Inflammation: A Preclinical Study Design
L. Petrenko (Kyiv, Ukraine)

- D1.127** Prevalence of Anxiety and Depression in Patients with Asthma: A Systematic Review and Meta-analysis Separating Screening Positivity from Clinical Diagnosis
K. Liu (Kun Ming Shi, China)

- D1.128** Use of Tezepelumab in four Patients with Allergic Bronchopulmonary Aspergillosis and severe uncontrolled Asthma: A Case Series
G. Poletti Jabbour (Madrid, Spain)

- D1.129** Transformative response to Tezepelumab in severe asthma with severe airflow limitation: a case study
G. Abdushukurova (Shymkent, Kazakhstan)

- D1.130** Immune markers after one year treatment with benralizumab in severe eosinophilic asthma
E. Kukarskytė (Kaunas, Lithuania)

- D1.131** Unconventional Group 2 Innate Lymphoid Cells Expressing C-Kit and IL-17A are Increased in Sputum from Severe Asthma with Mixed Granulocytic Airway Inflammation
R. Sehmi (Hamilton, Canada)

- D1.132** Novel CD8+CD122+ Regulatory T Cells Induced by B Cells Suppress T helper 2 Response and Attenuate Eosinophilic Infiltration in Allergic Asthma
J. N. Fan (Taipei, Taiwan)

- D1.133** The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases in China
T. Shi (Guangzhou, China)

- D1.134** Type 2 innate lymphoid cells promote development and differentiation of neonatal lung stem/progenitor activity
C.-C. Liao (Taipei, Taiwan)

12:00 - 13:00 TPS08 - Asthma 03

(Poster Zone, Thematic Poster Session)

Chair: C. M. Lloyd (London, United Kingdom), A. Ertugrul (Ankara, Türkiye)

- D1.138** Efficacy and Safety of Dupilumab Treatment for Adult Allergic Bronchopulmonary Aspergillosis: A Real-World Analysis of 16 Cases in China
X. Li (Ji Nan Shi, China)

- D1.139** Dupilumab was Effective in Black and Non-Black Patients with Asthma Completing 1 Year of the RAPID Registry
E. Heffler (Milano, Italy)

- D1.140** Beyond Severe Asthma: Eosinophilic Granulomatosis with Polyangiitis Unmasked by Acute Myopericarditis
M. A. Collado Arocha (Castellón de la Plana, Spain)

- D1.141** Added value of impulse oscillometry in the early detection of small airway dysfunction in asthma
S. Rink (Ljubljana, Slovenia)

- D1.142** Clinical remission in long-term biological therapy of severe asthma
K. Specjalski (Gdańsk, Poland)

- D1.143** Clinical Efficacy of Biologics and ATAD in NSAID-Exacerbated Respiratory Disease: A Phenotype-Based Comparative Study
M. Cihanbeylerden (Ankara, Türkiye)

- D1.144** Eosinophilic myocarditis as a complication of dupilumab treatment
A. Ruzinak Bobcakova (Martin, Slovakia), V. Spurna (Martin, Slovakia), P. Lecky (Martin, Slovakia), J. Krivus (Martin, Slovakia), M. Jesenak (Martin, Slovakia)

- D1.145** Clinical Impact of Type 2 Phenotype in Severe Asthma Patients with Exacerbations During Biologic Treatment
H. F. Avcı (İstanbul, Türkiye)

- D1.146** Improved nocturnal oxygenation in a severe allergic asthma patient with comorbid sleep apnea under anti-TSLP biologic therapy
S. Frent (Timișoara, Romania)

- D1.147** Efficacy of benralizumab in Chinese patients with severe eosinophilic asthma: subgroup analysis of the 16-week results from STEP, a phase IIIb study of step-down maintenance therapy
M. Zhang (Shanghai, China)

- D1.148** Real-world effectiveness of dupilumab administered every 4 weeks in patients with moderate to severe asthma
W. J. Lee (Yangsan, Korea, Republic of)

- D1.149** Healthcare Professionals Typically Apply Higher Blood Eosinophil Count Thresholds for Biologic Selection Versus Clinical Guidelines in Severe Asthma
P. Howarth (London, United Kingdom)

- D1.150** Patient characteristics and treatment patterns in adults with severe asthma in Poland (POLSAR): a retrospective, single-center real-world cohort from ISAR
E. Leszczyńska (Warszawa, Poland)

- D1.151** Changes in Treatment Steps After Biological Therapy in Patients with Severe Asthma: Real-World Data
N. Toker (İstanbul, Türkiye)

- D1.152** Treatment-induced remission after mepolizumab discontinuation: case series
O. Belik (Moscow, Russia)

- D1.153** Indirect Comparison of Biological Agents in Severe Asthma: Real-World Data
H. F. Avcı (İstanbul, Türkiye)

12:00 - 13:00 TPS09 - Asthma 04

(Poster Zone, Thematic Poster Session)

Chair: **M. Jesenak (Martin, Slovakia)**

- D1.154** Mepolizumab treatment in a patient with severe eosinophilic granulomatosis with polyangiitis: a case report
A. Brajdic Šćulac (Opatija, Croatia)

- D1.155** Clinical, Functional and Inflammatory Characteristics of Young Adults with Bronchial Asthma Using Conventional Cigarettes, Electronic Nicotine Delivery Systems and Heated Tobacco Products
N. Nenasheva (Moscow, Russia)

- D1.156** High relevance of upper airways comorbidities in T2 asthma inflammatory burden
J. A. Castillo (Barcelona, Spain)

- D1.157** Response to biologic therapy in severe asthma and chronic rhinosinusitis with nasal polyps according to nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity
D. Ochab (Chęciny, Poland)

- D1.158** Clinical and Functional Outcomes of Biological Therapy Switching in Severe Asthma: A Real-Life Retrospective Study
Y. Bozkurt (ISTANBUL, Türkiye)

- D1.159** Comorbidity of Asthma in Chronic Spontaneous Urticaria: Prevalence and Immunological Insights from a Sri Lankan Cohort
U. Amarasekara (Colombo, Sri Lanka)

- D1.160** Perceptions, Attitudes, and Real-World Use of FENO in Allergy and Asthma Practice: Results of a National Survey from Türkiye
B. Ozdel Ozturk (Ankara, Türkiye)

- D1.161** Clinical-epidemiological profile of pediatric difficult-to-control asthma in a tertiary referral center in Brazil
S. Regina Abu Jamra (Ribeirao Preto, Brazil)

- D1.164** Evaluation of the use of cyclooxygenase-2 inhibitors in patients with AERD
A. Sato (São Paulo, Brazil)

- D1.165** Asthma Predisposition and miRNA Expression in Children with Recurrent Infections
I. Karahan (Gaziantep, Türkiye)

- D1.166** REX-8756 is a First-in-Class Potent and Selective Orthosteric STAT6 Inhibitor That Demonstrates Efficacious Potential and Safety Differentiation in TH2-Mediated Inflammation
P. Metz (San Diego, United States of America)

- D1.167** Galectin-3 and Airway Remodelling: Diagnostic and Prognostic Implications in Children
P. Shahid (Sofia, Bulgaria)

- D1.168** Association Between Molecular Allergen Sensitization And Feno In Children With Allergic Asthma
M. Kryvopustova (Kyiv, Ukraine)

- D1.169** Monitoring of pulmonary function in pregnant women with severe asthma controlled in a monographic asthma and pregnancy unit
K. Baynova (Seville, Spain)

- D1.170** Direct Cost of Occupational Asthma in the Textile industry: Evidence from the private sector in central Tunisia
C. Sridi (Sousse, Tunisia)

12:00 - 13:00 TPS10 - Allergen immunotherapy 01 (Poster Zone, Thematic Poster Session)

Chair: J. Chauhan (London, United Kingdom)

- D1.180** Allergen-Specific mRNA Vaccination Induces Immune Regulation and Suppresses Allergic Airway Inflammation in a mouse model
J. Li (Beijing, China)

- D1.186** Three years treatment with HDM injection allergen immunotherapy, omalizumab, or combination therapy in allergic asthma
A. Bozek (Katowice, Poland)

- D1.187** A Novel Volume-Reduced Desensitization Protocol for Pembrolizumab Hypersensitivity in Advanced Lung Cancer
Y.-H. Li (Taichung, Taiwan)

- D1.188** Adverse Reactions During Honey Bee Venom Immunotherapy as an Indicator of Underlying Clonal Mast Cell Disease Independent of Baseline Serum Trypsin: A Case Report
A. Csuth (Linköping, Sweden)

- D1.189** Does Allergen Immunotherapy Add Clinically Meaningful Benefit in Paediatric Asthma and Allergic Rhinitis? A 36-Month Real-World Comparison
J. Prieto (Ciudad de México, Mexico)

- D1.190** Mitochondrial Augmentation Reprograms T Cell Metabolism to Enhance Adoptive T Cell Therapy
I. PARK (Seoul, Korea, Republic of)

- D1.191** Respiratory bacterial lysate (OM-85)-loaded dissolving microneedle array patch modulates HDM-induced allergic airway inflammation and airway hyperresponsiveness in a murine asthma model
T.-E. Guon (Seoul, Korea, Republic of)

- D1.192** Combined Polymerized Pollen and Animal Dander Immunotherapy Improves Rhinoconjunctivitis and Asthma in Polysensitized Patients: Real-World Evidence
C. Campagner (Madrid, Spain)

- D1.193** Oral Immunotherapy for food allergy through a personalised approach
A. Moracho Pascual (Leganés, Spain)

- D1.194** Real-World Effectiveness of Polymerized Dog Allergen Immunotherapy in Allergic Rhinoconjunctivitis and Asthma
C. Campagner (Madrid, Spain)

- D1.195** Fc-Engagers as a targeted approach for antigen-specific immune inhibition in HDM allergy
A. Vogel (Vienna, Austria)

- D1.196** Does age influence the effectiveness of allergen immunotherapy in asthma? Insights from multigenerational case series
Z. Mirzabekova (Shymkent, Kazakhstan)

- D1.197** Safety and efficacy of a modified one-day ultra-rush protocol for the induction of Hymenoptera venom immunotherapy in patients with anaphylaxis in Switzerland
J. Jin (Basel, Switzerland)

- D1.198** Efficacy of Cat Allergen Immunotherapy: A Multicenter Prospective Study
A. Bostanoğlu Karaçin (Ankara, Türkiye)

- D1.199** Severe vernal keratoconjunctivitis with allergic rhinitis treated with house dust mite (HDM) sublingual immunotherapy (SLIT)
M. Ahmed (Hyderabad, India)

12:00 - 13:00 TPS11 - Allergen immunotherapy 02 (Poster Zone, Thematic Poster Session)

Chair: **B. Bohle (Vienna, Austria), D. Antolin-Amerigo (Madrid, Spain)**

- D1.200 Allergenicity of profilin isoallergens from Korean melon**
K. Y. Jeong (Seoul, Korea, Republic of)

- D1.201 Safety and Effectiveness of Subcutaneous Immunotherapy with Non-Homologous Aeroallergen Mixtures: A Real-World Study**
A. C. Coelho (Vila Nova de Gaia, Portugal)

- D1.202 Comparison of 2 different medication scores for the calculation of the Combined Symptom and Medication Score – EAACI versus paediatric medication in Germany**
E. Raskopf (Köln, Germany)

- D1.203 Prospective study to investigate the symptom profile and medication consumption of patients with seasonal allergic rhinitis/rhinoconjunctivitis who are interested in allergen-specific immunotherapy**
S. Allekotte (Cologne, Germany)

- D1.204 Type I Hypersensitivity Among Private Dental Practitioners: Clinical Manifestations and Associated Factors**
I. Kacem (Sousse, Tunisia)

- D1.205 Immunological characterization of recombinant Sal k 1 produced in Nicotiana benthamiana and potential immunomodulatory role of HSP90 in Salsola kali allergy**
G. Gutiérrez-Díaz (Madrid, Spain)

- D1.206 Local allergic rhinitis to birch pollen: a case of transient IgE+ plasmablast detection and successful sublingual immunotherapy**
O. Elisyutina (Moscow, Russia)

- D1.207 Molecular Patterns and Age-Related Evolution of Pollen Sensitization in Children**
A. Kazancioglu (Ankara, Türkiye)

- D1.208 Monocentric retrospective study of asthma prevalence among patients allergic to birch and grass pollens at Strasbourg University Hospital**
A. Rancy (Strasbourg, France)

- D1.209 Study of Efficacy of Rush Sub Lingual Immunotherapy in Cases of Severe Persistent Allergic Rhinitis**
S. Jain (INDORE, India)

- D1.213 Staphylococcus aureus enterotoxins in allergic rhinitis: impact on disease severity and molecular sensitization profile**
I. Kalikina (Kyiv, Ukraine), A. Bogomolov (Vinnytsia, Ukraine)

- D1.214 Analysis of the time to achieve a maintenance dose of tree pollen allergen in specific immunotherapy of allergic rhinitis**
B. Prnjavorac (Tešanj, Bosnia and Herzegovina)

- D1.215 Safety of subcutaneous immunotherapy with purified native protein Alt a 1, a major allergen of Alternaria alternata: 7-year real-world data**
B. López-Cauce (Leganés, Spain)

- D1.216 AIT prescription drivers: a factor analysis of data from the CHOICE survey**
D. Caimmi (Montpellier, France)

- D1.217 Reduction in healthcare resource utilization in pediatric patients treated with 300 IR liquid SLIT: a real-world subanalysis from Spain and Italy**
R. González Pérez (Santa Cruz de Tenerife, Spain),

12:00 - 13:00 TPS12 - Dermatology 01

(Poster Zone, Thematic Poster Session)

Chair: E. Kocatürk (Berlin, Germany), E. Damadoğlu (Ankara, Türkiye)

- D1.235** Real-world analysis for long-term treatment of abrocitinib in Chinese patients with atopic dermatitis: a single-centre prospective study
C. Gu (Shanghai, China)

- D1.236** The role of tissue resident memory cells in immunodermatological disorders: A Systematic Review
A. De (Kolkata, India)

- D1.237** Mental Health and Neurodevelopmental Comorbidities in Pediatric Atopic Dermatitis: A Retrospective Study and Literature-Based Perspective
M. Niegowska (Barcelona, Spain)

- D1.238** Natural history of early onset atopic dermatitis and risk factors for persistency using Korean National Health Service data
M. Kim (Sejong, Korea, Republic of)

- D1.239** Are Maternal Epidermal Lipid Profiles Associated with Atopic Dermatitis Development in Early Childhood?
J. Kim (Seoul, Korea, Republic of)

- D1.240** ATH-409, a selective and covalent ITK inhibitor, protects against atopic dermatitis in preclinical models
F. Zhou (Shanghai, China)

- D1.241** Clinical and Immunological Phenotypes of Alopecia Areata in Children with Atopic Dermatitis
R. Khanferyan (Moscow, Russia)

- D1.242** Early-Life Dietary Diversity and the Risk of Atopic Dermatitis: A Nationwide Population-Based Cohort Study
J. H. Kim (Seoul, Korea, Republic of)

- D1.244** Clinical heterogeneity of pediatric atopic dermatitis: latent class analysis
K. Dumycz (Warsaw, Poland)

- D1.245** The role of advanced glycation end products as facilitating factors in the pathogenesis of atopic dermatitis in pediatric patients
E. Caldaria (Naples, Italy)

- D1.246** Characterization of Unmet Need for Targeted Precision Medication in Atopic Dermatitis Due to Inadequate Response or Adverse Reactions to Dupilumab
L. Loop (San Diego, United States of America)

- D1.247** Changes in the sensitization profile in allergic contact dermatitis: comparison between two populations separated by 10 years in a secondary hospital in northern Portugal
C. Macedo (Creixomil, Portugal)

- D1.248** Intersection of Autoimmune Mechanisms: Coexistence of Celiac Disease and Chronic Urticaria
G. Bedir Keser (Kırıkkale, Türkiye)

12:00 - 13:00 TPS13 - Dermatology 02

(Poster Zone, Thematic Poster Session)

Chair: **C. Traidl-Hoffmann** (Augsburg, Germany), **M. Cancian** (Padova, Italy)

- D1.249** Assessing Quality of Life in Patients with Chronic Urticaria: Impact and Measurement Tools
N. Teovska Mitrevska (Skopje, North Macedonia)

- D1.250** Real-World Effectiveness and Safety of Icatibant for Hereditary Angioedema in China: An Interim Analysis of the EASTERN Study
R. Zhu (Wuhan, China)

- D1.251** High Cost of Stigma: Anticipated Workplace Stigma Drives Absenteeism while Healthcare Stigma Provokes Anxiety in HAE
K. Kırdök (İzmir, Türkiye)

- D1.253** Probiotic Co-administration to Improve Gastrointestinal Tolerability of Berotralstat in Hereditary Angioedema: a multicenter case series from the ITACA network
M. D. Guarino (Civitanova Marche, Italy)

- D1.254** Comparison Between Classical and Updated Classifications in Patients Diagnosed with Isolated Angioedema: Finally, Did We Find the Ideal One?
E. Sahinoglu (Ankara, Türkiye)

- D1.255** Is it Angioedema? Unmasking a complete Melkersson-Rosenthal Syndrome
R. Geraldes (Coimbra, Portugal)

- D1.256** Chronic Inducible Urticaria in Real Life: A Single-Centre Retrospective Cohort
A. K. Erdol (Ankara, Türkiye)

- D1.257** Hereditary Angioedema in Bulgaria (1972-2025): A Longitudinal Comparative Study of Trends in Diagnosis, Mortality, and the Impact of Modern Therapies
F. Maksudov (Sofia, Bulgaria)

- D1.258** First real-life experiences with Sebetrastat as oral on-demand treatment for acute HAE attacks documented in a global angioedema disease registry
K. Schön (Berlin, Germany)

- D1.259** Icatibant Use During Pregnancy: A South African Case Series
C. Day (Cape Town, South Africa)

- D1.260** Clinical Characteristics and Hospitalization Patterns in Chronic Spontaneous Urticaria Patients in Bulgaria
E. Petkova (Sofia, Bulgaria)

- D1.261** Phenotypic and Immunological Profiles of Chronic Urticaria: A Cross- Sectional Study From South India
S. Begum (Thiruvananthapuram, India)

12:00 - 13:00 TPS14 - Food allergy 01

(Poster Zone, Thematic Poster Session)

Chair: **G. Kocatepe (Aksaray, Türkiye)**

- D1.264** A Case of Chronic Food Protein-Induced Enterocolitis Syndrome triggered by Egg Yolk via Breast Milk
Y. Inoue (Chiba, Japan)

- D1.265** Predicting Milk Ladder Outcomes for Management of IgE-Mediated Cow's Milk Protein Allergy: Feature Selection Using Machine Learning Methods
C. Cronin (Cork, Ireland)

- D1.266** Phenotypes of IgE-mediated Cow's Milk Protein Allergy in an Irish Cohort Using Latent Class Analysis
C. Cronin (Cork, Ireland)

- D1.267** Clinical Features and Dairy Triggers for Cow's Milk Allergy among 342 Chinese Children in a University-affiliated Allergy Clinic in Hong Kong
T. F. Leung (Shatin, Hong Kong)

- D1.268** Advancing Paediatric Egg Allergy Management via Telemedicine: Outcomes of Remote Egg Ladder Support
C. Cronin (Cork, Ireland)

- D1.269** Methemoglobinemia as a Key Diagnostic Clue for Acute FPIES in an Infant: A Case Report
J. Martínez Olmos (Cartagena, Spain)

- D1.270** Irish Infant Allergy and Nutrition: A Content Analysis of Public-Facing Online Guidance
L. Mack (Cork, Ireland)

- D1.271** Parental Vaccine Hesitancy And Immunization Practices In Children With Food Allergy
E. şenbaykal yiğit (Izmir, Türkiye)

- D1.272** Improving Culinary Medicine and Food Allergy Knowledge Through a STEM-Integrated Medical-Student-Led Cooking Program for Youth in New Orleans
M. Yang (Evanston, United States of America)

- D1.273** Burden of food allergy on daily life and emotions in children and parents: Insights from the IPAA French Cohort
C. Billard-Larue (Meaux, France), F. Amat (Paris, France)

- D1.274** Evaluating adherence to and effectiveness of food allergy advice in parents of infants under 6 months old suffering from atopic dermatitis
C. Billard-Larue (Meaux, France)

- D1.275** Pollen-Food Allergy Syndrome among Final-Year Primary School Students in the City of Olsztyn and Olsztyn County, Poland: A Questionnaire-Based Cross-Sectional Study
A. Marzec (Olsztyn, Poland)

- D1.276** Lyell's Syndrome: Response to Measles Vaccination
E. Stezhkina (Ryazan', Russia)

- D1.277** Selective goat's and sheep's milk anaphylaxis: Advocacy for mandatory food labeling of milk origins
C. Chatain (Grenoble, France)

12:00 - 13:00 TPS15 - Food allergy 02

(Poster Zone, Thematic Poster Session)

Chair: **A. Fiocchi (Roma, Italy)**

- D1.278 Dragon fruit Allergy: A Case of Cross-Reactivity and Dietary Risks**
M. A. Lopez-Matas (Tres Cantos, Spain)

- D1.279 Oral Immune Tolerance Induction Therapy with IFN-gamma in children with rice allergy**
M. Sung (GUMI, Korea, Republic of)

- D1.280 Microbiome Signatures Associated with Food Allergy Resolution in Children**
Y. H. Kim (Seoul, Korea, Republic of)

- D1.281 Development of a Peanut-Specific Human Mast Cell Assay for Screening Probiotics and other Nutritional Components with Anti-Allergic Potential**
A. Breedveld (Utrecht, Netherlands)

- D1.282 Chronically damaged intestinal epithelial cells create a pro-allergenic environment in the gut**
J. Parrón Ballesteros (Madrid, Spain)

- D1.283 Endolysosomal degradation of major peanut allergens revealed distinct degradation kinetics and T cell epitope regions**
E. Öztemiz (Salzburg, Austria)

- D1.284 Eosinophilic Esophagitis Before and After Milk Oral Immunotherapy in Children with Food Allergy: A Case Series Including the Eosinophil-to-Lymphocyte Ratio**
G. Kocatepe (Antalya, Türkiye)

- D1.285 Novel food supplement containing a combination of postbiotics and plant-derived compounds regulates epithelial barrier integrity and immune response in human enterocytes**
A. Cadavere (Napoli, Italy)

- D1.286 Allergenic Protein Profiling in a Patient with Long-standing Nut-Induced Anaphylaxis**
A. E. Fernandez Fernandez (Alcalá de Henares, Spain)

- D1.287 Polysensitization to Seed Storage Proteins, LTPs and Profilin in a Patient With Anaphylaxis After Consumption of Pesto Sauce**
A. E. Fernandez Fernandez (Alcalá de Henares, Spain)

12:00 - 13:00 TPS16 - Anaphylaxis 01

(Poster Zone, Thematic Poster Session)

Chair: I. Topalusic (Croatia, Croatia)

- D1.289** The buzz that nearly broke a heart: A case of Kounis Syndrome following a Hymenoptera sting
S. Tacu (Cluj-Napoca, Romania)

- D1.290** Identification of a Cheese-Derived κ -Casein Fragment as the Trigger of Anaphylaxis in a Patient with Suspected Pasta Allergy
E. Abel-Fernandez (Alcalá de Henares, Spain)

- D1.291** Real-world data of nasal adrenaline spray in anaphylaxis: Review of clinical evidence
A. Anagnostou (Houston, United States of America)

- D1.292** Anaphylaxis After Roasted Sunflower Seed Consumption in an Adult: A Case Report
Ö. ARGİN (Istanbul, Türkiye)

- D1.293** Hidden allergens revealed by prick-to-prick testing: anaphylaxis triggered by black pepper and cumin
Ö. ARGİN (Istanbul, Türkiye)

- D1.294** Comparative Analysis of Anaphylaxis Epidemiology in Georgia (2018–2024)
G. Shengelidze (Tbilisi, Georgia)

- D1.295** Patient Perceived Lifestyle Burden with a Nasal Adrenaline Spray vs an Adrenaline Auto-Injector
D. Mack (Hamilton, Canada)

- D1.296** Nasal Adrenaline Spray vs Adrenaline Auto-Injectors: When Will People Act?
D. Mack (Hamilton, Canada)

- D1.297** Clinical characteristics of red meat allergy in 19 cases in Jeju
J. Lee (Jeju, Korea, Republic of)

- D1.298** Does Previous Anaphylaxis Determine Differences between Patients Undergoing Oral Food Challenges to Cow's Milk and Hen's Egg?
U. Jedynak-Wąsowicz (Kraków, Poland)

- D1.299** Lychee-Induced Anaphylaxis: Data from the French Allergy-Vigilance Network since 2002
A. Piotin (Strasbourg, France)

- D1.300** Safety of Mesh Hernioplasty in a Patient with Combined Beta-Lactam and Aminoglycoside Allergy: A Perioperative Prophylaxis Challenge
P. Vidović (Foča, Bosnia and Herzegovina)

- D1.301** Non-specific lipid transfer protein allergy: the culprit in disguise
R. Sá Teixeira (Vila Nova de Gaia, Portugal)

- D1.302** Allergic Reactions Following Measles-Mumps-Rubella Vaccination in Children with Food Allergy: A Single Center Experience
G. I. Parlak Ozel (Ankara, Türkiye)

12:00 - 13:00 TPS17 - Anaphylaxis 02

(Poster Zone, Thematic Poster Session)

Chair: **T. Dribin (Cincinnati, United States of America)**

- D1.303** **Olipudase Alfa Allergy in Niemann-Pick Disease: Omalizumab-Aided Desensitization and Immune Response Dynamics**
F. Spataro (Bari, Italy)

- D1.304** **Exercise-induced anaphylaxis misdiagnosed as cholinergic urticaria in a child: a case report**
D. Yartseva (Zaporizhzhia, Ukraine)

- D1.305** **Patterns and Clinical Spectrum of Chronic Urticaria in Patients Attending a Dermatology Clinic**
V. Paudel (Lalitpur, Nepal)

- D1.306** **Cold-induced urticaria: Phenotypic characterization and risk factors for cold-induced anaphylaxis**
T. Correias Del Prado (San Sebastián de los Reyes, Spain)

- D1.307** **Lipid metabolic remodeling in Food-induced anaphylaxis revealed by integrated proteomic and lipidomic analyses**
S. Fernandez-Bravo (Madrid, Spain)

- D1.308** **Severe Chronic Spontaneous Urticaria with Recurrent Anaphylaxis and Extreme IgE Elevation Associated with Innate Immune Dysregulation**
T. Almalki (Riyadh, Saudi Arabia)

- D1.309** **The complexity of basal serum tryptase levels: Genotyping tryptase genes is not enough**
I. Dávila (Salamanca, Spain)

- D1.313** **Clinical Characteristics of Chronic Urticaria Patients With and Without Flares With Systemic Symptoms**
A. Pehlivanlar Ustaoglu (Ankara, Türkiye)

- D1.314** **Endothelial glycocalyx shedding in IgE- and IgG-mediated anaphylaxis**
L. Palacio-Garcia (Madrid, Spain)

- D1.315** **IgE antibody function and mast cell activation to egg in children undergoing baked and loosely cooked egg challenges**
V. Claro (London, United Kingdom)

- D1.316** **Identification of lipid classes to differentiate anaphylactic from non-anaphylactic allergic reactions. BANA study**
I. de María Camacho (Madrid, Spain)

- D1.317** **Systemic inflammatory indices in relation to anaphylaxis symptoms in adults with food allergy**
J. Wąsik (Łódź, Poland)

- D1.318** **Successful desensitization in a child with life-threatening reaction to basiliximab retreatment**
F. Carfora (Rome, Italy)

- D1.319** **Efficacy of Omalizumab in Refractory Cholinergic Urticaria and Cholinergic Anaphylaxis: A Case Series**
P. Letón-Cabanillas (Valladolid, Spain)

- D1.320** **IgE-mediated Perioperative Anaphylaxis to Latex with Concomitant Local Anesthetic Hypersensitivity in a Mexican Teenager: a Policy-Changing Case Report**
L. M. Espinosa Méndez (Ciudad de México, Mexico)

12:00 - 13:00 TPS18 - Immune deficiencies and autoimmunity 01

(Poster Zone, Thematic Poster Session)

Chair: **T. Jakjovska** (Skopje, North Macedonia)

- D1.322** Clinical Cardiovascular Safety Assessment of Oral Deucricitibant
A. Lesage (Schilde, Belgium)

- D1.323** Assessing Immune Responses to Conjugate Pneumococcal Vaccination in Infants with Transient and Unclassified Hypogammaglobulinemia: Insights from a Tertiary Pediatric Center
G. Öztürk (Ankara, Türkiye)

- D1.324** JAK Inhibitors in the Treatment of Chronic Mucocutaneous Candidiasis in a Patient with STAT1 Gain-of-Function Mutation
M. Moosavian (Tehran, Iran, Islamic Republic of)

- D1.325** Neurological Findings May Be Initial Presenting Symptom in Children with Inborn Errors of Immunity
D. Tekcan (Konya, Türkiye)

- D1.326** Behind The Scenes: Primary Immunodeficiencies in Pediatric Eosinophilic Gastrointestinal Diseases
A. K. Baskin (Ankara, Türkiye)

- D1.327** Genetic Analysis of Children with Suspected Immunodeficiency: Mimickers of Inborn Errors of Immunity
S. Y. Yilmaz (Konya, Türkiye)

- D1.328** CARD11 Dominant-Negative Mutation Presenting with Early Severe Bacterial Sepsis, Viral Susceptibility, and Alopecia Totalis in a Child
N. Alrajaan (Dublin, Ireland)

- D1.329** Late-Childhood Diagnosis of DNA Methyltransferase 3B Deficiency-ICF1 Syndrome
S. Y. Yilmaz (Konya, Türkiye)

- D1.330** Two different clinical presentations, two same immunological features in Purin nucleoside phosphorilase deficiency
M. Kurtuluş (Konya, Türkiye)

- D1.331** Analysis of early complement parameters and C1INH values in newborns with a positive family history of HAE-C1INH
L. Voloncs-Mindszenty (Budapest, Hungary)

- D1.332** Hepatic Findings in Patients Diagnosed with Combined Immunodeficiency
B. Koçali (Ankara, Türkiye)

- D1.333** Digital clinical registry pilot for hereditary angioedema: standardized monthly real-world monitoring of C1 inhibitor deficiency in Serbia
D. Marković (Niš, Serbia)

- D1.334** Association of Multiple Endocrinopathies with Immune Dysregulation, Allergies and Primary Immunodeficiency
S. Altiner (Ankara, Türkiye)

12:00 - 13:00 TPS20 - Drug Allergy 01

(Poster Zone, Thematic Poster Session)

Chair: **V. Sabato (Antwerp, Belgium), L. de las Vecillas Sanchez (Madrid, Spain)**

- D1.365** Long-term course of NSAID tolerance in patients with cross-hypersensitivity presenting with respiratory symptoms
B. Moya (Málaga, Spain)

- D1.367** Risk factors for immediate hypersensitivity reactions to rituximab
W. Piriyaanguanpong (Bangkok, Thailand), W. Laisuan (Bangkok, Thailand)

- D1.368** Clinical Characteristics and Management of Severe Cutaneous Adverse Reactions in Pediatric Patients
M. Aydın (İstanbul, Türkiye)

- D1.369** Immediate hypersensitivity to dostarlimab successfully managed with desensitization
S. Albarracín-Prados (Las Palmas de Gran Canaria, Spain)

- D1.370** Desensitisation to low-dose acetylsalicylic acid in NERD. Clinical follow-up of aspirin therapy after desensitisation (ATAD)
G. Cortellini (Rimini, Italy)

- D1.371** Nonsteroidal anti-inflammatory drug-induced acute urticaria/angioedema: antioxidant enzymes activities and associated genetic variants
J. Triano-Cornejo (Málaga, Spain)

- D1.372** Transition to SCIG as an Alternative in Patients with Cytokine Storm from IVIG
A. Marino Fernandez (Las Palmas de Gran Canaria, Spain)

- D1.373** Hypersensitivity to Biologic Therapies: Mechanism of Cross-reactivity
M.-J. Sanchez-Gonzalez (Alcalá de Henares (Madrid)

- D1.374** Genetic susceptibility to radiocontrast media-induced anaphylaxis: A microarray gene chip study in a Korean population
Y.-S. Chang (Seongnam-si, Korea, Republic of)

- D1.375** Retrospective Analysis of Perioperative Hypersensitivity Reactions: Single-Center Experience
E. Ülgen (İzmir, Türkiye)

- D1.376** Successful Desensitization with Temozolomide in a Patient with a Hypersensitivity Reaction to Temozolomide
E. Sahinoglu (Ankara, Türkiye)

- D1.377** Folic Acid Allergy: A Rare Case
F. Kapsouli (Athens, Greece)

- D1.378** Hypersensitivity During Continuous 5-Fluorouracil Infusion: Two Cases Successfully Managed With Desensitization
A. K. Erdol (Ankara, Türkiye)

12:00 - 13:00 TPS21 - Drug Allergy 02

(Poster Zone, Thematic Poster Session)

Chair: J. J. Laguna Martinez (Madrid, Spain)

- D1.379** Six-year data evaluating the results of skin tests and provocation tests with quinolones in patients with a history of quinolone allergy
K. Aksu (Ankara, Türkiye)

- D1.380** Hypersensitivity reactions with proton pump inhibitors: five years of clinical experience
K. Aksu (Ankara, Türkiye)

- D1.381** Antibiotic Allergy De-labelling in Children: Outcomes of Drug Provocation Testing and Feasibility of Non-Specialist Pathways to de-labelling
N. Rao (Manchester, United Kingdom)

- D1.382** Vitamin K-Induced Anaphylaxis: A Case Series from a Tertiary Hospital in Manila, Philippines (2024–2025)
M. A. Anzures-Custodio (Manila, Philippines)

- D1.383** Tolerance to alternative β -lactams in patients with severe delayed skin reactions: experience in a university hospital
E.-E. Muñoz-Díaz (Salamanca, Spain)

- D1.384** Safe Sulfonamide Delabeling in HIV-Negative Adults: Real-World Evidence with TMP-SMX Oral Challenge and SULF-FAST
M. Hormet Igde (Istanbul, Türkiye)

- D1.385** Lamotrigine-induced Stevens-Johnson syndrome in a pediatric patient with Takayasu arteritis: the steroid paradox
Y. Dytyatkovska (Dnipro, Ukraine)

- D1.386** Adverse infusion reactions to biologicals in the treatment of inflammatory bowel diseases
S. Colantuono (Rome, Italy)

- D1.387** Long-term Follow-up Outcomes of Patients Undergoing Desensitization for Non-Immediate Hypersensitivity Reactions Associated with Lenalidomide
N. Kahveci (Istanbul, Türkiye)

- D1.388** Aspirin maintenance after boost with dupilumab in aspirin-exacerbated respiratory disease
T. Popov (Sofia, Bulgaria)

- D1.389** Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis Due to Allopurinol With Subsequent Sensitization to Brentuximab: A Case Report
M. Fernandez Izquierdo (Madrid, Spain)

- D1.390** Hypersensitivity Reactions to Biological Agents in a Tertiary Hospital: A 3.5-Year Retrospective Study
P. S. Figueiredo (Lisboa, Portugal)

- D1.391** Pharmacist-led Risk-based β -Lactam Challenges in Patients with Penicillin Allergy: Impact on Antibiotic Days
N. A. Allameen (Singapore, Singapore)

- D1.392** Drug-Induced Hypersensitivity Syndrome Associated with β -Lactams and Hemophagocytic Lymphohistiocytosis: Overlapping Disorders or a Causal Relationship?
J. Román Sanabria (Toledo, Spain)

- D1.393** Safety of Aspirin Oral Provocation in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
A. Ventosa (Córdoba, Spain)

12:00 - 13:00 TPS22 - Basic immunology 01

(Poster Zone, Thematic Poster Session)

Chair: J. Asllani (Tirana, Albania), J. López-Rodríguez (Alcorcón, Spain)

- D1.404** Live Renal Transplantation Outcome in Egyptian Cohort: A Single Center Study
A. Elmazaly (Cairo, Egypt)

- D1.405** Establishment of a Mouse Nasal Epithelial Cell Air–Liquid Interface Culture System and Its Application in Mucosal Barrier Research
S. Xie (Changsha, China)

- D1.406** Immune Dysregulation and Autoinflammation in IL-10RA-Deficient VEO-IBD: Resolution via Cord Blood Transplantation
A. Ha (Hanoi, Vietnam)

- D1.407** Real-world patient characterization, prior long-term prophylactic prescribing patterns, and treatment outcomes for adults on berotralstat with hereditary angioedema in Japan
M. Hide (Hiroshima, Japan)

- D1.408** Linoleic Acid Regulates Fatty Acid Metabolism to Mediate Eosinophilic Inflammation in Nasal Polyps
J. Lie (Guangzhou, China)

- D1.409** Regulation of the intestinal epithelial barrier by the endocannabinoid system
A. Maldonado (Madrid, Spain)

- D1.413** A Novel Variant of CORO1A Gene Contributing to The Development of Primary Immunodeficiency in Children
Y. Alayed (Riyadh, Saudi Arabia)

- D1.414** The Clinical Course in a normal C1-Inhibitor Hereditary Angioedema family with Factor XII mutation
T. Kinacian (Vienna, Austria)

- D1.415** Regulatory T-Cell Deficiency and NF-κB/IL-1β Activation in Dilated Cardiomyopathy
H. Koval (Chernivtsi, Ukraine)

- D1.416** Regulatory T Cells Induced by B cells Decreased Osteoclast Activity and Alleviated Disease Severity of Collagen Antibody Induced Arthritis
Y.-T. Wu (Taipei, Taiwan)

- D1.417** Reproductive outcome after postpartum lymphocytic hypophysitis: a case of successful natural twin pregnancy
Y. MIZUGUCHI (Shinjuku City, Japan)

- D1.418** An EBP Gene Variant in a Child with Immunodeficiency: A Case from the Chondrodysplasia Pontata Spectrum
K. ÇEVİK TOKMAK (sakarya, Türkiye)

- D1.419** The management of Immunological Diseases in Internal Medicine Departments
M. Bova (Napoli, Italy)

- D1.420** Lymphoma in CVID: on the edge between immune dysregulation and malignancy
M. Franco (Treviso, Italy)

12:00 - 13:00 TPS23 - Biologicals 01

(Poster Zone, Thematic Poster Session)

Chair: **A. Vultaggio** (Florence, Italy), **R. Gore** (Cambridge, United Kingdom)

- D1.437** A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
S. Aktaş (konya, Türkiye)

- D1.438** Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
S. Foti Randazzese (Pavia, Italy)

- D1.439** Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)
N. Chapman-Rothe (Basel, Switzerland), P. Saraswat (Hyderabad, India)

- D1.440** “Looking Twice in Atopic Dermatitis Therapy: Pruritus Is Not Always the Same, and Eczema Is Not Always Atopic Dermatitis”
S. Isik (Göttingen, Germany)

- D1.441** A Bispecific Antibody Targeting IL13 and IL31 for the Treatment of Inflammatory Skin Diseases
Z. Zhu (Wilmington, United States of America)

- D1.442** Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
Z. Zhu (Wilmington, United States of America)

- D1.443** Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
Z. Zhu (Wilmington, United States of America)

- D1.444** Dual Blockade of IL22 and IL23 with a bispecific antibody: A Promising Strategy for the Treatment of Psoriasis and Other Autoimmune Skin Disorders
Z. Zhu (Wilmington, DE)

- D1.445** Baricitinib in Refractory Cholinergic Urticaria with Generalized Eczematous Involvement: A Case Report
M. Sola Fernández (València, Spain)

- D1.446** Lebrikizumab in patients with urticarial vasculitis - a case series
H. Bonnekoh (Berlin, Germany)

- D1.447** Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
B. S. Akyol (Aydın, Türkiye)

- D1.448** Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
B. Geng (San Diego, United States of America)

- D1.449** A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
M. Metz (Berlin, Germany)

12:00 - 13:00 TPS24 - Pediatrics 01

(Poster Zone, Thematic Poster Session)

Chair: **S. Arasi** (Rome, Italy), **C. Flohr** (London, United Kingdom)

- D1.466** Atopic dermatitis increases the risk of chronic systemic diseases in children and adolescents: a nationwide nested case-control study
S. Shin (Seoul, Korea, Republic of)

- D1.467** Economic Burden of Allergic Diseases in Children: Global Evidence and Implications for Kyrgyzstan
M. KOSHUKKEVA (Bishkek, Kyrgyzstan)

- D1.468** Association Between Autism Spectrum Disorder and Skin Barrier Integrity
C. Bülbüloğlu (Istanbul, Türkiye)

- D1.469** Long-term Cardiometabolic Outcomes Associated With Atopic Dermatitis in Childhood and Adolescence: Obesity, Hypertension, and Cardiovascular Risk in Early Adulthood
M. Y. Han (Seoul, South Korea, Korea, Republic of)

- D1.470** Comparison of long-term (52 week therapy) maintenance vs. as-needed intranasal corticosteroid therapy in pediatric allergic rhinitis: assessment using exhaled breath condensate leukotriene E4
Y. M. Park (Seoul, Korea, Republic of)

- D1.471** From Grandmother to Granddaughter: A Case Report of Hereditary Angioedema Diagnosed in the Third Generation
Z. Kalikyan (Yerevan, Armenia)

- D1.472** Features of the intestinal microbiota composition in infants with allergy: comparison of two diagnostic
L. Namazova-Baranova (Moscow, Russia)

- D1.473** Features of the intestinal microbiota composition in infants with IgE- and non-IgE-mediated allergy
L. Namazova-Baranova (Moscow, Russia)

- D1.475** Significance of air-trapping and pulmonary hyperinflation in the severity of broncho-obstructive manifestations in children with cystic fibrosis
S. Sciuca (Chisinau, Moldova)

- D1.476** Impact of neonatal vaccination on the incidence of atopic dermatitis in children by 36 months: a prospective cohort study
L. Namazova-Baranova (Moscow, Russia)

- D1.477** Zonulin levels and allergen sensitization in paediatric patients with chronic rhinitis
T. Mustakov (Sofia, Bulgaria)

- D1.478** Hyper-IgE in allergic bronchopulmonary aspergillosis: diagnostic challenges
S. Sciuca (Chişinău, Moldova)

- D1.479** Lung function in children with cystic fibrosis associated with wheezing
S. Sciuca (Chişinău, Moldova)

- D1.480** Polysomnographic phenotypes of sleep-disordered breathing in children with asthma: a systematic review
E. Wasilewska (Gdańsk, Poland)

12:00 - 13:00 TPS25 - ENT 01

(Poster Zone, Thematic Poster Session)

Chair: **N. Gupta (Delhi, India)**

- D1.481** Prevalence of Immunoglobulin Deficiency in Patients with Chronic Rhinosinusitis Followed in a Tertiary Referral Center
S. D. Dortas Junior (Rio De Janeiro, Brazil)

- D1.483** Establishment of Air-borne Pollen Monitoring and Allergic Pollen Prediction Model in Kunming
S. Qian (Yunnan, China)

- D1.484** The elongated ciliated cells derived from nasal polyp are distinctly different from ciliated cells in different parts of the nasal mucosa
M. Pan (Guangzhou, China)

- D1.485** Characterization of CRSwNP and associated Type 2 or Respiratory comorbidities in the biological era in Spain - The POLARIS study
J. Mullol (Barcelona, Spain)

- D1.486** Epidemiological Investigation of Pollen induced Allergic Diseases in China
T. T. Ma (Beijing, China)

- D1.487** Evaluation of Large Language Models in Otolaryngology: Accuracy on Structured Question Banks and S.C.O.R.E.-Based Interpretation of Guidelines and Consensus Statements
M. Chao (Macau, Macau)

- D1.488** Current Advances in Spatial Pathology of Nasal Polyps: Challenges, Opportunities for Artificial Intelligence, and Future Directions
Z. Hua (Guangzhou, China)

- D1.489** The establishment and characteristics of type 2 inflammation in nasal organoids
Y. Zhang (Davos, Switzerland)

- D1.490** Dupilumab in the treatment of Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Cystic Fibrosis patients
M. Cristallo (Bari, Italy)

- D1.491** Chronic Rhinosinusitis as the First Manifestation of Primary Immunodeficiency in Adults: A Retrospective Single-Center Study
G. Umarova (Almaty, Kazakhstan)

- D1.492** Efficacy and safety of a combined nasal spray with a fixed dose of mometasone and olopatadine for the treatment of allergic rhinitis in pets under save ongoing exposure to epidermal allergens
K. Pavlova (Moscow, Russia)

- D1.493** Circulating Exosomal miR-200 Family Downregulation in Allergic Rhinitis
X. Cui (Nanjing, China)

12:00 - 13:00 TPS26 - Biomarkers 01

(Poster Zone, Thematic Poster Session)

Chair: P. Pyatilova (Berlin, Germany), E. M. Latis (Pieve Emanuele, Italy)

- D1.495** Noninvasive Monitoring of Cutaneous Molecular Changes During Improvement of Infantile Atopic Dermatitis: Application of Skin Surface Lipid RNA (SSL-RNA) Analysis
K. Yamamoto-Hanada (Tokyo, Japan)

- D1.496** Variation in platelet-activating factor levels among patients with chronic spontaneous urticaria
L. Lapiņa (Riga, Latvia)

- D1.497** An integrated multiomic insight to nonsteroidal anti-inflammatory drug-induced acute urticaria/angioedema
J. Triano-Cornejo (Malaga, Spain)

- D1.498** Altered B Cell Dynamics in Childhood-Onset Systemic Lupus Erythematosus: Insights from Disease States and Rituximab Treatment
H.-T. Chang (Taipei, Taiwan)

- D1.499** A clinically validated kinin biomarker assay to differentiate bradykinin-mediated from mast cell-mediated angioedema
E. Pardali (Leiden, Netherlands)

- D1.503** Immunoglobulin Abnormalities in Cronkhite-Canada Syndrome: A Focus on IgE and IgG4
S. Liu (Beijing, China)

- D1.504** Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2: Clinical Characteristics and Outcomes in a series of pediatric cases
S. Sciuca (Chisinau, Moldova)

- D1.505** Impact of patient factors on the stability of anti-IgE treatment response in chronic spontaneous urticaria
D. Fomina (Moscow, Russia)

- D1.506** Mast cell activation and type 2 inflammation in heart failure with preserved ejection fraction: a pilot cross-sectional study
G. Loloci (Tiranë, Albania)

- D1.507** Biomarkers of T2-airway inflammation in patients with asthma and COPD overlap
A. Emelyanov (Sankt-Peterburg, Russia)

- D1.508** Assessment of automated serum sIgG testing for key bacterial pathogens in Cystic Fibrosis
M. Tena Campos (Cornellà de Llobregat, Spain)

- D1.509** Total Serum IgE Associations with Autoimmunity, ASST, and Disease Activity in Chronic Spontaneous Urticaria: A Prospective Cohort Study
V. Trajkova (Skopje, North Macedonia)

- D1.510** Fecal Calprotectin as a Marker for Differentiating Children with Atopic Dermatitis With and Without Food Allergy
B. Kvenić (Rijeka, Croatia)

- D1.511** Hereditary alpha-tryptasemia in chronic spontaneous urticaria: prevalence and clinical impact
A.-K. Höhnke (Munich, Germany)

- D1.512** Culicoides allergen induced in vitro sulphidoleukotriene release correlates with clinical lesion severity in Icelandic horses affected with insect bite hypersensitivity
S. Jonsdottir (Reykjavik, Iceland)

- D1.513** Reduced Expression of PDCD4 on CD14+ Monocytes Correlates with Inflammatory Severity in Neonatal Sepsis: A Pilot Study
J. Chen (Zhuhai, China)

- D1.514** Assessment of Serum Substance P Levels in Chronic Spontaneous Urticaria with Predominant Pruritus Refractory to H1-Antihistamines and Omalizumab
D. Fomina (Moscow, Russia)

12:00 - 13:00 TPS27 - Insect venom hypersensitivities

(Poster Zone, Thematic Poster Session)

Chair: G. Sturm (Graz, Austria), E. Boni (Bologna, Italy)

D1.515 Occupational Exposure of Patients Allergic to Hymenoptera Venom

M. Huete Herrera (Alcorcón, Spain)

D1.516 Compliance with hymenoptera venom immunotherapy (VIT)

P. Morales Sánchez (Alcorcón, Spain)

D1.517 Adverse Reactions to Insect Venom Immunotherapy in a Reference Center

A. Capelo (Rio De Janeiro, Brazil)

D1.518 Patient Phenotypes in Prolonged Immunotherapy for Hymenoptera Venom

F. Kapsouli (Athens, Greece)

D1.519 Safety of ultra-rush protocols in venom immunotherapy: a systematic review and meta-analysis of Portuguese data

N. Santos (Faro, Portugal)

D1.520 Immunological modulation during Apis mellifera venom immunotherapy

A. Gómez Garrido (Seville, Spain)

D1.521 Rarer occurrence of cancer and autoimmune diseases among older patients with life-threatening allergic reactions to insect venom

R. Pawłowicz (Wrocław, Poland)

D1.522 Efficacy of hymenoptera venom immunotherapy in Portugal: a systematic review

N. Santos (Faro, Portugal)

D1.523 Clinical characterization of patients with Hymenoptera venom allergy undergoing venom immunotherapy stratified by basal serum tryptase

R. Sá Teixeira (Vila Nova de Gaia, Portugal)

D1.524 StingReady: a safe and alternative method for controlled sting challenge tests

D. M. Tello Montúfar (Santiago de Compostela, Spain)

D1.525 Implementation of allergen-specific immunotherapy for insect allergy

I. Razikova (Toshkent, Uzbekistan)

D1.526 Epidemiologic Characteristics of Hymenoptera Venom Allergic Patients from Two Different Environmental Areas

S. Sartorio (Milan, Italy)

D1.527 Low tryptase and combined IgE biomarkers have limited predictive value in children with severe honeybee venom anaphylaxis

B. Klasa (Krakow, Poland)

12:00 - 13:00 TPS28 - Mastocytosis and mast cells

(Poster Zone, Thematic Poster Session)

Chair: **M. Castells** (Boston, United States of America), **I. D. Toprak** (İstanbul, Türkiye)

- D1.528** Clinical characterization of digestive manifestations of mast cell activation syndrome (MCAS-NOS) in young children: a study by the CEREMAST french reference center
F. Campeotto (Paris, France)

- D1.529** Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study
F. Siebenhaar (Berlin, Germany)

- D1.530** Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezucastinib
F. Siebenhaar (Berlin, Germany)

- D1.531** Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series
F. Koliofotis (Athens, Greece)

- D1.532** Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells
S. Guloglu (İstanbul, Türkiye)

- D1.533** Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis
C. Siouta (Linköping, Sweden)

12:00 - 13:00 TPS29 - Systems medicine

(Poster Zone, Thematic Poster Session)

- D1.536** Immunological basis of coexisting slowly progressive insulin-dependent diabetes mellitus (SPIDDM) and Vogt–Koyanagi–Harada disease (VKH)
S. Koga (Tokyo, Japan)

- D1.537** Immunopharmacogenomics as a Systems Medicine Framework for Precision Therapy in Allergic and Immune Mediated Diseases
L. Handzha (Istanbul, Türkiye)

- D1.538** First Report of the SERPING1 c.52-1G>A Variant in a Chinese HAE Pedigree: Severe Abdominal Phenotype Correlated with Attack-Phase Imaging
X. Gao (Tsingdao, China)

- D1.539** Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials
K. Saleh (Basyoun, Egypt)

- D1.540** Automated generation of real-world clinical databases in Allergy: a data-driven research framework
L. Carrasco Gómez (Madrid, Spain)

- D1.541** Addressing Allergy undergraduate education: Strategic Reforms for Specialist-Led Allergy teaching in Medical Curricula. A EAACI Tailored Education Committee Task Force
M. Ferrer (Pamplona, Spain)

- D1.542** Effects of chemical siRNA modifications on the duplex stability in blood plasma
D. Bagaev (Moscow, Russia)

12:00 - 13:00 Enlightenment talk
(Innovation Hub, EAACI Enlightening Talk)

13:15 The stories we carry on our skin
A. Barbaud (Paris, France)

13:45 The stories we carry to work
J. Walusiak-Skorupa (Lodz, Poland)

13:15 - 14:15 POC - PD1 - Panel Discussion : From Pipeline to Patient: Accelerating Access to Breakthrough Therapies
(EAACI Global Stage POC)

Chair: O. Ceylan (Istanbul, Türkiye)

Panel Discussion: From Pipeline to Patient: Accelerating Access to Breakthrough Therapies
C. Öztürk (Istanbul, Türkiye), K. Illy (Amersfoort, Netherlands)

13:15 - 14:45 L-FT03 Epithelial dysfunction from airway to gut
(Room Athens, Flash Talks)

Chair: S. Ardicli (Davos, Switzerland), Y. GAO (Hangzhou, China)

13:15 Hormonal regulation of airway pathology in sex-biased asthma
001866 I. Cerqua (Naples, Italy)

13:22 Anti-IL5R α therapy restores nasal epithelial cell barrier function in severe eosinophilic asthma
001354 K. L. Raby (London, United Kingdom)

13:29 Effect of IL-33 on the Production of Reactive Oxygen Species (ROS) by Eosinophils and Neutrophils from Asthmatic Subjects
001506 G. Marone (Naples, Italy)

13:36 IL-13 and IL-17A regulate the susceptibility and antiviral response of human rhinovirus in human nasal epithelial cells through Hippo-YAP
000559 H. Qiu (Guangzhou, China)

13:43 Quantitative Evidence That IL-17A Expands Nasal Epithelial Tight Junction Gaps in Allergic Rhinitis
000918 J. Chen (Guangzhou, China)

13:50 Hippo-YAP inhibits the autophagic degradation of Cyclin D1 in chronic rhinosinusitis with nasal polyps
000558 H. Qiu (Guangzhou, China)

13:57 Maltol and ethyl maltol induce barrier dysfunction and cellular stress in nasal organoids
001560 B. Zhao (Davos, Switzerland)

14:04 Lipid-Allergen Interactions and Chromatin Remodeling as Dual Drivers of Epicutaneous Sensitization
001656 H. Berreiros-Hortala (Madrid, Spain)

14:11 Evaluation of Epidermal Barrier Integrity in Children with Different Allergic Phenotypes Using Electrical Impedance Spectroscopy
000873 C. Bülbüloğlu (Istanbul, Türkiye)

14:18 Evaluation of the Efficacy of Innovative Antimicrobial Peptides for the Treatment of S.aureus and MRSA Infections Common in Atopic Dermatitis Disease
001486 E. Boyuk (Ankara, Türkiye)

14:25 Differential Expression of TSLP Isoforms and IL-33 and their Receptors in Pediatric Eosinophilic Esophagitis (EoE)
001420 G. Marone (Naples, Italy)

14:32 Polystyrene nanoplastics disrupt intestinal barrier integrity and promote allergen translocation and pro-sensitizing signals
001637 S. Bargiela (Madrid, Spain)

13:15 - 14:45 L-FT04 - Food allergy - From predictors to treatment

(Room Glasgow, Flash Talks)

Chair: B. Olivieri (Verona, Italy), P. J. Turner (London, United Kingdom)

13:15 Cord blood DNA methylation pattern predicts childhood food allergy

000610 L. Matzner (Berlin, Germany)

13:22 From Microbial Taxonomy to Function: Distinct Metagenomics and Metabolic Pathway Underlying IgE and Non-IgE Pediatric Food Allergy: the results of NIGEFA study

002035 A. Cadavere (Napoli, Italy)

13:29 Emerging Insights into the Role of Ultraprocessed Foods and Advanced Glycation End-Products in Eosinophilic Esophagitis

001564 L. Carucci (Napoli, Italy)

13:36 Food Allergy with Delayed Vomiting in Young Children: Multicenter Clinical Insights into Food Protein-Induced Enterocolitis Syndrome Phenotypes

000483 K. Jeong (Suwon, Korea, Republic of)

13:43 Ara h 1-2 complexes: key molecules for the activation of Ara h 2-specific B cells in the absence of Ara h 2-specific T cells?

001372 C. Castenmiller (Amsterdam, Netherlands)

13:50 2S Albumins As Hidden Panallergens: Uncovering Overlooked Cross-Reactivity In Food Allergy

000677 E. S. Castromil-Benito (Madrid, Spain)

13:57 Association of Walnut Allergen Components with Reaction Threshold, but Not Severity, During Oral Food Challenge in Children

001702 S. Sato (Kanagawa, Japan)

14:04 Clinical utility of specific IgE measurement of seed storage proteins in diagnosing macadamia allergy

001209 N. Maruyama (Kyoto, Japan)

14:11 High- and Low-Dose Oral Sesame Immunotherapy: Interim Analysis of a Randomized Single-Center Open-Label Trial

002116 A. Krupa-Łaska (Warszawa, Poland)

14:18 Early Markers of Baked Milk and Egg Tolerance in Young Children with IgE-mediated Immediate Reactions

001296 M. Yorgun Altunbas (Istanbul, Türkiye), E. Karakoc-Aydiner (Istanbul, Türkiye)

14:25 Single dosing with the ED20 of peanut is well tolerated in peanut allergic children

000210 J. Hourihane (Cork, Ireland)

14:32 Health-related quality of life benefits persist four years after peanut oral immunotherapy

001176 S. Rosser (Parkville, Australia)

13:15 - 14:45 JMA2 - IgG friend or enemy in allergic diseases?

(Room London, JMA)

Chair: J. Chauhan (London, United Kingdom), J. C. Cardet (Tampa, United States of America)

13:15 Modulatory role of B regulatory cells in allergic diseases

W. Van De Veen (Davos, Switzerland)

13:45 IgG B-cell antibody class switching and allergic diseases

L. James (London, United Kingdom)

14:15 IgG-IgE interaction, a key factor reducing the sensitivity of in vitro assays?

J. L. Paris (Málaga, Spain)

13:15 - 14:45 NAIS Forum - Challenges in anaphylaxis

(Room Florence, 3- Florence, NAIS Session)

Chair: M. Torres (Malaga, Spain), A. Akkor (Istanbul, Türkiye)

13:15 Data gaps and research priorities in anaphylaxis

T. Dribin (Cincinnati, United States of America)

13:45 Mast cell activation syndrome as a typical presentation of idiopathic anaphylaxis

F. Tobias (Munich, Germany)

14:15 Updated French recommendations in perioperative anaphylaxis

P. Mertes (Strasbourg, France)

13:15 - 14:45 OAS03 - Real world results of biologics in asthma

(Room Gothenburg, Oral Abstract Sessions)

Chair: O. Can Bostan (Ankara, Türkiye)

13:15 5 year follow-up of the RELight study: Long-term Evaluation of Mepolizumab in Patients with Severe Eosinophilic Asthma

001110 M. KALLIERI (Chaidari, Greece)

13:27 Real-world comparison of T2-biologics effectiveness in patients with severe allergic asthma and nasal polyps

001089 A. Tiotiu (Brussels, Belgium)

13:39 From Response to Clinical Remission with Biologic Therapy: Single-Center Real-World Data in Severe Asthma

000466 A. Yildirim (Ankara, Türkiye)

13:51 Dupilumab Improves Lung Function and Disease Burden vs Omalizumab in Patients With Severe Chronic Rhinosinusitis With Nasal Polyps and Coexistent Asthma With Highly Elevated Type 2 Inflammatory Biomarkers

000690 M. E. Wechsler (Denver, United States of America)

14:03 Efficacy of Tezepelumab in Chinese Patients with Severe Uncontrolled Asthma and Comorbidities: A Post-Hoc Analysis of the DIRECTION Study

001224 C. Chang (China)

14:15 Dupilumab Significantly Improves the Likelihood of Achieving Clinical Remission Components in Children With Moderate-to-Severe Type 2 Asthma: Win Ratio Analysis of VOYAGE

000684 S. Dell (Vancouver, Canada)

13:15 - 14:45 OAS04 - Adult drug allergy (Room Munich, Oral Abstract Sessions)

Chair: **L. H. Garvey** (Hellerup, Denmark), **M. Castells** (Boston, United States of America)

13:15 Natural Evolution of Hypersensitivity to NSAIDs in Adults

001752 A. Prieto-Moreno Pfeifer (Madrid, Spain)

13:27 Reducing diagnostic uncertainty after perioperative hypersensitivity: organisational factors identified by national allergy and anaesthesiology surveys in Spain

000787 J. J. Laguna Martinez (Madrid, Spain)

13:39 Hypersensitivity Reactions to Platinum and Taxane Chemotherapy Agents in Cancer Patients: A Retrospective Cohort Analysis of Desensitization Outcomes

001713 H. YAĞMUR (İzmir, Türkiye)

13:51 Rapid Drug Desensitization to Platinum-Based Chemotherapy Agents: A Single-Center Experience

001254 H. Kayıkcı (Ankara, Türkiye)

14:03 Revealing metabotypes of IgE-, COX-1 inhibitors-, and MRGPRX2 receptor-mediated drug hypersensitivity reactions

001367 A. Macías-Camero (Boadilla del Monte, Spain)

14:15 Relapse Risk stratification and biologic intervention in Severe Drug Reaction with Eosinophilia and Systemic Symptoms

001729 M. Lebedkina (Moscow, Russia)

14:27 TNF- α inhibition as a safe and effective alternative treatment option for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

001714 E. Nikitina (Moscow, Russia)

13:15 - 14:45 SYM3 - Biomarker driven personalised AIT (Room Istanbul, 1- Istanbul, Symposium)

Chair: **C. M. Rondon** (Málaga, Spain), **J. A. Layhadi** (London, United Kingdom)

13:15 Biomarkers beyond skin prick testing

R. Fernandez Santamaria (Madrid, Spain)

13:45 Biomarkers aiding AIT in polysensitized patients

Z. Pan (Beijing, China)

14:15 Omics and immunotherapy monitoring

D. Barber (Madrid, Spain)

13:15 - 14:45 SYM4 - EoE from bench to bedside (Room Paris, 2- Paris, Symposium)

Chair: **A. Bakirtas** (Ankara, Türkiye), **C. Berghea** (București, Romania)

13:15 Diagnosis and scoring of EoE

E. Savarino (Padua, Italy)

13:45 Targeted biological therapy

T. Greuter (Lugano, Switzerland)

14:15 How to assess disease control?

C. Ma (Calgary, Canada)

13:30 - 14:30 GBD1 - Groundbreaking Discoveries in airway diseases
(Room Zurich, 5- Zurich, Ground Breaking Discoveries)

Chair: **M. Lundberg (Helsinki, Finland), G. Celik (Ankara, Türkiye)**

13:30 Genetic and mechanistic view on asthma in early life
C. Schmidt-Weber (Munich, Germany)

13:50 Real-world evidence in AIT: the CHOICE-Global study
M. Calderon (San José, Costa Rica)

14:10 Updates in international asthma guidelines
A. Yorgancioglu (İzmir, Türkiye)

13:30 - 14:30 Satellite Symposium
(Room Utrecht, Sponsored Sessions)

13:30 - 14:30 Satellite Symposium
(Room Krakow, Sponsored Sessions)

14:30 - 15:15 P & C 1 - PRO CON 2: Antibiotics in CRS: Reasonable – or no reason at all?
(EAACI Global Stage, Pro Con)

Chair: **L. Klimek (Wiesbaden, Germany) 12:00**

14:30 Pro
P. Kopac (Golnik, Slovenia)

14:53 Con
M. Schiappoli (Verona, Italy)

15:00 - 16:00 Satellite Symposium
(Room London, Sponsored Sessions)

15:00 - 16:00 Satellite Symposium
(Room Krakow, Sponsored Sessions)

15:00 - 16:30 FT05 - Translational research in asthma: from biomarkers to genetics

(Room Athens, Flash Talks)

Chair: **S. Bavbek (Ankara, Türkiye), I. Adcock (London, United Kingdom)**

13:15 Intermediate ILC2 in Sputum from Subjects with Severe Asthma are Increased at Exacerbation and not Controlled by Biologic Treatment

001889 N. Emami Fard (Hamilton, Canada)

15:07 Impact of Asthma Biologic Therapies on Regulatory B Cell Levels in Children and Adolescents with Persistent Asthma

000824 W. Sheehan (Washington DC, United States of America)

15:14 C3 Regulates Macrophage Migration and Polarization to Mediate Immune Inflammation in Asthma

000302 C. Hao (suzhou, China)

15:21 The immunomodulatory and clinical effects of anti-IL-5 or anti-IL5R α treatment in patients with severe eosinophilic asthma

001037 E. Theofani (Athens, Greece)

15:28 IL-33 modulates cytotoxic NK Cell Subsets in Severe Eosinophilic Asthma

000601 L. Bergantini (Siena, Italy)

15:35 MV130 drives the differentiation of human monocytes into dendritic cells with antiallergic phenotype

000776 S. Sánchez Herrero (Madrid, Spain)

15:42 Tezepelumab Reduces Urine Levels of Eicosanoid Metabolites Indicative of Mast Cell Activation in Patients with Moderate to Severe, Uncontrolled Asthma: Results from the Phase 2 CASCADE Trial

000711 C. Wheelock (Stockholm, Sweden)

15:49 Role of MAPK13 in Airway Smooth Muscle Activation Under Asthmatic Inflammatory Stimuli

001267 R. Fernandez Santamaria (Madrid, Spain)

15:56 Allergic airway inflammation alters myeloid and fibroblast sub-populations within the murine lung

000303 M. Burgess (Aberdeen, United Kingdom)

16:03 Interaction Between Autoimmunity and Allergen Sensitization in Chronic Spontaneous Urticaria

001750 U. Amarasekara (Colombo, Sri Lanka)

16:10 MiRNome and secretome analysis in patients with severe eosinophilic asthma treated with biological drugs

000168 G. Guillén Sánchez (Madrid, Spain)

15:00 - 16:30 FT06 - Skin tests and molecular sensitization profile value applied in Allergy diagnosis (Room Glasgow, Flash Talks)

Chair: **K. Hoffmann-Sommergruber (Wien, Austria), M. Pascal-Capdevila (Barcelona, Spain)**

- 15:00** Early skin testing as a reliable tool for the management of immediate hypersensitivity reactions to chemotherapy (pleasing both the allergologist and oncologist)
001693 M. Perlato (Florence, Italy)
-
- 15:07** Use of skin testing in the management of hypersensitivity reactions to taxanes and platinum: a prospective observational study
000852 A. Marti (Milano, Italy)
-
- 15:14** Tolerance to porcine-derived pancreatic enzymes in a patient with alpha-gal syndrome: a case report
000586 E. Smolnikov (Moscow, Russia)
-
- 15:21** Fish-chicken meat Syndrome
000919 E. Gutiérrez (Pamplona, Spain)
-
- 15:28** Evolution of plant food allergy with lipid transfer protein sensitization over time in Northern Spain
002044 J. Gonzalez Romero (Pamplona, Spain)
-
- 15:35** Mite Allergy In Children: Assessment of the Relationship Between Mite-Specific IgE Positivity and Skin Prick Test Reactivity
000901 G. Yörüsün (Ankara, Türkiye)
-
- 15:42** Correlation of Grass Panel Specific Immunoglobulin E with Skin Prick Test Results in Grass Pollen-Sensitized Children
000627 F. Kuzucu (Ankara, Türkiye)
-
- 15:49** Optimization of a Minimal Allergen Panel Using Age-Stratified Component-Resolved Diagnostic Data: Istanbul, Türkiye
001813 F. Kırbiyık (Istanbul, Türkiye)
-
- 15:56** New Method for Evaluation of Sum Symptom Score for Conjunctival Provocation Test
002033 Y. Yarin (Dresden, Germany), I. Kalaitzidis (Dresden, Germany)
-
- 16:03** Psychological Burden and Quality of Life Impact of In Vivo Diagnostic Evaluation for Immediate Drug Hypersensitivity: A Prospective Stepwise Study
001124 A. F. Aslan (Istanbul, Türkiye)
-

15:00 - 16:30 IWS4 - New insights into food protein-induced enterocolitis syndrome (Room Zurich, 5- Zurich, Interactive Workshop)

Chair: **E. D'Auria (Milano, Italy), R. Meyer (Leuven, Belgium)**

- 15:00** Diagnostic criteria for FPIES: time for a change?
A. Nowak-Węgrzyn (New York, United States of America)
-
- 15:30** Oral food challenge protocols and predictors of severity in acute FPIES
M. Vazquez-Ortiz (London, United Kingdom)
-
- 16:00** Unmet needs in acute FPIES
J. Upton (Toronto, Canada)
-

15:00 - 16:30 JMA3 - Educational symposium (Room Utrecht, JMA)

Chair: **T. Chivato** (Alcorcon, Spain), **G. Silva** (Porto, Portugal)

15:00 Implementation of AI-driven tools in the clinical practice

P. Alves (Coimbra, Portugal)

15:30 Social media: How to deliver an effective scientific communication.

M. Jimenez Freites (Barcelona, Spain)

16:00 Meta-analysis in allergy: Statistical recommendations

M. Martini (Ancona, Italy)

15:00 - 16:30 OAS-CT1 - Clinical trials on allergic diseases (Innovation Hub, Oral Abstract Session on Clinical Trials)

Chair: **A. Nakonechna** (London, United Kingdom), **S. R. Durham** (London, United Kingdom)

15:00 VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children Aged 4-7 Years With Atopic Comorbidities

001928 J. E. Trujillo Wurttele (Cork, Ireland)

15:12 Efficacy and Safety of TQC2938 Injection in Patients with Moderate-to-severe Seasonal Allergic Rhinitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study

001301 Y. Zhang (Beijing, China)

15:24 Safety and Immunologic Evaluation of a Biodegradable Transdermal Microneedle Array Patch Immunotherapy (DF19001) in House Dust Mite-Sensitized Allergic Rhinitis: A Phase I Double-Blind, Placebo-Controlled Study

000288 K. H. Park (Seoul, Korea, Republic of)

15:36 Efficacy of 300IR birch pollen liquid sublingual immunotherapy in paediatric patients with birch allergic rhinoconjunctivitis in relation to disease activity: results from the YOB clinical trial

000752 O. Pfaar (Marburg, Germany)

15:48 Oral Deucricitbant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial

000028 M. Cancian (Padua, Italy)

16:00 Early and Clinically Meaningful Improvements in Nasal Polyp Symptoms Following Tezepelumab Treatment in Adults with Chronic Rhinosinusitis with Nasal Polyps: Interim Results from the Phase 3b ESSENCE Study

000678 E. Heffler (Milan, Italy)

16:12 Nemolizumab fast onset of action in adolescents with moderate-to-severe atopic dermatitis: Results from a pooled subgroup analysis of the ARCADIA Phase 3 Studies

100582 A. Wollenberg (Augsburg, Germany)

15:00 - 16:30 OAS05 - The prevention and prediction of food allergy

(Room Gothenburg, Oral Abstract Sessions)

Chair: R. Berni Canani (Naples, Italy), C. Venter (Aurora, United States of America)

15:00 Impact of a Nationwide Web-Based Training Programme on Food Allergy Knowledge and Perceived Competences Management in Schools

000206 R. Machado (Porto, Portugal)

15:12 Effect of early food intervention and skin emollients on food allergy at 7 years of age (PreventADALL); a factorial, multicentre, cluster-randomised trial

001892 H. O. Skjerven (Oslo, Norway)

15:24 Early life skin lysophosphatidylcholine may predict the development of food allergy in infants over and above a published risk prediction model

000474 C.-L. Chang (Parkville, Australia)

15:36 Gestational age shapes SCFA-driven T-cell immunometabolism and links to neonatal gut microbiome composition

001401 T. Bui (Auckland, New Zealand)

15:48 Type-2-inflammation biomarkers in pediatric eosinophilic esophagitis: diagnostic and prognostic value

000246 S. Viazankina (Moscow, Russia)

16:00 CD4 T cells disrupt the esophageal epithelial barrier and induce eosinophilic esophagitis-like epithelial transcriptional changes

000600 T. M. Bek (Utrecht, Netherlands)

15:00 - 16:30 OAS06 - Cellular mechanisms of immune regulation

(Room Munich, Oral Abstract Sessions)

Chair: W. Van De Veen (Davos, Switzerland), M. Moniuszko (Białystok, Poland)

15:00 The role of B cells expressing histamine receptor 1 or 2 in immune regulation

000438 M. Yang (Davos, Switzerland)

15:12 The role of B cells in allergic contact dermatitis and in tolerance to contact allergens

000254 A. Funch (Copenhagen, Denmark)

15:24 Prematurity is characterised by enhanced suppressive capacity of regulatory T cells

001673 A. Paul (Auckland, New Zealand)

15:36 Functional evaluation of rare plasmacytoid dendritic cells in children with asthma

000471 J. Leffler (Nedlands, Australia)

15:48 M1 macrophages facilitate neutrophilic inflammation by extracellular trapping formation in nasal polyps

001206 J. Chen (Guangzhou, China)

16:00 Eosinophil sub-phenotypes interaction with endothelial cells in inflammation status model

001645 M. Accinno (Florence, Italy)

16:12 Synergetic stimulation of alarmins and antigen-independent signals induce a potent IFN γ secretory phenotype on human MAIT cells with immunomodulatory properties

000190 C. García-Escribano (Madrid, Spain)

15:00 - 16:30 SYM6 - Insights in angioedema endotypes (Room Paris, 2- Paris)

Chair: **T. Caballero** (Madrid, Spain), **Ö. Özdemir** (Sakarya, Türkiye)

15:00 The role of endothelium in angioedema

M. Bova (Napoli, Italy)

15:30 The coagulation in angioedema

M. Guilarte (Barcelona, Spain)

16:00 The complement in angioedema

A. Akkor (Istanbul, Türkiye)

15:00 - 16:30 TSY1 - Mite allergy: climate change and workplace exposure (Room Florence, 3- Florence, Thematic Symposium)

Chair: **P. Mason** (PADOVA, Italy), **H. Suojalehto** (Helsinki, Finland)

15:00 Effect of climate change on mite allergy worldwide

L. Caraballo (Cartagena de Indias, Colombia)

15:30 Exposure and sensitization to mites in the workplaces

I. Sander (Bochum, Germany)

16:00 Diagnosing occupational mite allergy and asthma

S. Vrtala (Vienna, Austria)

15:00 - 16:30 SYM5 - Patient safety and outcome in the treatment of severe chronic rhinosinusitis (Room Istanbul, 1- Istanbul, Symposium)

Chair: **J. Mullol** (Barcelona, Spain), **M. Lundberg** (Helsinki, Finland)

15:00 Safety of systemic immuno-modulating treatment options in patients with or without N-ERD

J. Hagemann (Wiesbaden, Germany)

15:30 Safety and outcome of surgical approaches: will bio-sampling define the sequence of multi-modal treatment?

P. Gevaert (Gent, Belgium)

16:00 How patient education can change adherence and overall outcome

M. Lundberg (Helsinki, Finland)

16:30 From treatment to daily life: A patient perspective on safety, adherence and outcomes in severe CRS

15:30 - 16:30 L-OAS04 - Drug allergy (EAACI Global Stage, Oral Abstract Sessions)

Chair: J. A. Cornejo-Garcia (Málaga, Spain), F. Mori (Florence, Italy)

- 15:30** Diagnostic Value Of The Pen-Fast Score And Its Role In Determining The Need For Skin Testing In Children With Suspected Beta-Lactam Allergy
100089 D. Kacar (Istanbul, Türkiye)
- 15:42** Characterising endovascular profiles in ACE inhibitor-induced angioedema in a South African cohort
100370 S. Pedretti (Cape Town, South Africa)
- 15:54** Overlapping Phenotypes and Anaphylaxis in NSAID Hypersensitivity: Challenges to Current Classification Systems
100389 P. Korkmaz (Istanbul, Türkiye)
- 16:06** Risk of delayed hypersensitivity to beta-lactams in children according to the extent of the initial reaction
100401 A. Morel de Villiers (Paris, France)
- 16:18** Risk stratification scores for suspected beta-lactam allergy: Comparative performance of PEN-FAST and BL-Predictor
100525 D. Antunes (Lisboa, Portugal)

16:30 - 17:30 Satellite Symposium (Room London, Sponsored Sessions)

16:30 - 17:30 Satellite Symposium (Room Krakow, Sponsored Sessions)

16:45 - 17:45 L-OAS05 - Allergy diagnosis (EAACI Global Stage, Oral Abstract Sessions)

Chair: Ö. Cavkaytar (Istanbul, Türkiye), S. Uzunov (Sofia, Bulgaria)

- 16:45** The Basophil Activation Test (BAT) identifies high-risk cow's milk allergic children: clinically actionable severity cut-offs and low-dose reactivity
100149 H. Boyd (London, United Kingdom)
- 16:57** A Clinically Accessible Prediction Model for NSAID-Exacerbated Respiratory Disease in Chronic Rhinosinusitis with Nasal Polyps
100359 J. Meng (Chengdu, China)
- 17:09** Real-world impact of Allergy outpatient care in non-specific lipid transfer proteins (nsLTP) food allergy: effects on anaphylaxis and food avoidance
100503 M. I. Garcia (Funchal, Portugal)
- 17:21** Nationwide airborne marker and panallergen sensitisation revealed by the French Allergen Chip database
100678 C. Klingebiel (Marseille, France)
- 17:33** Predicting food allergy severity with molecular profiling: application to peach allergy
100691 C. Klingebiel (Marseille, France)

16:45 - 18:15 FT07 - Broaden the view in treating the united airways

(Room Athens, Flash Talks)

Chair: **M. Lundberg** (Helsinki, Finland), **J. Kappen** (Rotterdam, Netherlands)

16:45 Response to Eight-Week Budesonide-Formoterol Treatment in Patients with Chronic Cough: Results from the Multicenter, Prospective EFFICIENCY Study

001257 K. Lai (Guangzhou, China)

16:52 Aspirin Therapy After Desensitization With Multi-Compartment Approach In Aspirin Exacerbated Respiratory Disease

000367 P. Szatkowski (Kraków, Poland)

16:59 Objective and Subjective Treatment Responses to Intranasal Therapies in Moderate-to-Severe Perennial Allergic Rhinitis

001379 S. Yao (Beijing, China)

17:06 Effects of Breathing Exercises in Patients with Severe Asthma Receiving Biologic Therapy: A Prospective Non Randomized Controlled Clinical Study

001062 M. Cihanbeylerden (Ağrı, Türkiye)

17:13 Evaluation of the role of inhaled nasal corticosteroids on the olfactory function in a cohort of patients treated with dupilumab for Chronic Rhinosinusitis with Nasal Polyps

001104 A. G. Ledda (Cagliari, Italy)

17:20 Risk of Pneumonia and Upper Respiratory Tract Infections in COPD and Severe Asthma Under Inhaled Corticosteroid Therapy

001352 S. B. Kaya (Malatya, Türkiye)

17:27 A real world retrospective study to evaluate the effectiveness & safety of montelukast & fexofenadine FDC in the management of patients with allergic rhinitis

000110 B. Toshniwal (Nanded, India)

17:34 Optimising local IgE cut-off values to improve the diagnosis of allergic bronchopulmonary aspergillosis in a Caucasian population

001680 J. Goret (Bordeaux, France)

17:41 Assessment of Bronchodilator Responsiveness and Spirometric Predictors in Patients with Rhinitis and Suspected Asthma

000929 Z. Pan (Beijing, China)

17:48 Recent systemic corticosteroid exposure is associated with mild cognitive impairment in elderly patients with asthma: a prospectively collected cross-sectional study

001244 M. Taniguchi (Sagamihara, Japan)

16:45 - 18:15 FT08 - Clinical and translational ENT allergy

(Room Glasgow, Flash Talks)

- | | |
|-----------------|---|
| 16:45
000527 | Perennial aeroallergen sensitization associates with increased disease severity in CRSwNP
E. Schifino (Pieve Emanuele, Italy), |
| 16:52
000961 | Nasal Allergen Challenge Using Dissolved Tree Pollen SLIT (SQ) Tablets
E. Paziou (Stockholm, Sweden) |
| 16:59
000952 | Efficacy and Safety Study on Intratonsillar Immunotherapy for Dust Mites-Induced Allergic Rhinitis (Tonsil-AIT): An Interim Analysis
J. Ye (Nanchang, China) |
| 17:06
002083 | Performance Evaluation of a Semi-Quantitative Rapid Test Kit for Dust Mites: For Home Self-Monitoring and Control Effectiveness Assessment
H. Zhang (Guangzhou, China) |
| 17:13
001270 | H-PGDS-targeted PROTAC attenuates allergic rhinitis in mice
N. Ozaki (Tokyo, Japan) |
| 17:20
001683 | Pharmacological Silencing of Nasal TRPV1+ Nociceptors Ameliorates Eosinophilic Infiltration but Exacerbates Neutrophilic Infiltration in Murine Models of Allergic Rhinitis
F. Ye (Guangzhou, China) |
| 17:27
000305 | The SPRR2A–CSTA Axis Drives IL-17A–Induced Squamous Metaplasia and Steroid Resistance in Allergic Rhinitis
S. Xie (Changsha, China) |
| 17:34
001556 | Real-world knowledge, confidence and practice patterns in ocular allergy: results of an EAACI Task Force global survey
D. Silva (Porto, Portugal) |
| 17:41
000431 | Analysis of Immunological Characteristics in Children with Adenoid Hypertrophy: Exploration from Peripheral Blood to Tissue Inflammatory Factors
T. Chen (Fuzhou, China) |
| 17:48
000897 | Prevalence And Clinical Predictors Of Sleep Disturbances In Children With Seasonal Allergic Rhinitis
F. Güvenir (Ankara, Türkiye) |
| 17:55
001253 | Beyond Nasal Symptoms: The Relationship Between Rhinitis, Sleep Quality, and Depression
G. Bedir Keser (Kirikkale, Türkiye) |
| 18:02
100025 | Polystyrene micro- and nano-plastics compromise epithelial barrier function in a size-dependent manner via molecular remodelling
C. Lihong (Guangzhou, China) |
| 18:09
100118 | Epidemiological study of common allergens sensitizing hay fever patients in different regions of mainland China
J. Zhang (Guangzhou, China) |

16:45 - 18:15 IH 2 - Clinical translation of immunology research (Innovation Hub, Innovation Hub)

Chair: *R. Fernandez Santamaria (Madrid, Spain), M. Ollert (Esch-sur-Alzette, Luxembourg)*

16:45 Multiparameter flow cytometry for immunophenotyping: how deep can we go?

C. Mayorga (Málaga, Spain)

17:15 Single cell and bulk RNA sequencing: do we always need to be fancy?

C. Gomez-Casado (Düsseldorf, Germany)

17:45 Metabolomics: how can we make sense of it all?

M. Escribese (Madrid, Spain)

16:45 - 18:15 IWS5 - Assessment of sense of smell in airway diseases (Room Zurich, 5- Zurich, Interactive Workshop)

Chair: *S. Reitsma (Ede, Netherlands), J. Maza Solano (Sevilla, Spain)*

16:45 Prevalence of olfactory dysfunction in inflammatory airway disease

A. Chaker (Munich, Germany)

17:15 How does upper airway inflammation impact the sense of smell: pathophysiology and therapeutic consequences

J. Mullol (Barcelona, Spain)

17:45 Smell function tests suitable for clinical routine and scientific use

A. Izquierdo Dominguez (Terrassa, Spain)

16:45 - 18:15 JMA Poster Sessions (Poster Area, JMA)

16:45 - 18:15 JMA Poster session 1: Allergen Immunotherapy/Biologicals

(Poster Zone, JMA)

Chair: M. Perlato (Florence, Italy), T. Eiwegger (St. Poelten, Austria)

- D1.04** Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
N. Samson (London, United Kingdom)
- D1.05** Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
P. Lacwik (Kielce, Poland)
- D1.06** Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
B. Hijazi (Riyadh, Saudi Arabia)
- D1.07** Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
F. Bärhold (Wiesbaden, Germany)
- D1.08** Does Allergen Immunotherapy Add Clinically Meaningful Benefit in Paediatric Asthma and Allergic Rhinitis? A 36-Month Real-World Comparison
J. Prieto (Ciudad de México, Mexico)
- D1.09** Elucidating the Immunological Mechanisms of Pollen Immunotherapy in Treating Food Allergy in Patients with Pollen-Food Allergy Syndrome
Y. Shin (Seoul, Korea, Republic of)
- D1.10** Dose-Dependent Immunogenicity and Toxicity of Polypeptide-Conjugated Hepatitis B Core Antigen Virus-Like-Particle (HBcAg-VLP) Vaccine for Treatment of Shellfish Allergy
J. Z. X. Lee (Hong Kong SAR, China)
- D1.11** Preterm birth and allergic sensitization in school-aged children
X.-Y. Tsai (Taoyuan, Taiwan)
- D1.13** PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants
J. A. Layhadi (London, United Kingdom)
- D1.14** Fc-Engagers as a targeted approach for antigen-specific immune inhibition in HDM allergy
A. Vogel (Vienna, Austria)
- D1.15** Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D. Gialama (Berlin, Germany)
- D1.16** Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial
C. Pablo-Torres (Boston, United States of America)
- D1.17** Staphylococcus aureus enterotoxins in allergic rhinitis: impact on disease severity and molecular sensitization profile
I. Kalikina (Kyiv, Ukraine)
- D1.18** Carry-Over Effect of House Dust Mite (HDM) Immunotherapy for Allergic Respiratory Conditions in Pediatric and Adolescent Populations: A Systematic Review and Narrative Synthesis
N. Tran (Hanoi, Vietnam)
- D1.19** Real-world comparative effectiveness of dupilumab, JAK inhibitors, and azathioprine in severe adult atopic dermatitis: a 24-month longitudinal cohort
V. Gonzalez-Urbe (Ciudad de México, Mexico)
- D1.20** Norovirus-Like Particles as Novel Carriers of Hypoallergenic Artemisia vulgaris Allergen Art v 3 for Allergen-Specific Immunotherapy
L. Cepulyte (Vilnius, Lithuania)
- D1.21** Remission as a therapeutic goal in chronic rhinosinusitis with nasal polyps treated with Dupilumab: a multicenter real-world study
E. Cavaglia (Milan, Italy)

16:45 - 18:15 JMA Poster session 2: Basic Immunology/Infections/Omics (Poster Zone, JMA)

Chair: *J. López-Rodríguez (Alcorcón, Spain), J.-F. Lopez (Davos, Switzerland)*

- D1.25** **Altered Virulence of *Pseudomonas aeruginosa* from Polystyrene-Fed *Zophobas atratus* Larvae and Immunological Effects of Microplastics on Murine Lungs**
Y. Rybalchenko (Poltava, Ukraine)

- D1.26** **Machine Learning–Based Plasma Proteomic Signatures for Prediction of Chronic Rhinosinusitis**
D. Kim (Seoul, Korea, Republic of)

- D1.27** **Anti-tumoral effect of hydatid cyst fluid in a cell-derived breast cancer xenograft model**
R. S. BOUSSA (Bab Ezzouar, Algeria)

- D1.28** **Human memory CD4+T cells induce hyperresponsiveness in mast cells**
J. He (Berlin, Germany)

- D1.29** **Immune Dysregulation and Autoinflammation in IL-10RA-Deficient VEO-IBD: Resolution via Cord Blood Transplantation A. Ha (Hanoi, Vietnam)**

- D1.30** **An integrated multiomic insight to nonsteroidal anti-inflammatory drug-induced acute urticaria/angioedema**
J. Triano-Cornejo (Malaga, Spain)

- D1.31** **Type 2 neuro-immune signaling is upregulated in *Candida albicans*-driven itch**
A. Tyo (Seoul, Korea, Republic of)

- D1.32** **Post-COVID-19 Reshaping of Molecular IgE Sensitization Profiles to Seasonal and Indoor Allergens**
N. Zakhidova (Tashkent, Uzbekistan)

- D1.33** **Corticosteroids promoted organoid formation and differentiation of SSEA-1+ lung stem/progenitor cells**
Y.-H. Hsu (Taipei, Taiwan)

- D1.34** **Regulatory T Cells Induced by B cells Decreased Osteoclast Activity and Alleviated Disease Severity of Collagen Antibody Induced Arthritis**
Y.-T. Wu (Taipei, Taiwan)

- D1.35** **Novel CD8+CD122+ Regulatory T Cells Induced by B Cells Suppress T helper 2 Response and Attenuate Eosinophilic Infiltration in Allergic Asthma**
J. N. Fan (Taipei, Taiwan)

- D1.37** **Lymphoma in CVID: on the edge between immune dysregulation and malignancy**
M. Franco (Treviso, Italy)

- D1.38** **A mechanism for loss of biodiversity in the gut: Toxic effects and metabolic alterations of food additives on human fecal microbiome**
B. Zhao (Davos, Switzerland)

- D1.39** **Characterization of provocation-induced changes in transcription factors in the nasal mucosa of birch pollen-allergic and non-allergic individuals**
G. Lamorte (Vienna, Austria)

- D1.40** **Exploring the role of lipids on initiation of allergenic response in innate lymphoid cells**
D. Schnögl (Krems an der Donau, Austria)

- D1.41** **Extracellular vesicles isolated after cholinergic urticaria challenge carry MRGPRX2 and induce pro-inflammatory mast cell responses**
P. L. Quan-López (Pamplona, Spain)

- D1.42** **A TSLP Tuft Cell-Treg Cell Circuit promotes Food Allergy**
M. Martínez Blanco (Madrid, Spain)

16:45 - 18:15 JMA Poster session 3: Dermatology/mastocytosis/Venom allergy (Poster Zone, JMA)

Chair: *G. Sfriso (Verona, Italy), E. Boni (Bologna, Italy)*

- D1.50** Hereditary Angioedema in Bulgaria (1972-2025): A Longitudinal Comparative Study of Trends in Diagnosis, Mortality, and the Impact of Modern Therapies
F. Maksudov (Sofia, Bulgaria)

- D1.51** Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells
S. Guloglu (İstanbul, Türkiye)

- D1.52** Delayed Hypersensitivity Reactions to Iodinated Contrast Media: Diagnostic Outcomes and Alternative Selection
M.-L. Toader (Bucharest, Romania)

- D1.53** Successful management with Omalizumab and high-dose venom immunotherapy in a patient with Kounis Syndrome and Clonal Mast Cell Activation Syndrome
P. Viedma Ayllon (Castellon de la Plana, Spain)

- D1.55** Early serum IL-6 induction and delayed IL-17A suppression characterise wasp venom allergen-specific immunotherapy
E. Herzer (Munich, Germany)

- D1.56** Mental health and quality of life in patients with chronic spontaneous urticaria
C. Maçães (Vila Nova de Gaia, Portugal)

- D1.57** Long-Term Remission Patterns in Chronic Spontaneous Urticaria: A Real-Life Cohort Study
E. Açar (Kayseri, Türkiye)

- D1.58** REMA Score Outperforms C-kit and Tryptase in Identifying Mast Cell Disorders in Hymenoptera Venom Allergy
P. Harbham (London, United Kingdom)

- D1.59** Epidemiologic Characteristics of Hymenoptera Venom Allergic Patients from Two Different Environmental Areas
F. Nuccio (Messina, Italy)

- D1.60** Clinical and laboratory characteristics associated with chronic urticaria in a pediatric population
C. Ferrigno (Milano, Italy)

- D1.61** Dithranol loaded Dendritic nanoarchitectures for the treatment of psoriasis
M. Bhargava (Prayagraj, India)

- D1.62** SDRIFE induced by multiple systemic corticosteroids
J. Ramirez-Cortes (Majadahonda, Spain)

- D1.63** Etoricoxib-Induced Fixed Drug Eruption: A Case Series and Assessment of Tolerance to Alternative NSAIDs
D. De Zubiria (Cali, Colombia)

- D1.64** Food allergy in children with inherited epidermolysis bullosa: possible role of transcutaneous sensitization and features of the clinical course
A. Galimova (Moscow, Russia)

- D1.65** Sensitivity to Dental Materials and Its Clinical Implications: A Retrospective Patch Test Study
M. S. Bayrak Durmaz (Ankara, Türkiye)

- D1.66** Transition to SCIG as an Alternative in Patients with Cytokine Storm from IVIG
A. Marino Fernandez (Las Palmas de Gran Canaria, Spain)

- D1.67** Clinical Characteristics of Chronic Urticaria Patients With and Without Flares With Systemic Symptoms
A. Pehlivanlar Ustaoglu (Ankara, Türkiye)

16:45 - 18:15 JMA Poster session 4: Drug allergy/AllergoOncology (Poster Zone, JMA)

Chair: **V. Gueli (Verona, Italy), N. Orak Akbay (Ankara, Türkiye)**

- D1.70** Long-term course of NSAID tolerance in patients with cross-hypersensitivity presenting with respiratory symptoms
B. Moya (Málaga, Spain)
- D1.71** Risk factors for immediate hypersensitivity reactions to rituximab
W. Piriyaanguanpong (Bangkok, Thailand)
- D1.72** Risk Stratification Tools in Suspected Beta-Lactam Allergy: A RealLife Delabeling Study
E. Cavaglia (Milan, Italy)
- D1.73** Immediate hypersensitivity to dostarlimab successfully managed with desensitization
S. Albarracín-Prados (Las Palmas de Gran Canaria, Spain)
- D1.74** The Most Serious Threat in Perioperative Hypersensitivity Reactions (PHRs): Neuromuscular Blocking Agent (NMBA) Hypersensitivity and Cisatracurium as a Safe Haven in the Setting of Cross-Reactivity
H. F. Avci (Istanbul, Türkiye)
- D1.75** Nonsteroidal anti-inflammatory drug-induced acute urticaria/angioedema: antioxidant enzymes activities and associated genetic variants
I. M. Jiménez-Sánchez (Malaga, Spain)
- D1.76** AAV-Mediated IL-10 Gene Delivery Enhances Antitumor Immunity While Preserving Immune Tolerance in Hepatocellular Carcinoma
C.-I. Lin (Taipei, Taiwan)
- D1.77** Long-term Follow-up Outcomes of Patients Undergoing Desensitization for Non-Immediate Hypersensitivity Reactions Associated with Lenalidomide
N. Kahveci (Istanbul, Türkiye)
- D1.78** AllergoOncology: Basophil number and subpopulation proportions may offer potential as predictive biomarkers in non-small cell lung cancer
M. Lasa-Lazaro (Barcelona, Spain)
- D1.79** Evaluation of the use of cyclooxygenase-2 inhibitors in patients with AERD
A. Sato (São Paulo, Brazil)
- D1.80** Clinical Outcomes and Safety of Drug Desensitization in Chemotherapy-Induced Hypersensitivity
S. Rodríguez Cano (Córdoba, Spain)
- D1.81** Rare but Challenging to Manage: Severe Cutaneous Drug Reactions in Children
R. Mahmudov (Istanbul, Türkiye)
- D1.82** Pharmacist-led Risk-based β -Lactam Challenges in Patients with Penicillin Allergy: Impact on Antibiotic Days
N. A. Allameen (Singapore, Singapore)
- D1.83** Retrospective Analysis of Perioperative Hypersensitivity Reactions: Single-Center Experience
E. Ulgen (Izmir, Türkiye)
- D1.85** Drug hypersensitivity reactions in paediatric patients pre and post-liver transplant: a single-center study
E. Efstathiou (London, United Kingdom)
- D1.86** Safety Outcomes and Predictors of Clinically Significant Reactions in Positive Drug Provocation Tests: A 10-Year Tertiary-Center Cohort
B. Çelik Eroğlu (Ankara, Türkiye)
- D1.87** Progression from Immediate to Delayed Hypersensitivity: A Rare Case of Iodixanol-Induced Acute Generalised Exanthematous Pustulosis
S. Flores Regalo (Coimbra, Portugal)

16:45 - 18:15 JMA Poster session 5: Allergy diagnosis/Systems medicine/Epidemiology/Allied Health and Primary care
(Poster Zone, JMA)

Chair: *M. Zemelka-Wiacek (Wrocław, Poland), A. Dašić (Beograd, Serbia)*

- D1.98** Association between allergen-related antibodies and clinical phenotypes of IgG4-related disease (IgG4-RD)
L. Lyu (Beijing, China)
- D1.99** Anaphylaxis After Crayfish Consumption with Strong *Anisakis simplex* Sensitization
S. San Roman Sirvent (Villajoyosa, Spain)
- D1.100** Sensitization to Sesame Proteins Despite Negative Conventional Testing
T. Galán Díez (Alcalá de Henares, Spain)
- D1.101** Variation in platelet-activating factor levels among patients with chronic spontaneous urticaria
L. Lapiņa (Riga, Latvia)
- D1.102** Patient-reported outcomes following beta-lactam antibiotic allergy delabeling work-up
M. Powietrzyński (Gdańsk, Poland)
- D1.103** Sensitization Pattern and Characteristics of IgE Repertoire in Allergic Children with Excessively High Serum IgE Levels
C.-M. Kang (Taipei, Taiwan)
- D1.104** Clinical relevance of troponin C (Cr a c 6) sensitization in crustacean allergy
L. Frattini Llorens (València, Spain)
- D1.105** Baricitinib in Refractory Cholinergic Urticaria with Generalized Eczematous Involvement: A Case Report
M. Sola Fernández (València, Spain)
- D1.106** Population-based IgE profiling of adolescents using a multiplex allergen array
J. Rehr (Salzburg, Austria)
- D1.107** B cell responses to alarmins in type 2 inflammation
H. Du (Davos, Switzerland)
- D1.108** Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials
N. Hammad (Port Said, Egypt)
- D1.109** Characterizing Elderly Asthma Hospitalizations: Insights into Treatment Gaps and Outcomes; A Real-World Study Using the MIMIC-IV Dataset
Q. Najah (Khoms, Libya)
- D1.110** Advances in Drug Allergy & Penicillin Testing Phase 2 (ADAPT-2): an AI-powered drug allergy educational initiative spanning across 4 localities
H. W. F. Mak (Hong Kong, Hong Kong)
- D1.111** Safety and predictors of tolerance in rituximab hypersensitivity management
L. Carrasco Gómez (Madrid, Spain)
- D1.112** Production of recombinant Cuc ma 5: A Step Towards Molecular Diagnosis of Pumpkin Seed Allergy
B. Acikalin (Ankara, Türkiye)
- D1.113** Molecular characterization of food allergens in a case of suspected honey and mustard allergy
M. L. Quiñones Obando (Cuenca, Spain)
- D1.114** IgE sensitisation to parvalbumin, Ani s 1, tropomyosin and arginine kinase delineates distinct molecular endotypes of seafood allergy
C. Casale (Modena, Italy)
- D1.115** Validation of the Portuguese version of the Food Allergy Quality of Life Questionnaire Adult Form (P-FAQLQ-AF)
P. Alves (Coimbra, Portugal)

16:45 - 18:15 JMA Poster session 6: Food Allergy/Anaphylaxis (Poster Zone, JMA)

Chair: *D. İlğün Gürel (Ankara, Türkiye), G. Zanoni (Verona, Italy)*

- D1.119** Ensemble Immunoinformatic Prediction Reveals Novel Allergen Candidates in *Nigella sativa* Seeds and Oil
E. Mehmedović (Tuzla, Bosnia and Herzegovina)
- D1.120** Impact of Polyethylene Terephthalate Microplastics on the Digestibility of Shrimp Allergen Tropomyosin
M. Krstic Ristivojevic (Belgrade, Serbia)
- D1.121** Peanut Materials Used for Immunoassay Calibration Exhibit Distinct Allergen Profiles
M. Bermingham (Cardiff, United Kingdom)
- D1.122** Molecular Identification of Heat-Stable β -Parvalbumin in megrim (*Lepidorhombus boscii*) as the Likely Allergen in a Child With Selective Fish Reactivity
A. Ventosa (Córdoba, Spain)
- D1.123** Endothelial glycocalyx shedding in IgE- and IgG-mediated anaphylaxis
L. Palacio-Garcia (Madrid, Spain)
- D1.124** IgE antibody function and mast cell activation to egg in children undergoing baked and loosely cooked egg challenges
V. Claro (London, United Kingdom)
- D1.125** Identification of lipid classes to differentiate anaphylactic from non-anaphylactic allergic reactions. BANA study
I. de María Camacho (Madrid, Spain)
- D1.126** High Prevalence of Clinical Tolerance to Avoided Foods in LTP-Sensitized Patients
M. Andúgar (Málaga, Spain)
- D1.127** Systemic inflammatory indices in relation to anaphylaxis symptoms in adults with food allergy
J. Wąsik (Łódź, Poland)
- D1.128** Clinical characterization and predictors of diagnosis and severity in sunflower seed allergy in a pediatric population
N. Guerrero Huertas (Madrid, Spain)
- D1.129** Food Protein-Induced Enterocolitis Syndrome To Fish: A Multicentre Study From Southern Europe
C. Ferrigno (Milano, Italy)
- D1.131** Novel food supplement containing a combination of bioactive compounds in pediatric cow's milk protein allergy: results from a randomized, placebo-controlled trial
L. Carucci (Naples, Italy)
- D1.132** Distinct Transcriptomic Responses Across Intestinal Segments in Egg Allergy Murine Model
O. Liong (Helsinki, Finland)
- D1.133** Chronic type non-IgE-mediated gastrointestinal food allergies, Clinical features and unclassified subgroup in the recent cohort
T. Yaguchi (Setagaya City, Japan)
- D1.134** Optimal Single and Combinatorial Diagnostic Approaches for Wheat Allergy in Chinese Children
W. Zheng (Shatin, Hong Kong)
- D1.135** Cold-induced urticaria: Phenotypic characterization and risk factors for cold-induced anaphylaxis
T. Correias Del Prado (San Sebastián de los Reyes, Spain)
- D1.136** Lipid metabolic remodeling in Food-induced anaphylaxis revealed by integrated proteomic and lipidomic analyses
S. Fernandez-Bravo (Madrid, Spain)

16:45 - 18:15 JMA Poster session 7: Pediatrics/Immunodeficiencies (Poster Zone, JMA)

Chair: *M. Kostara (Ioannina, Greece)*

- D1.144** Oral Deucricitibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial
P. Li (Hong Kong, Hong Kong)
- D1.145** Novel nanostructured carrier for effective management of Rheumatoid Arthritis by Topical delivery
V. Bhargava (Kanpur, India)
- D1.146** Advancing Paediatric Egg Allergy Management via Telemedicine: Outcomes of Remote Egg Ladder Support
A. Gallagher (Cork, Ireland)
- D1.147** Atopic dermatitis increases the risk of chronic systemic diseases in children and adolescents: a nationwide nested case-control study
S. Shin (Seoul, Korea, Republic of)
- D1.148** Genetic Analysis of Children with Suspected Immunodeficiency: Mimickers of Inborn Errors of Immunity
S. Y. Yilmaz (Konya, Türkiye)
- D1.149** Development and Validation of the Thai School-aged Children with Asthma Quality of Life Questionnaire (TSCA-QOL)
S. Rojnawee (Bangkok, Thailand)
- D1.150** Irish Infant Allergy and Nutrition: A Content Analysis of Public-Facing Online Guidance
L. Mack (Cork, Ireland)
- D1.151** Longitudinal Airway Immune Responses to Respiratory Viruses in Asthmatic and Atopic Children
K. Reddy Kamarajan (Tbilisi, Georgia)
- D1.152** Early-Life Dietary Diversity and the Risk of Atopic Dermatitis: A Nationwide Population-Based Cohort Study
J. H. Kim (Seoul, Korea, Republic of)
- D1.153** Development of a Peanut-Specific Human Mast Cell Assay for Screening Probiotics and other Nutritional Components with Anti-Allergic Potential
A. Breedveld (Utrecht, Netherlands)
- D1.154** Clinical heterogeneity of pediatric atopic dermatitis: latent class analysis
K. Dumycz (Warsaw, Poland)
- D1.155** Characterization of Unmet Need for Targeted Precision Medication in Atopic Dermatitis Due to Inadequate Response or Adverse Reactions to Dupilumab
L. Loop (San Diego, United States of America)
- D1.156** Neuropsychiatric events associated with montelukast in children: a systematic review
K. Moliszewska (Warszawa, Poland)
- D1.157** Activated PI3K δ Syndrome in Inborn Errors of Immunity: Diagnostic Strategies and Clinical Challenges
S. Bozkurt (Istanbul, Türkiye)
- D1.158** Incidental Low Serum IgE: A Marker of Underlying Inborn Errors of Immunity?
B. Gorgulu Akin (Ankara, Türkiye)
- D1.159** Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiencies (CVIDs): preliminary results of a multicenter retrospective observational study
D. Pilastro (Pavia, Italy)
- D1.160** Evaluation of User Experience with a Skin Prick Automated Test (SPAT) Device compared to a Manual Skin Prick Test (SPT) in Pediatric Patients
U. Pöppel (Bielefeld, Germany)
- D1.161** Evaluation of CD4⁺ CD8⁺ T Cell Population According to Patient Diagnostic Groups: A Single-Center Study
D. M. Durak Ansin (Ankara, Türkiye)

16:45 - 18:15 JMA Poster session 8: ENT/Asthma/Environmental Allergy/Ocupational Allergy (Poster Zone, JMA)

Chair: *D. İlgün Gürel (Ankara, Türkiye), G. Zanoni (Verona, Italy)*

- D1.164** Identification of Two IgE-Reactive Proteins in *Planococcus citri* Larvae: A Novel Case of Occupational Respiratory Allergy in a Pest-Control Laboratory Worker
A. E. Fernandez Fernandez (Alcalá de Henares, Spain)
- D1.165** Visualization of neutrophil extracellular traps (NETs) and autoantibodies targeting myeloperoxidase (MPO) and neutrophil elastase (NE) in sputum by confocal microscopy
S. Beyatli (London, United Kingdom)
- D1.166** Efficacy of Inhaled Granulocyte-Macrophage Colony-Stimulating Factor in Autoimmune Pulmonary Alveolar Proteinosis: A Meta-Analysis of Randomized Placebo-Controlled Trials
N. Hammad (Port Said, Egypt)
- D1.167** Combined Polymerized Pollen and Animal Dander Immunotherapy Improves Rhinoconjunctivitis and Asthma in Polysensitized Patients: Real-World Evidence
C. Campagner (Madrid, Spain)
- D1.168** Clinical and functional characteristics of patients with suspected epoxy resin-related occupational asthma
L. Aparicio Armengol (Madrid, Spain)
- D1.169** Beyond the Barrier: Does Atopic Dermatitis Shape Patch Test Reactivity? – A Romanian Retrospective Study
T-A. Apetrei (Bucharest, Romania)
- D1.171** Airborne pollen where and when it should not exist – Towards ‘allergy-safe’ environments or adopting a Planetary Health approach?
E. Papakonstantinou (Thessaloniki, Greece)
- D1.173** Evidence of Lower Airway Inflammation in Children with Allergic Rhinitis without Asthma
A. V. Soares (Porto, Portugal)
- D1.174** #berlinbreathing: An app-based citizen science project for pollen allergies
C. J. Hernandez Toro (Berlin, Germany)
- D1.175** Exploring the Early-Life Interplay Between Respiratory Health and Neurodevelopmental disorders
C. Grube (Gentofte, Denmark)
- D1.176** Secondary Domestic Exposure to Colophony as a Cause of Allergic Contact Dermatitis: A Case Report
P. Letón-Cabanillas (Madrid, Spain)
- D1.177** Occupational Cobalt Contact Dermatitis: Clinical Profile and Work implications
E. Baraketi (Tunis, Tunisia)
- D1.178** Long-term retention of mouse blood proteins in *Ixodes ricinus* suggests residual host blood as a potential source of α -Gal
J. Petry (Esch-sur-Alzette, Luxembourg)
- D1.179** Genetic Associations with Asthma in the Kazakh Population: A Case–Control Study
R. Bekmagambetova (Almaty, Kazakhstan)
- D1.180** Prognostic Evaluation of the Allergic March in Patients with Atopic Dermatitis
I. Turgay Yagmur (Ankara, Türkiye)
- D1.181** Hidden fragility behind optimal ACT score: identifying silent-risk phenotypes through clinical-biological dissociation
E. Cataldo (Roma, Italy)

16:45 - 18:15 OAS07 - Two faces of immune imbalance: immunodeficiencies and allergic diseases (Room Gothenburg, Oral Abstract Sessions)

Chair: E. Yucel (Istanbul, Türkiye), F. Cinetto (Treviso, Italy)

16:45 Allergic Phenotypes and Extremes of IgE Levels in Inborn Errors of Immunity

001850 S. Kaplan Sarikavak (Istanbul, Türkiye)

16:57 Retrospective evaluation of clinical and laboratory results of patients with Selective Immunoglobulin E Deficiency/Low

001423 H. Ercan Saricoban (Istanbul, Türkiye), A. Dagdeviren Ercan (Istanbul, Türkiye)

17:09 Drug Allergy in Primary Immunodeficiency: Clinical Spectrum and Predictors in Children

001435 C. Caka (Ankara, Türkiye)

17:21 Treatment Response and Survival in LRBA and CTLA-4 Deficiencies: A Turkish Multicenter Prospective Evaluation Experience

001228 S. Bozkurt (Istanbul, Türkiye)

17:33 Retrospective Evaluation of Allergic Diseases in Adults with Inborn Errors of Immunity: Experience of an Immunology Referral Center

000306 Ü. Ateş (İzmir, Türkiye)

17:45 Clinical and Immunological Spectrum of Spondyloenchondrodysplasia: Insights from Type I Interferon Signatures

000156 Z. Meric (Istanbul, Türkiye)

17:57 Evaluation of Hematologic Manifestations in Patients with Primary Antibody Deficiency: Single-Center Outcomes

001802 G. D. Isbilir Yasar (Ankara, Türkiye)

16:45 - 18:15 OAS08 - Markers of sensitization and tolerance in food allergy (Room Munich, Oral Abstract Sessions)

Chair: C. Anania (Rome, Italy), I. Skypala (London, United Kingdom)

16:45 Allergic Phenotypes and Extremes of IgE Levels in Inborn Errors of Immunity

001659 M. Fernandez Rivas (Madrid, Spain)

16:57 Molecular Clusters of Sensitization to Peanut, Tree Nuts, and Seeds in a Spanish Population

001461 M. J. Goikoetxea Lapresa (Pamplona, Spain)

17:09 The Importance of Clinical and Laboratory Findings in Predicting Tolerance Development in Food Protein Induced Enterocolitis Syndrome

001074 G. Kaymakoglu (İzmir, Türkiye)

17:21 Changes in age distribution and causative allergens in nationwide food allergy surveys in the past 2 decades

000649 C. Sugizaki (Sagamihara, Japan)

17:33 Oral Food Challenges to Nuts in Children: A Retrospective Study of Sensitization and Post-Challenge Tolerance

001477 A. Morales-Janke (Madrid, Spain)

17:45 When Do Symptoms Reflect Disease Activity in Pediatric Eosinophilic Esophagitis? An Age-Stratified Analysis

001737 S. Polat Terece (Ankara, Türkiye)

17:57 Higher levels of neonatal vitamin D are associated with reduced risk of persistent peanut allergy up to 10 years of age

000154 K. Perrett (Parkville, Australia)

16:45 - 18:15 SYM7 - Mast cell activation pathways in chronic urticaria beyond the high affinity IgE receptor (Room Paris, 2- Paris)

Chair: **M. Goncalo (Coimbra, Portugal), R. Asero (Paderno Dugnano, Milano, Italy)**

16:45 The coagulation cascade in CSU

M. Hide (Hiroshima, Japan)

17:15 The platelet activating factor and its activation

M. Metz (Berlin, Germany)

17:45 The MRGPRX2 receptor-induced mast cell degranulation

P. Kolkhir (Berlin, Germany)

16:45 - 18:15 TSY2 - Immediate drug hypersensitivity beyond IgE (Room Utrecht, 4- Utrecht, Thematic Symposium)

Chair: **A. Romano (Rome, Italy), J. A. Cornejo-Garcia (Málaga, Spain)**

16:45 Understanding MRGPRX2-Mediated IDHSRs

V. Sabato (Antwerp, Belgium)

17:15 Beyond MRGPRX2: Exploring alternative mechanisms in Non-IgE-Mediated IDHSRs

S. Alvarez Arango (Dallas, United States of America)

17:45 Non-IgE-Mediated IDHSRs: Current biomarkers and the quest for better diagnostic

M. Kumar (Pok Fu Lam, Hong Kong)

16:45 - 18:30 SYM8 - Environmental exposures and immunity (Room Florence, 3- Florence, Symposium)

Chair: **U. M. Sahiner (Ankara, Türkiye), I. Paciência (Oulu, Finland)**

16:45 Air pollution and immunity

C. Traidl-Hoffmann (Augsburg, Germany)

17:15 Climate and climate change and immunity

R. Pawankar (Tokyo, Japan)

17:45 Solar radiation, infection and inflammation

C. Skevaki (Marburg, Germany)

18:00 - 18:30 Mini-Satellite Symposium

(Room London, Sponsored Sessions)

18:00 - 18:30 Mini-Satellite Symposium

(Room Krakow, Sponsored Sessions)

18:30 - 19:30 Opening Ceremony

(Room Istanbul, 1- Istanbul, Ceremony)

07:45 - 08:30 MTE 5 - Practical management of venom immunotherapy
(Room Gothenburg, Meet The Expert)

07:45 Practical management of venom immunotherapy
M. B. Bilò (Ancona, Italy)

07:45 - 08:30 MTE 6 - Management of anaphylaxis
(Room Munich, Meet The Expert)

07:45 Management of anaphylaxis
A. Muraro (Padova, Italy)

07:45 - 08:30 MTE 7 - Designing meaningful registries and RWE in airway allergy
(Room Athens, Meet The Expert)

07:45 Designing meaningful registries and RWE in airway allergy
M. Kupczyk (Łódź, Poland)

07:45 - 08:30 MTE 8 - Regional differences in sensitization patterns to pollen allergens
(Room Glasgow, Meet The Expert)

07:45 Regional differences in sensitization patterns to pollen allergens
H.-J. Huang (Vienna, Austria)

08:30 - 10:00 IH 3 - In vitro testing in immediate drug allergy
(Innovation Hub, Innovation Hub)

Chair: P. Kopac (Golnik, Slovenia), S. Alvarez Arango (Dallas, United States of America)

08:30 Common pitfalls in in-vitro testing
O. Hausmann (Lucerne, Switzerland)

09:00 New biomarkers in drug anaphylaxis
V. Esteban (Madrid, Spain)

09:30 Comparison of specific IgE and BAT
L. H. Garvey (Hellerup, Denmark)

08:30 - 10:00 IWS6 - How to manage a red face? (Room Utrecht, 4- Utrecht, Interactive Workshop)

Chair: **B. Buyuktiryaki (Istanbul, Türkiye), T. Zuberbier (Berlin, Germany)**

08:30 Head and neck dermatitis in atopic dermatitis

A. Soria (Paris, France)

09:00 How to determine the cause of a face contact dermatitis?

M. Goncalo (Coimbra, Portugal)

09:30 All the red faces are not allergic

O. Su Kucuk (Istanbul, Türkiye)

08:30 - 10:00 JMA4 - Type 2 vs. Non-Type 2 Asthma: Differences, overlaps, and treatment challenges (Room Krakow, JMA)

Chair: **P. Alves (Coimbra, Portugal), A. F. Kalpaklıoglu (Ankara, Türkiye)**

08:30 Can Type 2 biologics be effective for non-Type 2 asthma?

C. Janson (Uppsala, Sweden)

09:00 New biomarkers for treatment stratification

Y. GAO (Hangzhou, China)

09:30 Emerging biologics and their real-world effectiveness.

O. Can Bostan (Istanbul, Türkiye)

08:30 - 10:00 OAS09 - Angioedema (Room Gothenburg, Oral Abstract Sessions)

Chair: **M. Bova (Napoli, Italy), M. Guilarte (Barcelona, Spain)**

08:30 Hereditary angioedema due to F12 gene mutations: clinical and genetic characterization of nine Spanish families

001355 L. E. Panique Lazcano (Madrid, Spain)

08:42 When On-Demand Therapy Falls Short: Behavioural Factors Undermining Attack Control in Older Adults with C1-Inhibitor Hereditary Angioedema from the ITACA Network

001565 L. C. Zingale (Milan, Italy)

08:54 Therapeutic Management of Hereditary Angioedema Attacks by Patients: Analysis of Barriers to Early Treatment

001715 A. Bocquet (Grenoble, France)

09:06 Clinical Characteristics And Unmet Treatment Needs In Patients With Hereditary Angioedema Treated With Long-Term Prophylaxis In Europe: A Real-World Survey

000801 S. Cimbollek (Sevilla, Spain)

09:18 Towards total disease control in hereditary angioedema: development of an integrated optimal care pathway in Spain

001499 T. Caballero (Madrid, Spain)

09:30 A Comprehensive Assessment of Health-Related Quality of Life in Hereditary Angioedema as a Patient Centered Approach

001236 E. Yalcin Gungoren (Istanbul, Türkiye)

09:42 POLYPHEMOS study: a cartography of normal C1-INH-HAE and recurrent isolated angioedema among the Italian Reference Centers Network for Angioedema (ITACA) over the last 10 years

000840 D. Firinu (Monserrato, Italy)

09:54 Analyzing the clinical profile and potential biomarkers to differentiate idiopathic angioedema from hereditary or mast cell-mediated angioedema

001421 J. Liu (Beijing, China)

08:30 - 10:00 OAS10 - Immunologic mechanisms and biomarkers in AIT

(Room Munich Oral Abstract Sessions)

Chair: **M. Pérez-Gordo (Madrid, Spain), U. M. Sahiner (Ankara, Türkiye)**

08:30 Insights on the Unknown Role of IgD⁺ Memory B Cells in Allergy and Tolerance

001381 J.-F. Lopez (Davos, Switzerland)

08:42 Functional CD52⁺ Regulatory T cells as Biomarkers of Immune Tolerance in Grass Pollen Immunotherapy

001400 J. Han (London, United Kingdom)

08:54 Clinical Development of Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergic patients – results from 5 consecutive trials

001413 R. Mösges (Cologne, Germany)

09:06 Regulatory B-Cell Differentiation during Allergen Immunotherapy Is Driven by a BACH2/SMAD3 Transcriptional Program

000738 A. Gabr (Munich, Germany)

09:18 Rational design of a Der p 2 hypoallergen based on three IgE dominant epitopes

000521 A. Pomés (Charlottesville, United States of America)

09:30 Serum Metabolomic Profiling Identifies Taurolithocholic Acid as a Predictor of HDM SCIT Response in Allergic Rhinitis: Clinical Discovery and Experimental Validation

000645 J. Zhang (Beijing, China)

09:42 Plasma Proteomic Signatures of Sustained Unresponsiveness in Pediatric Peanut Oral Immunotherapy

001168 A. S. Y. Leung (Hong Kong, China)

08:30 - 10:00 SYM10 - Lymphoid cells: Metabolic modulation in allergy

(Room Florence, 3- Florence, Symposium)

Chair: **G. Deniz (Istanbul, Türkiye), C. Aranda Clemente (Málaga, Spain)**

08:30 Metabolic control of MAIT cell responses

A. E. Hogan (Maynooth, Ireland)

09:00 NK cells in AIT

L. Aglas (Helsinki, Finland)

09:30 Gamma - Delta T cells in allergic diseases

M. Muñoz-Ruiz (Madrid, Spain)

08:30 - 10:00 SYM11 - Immunotherapy and asthma

(Room Zurich, 5- Zurich, Symposium)

Chair: **D. Barber (Madrid, Spain), J. Kappen (The Hague, Netherlands)**

08:30 Unmet needs of current allergic asthma therapy?

G. W. Canonica (Milan, Italy)

09:00 Outcome measures of AIT in asthma

Z. Celebi sozener (Ankara, Türkiye)

09:30 Severe asthma and AIT: a good marriage

C. Porsbjerg (Copenhagen, Denmark)

08:30 - 10:00 SYM33 - Planetary health considerations in asthma and allergy management (Room Istanbul, 1- Istanbul, Symposium)

Chair: *H. Bayram (Istanbul, Türkiye), Z. Diamant (Groningen, Netherlands)*

08:30 Foundations of planetary health in the context of respiratory health

E. Fuertes (London, United Kingdom)

09:00 Integrating planetary health into clinical guidelines: The case of asthma and allergy

A. Bognanni (Milan, Italy)

09:30 Evaluating allergy interventions: Integrating planetary health into health technology assessment

R. J. Vieira (Porto, Portugal)

08:30 - 10:00 SYM09 - Applying biomarkers for respiratory allergy (Room Istanbul, 1- Istanbul, Symposium)

Chair: *J. Dominguez-Ortega (Madrid, Spain), J. Bousquet (Montpellier, France)*

08:30 Biomarkers for allergic inflammation in chronic rhinitis

I. Eguiluz (Malaga, Spain)

09:00 Biomarkers to choose a biological treatment in chronic rhinosinusitis

L. Klimek (Wiesbaden, Germany)

09:30 Patient-centered digital biomarkers in asthma

B. Sousa-Pinto (Porto, Portugal)

08:45 - 09:45 L-FT03 - Skin Allergy (Room Athens, Flash Talks)

Chair: *M. Pereira (Berlin, Germany)*

08:45 Social Exposome in Atopic Dermatitis

100069 H. Mehta (Chandigarh, India)

08:52 Changing the Standard of Care: Outcomes of a Regional Atopic Dermatitis Implementation Program in Argentina

100095 C. Cavallo (Parana, Argentina)

08:59 Longitudinal blood proteomics in childhood atopic dermatitis

100273 A.-M. Schoos (Copenhagen, Denmark)

09:06 Association Between Inflammatory Markers and Median Nerve Sensory Conduction Velocity in Chronic Spontaneous Urticaria: A Neuroinflammatory Perspective

100435 E. Lekli (Tirana, Albania)

09:13 Provocation tests in Chronic Inducible Urticaria

100439 J. Guimarães (Setúbal, Portugal)

09:20 Effectiveness of a digital care concept for patients with atopic dermatitis – results of the ADCompanion multicentre randomised controlled trial

100476 J. Telschow (Berlin, Germany)

09:27 The effect of Bifidobacterium longum subspecies infantis EVC001 in reducing the risk of atopic dermatitis in high-risk infants - A randomized, double-blind, placebo-controlled trial

100548 P. Kuokkanen (Helsinki, Finland)

08:45 - 09:45 L-FT04 - Immune deficiencies and autoimmunity

(Room Glasgow, Flash Talks)

Chair: S. Lau (Berlin, Germany)

- 08:45** Prospective Evaluation of Quality of Life in Pediatric Patients with IgG Subclass Deficiency Receiving IVIG Replacement Therapy
100029 L. KILINÇKAYA (Sakarya, Türkiye)
- 08:52** Integrative Transcriptomics and Machine Learning Identify Osteoblast Immunology Dysregulation in STAT3 LOF Hyper-IgE Syndrome
100082 R. Garg (Chandigarh, India)
- 08:59** Long Term Outcome of Bone Marrow Transplantation In NIK Deficiency: Essential Role of Non-Canonical NF-κB Signaling In Thymic Reconstitution and Lymph Node Development
100178 A. S. Köstel Bal (Ankara, Türkiye)
- 09:06** Beyond Food Allergy: Autoimmune Enteropathy and VEO-IBD as Red Flags for Inborn Errors of Immunity
100263 P. Falabella (Esplugues de Llobregat, Spain)
- 09:13** CD3 subunit deficiencies
100491 L. Lamara Mohammed (Beni Messous, Algeria)
- 09:20** Thoracic CT Phenotypes of Lung Disease in Common Variable Immunodeficiency
100737 O. Ozturk Aktas (Ankara, Türkiye)
- 09:27** HAELO, a Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran Ziclumeran, a CRISPR-Based Gene Editing Therapy, in Patients with Hereditary Angioedema
100217 D. M. Cohn (Amsterdam, Netherlands)
- 09:34** Onvuzosiran provides deep and sustained reduction of plasma kallikrein levels for the treatment of HAE
100399 M. Cancian (Padova, Italy)

09:00 - 09:15 Romania - ROMANIAN SOCIETY OF ALLERGOLOGY AND CLINICAL IMMUNOLOGY (EAACI Global Stage, NAIS Session)

- 09:00** The way to performance in allergology
C. Berghea (Bucureşti, Romania)

09:00 - 10:00 Satellite Symposium (Room London, Sponsored Sessions)

09:15 - 09:30 Italy - Italian Society of Allergology and Clinical Immunology (SIAIC) (EAACI Global Stage, NAIS Session)

- 09:15** Climate Change, Air Quality and the Rising Burden of Allergic and Immunologic Diseases: New Challenges and Precision Strategies.

09:30 - 09:45 Germany - German Society of Allergology (AEDA) (EAACI Global Stage, NAIS Session)

- 09:30** Registries for chronic airway diseases
F. Bärhold (Wiesbaden, Germany)

09:45 - 10:00 Türkiye - Turkish Thoracic Society
(EAACI Global Stage, NAIS Session)

09:45 Pulmonology meets allergy: A multidisciplinary perspective on severe asthma from Türkiye
E. Damadoğlu (Ankara, Türkiye)

10:15 - 11:45 PL4 - Advances in immunotherapy
(Room Istanbul, 1- Istanbul, Plenary Lectures)

Chair: **O. Pfaar (Marburg, Germany), O. Palomares (Madrid, Spain)**

10:15 Allergen-specific B cell dynamics in peanut and cashew oral immunotherapy
M. Akdis (Davos Wolfgang, Switzerland)

10:45 Immunological reprogramming through lipid transfer protein SLIT
M. Torres (Malaga, Spain)

11:15 Bridging basic science, biomarkers, and artificial intelligence
M. Shamji (London, United Kingdom)

10:15 - 11:45 PL5 - Novel insights into allergy mechanisms
(Room Paris, 2- Paris, Plenary Lectures)

Chair: **I. Adcock (London, United Kingdom), M. Sokolowska (Davos, Switzerland)**

10:15 Mitochondrial control of tissue homeostasis
G. NAMASIVAYAM (Kyoto, Japan)

10:45 Gut epithelial-immune circuits
T. Chatila (Boston, United States of America)

11:15 Commensal bacteria
J. Coquet (Stockholm, Sweden)

10:15 - 11:45 PL6 - EAACI-AAAAI PRACTALL: Clinical algorithms in mastocytosis
(Room Florence, 3- Florence, Plenary Lectures)

Chair: **J. Walusiak-Skorupa (Lodz, Poland), F. S. Virant (Seattle, United States of America)**

10:15 Diagnostic approach to pediatric mastocytosis
M. Carter (Bethesda, United States of America)

10:33 Diagnostic approach to systemic mastocytosis in adults
C. Akin (Michigan, United States of America)

10:51 Management of anaphylaxis risk in mastocytosis
P. Bonadonna (Vicenza, Italy)

11:09 Management of symptomatic and cytoreductive treatments
V. Sabato (Antwerp, Belgium)

11:27 Long-term follow-up and unmet needs
T. Pongdee (Rochester, United States of America)

12:00 - 12:15 Greece - Greek Pediatric Allergy Society (GPAS) (EAACI Global Stage, NAIS Session)

12:00 From Guidelines to Real Life: National Initiatives to Support Allergic Children in Greece During the Past Year
M. Papadopoulos (Athens, Greece)

12:00 - 13:00 L-FT06 - Food allergy (Room Glasgow, Flash Talks)

Chair: S. Lau (Berlin, Germany), H. Sampson (New York, United States of America)

12:00 Investigation of Sensory Integration and Praxis Functions in Children with IgE-Mediated Food Allergy: A Prospective Case-Control Study

100518 B. uzunoğlu (İzmir, Türkiye)

12:07 Comparative Evaluation Of Seven Severity Grading Systems In Pediatric Oral Food Challenges: Distinctions Between Anaphylactic And Non-Anaphylactic Reactions

100081 T. Y. akın (İzmit, Türkiye)

12:14 A Clinical History-, Skin Prick Test- and Specific IgE-Based Algorithm to Safely Reduce Unnecessary Elimination in Pediatric Tree Nut and Peanut Allergy

100083 T. Y. akın (İzmit, Türkiye)

12:21 Evaluation of Pediatric Patients Diagnosed with Food Protein-Induced Enterocolitis Syndrome

100202 A. Toksoz (Ankara, Türkiye)

12:28 Component-resolved diagnosis in nut and peanut allergy across Spain in patients from the BIOGRAL study

100394 R. N. Vera-Berrios (Madrid, Spain)

12:35 Food challenges in a District General Hospital: Ethnic and Deprivation index variations

100451 S. KAUR (Smethwick, United Kingdom)

12:42 Stepwise reintroduction of culprit antigens in cow's milk and hen's egg triggered pedEoE: clinical outcomes, local IgG4 and systemic immune responses

100581 C. Keppens (Leuven, Belgium)

12:00 - 13:00 L-OAS06 - Allergen immunotherapy (Room Munich, Oral Abstract Sessions)

Chair: A. Bozek (Katowice, Poland)

12:00 Distinct baseline functional profiles of peanut-reactive T cells associate with sustained unresponsiveness after oral immunotherapy

100037 D. Ni (Camperdown, Australia)

12:12 Rational design and recombinant expression of a multi-epitope chimera targeting major cow's milk allergens

100438 K. Souza Santos (São Paulo, Brazil)

12:24 Explainable Machine Learning Integrating Symptom–Medication Scores and Component-Resolved Diagnostics to Predict 1-Year Outcomes of Dual-Mite Subcutaneous Allergen Immunotherapy: A Multi-Center Study

100454 Y. Fu (Wuhan, China)

12:36 OFC before OIT: Accurate diagnosis of peanut allergy using a threshold oral food challenge in the ADAPT peanut oral immunotherapy program

100480 T. Brettig (Melbourne, Australia)

12:48 Dynamic remodeling of the plasma proteome during cashew oral immunotherapy

100593 H. Babayev (Davos, Switzerland)

12:00 - 13:00 OAS11 - Microbiome profile in controlling inflammation

(Room Gothenburg, Oral Abstract Sessions)

Chair: C. Riggioni-Viquez (Toronto, Canada), L. O'Mahony (Cork, Ireland)

12:00 The Upper-Airway Microbiome Involved in Asthma Exacerbations is Associated with Methylation Markers Linked to Immunity and Asthma Comorbidities

001781 E. Martin-Gonzalez (La Laguna, Spain)

12:12 Comparative Nasal Microbiome Signatures Across Distinct Primary Antibody Deficiency Phenotypes

001105 S. Aydemir (Istanbul, Türkiye)

12:24 Early life oral microbiome and risk of subsequent eczema and food allergy

001229 D. J. Lopez (Parkville, Australia)

12:36 Cutaneous Microbiome Profiles in Individuals With HIV: Links to Antiretroviral Treatment and Host Characteristics

001953 M. Anshory (Rotterdam, Netherlands)

12:00 - 13:00 TPS - Poster Sessions

(Poster Area, Poster Walk)

12:00 - 13:00 SSS3 - EAACI AAAeIC Sister Society Symposium

(Room Florence, 3- Florence, Sister Society Symposium)

Chair: S. De Barayazarra (Córdoba, Argentina), C. Cavallo (Paraná, Argentina)

Real-Life Epidemiological Data on Cow's Milk Protein Allergy in Pediatric Patients from Buenos Aires

S. Monsell (Ciudad Autónoma de Buenos Aires, Argentina)

False Labels, Real Consequences: Facing the Challenge of Antibiotic Allergy Delabeling in Argentina

J. Martinez (Buenos Aires, Argentina)

NoPhenotyping and remission outcome with biologic therapy in allergic patients with severe asthma.

Real World experience from Argentina

C. Ritchie (Argentina)

12:00 - 13:00 Satellite Symposium

(Room Paris, Sponsored Sessions)

12:00 - 13:00 Satellite Symposium

(Room Utrecht, Sponsored Sessions)

12:00 - 13:00 Satellite Symposium

(Room Zurich, Sponsored Sessions)

12:00 - 13:00 Satellite Symposium

(Room Krakow, Sponsored Sessions)

12:00 - 13:00 L-TPS09 - Allergy diagnosis 19

(Poster Zone, Thematic Poster Session)

Chair: J. L. Paris (Málaga, Spain), G. Wandalsen (Sao Paulo, Brazil)

- D2.75** Prevalence of Attention Deficit Hyperactivity Disorder and Related Factors in Children Aged 6-14 Years Diagnosed with Allergic Rhinitis
S. Çevik (Istanbul, Türkiye)

- D2.76** Disease Control, Activity and Quality of Life in Chronic Spontaneous Urticaria A Cross-Sectional Study from Kazakhstan
A. Batyrbaeva (Almaty, Kazakhstan)

- D2.77** Lanadelumab in C1-Esterase Inhibitor Non-Responding patient: A Case Report
A. Batyrbaeva (Almaty, Kazakhstan)

- D2.78** Comparative analysis of IgE reactivity to fish extracts versus beta-parvalbumin molecules in allergic patients
Y. Marushko (Kyiv, Ukraine)

- D2.79** Cannabis Sensitization as an Underrecognized Airborne Trigger in Uncontrolled Asthma: A Case Report
C. Batard Ruiz (Berlin, Germany)

- D2.80** Development of Standardized Case Report Forms to Support Biomarker-Based Differential Diagnosis of Bradykinin-Mediated Angioedema
Z. Kalikyan (Yerevan, Armenia)

- D2.82** Analytical Performance Evaluation of Cor a 8, Cor a 9, and Cor a 14 Hazelnut Components on IMMULITE 2000 XPi*
N. Ready (Llanberis, United Kingdom)

- D2.83** Management of Non IgE Cow's Milk Allergy: Current Practices and Challenges
A. Das (Glasgow, United Kingdom)

- D2.84** Avoiding Mislabeling of Drug Allergy in Patients with Recurrent Cutaneous Symptoms
S. Flores Regalo (Coimbra, Portugal)

- D2.85** Analytical Performance Evaluation of Bet v 4 and Cor a 1 on IMMULITE 2000 XPi*
N. Ready (Llanberis, United Kingdom)

- D2.86** Nasal Nitric Oxide in Routine Practice: Results of a One-Year Clinical Experience in Pediatric Allergology
Y. Marushko (Kyiv, Ukraine)

- D2.88** Drug Provocation Testing for Suspected Beta-Lactam Allergy in Children: Experience from a Secondary Hospital in the Community of Madrid
N. Cerdeira (Madrid, Spain)

- D2.89** Basophil Testing Beyond Positivity: Are There More Endotypes in Chronic Spontaneous Urticaria?
S. Flores Regalo (Coimbra, Portugal)

12:00 - 13:00 L-TPS11 - Allergy diagnosis 20

(Poster Zone, Thematic Poster Session)

- D2.90** Potato Allergy in Children: Clinical Features, Laboratory Findings, and Tolerance Development
Z. Gulec Koksall (Ankara, Türkiye)
- D2.91** Exploring Geographic Differences in Ragweed and Mugwort Hypersensitivity Among Patients with Respiratory Symptoms of Allergy in Eastern and Western Europe
K. Gashynova (Dnipro, Ukraine)
- D2.92** LTP-Mediated Corn-Induced Anaphylaxis
V. Brocovschii (Chişinău, Moldova)
- D2.93** The role of tropomyosins in allergenic cross-reactivity
S. Cemirtan (Chişinău, Moldova)
- D2.94** Anaphylaxis to human serum albumin in a patient with liver cirrhosis – a diagnostic challenge
D. N. Silva (Porto, Portugal)
- D2.95** Comparative Molecular IgE Sensitization Patterns Across Developmental Stages: A Cross-Sectional Study in Clinical Cohorts from Ankara and Tehran
M. Mesdaghi (Tehran, Iran, Islamic Republic of)
- D2.96** Perioperative Anaphylaxis in Sri Lanka: Evaluation in a Low-Resource Setting
P. H. Chathurangika (Colombo, Sri Lanka)
- D2.97** Overall Prevalence and Particular Importance of Studying Sensitization to Peanut Molecules
M. Vafokulova (Tashkent, Uzbekistan)
- D2.99** The mysterious cases of anaphylaxis to döner kebab in Germany/Switzerland with subsequent tolerance in Türkiye: an unwelcome guest causes trouble
C. Morales Mateluna (Basel, Switzerland)
- D2.98** Allergic Contact Dermatitis from 2-Hydroxyethyl Methacrylate in a Nail Technician
S. Cemirtan (Chişinău, Moldova)
- D2.100** Carcinoid Crisis Mimicking IgE-Mediated Hypersensitivity Reaction During Peptide Receptor Radionuclide Therapy (PRRT): A Diagnostic Dilemma
B. Baghlaf (Riyadh, Saudi Arabia)
- D2.101** Phenotypic and molecular characterization of a large multi-family Hereditary Angioedema type 1 cluster in Boyacá, Colombia
C. Gomez Parada (Bogotá, Colombia)
- D2.102** Hidden metal triggers in allergic contact dermatitis
V. Brocovschii (Chişinău, Moldova)
- D2.103** Severe Persistent Allergic Rhinitis in an Adolescent: A SNOT-22–Based Case Report
L. Mouangue-Mbonjo (Yaounde, Cameroon)
- D2.104** Mental Health Care and Support in Patients with Atopic Dermatitis in Kazakhstan: One-Year Follow-Up Study
Z. Ispayeva (Almaty, Kazakhstan)

12:00 - 13:00 L-TPS10 - Allergy diagnosis 20
(Poster Zone, Thematic Poster Session)

Chair: **A. Gabr (München, Germany)**

- D2.165** Geographic Disparities in Air Pollution and Th2-Mediated Airway Inflammation in Pediatric Asthma: A Cross-Sectional Study from Mexico City
L. A. Hernandez Zarate (Ciudad de México, Mexico)
- D2.166** The role of microcirculatory disorders in children with asthma during exacerbation and remission
A. Khurgaeva (Moskva, Russia), P. Berezhanskiy (Moskva, Russia)
- D2.167** Impact of body mass index on oscillometry parameters in children with respiratory symptoms
R. Sá Teixeira (Vila Nova de Gaia, Portugal)
- D2.168** Impact of type two inflammation inflammation suppression on polyp burden in patients with nasal polyposis and concomitant asthma a comparative evaluation of biologic therapies
E. Atayik (Konya, Türkiye)
- D2.169** TLR8-dependent differential signal transduction induced by methanogenic archaea is controlled by NF-κB p65- and STAT1/2-regulated gene classes
H. Heine (Borstel, Germany)
- D2.170** Real-world effectiveness of anti-IL-5/IL-5Rα agents as induction therapy in eosinophilic granulomatosis with polyangiitis
L. de las Vecillas Sanchez (Madrid, Spain)
- D2.171** Clinical and demographic characteristics associated with a classification as difficult-to-treat asthma: data from the EPI-ASTHMA study
A. M. Pereira (Porto, Portugal)
- D2.172** Effectiveness of Mepolizumab in patients with severe asthma and allergic rhinitis: Real-World Evidence from the TYREX Study
J. Dominguez-Ortega (Madrid, Spain)
- D2.173** Real-World Evidence From the TYREX Study on the effectiveness of Mepolizumab in patients with severe asthma and clinically relevant aeroallergen sensitization
J. Dominguez-Ortega (Madrid, Spain)
- D2.174** Association Between Environmental Conditions and Mold Sensitization in Children with Allergic Rhinitis and Asthma
D. ALTINTAŞ (ANTALYA, Türkiye)
- D2.175** Five-Year Real-World Outcomes of Mepolizumab Treatment in Severe Eosinophilic Asthma
B. Huttyrova (Olomouc, Czech Republic)
- D2.176** Comparison of different treatment strategies for allergic rhinitis in children and their impact on bronchial asthma
M. Malysheva (Moscow, Russia)
- D2.177** Developmental Problems and Maternal Perception of Child Vulnerability in Children Aged 2–5 Years Diagnosed with Asthma
Ç. Torun Özel (Ankara, Türkiye)
- D2.178** Evaluation of Therapeutic Potential of The miRNAs In Asthma via Transfection of Airway Epithelial Cells with Agomir/Antagomir Loaded Exosomes
E. Birben (Ankara, Türkiye)
- D2.179** Chronic cough triggered by industrialised milk and wheat products
K. Kefala (Paris, France)

12:00 - 13:00 L-TPS12 - Dermatology 07

(Poster Zone, Thematic Poster Session)

Chair: **A. Bingol (Antalya, Türkiye), M. Triggiani (Salerno, Italy)**

- D2.261** Mental health and quality of life in patients with chronic spontaneous urticaria
C. Maçães (Vila Nova de Gaia, Portugal)

- D2.264** Food Allergy in Ukrainian Children: Risk Factors, Early Allergen Introduction and Natural History
O. Mozyrska (Kyiv, Ukraine)

- D2.265** Standard dosage vs. increased dosage of non-sedating antihistamines in pharmacotherapy of chronic spontaneous urticaria
A. Vitshuk (Smolensk, Russia)

- D2.266** Comparative Efficacy of Dupilumab, Janus Kinase Inhibitors, and Conventional Immunosuppressants on Neuropsychiatric Outcomes in Patients with Atopic Dermatitis: A Retrospective Cohort Study
T.-J. Li (Taichung, Taiwan)

- D2.267** Real-World Clinical Outcomes of Chronic Urticaria Patients in Greece: Longitudinal Data from the CURE Registry
E. Chatzimina (Chaidari, Greece)

- D2.268** Clinical characteristics and Therapeutic Management of Hereditary Angioedema due to C1-Inhibitor Deficiency: A Retrospective Cohort Study in Colombia
M. Sarrazola Sanjuan (Cucuta, NdS. , Colombia)

- D2.269** Predictors of Poor Disease Control in Greek Patients with Chronic Urticaria: Real-World Evidence from the CURE Registry
E. Chatzimina (Athens, Greece)

- D2.270** Clinical and Laboratory predictors of treatment response among adult Egyptian patients with Chronic Spontaneous Urticaria
M. Farouk (Cairo, Egypt)

- D2.271** The effect of Organic Light Emitting Diode(OLED) phototherapy in atopic mouse model
S. T. Kim (Incheon, Korea, Republic of)

- D2.272** Long-Term Remission Patterns in Chronic Spontaneous Urticaria: A Real-Life Cohort Study
E. Açar (Kayseri, Türkiye)

- D2.273** The frequency of metal sensitisation in patients who are about to undergo joint replacement
G. Marco-Martín (Madrid, Spain)

12:00 - 13:00 L-TPS13 - Food allergy 07

(Poster Zone, Thematic Poster Session)

Chair: **A. Bingol (Antalya, Türkiye), M. Triggiani (Salerno, Italy)**

- D2.303** The effect of extrusion on the in vivo allergenicity of pistachio and walnut in allergic children
S. Vasileiadou (Athens, Greece)

- D2.304** Allergy and Exercise: A Sporting Challenge
F. Pilz (München, Germany)

- D2.305** Alpha-gal syndrome
T. Piñero Cáceres (Santa Cruz de Tenerife, Spain)

- D2.306** From baked cookie to unheated milk: Desensitization in a high-risk cow's milk protein allergy patient
T. Piñero Cáceres (Santa Cruz de Tenerife, Spain)

- D2.307** Parental and Healthcare Professional Experiences of Food Allergen Introduction during Complementary Feeding: A Behavioural Theory-Informed Systematic Review
K. Wright (Southampton, United Kingdom)

- D2.308** Diet quality and intake behaviours among alpha-gal-positive patients at a specialized allergy clinic in Sri Lanka
J. Jayamali (Nugegoda, Sri Lanka)

- D2.309** HAL-MPE1, a novel subcutaneous immunotherapy candidate for peanut allergy. Phase I randomized placebo-controlled study
K. Bluemchen (Frankfurt am Main, Germany)

- D2.313** Scientific Evidence Gaps in FAO/WHO Food Allergen Threshold Guidance: Implications for Risk Assessment and Regulatory Decision-Making
B. JAVED (Oldham, United Kingdom)

- D2.314** Food Protein-Induced Enterocolitis Syndrome To Fish: A Multicentre Study From Southern Europe
C. Ferrigno (Milano, Italy)

- D2.315** Clinical Characteristics and Diagnostic Challenges in Pediatric Peanut and Tree Nut Allergies: The Impact of Unnecessary Elimination
G. Kiğılı (Istanbul, Türkiye)

- D2.316** Novel Homozygous Mutation in CARD11 gene Predisposing To Recurrent Infections and Atopies, and Response to Immunoglobulin therapy
D. AL-Zahrani (Jeddah , Saudi Arabia)

- D2.317** "Cutaneous Anaphylaxis to Raw Egg White in a Patient with Established Oral Tolerance: Clinical Evidence Supporting the Dual-Allergen-Exposure Hypothesis"
G. Yáñez Lema (Barcelona, Spain)

12:00 - 13:00 L-TPS14 - Anaphylaxis 06

(Poster Zone, Thematic Poster Session)

Chair: R. Bahri (Manchester, United Kingdom), C. Sackesen (İstanbul, Türkiye)

- D2.332** First reported case of IgE-mediated food allergy to *Tetragonia tetragonioides* (New Zealand spinach)
A.-C. Fougerousse (Saint-Mandé, France)

- D2.333** Glatiramer acetate: when immunomodulation is not enough
I. Baglivo (Rome, Italy)

- D2.334** Gut microbiome in adults with shrimp anaphylaxis compare to healthy control
P. Boriboon (Thung Phaya Thai, Bangkok, Thailand)

- D2.335** Single-nucleotide polymorphisms in the Mas-related G protein-coupled receptor X2 alter in vitro cellular responses to specific drugs
G. Porebski (Krakow, Poland)

- D2.336** Risk of systemic reactions among school-age children sensitized to fish, crustaceans and molluscs
E. Moskovenko (Kyiv, Ukraine)

- D2.337** REMA Score Outperforms C-kit and Tryptase in Identifying Mast Cell Disorders in Hymenoptera Venom Allergy
P. Harbham (London, United Kingdom)

- D2.338** Gaps in Adrenaline Autoinjector Education Among Patients at Risk of Anaphylaxis: A Cross-Sectional Study
E. Cichocka-Jarosz (Kraków, Poland)

- D2.339** Cutaneous exposure to food allergens as an underrecognized trigger of anaphylaxis in children
J. Biela-Mazur (Rabka-Zdrój, Poland)

- D2.340** Improving Post-Anaphylaxis Referral Pathways in the Emergency Department: A Quality Improvement Initiative
A. Sivadasan (Leicester, United Kingdom)

- D2.341** Comparative Evaluation of Diagnostic Criteria for Food Allergy-Induced Anaphylaxis: Accuracy, Clinical Applicability, and Validation
E. Anastasiou (Athens, Greece)

- D2.342** Environmental Exposure Predicts Severity of Hymenoptera Venom Anaphylaxis Better Than Classical Biomarkers: Added Value of Component-Resolved Diagnostics
N. ANDREWS VON JOHNN (Santiago, Chile)

- D2.343** Anaphylactic Reaction to Methylprednisolone Acetate in a Young Adult
N. Petridou (Athina, Greece)

- D2.344** National Data on Anaphylaxis in Brazil: Findings from the Brazilian Registry
M. Felix (Rio de Janeiro, Brazil)

- D2.345** Successful Desensitization in a Pediatric Patient Who Developed an Immediate-Type Systemic Hypersensitivity Reaction to FVIII/vWF Concentrate
C. Duran (Istanbul, Türkiye)

- D2.346** When cold triggers anaphylaxis
J. Coelho (Faro, Portugal)

- D2.347** Filaggrin Mutation in a Patient with Ant Anaphylaxis: Case Report and Literature Review
M. Jefri (Riyadh, Saudi Arabia)

12:00 - 13:00 L-TPS15 - Immune deficiencies and autoimmunity 06

(Poster Zone, Thematic Poster Session)

Chair: **F. Pulvirenti (Rome, Italy)**

- D2.379** Activated PI3K δ Syndrome in Inborn Errors of Immunity: Diagnostic Strategies and Clinical Challenges
S. Bozkurt (Istanbul, Türkiye)

- D2.380** Incidental Low Serum IgE: A Marker of Underlying Inborn Errors of Immunity?
B. Gorgulu Akin (Ankara, Türkiye)

- D2.381** Early Infantile Immune Dysregulation with an Atopic Phenotype: A Case of Genetically Confirmed Otolipenia
M. C. Şentürk (Istanbul, Türkiye)

- D2.382** Contribution of Clinical and Laboratory Findings to Genetic Testing Decisions and Diagnostic Yield in Patients with Suspected Primary Immunodeficiency
N. Deveci Demirbaş (Ankara, Türkiye)

- D2.383** Ocular Cicatricial Pemphigoid: Experience with Methotrexate immunosuppression in a case series from Mar del Plata, Argentina
F. Baillieu (Mar del Plata, Argentina)

- D2.384** Early inflammatory manifestations in a child carrying a heterozygous TREX1 variant: possible evolving interferonopathy?
T. Savevska Milanovska (Skopje, North Macedonia)

- D2.385** Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiencies (CVIDs): preliminary results of a multicenter retrospective observational study
D. Pilastro (Pavia, Italy)

- D2.386** Intravenous Immunoglobulin–Associated Severe Prolonged Neutropenia: A Rare but Life-Threatening Complication in Primary Immunodeficiency
G. Tokmak (Ankara, Türkiye)

- D2.387** Hemophagocytic Lymphohistiocytosis and Progressive Neurological Involvement in Two Patients with Severe Congenital Neutropenia Due to VPS45 Deficiency
A. Kuzu Kusakli (Ankara, Türkiye)

- D2.388** Is Sarcoidosis a preliminary feature of Inborn Errors of Immunity?
D. İlgin Gürel (Ankara, Türkiye)

- D2.389** Optic disc swelling in Common variable immunodeficiency, two cases from a small U.K. cohort
J. Fuller (Guildford, United Kingdom)

- D2.390** Evaluation of CD4⁺ CD8⁺ T Cell Population According to Patient Diagnostic Groups: A Single-Center Study
D. M. Durak Ansin (Ankara, Türkiye)

- D2.391** Assessment of Small Airway Dysfunction by Impulse Oscillometry in Patients with CVID and Selective IgA Deficiency
M. Sezgin (Istanbul, Türkiye)

12:00 - 13:00 L-TPS16 - Drug Allergy 06

(Poster Zone, Thematic Poster Session)

Chair: **T. Arıkoğlu (Mersin, Türkiye), T. Pongdee (Rochester, United States of America)**

D2.407 Treating Through in Pediatric Patients: A Single-Center Experience

H. I. Celik (Ankara, Türkiye)

D2.408 Hypersensitivity Reactions to Corticosteroids: A Retrospective Cohort Study

L. C. Sánchez Méndez (Madrid, Spain)

D2.409 Severe IgE-Mediated Anaphylaxis to Amoxicillin/Clavulanate During Intradermal Testing in a Healthcare Worker with Occupational Exposure

M. Piantanida (Milano, Italy)

D2.413 Diagnostic Value of the Basophil Degranulation Test in High-Risk Drug-Induced Anaphylaxis

Z. Yegin Katran (İst, Türkiye)

D2.414 Diagnostic Distribution of Patch, Delayed-Reading Intradermal, and Drug Provocation Tests in Delayed-Type Cutaneous Drug Hypersensitivity

S. Karaaslan Yetemen (İzmir, Türkiye)

D2.415 DRESS Syndrome induced by Lenalidomide

E. Armas Sosa (Santa Cruz de Tenerife, Spain)

D2.416 Skin reaction to Kaftrio/Kalydeco (CFTR) in cystic fibrosis: safe reintroduction using an outpatient desensitization protocol

R. Picos Baliña (Sevilla, Spain)

D2.417 Desensitization to Cefiderocol in Multidrug-Resistant Pseudomonas aeruginosa Bacteremia: A Therapeutic Strategy in a Beta-Lactam-Allergic Patient

L. Martínez Jiménez (Alicante, Spain)

D2.418 Tolperisone Hypersensitivity: An Underrecognized Drug Allergy in the Context of Widespread Off-Label Use

T. Nicola-Varo (Târgu Mureş, Romania)

D2.419 DRESS syndrome in the context of carbamazepine treatment - case report

K. Machavariani (T'bilisi, Georgia)

D2.420 A challenging case of cardiotoxicity following palbociclib therapy

N. Fathallah (Sousse, Tunisia)

12:00 - 13:00 L-TPS17 - Biologicals 06

(Poster Zone, Thematic Poster Session)

Chair: **S. Agarwal** (Chennai, India), **F. Ryser** (Bern, Switzerland)

- D2.464** **Stapokibart (anti-IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid**
L. Wang (Shanghai, China)

- D2.465** **Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients**
I. Karahan (Gaziantep, Türkiye)

- D2.466** **More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab**
A. Domínguez Estirado (Madrid, Spain)

- D2.467** **Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case**
S. Sartorio (Milan, Italy)

- D2.468** **Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study**
A. C. Coelho (Vila Nova de Gaia, Portugal)

- D2.469** **Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey**
J. P. Ferrer-González (València, Spain)

- D2.470** **Potential Clinical and Laboratory Biomarkers for Predicting Omalizumab Response in Chronic Spontaneous Urticaria**
B. Özkan Kirgin (Ankara, Türkiye)

- D2.471** **Efficacy of omalizumab in the treatment of chronic spontaneous urticaria in children**
J. Janković (Beograd, Serbia)

- D2.472** **Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation**
T. De Vos (Gent, Belgium)

- D2.473** **Omalizumab as adjuvant therapy in drug desensitization to chemotherapy- a single Center experience**
M. Perlato (Firenze, Italy)

- D2.474** **Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report**
J. G. Maiese (Bilbo, Spain)

- D2.475** **Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study**
A. Mościcka (Chęciny, Poland)

- D2.476** **Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months**
P. Howarth (London, United Kingdom)

12:00 - 13:00 L-TPS30 - Allergy diagnosis 06
(Poster Zone, Thematic Poster Session)

Chair: **M. Martini (Ancona, Italy), M. Huffaker (Stanford, United States of America)**

- D2.01** Differences in Sensitization Patterns Between Infants and Children: A Cross-Sectional Study of Patients Aged 0-14 Years in Urban China
B. Sun (Guangzhou, China)

- D2.02** Clinically Relevant Cross-Reactivity Between *Artemisia vulgaris* and Bee Pollen: A New Paradigm in Postprandial Exercise-Induced Anaphylaxis
J. Subiza Garrido-Lestache (Madrid, Spain)

- D2.03** Cofactor-Dependent Anaphylaxis to Rosaceae and Citrus Fruits: Molecular Characterization Reveals High-Molecular-Weight Allergens Beyond Classical Panallergens
F. Pineda de la Losa (Alcalá de Henares, Spain)

- D2.04** Prevalence Of Alpha-Gal Sensitization In Patients With Arthropod Bite Reactions, Chronic Spontaneous Urticaria And Gastrointestinal Symptoms In La Rioja (Spain). Introduction
I. Vidal Oribe (Logroño, Spain)

- D2.05** Quail Egg Allergy with Independent Hen Egg Sensitization: Insights From Protein Profiling and Inhibition Assays
E. Abel-Fernandez (Alcalá de Henares, Spain)

- D2.06** Clinical Characteristics of Reactions to Oral Food Challenges with Egg- and Milk-Based Muffins in Children
T. Itazawa (Saitama, Japan)

- D2.07** Cross-reactivity of Major Pollen Allergens in Spring in Beijing
W. Ming (Beijing, China)

- D2.08** Extraction Efficiency Studies and Quantification of Major Peanut Allergens in Peanut Challenge Meals and Peanut Flour
H. Payne (Deeside, United Kingdom)

- D2.09** Qualitative concordance between two multiplex molecular diagnostic platforms in LTP allergy
F. T. Di Bernardo Delgado (València, Spain)

- D2.10** Early-onset cow's milk protein and tree nut allergy: the value of component-resolved diagnosis in interpreting low-level alpha-gal sensitization
S. Samoud (Tunis, Tunisia)

- D2.11** Cow's milk-induced FPIES in adolescents and adults, not all is lactose intolerance
M. B. Contreras García (Alicante, Spain)

- D2.13** Migratory locust and house cricket as food allergy: cross reactivity or primary sensitisation
D. QERIMI (Durrës, Albania)

- D2.12** Resolving heterophile antibody interference in the ISAC multiplex assay using HBT (Scantibodies)
M. Tena Campos (Cornellà de Llobregat, Spain)

- D2.14** Component ratio analysis supports a targeted diagnostic approach in house dust mite allergy
M. Tena Campos (Cornellà de Llobregat, Spain)

12:00 - 13:00 L-TPS31 - Allergy diagnosis 07

(Poster Zone, Thematic Poster Session)

Chair: **S. Arandjelovic (Belgrade, Serbia), P. Mason (Padova, Italy)**

- D2.15** **Med-Timeline: A Digital Tool for Assessing Drug Causality in Suspected Drug-Induced Skin Reactions**
C. SVABEK (Lille, France)

- D2.16** **NSAID-induced fixed drug eruptions**
A. Moreno (Cuenca, Spain), C. Figueroa (Toledo, Spain)

- D2.17** **Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from January 2023 to December 2025**
C. MORENO LOPEZ (Sevilla, Spain)

- D2.18** **Evaluating the Penicillin Allergy Diagnosis Process with Real-Life Data**
Y. Itmec (Kırıkkale, Türkiye)

- D2.19** **Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?**
R. D. P. Garcia Brito (València, Spain)

- D2.20** **Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing**
S. Rodríguez Cano (Córdoba, Spain)

- D2.21** **The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity**
O. Hausmann (Bern & Lucerne, Switzerland)

- D2.25** **Epicutaneous responses to Bradykinin Receptor 1 and 2 agonists, Histamine, and mast cell agonists in Angiotensin Converting Enzyme Inhibitor angioedema**
C. Day (Cape Town, South Africa)

- D2.26** **Applying a phenotype-driven diagnostic algorithm to suspected hypersensitivity reactions to biologicals: a real-world experience**
I. Rosmaninho (Porto, Portugal)

- D2.27** **"Chronic Urticaria Following Dental Filling Procedure: A Clinical Evaluation"**
L. Bugadze (Tbilisi, Georgia)

- D2.28** **When Cross-Reactivity Is Not the Answer: Immediate Multiple Drug Hypersensitivity to Aminopenicillins and Ceftriaxone**
I. Rosmaninho (Porto, Portugal)

- D2.29** **Use and knowledge of Phadiatop Infant and Fx5 in children from a primary care healthcare area**
I. Costa Farinha (Coimbra, Portugal)

12:00 - 13:00 L-TPS32 - Allergy diagnosis 08
(Poster Zone, Thematic Poster Session)

Chair: **V. Esteban (Madrid, Spain), S. Ardicli (Davos, Switzerland)**

- D2.30** **A Case of Kimura's Disease with Atypical Presentation and Novel Genetic Findings**
G. Andrenova (Moscow, Russia)

- D2.31** **A Case of Acquired C1 Inhibitor Deficiency Angioedema with Anti-C1q Antibodies in Systemic Lupus Erythematosus and Negative Exome Sequencing**
G. Andrenova (Moscow, Russia)

- D2.32** **A Positive Drug Challenge to Amoxicillin and Clavulanate (AMX) in a Child, Six Years After the Initial Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE)**
P. Jaovisidha (Bangkok, Thailand)

- D2.33** **Complex occupational allergic contact dermatitis: polysensitization in a worker exposed to metals, adhesives, and plastics**
E. Baraketi (Tunis, Tunisia)

- D2.34** **Pediatric allergic contact cheilitis associated with propolis sensitization**
E. Baraketi (Tunis, Tunisia)

- D2.35** **Occupational Protein Contact Dermatitis to Latex Compromising Fitness for Work in a Nurse**
E. Baraketi (Tunis, Tunisia)

- D2.36** **A Case of Occupational Allergic Contact Dermatitis in the Automotive Industry: Role of 2-Hydroxyethyl Methacrylate (HEMA)**
F. Taleb (Tunis, Tunisia)

- D2.37** **Occupational Allergic Dermatoses of the Face: Allergen Distribution and Work-Related Outcomes**
E. Baraketi (Tunis, Tunisia)

- D2.38** **Occupational Exposure to Propolis: A Rare Cause of Allergic Contact Dermatitis in Textile Workers**
E. Baraketi (Tunis, Tunisia)

- D2.39** **Occupational Contact Dermatitis with Polysensitization to Metals: Challenges for Work Fitness and Prevention**
E. Baraketi (Tunis, Tunisia)

- D2.40** **Occupational allergic contact dermatitis to metals: clinical features and impact on work fitness**
E. Baraketi (Tunis, Tunisia)

- D2.41** **Production of recombinant Cuc ma 5: A Step Towards Molecular Diagnosis of Pumpkin Seed Allergy**
B. Acikalin (Ankara, Türkiye)

- D2.42** **Evaluation of User Experience with a Skin Prick Automated Test (SPAT) Device compared to a Manual Skin Prick Test (SPT) in Pediatric Patients**
U. Pöppel (Bielefeld, Germany)

12:00 - 13:00 L-TPS33 - Allergy diagnosis 09

(Poster Zone, Thematic Poster Session)

Chair: **D. Yazici (Rochester, NY, United States of America), A. Eggel (Bern, Switzerland)**

- D2.43** Hereditary Angioedema Can Hit at Any Age: A Case Report in Egypt
A. Elmazaly (Cairo, Egypt)

- D2.44** Subjective assessment of sleep quality in adult patients with hereditary angioedema
E. KARABİBER (İstanbul, Türkiye)

- D2.45** Fixed Drug Eruption Due to Fenofibrate Hypersensitivity
A. Rodríguez San Blas (Badajoz, Spain)

- D2.46** Patient with the overlap of Hereditary angioedema and Chronic spontaneous urticaria
M. Barešić (Zagreb, Croatia)

- D2.47** Unmasking Melkersson-Rosenthal Syndrome: Diagnostic Challenges in a Patient Presenting With Angioedema
N. Martos Bianqui (Alicante, Spain)

- D2.48** When Treatment Becomes the Cause: Allergic Contact Dermatitis to Topical Corticosteroids
I. Kacem (Sousse, Tunisia)

- D2.49** Quality of Life and Affecting Factors in Patients with Chronic Urticaria
Z. Köybaşı (Ankara, Türkiye)

- D2.50** When Angioedema Is Not Angioedema: Orophacial Sarcoidosis Mimicking Refractory Facial Swelling
A. M. Camargo (Ribeirao Preto, Brazil)

- D2.51** Contact dermatitis due to continuous glucose monitoring sensors: limitations of standard patch testing
V. Vatnani Moolchandani (Las Palmas de Gran Canaria, Spain)

- D2.52** Allergic Contact Dermatitis to a Testosterone Gel Revealed Through Patch Testing and LTT: A Case of Excipient-Specific Sensitization
F. De Pablo-Cortés (Madrid, Spain)

- D2.53** Impact of Smoking on the Clinical and Allergological Profile of Allergic Contact Dermatitis: An 8-Year Analytical Study
I. Kacem (sousse, Tunisia)

- D2.54** Correlation Between IgE Anti-Thyroid Peroxidase And Chronic Spontaneous Urticaria
A. Elmazaly (Cairo, Egypt)

- D2.55** Allergic contact dermatitis and cross-sensitization after laser-assisted 5-aminolevulinic acid PDT
S. Rupp (Munich, Germany)

- D2.56** Regionally Adapted Patch Test Panels Improve Diagnostic Resolution by Revealing Hidden Polysensitization in Allergic Contact Dermatitis
A. M. Camargo (Ribeirao Preto, Brazil)

- D2.57** Evidence of Lower Airway Inflammation in Children with Allergic Rhinitis without Asthma
A. V. Soares (Porto, Portugal)

12:00 - 13:00 L-TPS34 - Allergy diagnosis 10 (Poster Zone, Thematic Poster Session)

Chair: **G. Karakaya (Ankara, Türkiye), S. Halken (Odense, Denmark)**

- D2.58** Nickel Sensitization and Reversible Airway Dysfunction: Evidence from Pulmonary Function Response to Nickel Avoidance
B. Neziri (Pristina, Kosovo)

- D2.59** Refining Quality of Life Assessment in CSU: Validation and Threshold Determination of the CU-Q2oL questionnaire
J. Marcelino (Berlin, Germany)

- D2.60** Beyond the Barrier: Does Atopic Dermatitis Shape Patch Test Reactivity? – A Romanian Retrospective Study
T.-A. Apetrei (Bucharest, Romania)

- D2.61** Allergic Contact Dermatitis Due to Disperse Textile Dyes: A 10-Year Review
I. Kacem (Sousse, Tunisia)

- D2.62** Atypical Chronic Cheilitis as Manifestation of Atopic Dermatitis: A Diagnostic Dilemma
I. Caraman (Bucharest, Romania)

- D2.63** Airborne allergic contact dermatitis in a textile worker: role of formaldehyde and methylisothiazolinones
E. Baraketi (Tunis, Tunisia)

- D2.64** Occupational allergic contact dermatitis due to rubber additives: clinical features and occupational implications
E. Baraketi (Tunis, Tunisia)

- D2.65** Allergic cheilitis related to vaginal lubricant: a case report
I. Kacem (Sousse, Tunisia)

- D2.66** Allergic contact dermatitis to cobalt and concomitant sensitization to nickel and chromium
I. Kacem (Sousse, Tunisia)

- D2.67** Clinical Profile of Allergic Contact Dermatitis in Workers and Factors Associated with Occupational Outcomes
I. Kacem (Sousse, Tunisia)

- D2.71** Metal Skin Sensitization in High-Risk Occupations: A 31-Year Patch Test analysis from a Tunisian Occupational Medicine Unit
C. Sridi (Sousse, Tunisia)

- D2.70** Contribution of Patch Testing with the Hairdresser-Specific Additional Series in the Etiological Identification of Contact Dermatitis in Hairdressers
C. Sridi (Sousse, Tunisia)

- D2.72** Radiological heterogeneity and inflammatory phenotypes in allergic bronchopulmonary aspergillosis
M. E. T. Zanetti (Ribeirao Preto, Brazil)

- D2.73** Secondary Domestic Exposure to Colophony as a Cause of Allergic Contact Dermatitis: A Case Report
P. Letón-Cabanillas (Madrid, Spain)

- D2.74** Patterns of Contact Allergen Co-sensitization and polysensitization in children with suspected Allergic Contact Dermatitis
C. Sridi (Sousse, Tunisia)

12:00 - 13:00 L-TPS35 - Asthma 05

(Poster Zone, Thematic Poster Session)

Chair: **A. Izquierdo Dominguez** (Terrassa, Spain), **C. Janson** (Uppsala, Sweden)

- D2.105** A Newly Identified Indoor Fungus, *Fusarium hechiense*, Modulates Allergic Airway Inflammation in a Murine Asthma Model
Y. Yoo (Seoul, Korea, Republic of)

- D2.106** Impact of Meteorology and Air Pollution on Allergic Rhinitis and Asthma in Guangzhou
X.-Y. Zheng (Guangzhou, China)

- D2.107** Genotype–Phenotype Segregation in Chronic Rhinosinusitis with Nasal Polyp and associated comorbid Asthma: Multivariate Clustering of Interleukin-4, Interleukin-6, Interleukin-13, and TNF- α Variants with Type-2 Biomarkers and Clinical Traits
M. Al-Ahmad (Jabriya, Kuwait)

- D2.108** Type 2 Inflammation Biomarkers in Patients with Chronic Rhinosinusitis with Nasal Polyps Under Treatment with Biologic Agents
F. Kapsouli (Athens, Greece)

- D2.109** Single-Cell Sequencing Reveals the Immunological Mechanism of Astragaloside IV in the Treatment of Allergic Rhinitis Complicated with Asthma
R. Wang (Guangzhou, China)

- D2.110** Real-world evaluation of tezepelumab in patients with severe asthma and chronic rhinosinusitis in France: preliminary results from the ROSE retrospective study
A. Boudjemaa (Créteil, France)

- D2.111** From Energy Poverty to Acquired Asthma and Allergy: PM_{2.5}/PM₁₀ Exposure, Epithelial Barrier Dysfunction, and Epigenetic Mechanisms in Low-Resource Countries
M. H. Arian (Kabul, Afghanistan)

- D2.112** The Impact of Inflammation on Protective Immune Responses in the Airways
I. Akehurst (London, United Kingdom)

- D2.113** Comparison of Non-Asthmatic Allergic Rhinitis Patients with Normal and Low FEF_{25–75} Levels
E. Gülşen (Kırıkkale, Türkiye)

- D2.114** Occupational asthma and rhinitis in a worker in the single-use food packaging industry: challenges of multi-agent exposure
E. Baraketi (Tunis, Tunisia)

- D2.115** Occupational asthma and rhinitis to isocyanates in industrial settings
E. Baraketi (Tunis, Tunisia)

- D2.119** From Environment to Epithelium: Biological and Clinical Effects of Indoor and Outdoor Pollution in Campania's Schoolchildren
M. Simonelli (Napoli, Italy)

- D2.120** Missing the Red Flags? Identification of High-Risk Paediatric Asthma Admissions Following the 2024 BTS/NICE/SIGN Update
N. Rao (Manchester, United Kingdom)

- D2.121** sSeroprotection to influenza virus in vaccinated patients with bronchial asthma on biological treatment
A. Kostinova (Moscow, Russia)

12:00 - 13:00 L-TPS36 - Asthma 06

(Poster Zone, Thematic Poster Session)

Chair: Y. GAO (Hangzhou, China), M. Kupczyk (Łódź, Poland)

- D2.122** Impact of Asthma on Outcomes after out-of-hospital cardiac arrest: A nationwide pathway-based analysis, 2013-2023
S. Yoon (Seoul, Korea, Republic of)
- D2.123** Temporal Stability of Asthma-Related Out-of-Hospital Cardiac Arrest: A Nationwide SARIMA Analysis of Korean Data From 2013 to 2023
S. Yoon (Seoul, Korea, Republic of)
- D2.124** Clinical Significance of Humoral Immunodeficiency in Patients with Severe Asthma
J.-H. Kim (Anyang, Korea, Republic of)
- D2.125** When Severe Asthma Isn't Asthma: A Case of Humoral Immunodeficiency With Suspicion of Lymphoproliferative Disease
M. Adamczewska (Łódź, Poland)
- D2.126** Analysis of Clinical Characteristics and Airway Morphological Structure Parameters in Patients with Bronchial Asthma Combined with Bronchiectasis
L. Yun (Shaanxi Province, Xi'an City, China)
- D2.127** Rhinovirus Infection in Early Childhood and Risk of Asthma: A Two-Year Follow-Up Study
H. Essaadi (Rabat, Morocco)
- D2.129** Cardiac onset of EGPA in a postpartum woman: the importance of early diagnosis
C. Ríos Márquez (Seville, Spain)
- D2.130** Dupilumab for asthma and chronic rhinosinusitis with or without nasal polyps : A Multi-Timepoint Real-World Analysis
X. Gao (Tsingdao, China)
- D2.131** Application of a Neural Network Model for Predicting Clinical Outcomes of Acute Bronchitis with Bronchospasm Based on Comorbidities
T. Panahova (Baku, Azerbaijan)
- D2.132** Prediction of Clinical Outcomes of Acute Bronchitis with Bronchospasm Based on Trigger Factors Using a Neural Network Model
T. Panahova (Baku, Azerbaijan)
- D2.133** Assessment of growth pattern in wheezing children (3-12 years of age)
M. Ahmed (Hyderabad, India)

12:00 - 13:00 L-TPS37 - Asthma 07

(Poster Zone, Thematic Poster Session)

Chair: **M. Mukherjee** (Hamilton, Canada), **D. Karaguzel** (Ankara, Türkiye)

- D2.134** Fidelity to Maintenance and Reliever Therapy in Paediatric Asthma: A Mixed Methods Study of Prescription Consistency in Clinical Practice
A. Odeniyi (Dartford, United Kingdom)
- D2.135** Preventive counseling regarding the risk factors for individuals with asthma or chronic obstructive pulmonary disease
M. Kashutina (Moscow, Russia)
- D2.136** Association Between Serum 25-Hydroxyvitamin D Levels and Asthma Severity in Preschool Children
F. Kuzucu (Ankara, Türkiye)
- D2.137** Association of GLP-1 Receptor Agonists with Asthma Incidence among Patients with Obesity
H.-J. Tsai (Zhunan, Taiwan)
- D2.138** Type 3 cytokine - dependent E3 epithelial programming is driven by a novel transcriptional regulator that impacts airway barrier integrity in asthma
H. Charles (Munich, Germany)
- D2.139** Atypical Presentation of House Dust Mite-Induced Atopic Asthma in an Adolescent Girl: A Case Report from a Remote Region of Kyrgyzstan
M. KOSHUKEEVA (Bishkek, Kyrgyzstan)
- D2.140** Development and Validation of the Thai School-aged Children with Asthma Quality of Life Questionnaire (TSCA-QOL)
S. Rojnawee (Bangkok, Thailand)
- D2.141** Predictors of inpatient admission amongst children presenting with acute asthma exacerbation: influence of the patient's prior clinical profile
R. Geraldes (Coimbra, Portugal)
- D2.142** Longitudinal Airway Immune Responses to Respiratory Viruses in Asthmatic and Atopic Children
K. Reddy Kamarajan (Tbilisi, Georgia)
- D2.143** Cypress pollen as a major aeroallergen in paediatric respiratory allergy: experience in Gaziantep, south-eastern Türkiye
E. Küçükosmanoğlu (Gaziantep, Türkiye)
- D2.144** Bronchial Inflammation and Lung Function in Children with Asthma and Allergic Rhinitis: The Contribution of FeNO and Spirometry
Z. Lafi (Rabat, Morocco)
- D2.145** Parental Recognition and Consistency of Noisy Breathing Reports: Treatment and Symptom Associations
D.-A. Jesenkovic (Sarajevo, Bosnia and Herzegovina)
- D2.146** Neuropsychiatric events associated with montelukast in children: a systematic review
K. Moliszewska (Warszawa, Poland)
- D2.148** Exploring the Role of Bacterial Lysate OM-85 on Immune Mechanisms in Type 2-high Asthma
G. Tramper (Rotterdam, Netherlands)

12:00 - 13:00 L-TPS38 - Asthma 08

(Poster Zone, Thematic Poster Session)

Chair: **A. Ertugrul (Ankara, Türkiye), A. Bognanni (Milan, Italy)**

D2.149 Occupational asthma in a tea-packaging worker: a case report

T. Özkan (Trabzon, Türkiye)

D2.150 Clinical and functional outcomes after the diagnosis of baker's asthma: ended vs. reduced exposure

J. Minov (Skopje, North Macedonia)

D2.151 HZ-Y030, an Oral STAT6 Degradar, Attenuates Type 2 Inflammation in Preclinical Asthma Models

Y. Wu (Hangzhou, China)

D2.152 Clinical and functional characteristics of patients with suspected epoxy resin-related occupational asthma

L. Aparicio Armengol (Madrid, Spain)

D2.153 Allergic asthma in a sample of dairy farmers

S. Stoleski (Skopje, North Macedonia)

D2.154 Small airway dysfunction defined by reduced FEF25–75% identifies a distinct clinical phenotype in children with preserved FEV1

Y. Park (Chuncheon, Korea, Republic of)

D2.155 Mapping the Architecture and Spectrum of the Cough Hypersensitivity Questionnaire Across Respiratory Diseases

J.-Y. Moon (Seoul, Korea, Republic of)

D2.156 Defining the Systemic Boundary Between N-ERD and EGPA: Avoiding Misclassification of Eosinophilic Diseases

M. TANIGUCHI (Sagamihara, Japan)

D2.157 Clinical remission with tezepelumab in severe asthma: prevalence and predictors in a real-world multicentre study

D. Betancor (Madrid, Spain)

D2.158 Circulating 1-methylnicotinamide can predict the treatment response of dupilumab in adult asthma

T.-B. Kim (Seoul, Korea, Republic of)

D2.159 Idiopathic Chronic Eosinophilic Pneumonia: A Case Series

H. Yilmazlı (İzmir, Türkiye)

D2.160 Household Overcrowding and Number of Siblings as Risk Factors for Uncontrolled Asthma in Inner-City Children

B. Karakaya (Istanbul, Türkiye)

D2.161 Exploring the Early-Life Interplay Between Respiratory Health and Neurodevelopmental disorders

C. Grube (Gentofte, Denmark)

D2.164 Efficacy and Safety of Omalizumab Combined with Allergen-Specific Immunotherapy in the Treatment of Moderate-to-Severe Allergic Asthma: A Prospective Cohort Study in a Chinese Population

X. Li (Jinan, China)

12:00 - 13:00 L-TPS39 - Allergen immunotherapy 03

(Poster Zone, Thematic Poster Session)

Chair: *D. Eyice Karabacak (Istanbul, Türkiye), M. Jimenez Freites (Barcelona, Spain)*

- D2.181** Managing asthma and allergies during the Russo-Ukrainian war: The damage assessment
I. Kaydashev (Poltava, Ukraine)

- D2.182** Mass Spectrometric Identification of Allergens from Dermatophagoides spp. and Blomia tropicalis in Native, Depigmented and Depigmented-Polymerized Extracts
M. A. Lopez-Matas (Tres Cantos, Spain)

- D2.183** Differential Sensitization to Goat and Sheep Milk with Partial Tolerance to Cow's Milk
C. Pesántez Méndez (Ojeda, Spain)

- D2.184** Sensitization profile to vespid venom: limitations in clinical practice
J. M. Gutierrez Posso (Madrid, Spain)

- D2.185** A multicenter rEgistry study eXamining the efficacy of sPecific immunotherapy guided by component-resolved diagnOsis for dust mite alleRgens in chinese pEdiatric patients with Rhinitis and/or asthma. (EXPLORER STUDY)
L. Tang (Hangzhou, China)

- D2.186** In vivo and ex vivo evaluation of the immunological responses induced by a grass depigmented-polymerized allergenic extract in dogs
R. Moya (Tres Cantos, Spain)

- D2.187** Are Component-Based Skin Tests Reliable? Correlation between Skin Prick Testing and Specific IgE to Der p 1, Der p 2 and Der p 23
D. Hervas (Palma, Spain)

- D2.188** Spectrum of Sensitization to Respiratory Allergens in Patients in the Republic of Kazakhstan
O. Ussenova (Astana, Kazakhstan)

- D2.189** The Synergistic Effect of Sphenopalatine Ganglion Acupuncture Combined with Cluster Immunotherapy in Treating Allergic Rhinitis and Chronic Rhinosinusitis
H. Lin (Qingdao, China)

- D2.190** Evaluation of a commercially available Birch Pollen Extract for its suitability in Nasal Allergen Challenges: Feasibility and Dose-Response Assessment
S. Haider (Mississauga, Canada)

- D2.191** Tolerogenic Immune Shifts Following PQ Grass 27600 SU Treatment in Seasonal Allergic Rhinitis
M. Shamji (London, United Kingdom)

- D2.192** Comparison of the Multiplex ALEX Method and Single-Plex ImmunoCAP Method in the Diagnosis of Seasonal Allergic Rhinitis in Adults Caused by Birch Pollen
J. Nevrlka (Brno, Czech Republic)

- D2.193** Real-World Effectiveness of Allergen Immunotherapy in Polysensitized Patients: A Retrospective Study of 260 Cases
G. Loloci (Tiranë, Albania)

- D2.194** Norovirus-Like Particles as Novel Carriers of Hypoallergenic Artemisia vulgaris Allergen Art v 3 for Allergen-Specific Immunotherapy
L. Cepulyte (Vilnius, Lithuania)

- D2.195** AIT prescription drivers: a cluster analysis of data from the CHOICE survey
D. Caimmi (Montpellier, France)

12:00 - 13:00 L-TPS40 - Allergen immunotherapy 04

(Poster Zone, Thematic Poster Session)

Chair: *W. Van De Veen (Davos, Switzerland), Y. Pat (Boston, United States of America)*

- D2.196** Elucidating the Immunological Mechanisms of Pollen Immunotherapy in Treating Food Allergy in Patients with Pollen-Food Allergy Syndrome
Y. Shin (Seoul, Korea, Republic of)

- D2.197** Dose-Dependent Immunogenicity and Toxicity of Polypeptide-Conjugated Hepatitis B Core Antigen Virus-Like-Particle (HBcAg-VLP) Vaccine for Treatment of Shellfish Allergy
C. Y. Y. Wai (Shatin, Hong Kong)

- D2.198** Allergen identification and characterization of lysine modification in monomeric allergoid of *Olea europea* pollen extract
E. Compalati (Milano, Italy)

- D2.199** Preterm birth and allergic sensitization in school-aged children
X.-Y. Tsai (Taoyuan, Taiwan)

- D2.200** An interim analysis of a multiCenter study on the effect of SCIT on tic symptoms in Children and Adolescents with HDM allergy and coMorbidity disorders (CALM study)
L. Shan (Shenyang, China)

- D2.201** Effects of Subcutaneous Immunotherapy in children with allergic symptoms: a two-year, prospective study
Y. Lin (Zhejiang, China)

- D2.202** Evaluation of Telemedicine Use in Dietary Advancement Therapy of Cow's Milk and Egg Allergy: A Retrospective Study
Z. S. T. Isaacs (Cork, Ireland)

- D2.203** Real-World Adherence, Efficacy, and Safety of Allergen Immunotherapy in Young Patients: Experience from Mauriziano Hospital in Turin, Italy
A. Rosata (Torino, Italy)

- D2.204** Allergic potential of plant-derived oils: in vitro murine model of allergies
O. K. Inci (Ankara, Türkiye)

- D2.205** Profilin Allergy: Study of the Efficacy and Safety of an Immunotherapy Protocol for the Treatment of Profilin-Related Oral Allergy Syndrome
A. OSullivan Guijarro (Madrid, Spain)

- D2.206** Successful treatment of LTP syndrome using allergen immunotherapy: a clinical case
M. Lykova (Kyiv, Ukraine)

- D2.207** Early serum IL-6 induction and delayed IL-17A suppression characterise wasp venom allergen-specific immunotherapy
E. Herzer (Munich, Germany)

- D2.208** Efficacy of Inhaled Granulocyte-Macrophage Colony-Stimulating Factor in Autoimmune Pulmonary Alveolar Proteinosis: A Meta-Analysis of Randomized Placebo-Controlled Trials
N. Hammad (Port Said, Egypt)

- D2.209** 'Which bee was it?': A literature review of Honeybee Venom Immunotherapy used in paediatric patients stung by different bee subspecies
D. Nagra (Sheffield, United Kingdom)

- D2.213** Study of Efficacy of Rush Sub Lingual Immunotherapy in Cases of Severe Persistent Allergic Rhinitis
S. Jain (INDORE, India)

12:00 - 13:00 L-TPS41 - Allergen immunotherapy 05

(Poster Zone, Thematic Poster Session)

Chair: **L. Aglas (Helsinki, Finland), N. N. Bahçeciler (Nicosia, Cyprus)**

- D2.214** TAPAS – non-inferiority of clinical effectiveness in children compared to adults: 3-year interim results of a long-term NIS
M. Gerstlauer (Augsburg, Germany)

- D2.215** A Prospective Long-Term Cohort Study with Seasonal Allergic Rhinitis (TAPAS) with MATAs in tree- and grass-allergic patients
R. Mösges (Cologne, Germany)

- D2.216** Effectiveness and safety of subcutaneous immunotherapy with Depigmented-Polymerized Cat Extract: real-world clinical evidence
B. Torres-Pérez (Madrid, Spain)

- D2.217** Structured Follow-Up Intervals Enhance Adherence to Sublingual Immunotherapy in Patients with Allergic Rhinitis: Real-World Evidence from a Stepwise Approach
L. van der Putten (Alkmaar, Netherlands)

- D2.218** Effectiveness of the 300IR house dust mite sublingual tablet according to the patients' sensitisation and allergy profile in the real-world, non-interventional VORAN study
U. Reineke (Herford, Germany)

- D2.219** Effectiveness of the 300IR house dust mite sublingual tablet in the real-world, non-interventional VORAN study: a responder analysis
A. Nöding (Falkensee, Germany)

- D2.220** US Regional Difference in Allergen Immunotherapy Prescription Patterns: Focus on the South
J. C. Cardet (Tampa, United States of America)

- D2.221** Exploring the effect of HDM SLIT-tablets on atopic dermatitis prescriptions in patients with pre-existing atopic dermatitis: Results from the Real-world Evidence of house dust Mite Immunotherapy Tablets (REMIT) study
C. Woehlk (Hørsholm, Denmark)

- D2.222** A real-world observational study following the first year of SQ grass or SQ tree SLIT-tablet treatment to evaluate persistence and adherence in routine clinical practice among general practitioners in Norway
S. Steinsvåg (Kristiansand, Norway)

- D2.223** Using IgG antibodies to measure product potency for modified allergoid AIT
H. Young (Worthing, United Kingdom)

- D2.224** Real-world effectiveness and safety of olive pollen sublingual immunotherapy in patients with respiratory allergy
C. M. Ruiz González (Jaén, Spain)

- D2.225** Characterizing skin-resident antigen presenting cell responses to plant-based Fel d 1 Bioparticles
E. Taanman (Amsterdam, Netherlands)

- D2.226** Evaluation of the Immunogenicity and Stability of an Aluminum-Adsorbed Allergen Immunotherapy Using Specific IgG Titration in a Murine Model
S. Picos (Leganés, Spain)

- D2.227** US Regional Difference in Allergen Immunotherapy Prescription Patterns: Focus on Puerto Rico
J. C. Cardet (Tampa, United States of America)

- D2.228** Effectiveness and Safety of Subcutaneous Immunotherapy for Patients Allergic to Either Cat Dander or Dermatophagoides/Cat Dander: Real World Data
Y. Ruiz García (Alcalá de Henares, Spain)

12:00 - 13:00 L-TPS42 - Dermatology 03

(Poster Zone, Thematic Poster Session)

Chair: **M.-C. Brüggen** (Zürich, Switzerland), **E. Damadoğlu** (Ankara, Türkiye)

- D2.230** Flushing in a Child with Solitary Cutaneous Mastocytoma: A Case Associated with Sesame Allergy
N. Ozciftci Ertugral (Giresun, Türkiye)

- D2.231** Psychological Profiles and Personality Traits in Chronic Spontaneous Urticaria: A Pilot Study
C. Pitsios (Nicosia, Cyprus)

- D2.232** Aquagenic Urticaria: High Atopic Comorbidity, Familial Aggregation, and Differential Water Reactivity
G. Jimenez (Badajoz, Spain)

- D2.233** Epidemiology, Patient Characteristics, and Treatment Responses of Chronic Urticaria in Türkiye: A Systematic Literature Review
M. Türk (Kayseri, Türkiye)

- D2.234** Mimicry of delayed pressure urticaria. Clinical case reports
K. Riabova (Moscow, Russia)

- D2.235** Urticaria Voices: Patient-reported disease burden and treatment experiences in Chronic Spontaneous Urticaria in China - A real-world evidence study (UV in China)
N. Chapman-Rothe (Basel, Switzerland)

- D2.236** Alexithymia and Depression in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
G. G. Atay (İstanbul, Türkiye)

- D2.237** Patient-reported changes in urticaria activity after tattoo placement
M. Powietrzyński (Gdańsk, Poland)

- D2.238** Bilastine fast onset and strong peripheral antihistaminic activity: comparison with oral second-generation antihistamines and intramuscular dexchlorpheniramine in histamine-induced wheal and flare models
A. Padilla-Ferrer (Leioa, Spain)

- D2.239** Oral and parenteral bilastine, fast onset and strong peripheral antihistaminic activity: comparison with oral second-generation antihistamines and intramuscular dexchlorpheniramine in wheal and flare models
A. Padilla-Ferrer (Leioa, Spain)

- D2.240** Chronic spontaneous urticaria exacerbated by omalizumab administration: A series of 8 patients
M. Güleğül (Ankara, Türkiye)

- D2.241** Successful Slow Desensitization to Niraparib Following Failed Olaparib Desensitization in a Patient with Ovarian Cancer
A. Nin Valencia (Barcelona, Spain)

- D2.242** Chronic Urticaria and Thyroid Disease: Analysis of Clinical, Laboratory Data and Therapeutic Response in the Mediterranean Area of Tarragona
J. Gassol Puigjaner (Tarragona, Spain)

- D2.244** Case Report: Postpartum Chronic Spontaneous Urticaria
E. Lekli (Tirana, Albania)

- D2.243** Impact of simultaneous skin clearance and itch relief with lebrikizumab in patients with atopic dermatitis: post-hoc analysis from ADvocate1/2
M. Metz (Berlin, Germany)

12:00 - 13:00 L-TPS43 - Dermatology 04

(Poster Zone, Thematic Poster Session)

Chair: *I. Topalusic (Croatia, Croatia), N. Douladiris (Nea Kallikratia, Chalkidiki, Greece)*

- D2.245** Dithranol loaded Dendritic nanoarchitectures for the treatment of psoriasis
M. Bhargava (Prayagraj, India)

- D2.246** Occupational contact dermatitis to chromium in guitarist
L. Pellicer-Garcia (Besançon, France)

- D2.247** Vitamin D Status as a Modifiable Factor in Chronic Spontaneous Urticaria
A. Kovchun (Sumy, Ukraine)

- D2.248** Asthma control in patients with moderate-to-severe atopic dermatitis and comorbid-asthma treated with lebrikizumab in a real-world-setting: interim analysis of the non-interventional study ADLife
S. Diemert (Hamburg, Germany)

- D2.249** The impact of the coronavirus infection and vaccination against SARS-CoV-2 in the course of chronic urticaria
A. Klyucharova (Kazan, Russia)

- D2.250** Sensitivity to Dental Materials and Its Clinical Implications: A Retrospective Patch Test Study
M. S. Bayrak Durmaz (Ankara, Türkiye)

- D2.251** Allergic Contact Dermatitis to Clonidine Transdermal Patch: Insights From a Rare Case With Prolonged Cutaneous Exposure
M. R. Messina (Milan, Italy)

- D2.252** Occupational Allergic Contact Dermatitis: Impact on Work Productivity and Professional Activity
I. Kacem (Sousse, Tunisia)

- D2.253** Trends in Allergic Contact Dermatitis to Metals According to Gender
I. Kacem (Sousse, Tunisia)

- D2.254** Thyroid Autoantibody Seroconversion in Chronic Spontaneous Urticaria: Insights from Omalizumab Treated Patients
R. Oztas (Sakarya, Türkiye)

- D2.255** Adult-onset Still's disease mimicking chronic spontaneous urticaria: a case report
A. Zhunussova (Astana, Kazakhstan)

- D2.256** Aquagenic syringeal acrokeratoderma: a diagnostic challenge triggered by water exposure
P. S. Figueiredo (Lisboa, Portugal)

- D2.257** Is It Beneficial To Expand The Allergy Test Panel Based On Component-Based Test Results In Chronic Urticaria?
F. Kırbiyık (Istanbul, Türkiye)

- D2.259** Beyond Contact with Water: A Case of Aquagenic Urticaria
G. Bedir Keser (Kırıkkale, Türkiye)

- D2.260** The Burden of Chronic Urticaria
I. Stancheva (Sofia, Bulgaria)

12:00 - 13:00 L-TPS44 - Food allergy 03

(Poster Zone, Thematic Poster Session)

Chair: **S. Arudi Nagarajan** (Bengaluru, India), **S. Bunyavanich** (New York, United States of America)

- D2.275** Distinct Transcriptomic Responses Across Intestinal Segments in Egg Allergy Murine Model
O. Liong (Helsinki, Finland)

- D2.276** Clinical and Immunological Differences in Shellfish Allergy
F. Pineda de la Losa (Alcalá de Henares, Spain)

- D2.277** Allergy to CHIA and Reactivity with SESAME
M. Aznar (Madrid, Spain)

- D2.278** Dose-response analysis of remibrutinib in oral food challenge outcomes among adults with IgE-mediated peanut allergy
B. Ortiz (East Hanover, United States of America)

- D2.279** Preventive capacity of single-nut sublingual immunotherapy in Brown Norway rats
A. I. Sancho (Kongens Lyngby, Denmark)

- D2.280** Biphasic anaphylaxis due to psyllium (*Plantago ovata*) allergy, the primary component of a plant-based sausage
E. Rodríguez (Madrid, Spain)

- D2.281** Ensemble Immunoinformatic Prediction Reveals Novel Allergen Candidates in *Nigella sativa* Seeds and Oil
E. Mehmedović (Tuzla, Bosnia and Herzegovina)

- D2.282** Impact of Polyethylene Terephthalate Microplastics on the Digestibility of Shrimp Allergen Tropomyosin
M. Krstic Ristivojevic (Belgrade, Serbia)

- D2.283** Efficacy and safety of remibrutinib in adults with IgE-mediated peanut allergy: A Phase 2 study
B. Ortiz (East Hanover, United States of America)

- D2.284** Peanut Materials Used for Immunoassay Calibration Exhibit Distinct Allergen Profiles
M. Bermingham (Cardiff, United Kingdom)

- D2.285** Baked egg oral Immunotherapy as an alternative in patients who failed raw egg oral immunotherapy
S. Henao-Escobar (Madrid, Spain)

- D2.286** High Prevalence of Clinical Tolerance to Avoided Foods in LTP-Sensitized Patients
M. Andúgar (Málaga, Spain)

- D2.287** Clinical characterization and predictors of diagnosis and severity in sunflower seed allergy in a pediatric population
N. Guerrero Huertas (Madrid, Spain)

- D2.288** Real- World Safety of Supervised Feeds: Evidence from Outpatient Clinic and Dayward Settings
J. Hourihane (Dublin, Ireland)

12:00 - 13:00 L-TPS45 - Food allergy 04

(Poster Zone, Thematic Poster Session)

Chair: J. Eisenblätter (Bern, Switzerland)

D2.289 Independent Sensitization to Poultry and Fish in a Young Adult

M. D. P. Saura Foix (Terrassa, Spain)

D2.290 Cucurbitaceae allergy, a new enemy identified in Watermelon

I. Raducan (Castelló de la Plana, Spain)

D2.291 Trends and Patterns Observed Among Suspected Egg-allergic Children in Hong Kong: A 26-year Retrospective Study

C. W. M. Leung (Hong Kong, Hong Kong)

D2.292 Effects of Milk Oral Immunotherapy on Human Basophils in Children with Cow's Milk Protein Allergy

M. T. Cilingiroglu (Istanbul, Türkiye)

D2.293 Differential Clinical Implications of Peach Allergen Components Pru p 3 and Pru p 7

M. Hane (Tsu, Japan)

D2.294 Clinical Characteristics of Food-Allergic Children with Peripheral Blood Hypereosinophilia

O. Uğurlu (Ankara, Türkiye)

D2.296 Heat-Stable Egg Allergens in a Patient With Severe Reactions to Cooked and Raw Hen's Egg

M. I. Rodriguez Cabrereros (Majadahonda, Spain)

D2.297 Assessing thresholds for undertaking baked milk food challenges

H. Jackman (Bristol, United Kingdom)

D2.298 Diagnostic performance of skin prick testing with fresh and frozen cow's milk in addition to commercial extract in cow's milk allergy

C. Kavukcu Horosan (Denizli, Türkiye)

D2.299 ARFID: The Hidden Face of Food Allergy?

B. uzunoğlu (izmir, Türkiye)

D2.300 Food allergy and food sensitization in children with Netherton syndrome

S. Makarova (Moscow, Russia)

D2.301 High Prevalence of Familial Meat Allergy on the Black Sea Coast: Insights into Alpha-Gal Syndrome

F. E. Gunaydin (Frimley, United Kingdom)

12:00 - 13:00 L-TPS46 - Anaphylaxis 03

(Poster Zone, Thematic Poster Session)

Chair: **T. Chatila** (Boston, United States of America), **S. Fernandez-Bravo** (Madrid, Spain)

- D2.319** A clinical case of polysensitization and multiple allergies in a 1.5-year-old child
D. Egorshina (Saint Petersburg, Russia)

- D2.320** Safety and tolerability of stepwise oral food challenge using heated whole egg powder: a multicenter study
N. Yanagida (Sagamihara, Japan)

- D2.322** Identifying Risk Factors for Food Allergy and Food-Induced Anaphylaxis Among Korean School-Aged Children: A Nationwide Population-Based Study
Y. H. Jeon (Hwaseong-si, Korea, Republic of)

- D2.323** Evaluation of Artificial Intelligence Models with Case Scenarios in the Diagnosis and Management of Pediatric Anaphylaxis
I. N. Safak (Izmir, Türkiye)

- D2.324** Anaphylaxis in very early childhood: An ongoing challenge
K. Rueter (Crawley, Australia)

- D2.325** Desensitization of Olipudase alfa-induced anaphylaxis in a child with chronic neurovisceral acid sphingomyelinase deficiency and ochoa syndrome
B. Sarigul Cimi (Ankara, Türkiye)

- D2.326** The frequency of hereditary α -tryptasemia (H α T) in patients with insect venom anaphylaxis and in patients with mastocytosis – preliminary results
M. Niedozytko (Gdańsk, Poland)

- D2.327** Patient and caregiver perspectives on sublingual adrenaline for anaphylaxis: findings from an international survey
M. Vazquez-Ortiz (London, United Kingdom)

- D2.328** Pediatric Anaphylaxis in Turkey: Clinical Characteristics, Triggers, and Severity in a Nation-wide Registry
E. Sari (Çanakkale, Türkiye)

- D2.329** Profilin-mediated anaphylaxis with cofactor
T. Galán Díez (Alcalá de Henares, Spain)

- D2.331** An Adult Case of Cofactor-Induced Anaphylaxis Associated with Physical Exercise
A. Bostanoğlu Karaçin (Ankara, Türkiye)

12:00 - 13:00 L-TPS47 - Immune deficiencies and autoimmunity 03

(Poster Zone, Thematic Poster Session)

Chair: **T. Chatila** (Boston, United States of America), **S. Fernandez-Bravo** (Madrid, Spain)

- D2.349** **RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucricitibant for On-Demand Treatment of Hereditary Angioedema Attacks**
A. Valerieva (Sofia, Bulgaria)

- D2.350** **Exploring the Psychological Burden of Hereditary Angioedema Using the Pictorial Representation of Illness and Self Measure (PRISM): Updated Insights from a Prospective Real-Life Cohort**
D. GOBERT (Paris, France)

- D2.351** **Germline Variant in the GNAI2 Gene Associated with Severe Immune Dysregulation and Autoimmune Hemolytic Anemia in a Pediatric Patient**
I. Guryanova (Baraŭliany, Belarus)

- D2.352** **Epidermodysplasia verruciformis as a sign for STK4 deficiency**
A. K. Baskin (Ankara, Türkiye)

- D2.353** **Same Disease, Different Clinical Phenotypes: A20 Haploinsufficiency**
M. Suleyman (Ankara, Türkiye)

- D2.354** **Evaluation of Subjective Sleep Quality and Psychological Status in Adult Patients with Inborn Errors of Immunity**
E. Sahinoglu (Ankara, Türkiye)

- D2.355** **Treatment-refractory chronic spontaneous urticaria: a diagnostic pitfall**
E. Marquart (Vienna, Austria)

- D2.356** **Multidimensional Assessment of Patient-Reported-Outcomes in a Multicenter Cohort of IEIs**
M. Yorgun Altunbas (İstanbul, Türkiye)

- D2.357** **Reductions in Hereditary Angioedema Attacks among Patients with C1 Esterase Inhibitor Deficiency who Switched from Another Long-Term Prophylaxis to Berotralstat**
S. Nestler-Parr (Durham, NC, United States of America)

- D2.360** **Hereditary Angioedema Attack Rates among Patients with Normal C1 Esterase Inhibitor Before and After Switching from Another Long-Term Prophylaxis to Berotralstat**
S. Nestler-Parr (Durham, NC, United States of America)

- D2.361** **Reductions in Healthcare Resource Utilization in Adolescents with Hereditary Angioedema on Berotralstat**
S. Nestler-Parr (Durham, NC, United States of America)

- D2.362** **Clinical and Immunological Characteristics of Non-Infectious Complications in Common Variable Immunodeficiency: A Single-Center Retrospective Evaluation in Adult Patients with CVID**
E. Çetin Başaran (Ankara, Türkiye)

- D2.363** **Immunologic Basis of Coexisting Slowly Progressive Insulin-Dependent Diabetes Mellitus (SPIDDM) and Generalized Myasthenia Gravis (MG)**
S. Koga (Tokyo, Japan)

- D2.364** **Perioperative Management and Safety of Bradykinin-Mediated Angioedema: A 9-Year Retrospective Study**
D. GOBERT (Paris, France)

12:00 - 13:00 L-TPS48 - Immune deficiencies and autoimmunity 04

(Poster Zone, Thematic Poster Session)

Chair: **H. Bonnekoh (Berlin, Germany)**

- D2.367** Hepatic Involvement and Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Retrospective Evaluation
Z. Genc Ozbay (Ankara, Türkiye)

- D2.368** Concurrent Hereditary Angioedema Type I and Common Variable Immunodeficiency Presenting as Suspected Antibiotic Hypersensitivity: Case Report and Literature Review
D. Urdea (Iasi, Romania)

- D2.369** Acute Myeloid Leukemia in a Patient With X-linked Agammaglobulinemia
F. Genel (İzmir, Türkiye)

- D2.370** Chronic urticaria and autoimmunity: clinical, laboratory and molecular correlations
A. Dimitriou (Athens, Greece)

- D2.371** Hematologic Findings in Primary Immunodeficiency Disorders: A Single-Center Experience
R. S. Cansunar (Adana, Türkiye)

- D2.373** Characterizing the clinical allergic profile of Romanian adult patients with inborn errors of immunity: results from a tertiary center
A. Gheorghiu (București, Romania)

- D2.374** Diagnostic delay in children with primary immunodeficiencies: clinical consequences in a single-country cohort from the Republic of Moldova
S. Sciuca (Chisinau, Moldova)

- D2.37** Structural lung changes detected by chest CT in pediatric patients with combined immunodeficiencies
S. Sciuca (Chisinau, Moldova)

- D2.376** Mevalonate kinase deficiency: An analysis of a Slovakian Cohort of MKD patients
E. Jurkova Malicherova (Martin, Slovakia)

- D2.377** Severe Eosinophilia as an Atypical Initial Presentation of X-Linked Hyper-IgM Syndrome Due to CD40LG Deficiency
C. Tomacinschi (Chișinău, Moldova)

- D2.378** Evaluations of Safety Margins and Response to Deucritibant Extended-Release (XR) Tablet in Combination with Deucritibant Immediate-Release (IR) Capsule
A. Lesage (Schilde, Belgium)

12:00 - 13:00 L-TPS49 - Drug Allergy 03

(Poster Zone, Thematic Poster Session)

Chair: J. J. Laguna Martinez (Madrid, Spain), M. Atanaskovic-Markovic (Beograd, Serbia)

D2.394 Mycoplasma-Induced Drug Hypersensitivity: Rare Complication or Coincidence?

P. Jungsanguanpornasuk (Bangkok, Thailand)

D2.395 Erdosteine-induced multifocal fixed drug eruption: a case series of five patients

J.-H. Choi (Hwaseong-si, Korea, Republic of)

D2.396 Successful Desensitization in a Patient with a Delayed Type Hypersensitivity Reaction to Ethambutol

M. Zande (Athens, Greece)

D2.397 Immediate and Delayed Hypersensitivity Reactions to Multiple Thyroid Hormone Preparations: A Challenging Case

M. Akarsu (Ankara, Türkiye)

D2.398 Ibuprofen Challenge or Desensitisation in Myo-Pericardial Disease: A Case Series

G. Cortellini (Rimini, Italy)

D2.399 Successful Deferasirox Desensitization in a Patient with Delayed-Type Hypersensitivity

D. Azkur (Kırıkkale, Türkiye)

D2.400 Vitamin Hypersensitivity in the Era of Intravenous 'Cocktails': Diagnostic Pitfalls and Clinical Consequences

N. Kahveci (İstanbul, Türkiye)

D2.402 Latex Sensitization as a Risk Factor for Perioperative Hypersensitivity Reactions in Asthmatic Children

O. Sharikadze (Kiev, Ukraine)

D2.403 When a Topical Drug Goes Systemic: A Case of Dual Hypersensitivity to Diltiazem

D. Stoyanova (Sofia, Bulgaria)

D2.405 UnDRESSing AGEP and Revealing Erythema Multiforme

T. Nedelcheva (Sofia, Bulgaria)

D2.406 Severe DRESS in an oncohematological patient: diagnostic and therapeutic challenges

A. J. BARBA GIL (Madrid, Spain)

12:00 - 13:00 L-TPS50 - Basic immunology 02

(Poster Zone, Thematic Poster Session)

Chair: *S. Boyd (Stanford, United States of America), J.-F. Lopez (Davos, Switzerland)*

- D2.423** Changes in the expression of regulatory receptors on CD8+ T cytotoxic lymphocytes as a marker of the risk of developing a post COVID-19 condition in patients after a severe course of COVID-19
S. Zubchenko (L'viv, Ukraine)

- D2.425** Type 2 neuro-immune signaling is upregulated in Candida albicans-driven itch
A. Tyo (Seoul, Korea, Republic of)

- D2.426** Polarization of PBMCs during SARS-CoV-2 Infections
M. Yaman (Ankara, Türkiye)

- D2.427** Inhibition of the IL-17 pathway in the treatment of systemic vasculitis: molecular biology and case review
L. Tchelidze (Tbilisi, Georgia)

- D2.428** Contribution of Allelic Gene Variants of the Indoleamine-2,3-Dioxygenase and Dectin-1 to the Risk of Invasive Aspergillosis in Oncohematological Patients
E. Burygina (Saint Petersburg, Russia)

- D2.429** Virus-Specific Regulatory T-Cell Dysregulation in Post-COVID-19 and EBV-Associated Vasculitis
K. Lishchuk–yakymovych (Lviv, Ukraine)

- D2.430** Automated 24-Hour Quantification of Scratching Behavior Reveals Distinct Physiological and Allergic Pruritus Signatures in Mice
T. Murata (Bunkyo City, Japan)

- D2.432** Therapeutic Efficacy of Platelet-Rich Plasma in Androgenic Alopecia: A Meta-Analysis of Single Versus Double-Blinded Randomized Controlled Trials
N. K. Karna (Dharan, Nepal)

- D2.433** Clinical and Oxidative Function Profiles in Heterozygous Female Carriers of X-Linked Chronic Granulomatous Disease
T. Freitas (Coimbra, Portugal)

12:00 - 13:00 L-TPS51 - Basic immunology 03

(Poster Zone, Thematic Poster Session)

- D2.436** Anti-tumoral effect of hydatid cyst fluid in a cell-derived breast cancer xenograft model
R. S. BOUSSA (Bab Ezzouar, Algeria)

- D2.437** Human memory CD4+T cells induce hyperresponsiveness in mast cells
J. He (Berlin, Germany)

- D2.439** Corticosteroids promoted organoid formation and differentiation of SSEA-1+ lung stem/progenitor cells
Y.-H. Hsu (Taipei, Taiwan)

- D2.440** From Steroid Dependence to Remission: Anti-IL-5 Therapy in Gastrointestinal Hypereosinophilic Syndrome
C. Macedo (Creixomil, Portugal)

- D2.441** Association of High Sensitive-C-reactive Protein with Left Ventricle Remodeling in Type 1 Diabetes Mellitus
L. DuBuske (Gardner, United States of America)

- D2.442** AAV-Mediated IL-10 Gene Delivery Enhances Antitumor Immunity While Preserving Immune Tolerance in Hepatocellular Carcinoma
C.-I. Lin (Taipei, Taiwan)

- D2.443** Serum Zonulin Reflects Disease Activity and Psychiatric Burden in Hereditary Angioedema
R. F. Kural (İzmir, Türkiye)

- D2.444** Clinical and Genetic Features of Primary Immunodeficiencies with a High Risk of Cancer in Children of the Kazakh Population
A. Salimova (Astana, Kazakhstan)

- D2.445** Systemic Nitric Oxide: a promising inflammatory biomarker for early detection, prognosis, and monitoring of patients with colon cancer
R. S. BOUSSA (Algiers, Algeria)

12:00 - 13:00 L-TPS52 - Biologicals 02

(Poster Zone, Thematic Poster Session)

Chair: J. Coquet (Copenhagen, Denmark), J. Asllani (Tirana, Albania)

- D2.447** Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
V. Naumova (Ekaterinburg, Russia)

- D2.448** Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
F. Bärhold (Wiesbaden, Germany)

- D2.449** Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥ 150 cells/ μ L Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
C. Wyss (Baar, Switzerland)

- D2.450** EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
A. Chaker (Ghent, Belgium)

- D2.451** Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
M. Lundberg (Helsinki, Finland)

- D2.452** Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
C. Wyss (Baar, Switzerland)

- D2.453** Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
Y.-H. Nam (Busan, Korea, Republic of)

- D2.455** Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
M. A. Demirkol (İstanbul, Türkiye)

- D2.456** Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
Y. Bektas (Ulm, Germany)

- D2.457** Hypersensitivity reactions for Enzyme Replacement Therapy in a Patient with Hunter syndrome
J. Levina (Moscow, Russia)

- D2.460** Does Aspirin change outcomes of dupilumab therapy?
G. Muehlmeier (Ulm, Germany)

- D2.461** Endothelial related miRs are dysregulated in C1-INH Angioedema patients: new potential biomarkers and therapeutic targets
M. Bova (Napoli, Italy)

- D2.462** Safety and predictors of tolerance in rituximab hypersensitivity management
L. Carrasco Gómez (Madrid, Spain)

- D2.463** Development of a novel anti-CD19 x BCMA dual targeted T cell engager for the treatment of autoimmune diseases and B cell malignancies
Z. Zhu (Wilmington, DE)

12:00 - 13:00 L-TPS53 - Pediatrics 02

(Poster Zone, Thematic Poster Session)

Chair: **E. Gomes** (porto, Portugal), **C. Berghea** (București, Romania)

D2.477 Nationwide Survey of Healthcare Transition from Paediatric to Adult Services for Allergic Diseases in Japan
Y. Tsurinaga (Habikino, Japan)

D2.478 HEREDITARY ANGIOEDEMA - A case report
D. D. Volvoikar (Goa, India)

D2.479 The bullous pemphigoid in a baby
V. Semianchuk (Ivano-Frankivs'k, Ukraine)

D2.480 Features of the molecular sensitization profile in children with autism spectrum disorder
L. Namazova-Baranova (Moscow, Russia)

D2.481 Severe obstructive syndrome in children with bronchopulmonary malformations
S. Sciuca (Chisinau, Moldova)

D2.482 Neuroendocrine Cell Hyperplasia of Infancy (NEHI): Report of 7 Cases
P. Shahid (Sofia, Bulgaria)

D2.483 Outdoor Activity and Screen Time at Age 3 years and Allergic Symptoms at Age 6 years: A Nationwide Birth Cohort Study (JECS)
D. Harama (Tokyo, Japan)

D2.485 Comprehensive Understanding of the Characteristics of Pediatric Pollen Allergy Patients
M. J. Kim (Yongin, Korea, Republic of)

D2.486 Levels of house dust mite in dust settlements are associated with risk for allergic rhinitis in children
I. Banic (Zagreb, Croatia)

D2.487 Avoiding Unnecessary Food Avoidance: Outcomes of Infants with Localised Reactions During Weaning
J. Hourihane (Dublin, Ireland)

D2.488 Functional confirmation of exercise-induced bronchoconstriction in children: A three-year retrospective study
D. Antunes (Lisboa, Portugal)

D2.489 B-Cell Subset Reconstitution After Rituximab-Containing Chemotherapy in Children and Adolescents With Non-Hodgkin Lymphoma: A Single-Center Experience
E. Hlavackova (Brno, Czech Republic)

12:00 - 13:00 L-TPS54 - Clinical Trials 01

(Poster Zone, Thematic Poster Session)

Chair: C. Flohr (London, United Kingdom)

- D2.490** Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial
O. Pfaar (Marburg, Germany)

- D2.491** Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial
M. Gerstlauer (Augsburg, Germany)

- D2.492** Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial
O. Pfaar (Marburg, Germany)

- D2.494** Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study
F. Teodora (Ballerup, Denmark)

- D2.495** Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study
M. Muñoz (Berlin, Germany)

- D2.496** First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis
J. Kim (Seoul, Korea, Republic of)

- D2.497** Oral Deucricitbant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial
P. Li (Hong Kong, Hong Kong)

- D2.498** Berostralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to <12 years: APeX-P Results Through 48 Weeks
T. Khuu (Durham, United States of America)

- D2.499** Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial
C. Pablo-Torres (Boston, United States of America)

- D2.503** LP-003 Injection for the treatment of H1 Antihistamine-Inadequately Controlled Chronic Spontaneous Urticaria (CSU): A Multicenter, Randomized, Double-Blind, Controlled Phase II Study
H. Cuicui (Shanghai, China)

- D2.504** Novel food supplement containing a combination of bioactive compounds in pediatric cow's milk protein allergy: results from a randomized, placebo-controlled trial
L. Carucci (Naples, Italy)

12:00 - 13:00 L-TPS55 - Environmental allergy and climate change + One Health 01
(Poster Zone, Thematic Poster Session)

Chair: **M. Raulf** (Bochum, Germany)

- D2.505 Sustainable Allergy Management: a Task force report**
I.-J. Wang (Taipei Hospital Ministry of Health and Welfare, Taiwan)
-
- D2.506 Mold amounts decreased annual concentration, even some species faded away with allergic sensitization rate in Seoul for 28 years**
J.-W. Oh (Uij, Korea, Republic of)
-
- D2.507 School dust Streptomyces and Mycobacterium exposure and respiratory health in European children: the SINPHONIE study**
I. Annesi-Maesano (Montpellier, France)
-
- D2.508 Climate Change, Allergic Diseases, and Mental Health in Outdoor Workers: A Transdisciplinary Perspective from CliMent COST Action**
D. Mijakoski (Skopje, North Macedonia)
-
- D2.509 Do macrophages modulate the response of injured bronchial epithelium after PM2.5 and microplastic exposure?**
M. Paplinska-Goryca (Warszawa, Poland)
-
- D2.511 Beyond PFAS: Atypical oral manifestation of eosinophilic esophagitis in a patient with birch allergy. Case Description**
A. Rucińska (Wrocław, Poland)
-
- D2.512 Analysis of temporal and regional trends in Internet searches for pollen allergies (MELIUS)**
S. Ugur (Munich, Germany)
-
- D2.513 Weed pollen exposure in Almaty: aerobiological monitoring and component-resolved IgE sensitization patterns**
N. Akhtemova (Almaty, Kazakhstan)
-
- D2.514 Breathing zone pollen and fungal spore monitoring with an IOM Personal Sampler: A pilot study**
T. Ribeiro (Porto, Portugal)
-
- D2.515 Symptom forecasting for birch and grass pollen allergy: the #berlinbreathing project**
C. J. Hernandez Toro (Berlin, Germany)
-
- D2.516 Can social media track seasonal allergy burden? An evidence-weighted geo-location pipeline and validation against airborne pollen exposure in Augsburg, Germany**
M. P. Plaza (Augsburg, Germany)
-
- D2.517 #berlinbreathing: An app-based citizen science project for pollen allergies**
C. J. Hernandez Toro (Berlin, Germany)
-
- D2.518 Clinical pattern of weed pollen sensitization in a Romanian population**
A. Sirbu (Cluj-Napoca, Romania)
-

12:00 - 13:00 L-TPS56 - Allied health and primary care 01

(Poster Zone, Thematic Poster Session)

Chair: **G. Feketea** (Patra, Greece), **R. Meyer** (Leuven, Belgium)

- D2.521** Reshaping Allergy Assessment Pathways In The United Kingdom: Modeling System-Level Gains Through Discrete Event Simulation
M. Tena Campos (Cornellà de Llobregat, Spain)

- D2.522** An Observational Study of techniques of Intanasal Spray in Allergic Rhinitis
M. Ahmed (Hyderabad, India)

- D2.523** Dyadic parenting stress and marital communication among parents of young children with food allergies
M. Oikawa (Minato City, Japan)

- D2.524** How much does wheat oral immunotherapy improve quality of life?
N. S. Cheng (Shatin, Hong Kong)

- D2.525** Efficacy of Combined Antileukotriene and Antihistamine Therapy in Allergic Rhinitis
O. Belik (Moscow, Russia)

- D2.527** Lessening the food allergy burden through education: A Canadian focus
J. Protudjer (Winnipeg, Canada)

- D2.528** Corticophobia Among Caregivers of Children with Atopic Diseases: Causes and Outcomes
G. Yörüsün (Ankara, Türkiye)

- D2.529** Asymptomatic QT Prolongation Developing After Anthistamine Use
H. Ercan Saricoban (Istanbul, Türkiye)

- D2.530** Digital patient-reported data uncover key clinical features of mastocytosis: insights from the MASTHAVE App
P. Pyatlova (Berlin, Germany)

- D2.531** Expert Panel Discussion on a New Oral On-Demand Treatment in Hereditary Angioedema
W. Lumry (Dallas, TX, United States of America)

- D2.532** Does Bathing Frequency Matter in Pediatric Atopic Dermatitis? Insights from Real-Life Practice
G. Unlu Kilavuz (İstanbul, Türkiye)

- D2.533** Characterizing Elderly Asthma Hospitalizations: Insights into Treatment Gaps and Outcomes; A Real-World Study Using the MIMIC-IV Dataset
Q. Najah (Khoms, Libya)

- D2.536** Seasonal Influenza Vaccination: Uptake Rate, Profile, and Motivating Factors Among Healthcare Workers
I. Kacem (Sousse, Tunisia)

- D2.537** Advances in Drug Allergy & Penicillin Testing Phase 2 (ADAPT-2): an AI-powered drug allergy educational initiative spanning across 4 localities
P. Li (Hong Kong, Hong Kong)

12:00 - 13:00 L-TPS57 - Epidemiology (Poster Zone, Thematic Poster Session)

Chair: C. M. Rossi (Pavia, Italy)

D2.540 Nationwide Analysis of Domestic Mites in Germany

A. Sager (Witten, Germany)

D2.541 Healthy and unhealthy plant-based dietary patterns and asthma: a systematic review using validated dietary indices

E. Wasilewska (Gdańsk, Poland)

D2.542 Prevalance and risk factors of atopic dermatitis among preschool children Gaziantep, a province in South-Eastern Turkey

E. Küçükösmanoğlu (Gaziantep, Türkiye)

D2.543 Clinical and Epidemiological Characteristics of Workers with Inflammatory Bowel Disease: A Cross-Sectional Study

C. Sridi (Sousse, Tunisia)

D2.544 Validation of the Turkish Version of the Mastocytosis Control Test

D. Unal (İstanbul, Türkiye)

12:15 - 12:30 Poland - Polish Society of Allergology (EAACI Global Stage, NAIS Session)

12:15 National Anaphylaxis Awareness in Poland: from public education to health policy implementation

P. Lacwik (Chęciny, Poland)

12:30 - 12:45 Türkiye - Society of Pediatric Allergy Immunology and Asthma (CAIAD) (EAACI Global Stage, NAIS Session)

12:30 Traditional fermented foods and early life nutrition in allergic diseases; from pregnancy to childhood

Ö. Yılmaz (Çanakkale, Türkiye)

12:30 - 12:45 Product Theatre 2-3 (Innovation Hub, Product Theatre)

12:45 - 13:00 Spain - SEICAP (Spanish Society of Paediatric Clinical Immunology, Allergy and Asthma) (EAACI Global Stage, NAIS Session)

12:45 Alergopediatria 2024: The Situation of Pediatric Allergy Units in Spain

13:15 - 14:00 P & C 3 - Pro Con 3: Is the specific provocation sufficiently standardized for occupational asthma?
(EAACI Global Stage, Pro Con)

Chair: *H. Suojalehto (Helsinki, Finland)*

13:15 Pro

P. Mason (PADOVA, Italy)

13:38 Con

J. Walusiak-Skorupa (Lodz, Poland)

13:15 - 14:15 Enlightenment talk
(Poster Zone, Thematic Poster Session)

13:15 How early is too late?

A. Custovic (London, United Kingdom)

13:45 Why optimizing AIT-clinical trial designs in the era of EBM?

O. Pfaar (Marburg, Germany)

13:15 - 14:15 SSS4 - EAACI WAO Sister Society Symposium: World Allergy Forum – Addressing the Global Problem of Food Allergy
(Room London, 6- London, Sister Society Symposium)

Chair: *M. Torres (Malaga, Spain), B. Martin (Columbus, United States of America)*

13:15 WAO Calls to Action regarding Omalizumab, Immunotherapy, and Ending First Generation Antihistamine Treatment

M. Morais-Almeida (Lisbon, Portugal)

13:35 The Critical Need for Precautionary Allergen Labelling

A. Fiocchi (Roma, Italy)

13:55 Why We Must Have Minimum Dataset Reporting in Food Allergy Trials

A. S. Y. Leung (Hong Kong, China)

13:15 - 14:45 FT09 - Molecular allergology advances in allergy diagnosis (Room Athens, Flash Talks)

Chair: **B. Eberlein** (Munich, Germany), **C. Hilger** (Esch-sur-Alzette, Luxembourg)

13:15 The human allergen atlas - high-throughput epitopic identification of allergens

001431 M. Møiniche (Lyngby, Denmark)

13:22 Expanding grass pollen allergomes to improve molecular characterization of diagnostic and allergen immunotherapy products

000765 T. Batard (Antony, France)

13:29 Arginine kinase as an important house dust mite component, in skin prick test negative allergic rhinitis and asthma patients

000490 D. Pujari (Pune, India)

13:36 Development of a lectin based ELISA for determination of IgE sialylation in serum

000161 J. Alvarez (Tres Cantos, Spain)

13:43 The antibody-binding capacity of casein and whey hydrolysates is primarily determined by the degree of hydrolysis, with physicochemical properties contributing to additional variability

001545 A. Looi (Kongens Lyngby, Denmark)

13:50 Integrated Assessment of Small Airway Function, Bronchodilator Response, and FeNO to Identify High-Risk Patients with Bronchial Hyperresponsiveness

001278 L. Yun (Shaanxi Province, Xi'an City, China)

13:57 Nasal Allergen Challenge (NAC) with dissolved SQ HDM SLIT-tablet

000508 E.-J. Katle (Stavanger, Norway)

14:04 Combining basophil activation test and IgE test against grass carp extract for endotyping fish allergy

000682 C. Y. Y. Wai (Hong Kong, Hong Kong)

14:11 Allergen-Specific Neutrophil Activation and LPS-Enhanced Basophil Reactivity as a Mechanism for Infection Exacerbated Reactions in Childhood Nut Allergy

001320 J. Trayer (Dublin, Ireland)

14:18 Basophil Activation Test in the Diagnostic Procedure of Cow's Milk Allergy among Brazilians

001387 L. Camargo Lopes de Oliveira (São Paulo, Brazil)

14:25 Molecular Composites of Purified Allergens for Improved Basophil Activation Testing

000626 S. Wuenschmann (Charlottesville, United States of America)

14:32 Stimulation Ratios as a New approach to Objective Datamining in Basophil Activation Test

001434 J. M. Busnel (Marseille, France)

13:15 - 14:45 FT10 - Omics studies in allergic diseases, potential application in biological treatments
(Room Glasgow, Flash Talks)

Chair: **C. Karaaslan** (Ankara, Türkiye), **U. Radzikowska** (Davos, Switzerland)

13:15 Integrated Proteomic and Metabolomic Analysis of Plasma-Derived Extracellular Vesicles Reveals the Impact of Allergen-Specific Immunotherapy in Pediatric Allergic Asthma

000158 W. Luo (Guangzhou, China)

13:22 A Distinct and Stable Lipidomic Signature in Food-Allergic Patients Reveals a Predisposing Metabolic State for Cofactor-Induced Anaphylaxis

001073 B. Raposo-Martínez (Boadilla del Monte, Spain)

13:29 Early epigenetic changes associated with mepolizumab treatment in severe asthma

001676 D. Gonzalez-Garcia (Santa Cruz de Tenerife, Spain)

13:36 Inhibitory Effects of Tezepelumab on Proinflammatory Mediators in Nasal Lining Fluid from Patients with CRSwNP in the Phase 3 WAYPOINT Study

000755 B. J. Lipworth (Dundee, United Kingdom)

13:43 Integrated Barrier and Multi-Omic Analysis Identifies Molecular Signatures of Response to Tralokinumab in Atopic Dermatitis

002071 C. Zeyneloglu (Davos, Switzerland)

13:50 Integrated Multi-Omics Analysis Reveals Abatacept-Mediated Immune Restoration in CTLA-4 Insufficiency and LRBA Deficiency

001672 M. C. Catak (Istanbul, Türkiye)

13:57 Polygenic and methylation risk scores for asthma and biologic therapy response in the Spanish population

001740 M. Martin Almeida (Santa Cruz de Tenerife, Spain)

14:04 Nasal DNAm markers associated with asthma exacerbations in the Spanish population

000614 E. Martin-Gonzalez (San Cristóbal de La Laguna, Spain)

14:11 Nasal secretions are a valuable tool in defining the inflammatory endotype in upper airway inflammatory diseases

001268 E. Vandewalle (Ghent, Belgium)

13:15 - 14:45 OAS12 - Advancing AIT clinical efficacy and novel combination

(Room Gothenburg, Oral Abstract Sessions)

Chair: L. Aglas (Helsinki, Finland), A. Bozek (Katowice, Poland)

13:15 Rapid and Sustained Suppression of Allergen-Induced Skin Responses After Combination of Dupilumab and Grass Pollen Sublingual Immunotherapy Tablet

000908 A. Eifan (London, United Kingdom)

13:27 Weekly Combined Symptom Medication Score to Assess Seasonal Allergic Rhinitis Burden and Efficacy of Grass Sublingual Immunotherapy Tablet

000272 M. Huffaker (Stanford, United States of America)

13:39 Long-term effectiveness of HDM SLIT-tablets on symptom-relieving prescriptions: Results from the Japanese register-based study, Real-world Evidence of house dust Mite sublingual Immunotherapy Tablets (REMIT)

001258 S. R. Durham (London, United Kingdom)

13:51 Effectiveness of sublingual immunotherapy (SLIT) tablets on dispensed asthma medications and treatment regimens: Results from the Real-world Evidence of aLlergy immunotherapyY (RELY) study

000751 C. Woehlk (Hørsholm, Denmark)

14:03 Risk Stratification for Systemic Reactions During House Dust Mite Subcutaneous Immunotherapy: A Multicenter Real-World Prediction Model

001402 S. Yao (Beijing, China)

14:15 Patient-reported outcome measurements (PROMs) in monitoring the effectiveness of allergen immunotherapy

001068 T. Chin-See-Chong (Rotterdam, Netherlands)

14:27 Synergistic Effect of Dupilumab and Grass Pollen Sublingual Immunotherapy: Sustained Clinical and Immunologic Benefits After Treatment Cessation

000903 M. Huffaker (Stanford, United States of America)

13:15 - 14:45 OAS13 - Atopic dermatitis urticaria

(Room Munich, Oral Abstract Sessions)

Chair: P. Schmid-Grendelmeier (Davos, Switzerland), E. Kocatürk (Berlin, Germany)

13:15 Interaction between sex, Filaggrin (FLG) mutation, and early interventions in the prevention of atopic diseases

000737 B. Tan (Stockholm, Sweden)

13:27 Skin Microbiome Dysbiosis and Immune Activation in Dupilumab Associated Head and Neck Dermatitis: A Shotgun Metagenomic Analysis

000721 W. Kim (Seoul, Korea, Republic of)

13:39 Maternal plasma metabolomic and proteomic signatures of urban living and risk of offspring atopic dermatitis

001111 W. Tingting (Copenhagen, Denmark)

13:51 The burden and trajectory of multimorbidity in 6892 adults with moderate-to-severe atopic dermatitis-a 20 year nationwide population-based cohort study

000430 K. T. Tang (Taichung City, Taiwan)

14:03 Comparing azathioprine with cyclosporine in the treatment of antihistamine refractory chronic spontaneous urticaria. A randomized prospective active-controlled non-inferiority study

000496 Y. PATHANIA (Rajkot, India)

14:15 C5aR expressing neutrophils are increased in the skin of chronic spontaneous urticaria patients

000762 M. Muñoz (Berlin, Germany)

14:27 Longer Duration of Chronic Spontaneous Urticaria Is Associated with Lower Disease Activity but Higher Comorbidity Burden: Results from the CURE Registry

000694 P. Kolkhir (Berlin, Germany)

13:15 - 14:45 SYM12 - Update in pediatric asthma (Room Istanbul, 1- Istanbul, Symposium)

Chair: *S. Foti Randazzese (Pavia, Italy), M. Serbes (Adana, Türkiye)*

- 13:15** **Asthma biologics for children: What's new**
S. Saglani (London, United Kingdom)

- 13:45** **Montelukast for asthmatic children: to give or not to give**
W. Feleszko (Warszawa, Poland)

- 14:15** **Prevention of childhood asthma: where do we stand?**
K. Bønnelykke (Lillerød, Denmark)

13:15 - 14:45 SYM13 - Novel tools for the personalised management of allergic diseases (Room Paris, 2- Paris, Symposium)

Chair: *P. Matricardi (Berlin, Germany), N. Mikos (Athens, Greece)*

- 13:15** **Latest developments of molecular allergology**
S. Dramburg (Berlin, Germany)

- 13:45** **Estimating the risk of severe reactions in food allergy**
K. Hoffmann-Sommergruber (Wien, Austria)

- 14:15** **Omics and allergic diseases: fact or fiction**
A. Villasenor Solis (Madrid, Spain)

13:15 - 14:45 SYM14 - Delabeling antibiotic allergy (Room Zurich, 5- Zurich, Symposium)

Chair: *L. H. Garvey (Hellerup, Denmark), V. Chiang (Hong Kong, Hong Kong)*

- 13:15** **The role of Antibiotic allergy assessment in antimicrobial stewardship**
J. Sandoe (Leeds, United Kingdom)

- 13:45** **Drug Provocation with Penicillins: Single dose vs prolonged provocation?**
J. A. Trubiano (Heidelberg, Australia)

- 14:15** **Penicillin Allergy Delabeling in Primary Care**
F. Stul (Ghent, Belgium)

13:15 - 14:45 TSY3 - Microbiome and allergy: beyond the gut axis (Room Florence, 3- Florence, Thematic Symposium)

Chair: *C. Riggioni-Viquez (Toronto, Canada), M. Pérez-Gordo (Madrid, Spain)*

- 13:15** **Mom knows best - maternal microbiome influences on allergic disease**
K. Jarvinen-Seppo (Rochester, United States of America)

- 13:45** **Lung-microbiome axis in asthma and allergic airway diseases**
L. O'Mahony (Cork, Ireland)

- 14:15** **The oral microbiome and its potential role in allergic diseases**
S. Bunyavanich (New York, United States of America)

13:45 - 14:45 Satellite Symposium
(Room Utrecht, Sponsored Sessions)

13:45 - 14:45 Satellite Symposium
(Room Krakow, Sponsored Sessions)

14:15 - 15:00 P & C4 - PRO CON 4 - Are biosimilars and reference biologicals interchangeable?
(EAACI Global Stage, Pro Con)

Chair: **G. W. Canonica (Milan, Italy)**

14:15 Pro
L. de las Vecillas Sanchez (Madrid, Spain)

14:38 Con
A. Vultaggio (Florence, Italy)

14:30 - 15:00 Satellite Symposium
(Room London, Sponsored Sessions)

15:00 - 16:30 FT11 - From pregnancy to pandemic: early predictions of allergy disease
(Room Athens, Flash Talks)

Chair: **M. Papadopoulos (Athens, Greece), C. Berghea (București, Romania)**

15:00 Fertility treatment with ovulation induction or intrauterine insemination and the risk of childhood atopic diseases
000956 L. O. Kettner (Aarhus, Denmark)

15:07 Impact of Insulin Therapy on Maternal Allergic Diseases and Neonatal Immune Modulation in Gestational Diabetes
002036 P. Kumar (New Delhi, India)

15:14 The integral model of personalized genotype-associated prediction of the atopic march poly-organ phenotypes in children
001145 V. Dytiatkovskiy (Dnipro, Ukraine)

15:21 Childhood lung function trajectories and their association with asthma: Evidence from the Generation XXI birth cohort
000982 F. Mendes (Porto, Portugal)

15:28 Trajectories of adherence to the Planetary Health Diet from childhood to adolescence and asthma risk: findings from the Generation XXI birth cohort
001346 M. Rodrigues (Porto, Portugal)

15:35 Association between postnatal growth pattern and childhood asthma: Evidence from a twin cohort
001310 R. Putri (Stockholm, Sweden)

15:42 Eating behavior assessment in children with atopic dermatitis and food allergy
000741 S. Makarova (Moscow, Russia)

15:49 Management of IgE-Mediated Egg Allergy in Ireland and Spain: A 10-Year Multicentre Review
000871 J. E. Trujillo Wurttele (Cork, Ireland)

15:56 Emotional-Behavioral Difficulties and Maternal Psychosocial Factors in Preschool Children with Food Allergy
000695 S. Büyük Yaytokgil (Ankara, Türkiye)

16:03 Atopic outcomes of the CORAL cohort born in COVID-19 lockdown at 5 years
000233 A. Sokay (Dublin, Ireland)

16:10 Infant feeding practices at 6 months in infants born during and after the COVID-19 pandemic: A comparison of the CORAL and FLORAL birth cohorts
001695 A. Sokay (Dublin, Ireland)

13:15 - 14:45 FT12 - Hereditary angioedema

(Room Glasgow, Flash Talks)

Chair: A. Valerieva (Sofia, Bulgaria), M. Bova (Napoli, Italy)

- | | |
|---------------|---|
| 15:00 | Prevalence and Clinical Characteristics of Hereditary Angioedema Due to Plasminogen Gene Mutation: Expanding the Map to Bulgaria |
| 001915 | A. Fam (Sofia, Bulgaria) |
| 15:07 | Treatment choices and effectiveness among HAE type 1 and 2 patients: data from the Italian Reference Centers Network for Angioedema (ITACA) Registry |
| 000958 | R. Senter (Padova, Italy) |
| 15:14 | Expanded Genetic Profiling of SERPING1 and Associated Genes in Chinese HAE Cohorts |
| 001589 | N. ZHOU (beijing, China) |
| 15:21 | Disease control and patient-reported outcomes from a Phase 4 open-label study in patients with hereditary angioedema switching to garadacimab from prior long-term prophylaxis |
| 000754 | P. K. Keith (Hamilton, ON, Canada) |
| 15:28 | Safety analysis of a Phase 4 study of patients with hereditary angioedema switching to garadacimab from prior prophylaxis |
| 000743 | P. K. Keith (Hamilton, ON, Canada) |
| 15:35 | Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucricitibant for Prophylaxis in Hereditary Angioedema |
| 000022 | M. Magerl (Berlin, Germany) |
| 15:42 | CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucricitibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema |
| 000023 | M. Magerl (Berlin, Germany) |
| 15:49 | Lanadelumab Effectiveness and Treatment Patterns in Patients With High Baseline Attack Rates: Results from INTEGRATED |
| 000215 | M. Magerl (Berlin, Germany) |
| 15:56 | Lanadelumab Bodyweight-Band-Based Dosing in Paediatric Patients with Hereditary Angioedema Generates Exposure Comparable to Dosing in Adult Patients |
| 000219 | H. Farkas (Budapest, Hungary) |
| 16:03 | Sustained Disease Control in Patients with Hereditary Angioedema who Extend Lanadelumab Dose Intervals to Every 4 Weeks Directly from Every 2 Weeks |
| 000218 | T. Kinaciyan (Vienna, Austria) |
| 16:10 | Transforming Hereditary Angioedema Management in China: Interim Real-World Evidence of Lanadelumab from the EASTERN Study |
| 000244 | R. Zhu (Wuhan, China) |
| 16:17 | The SERPING1 c.-21T>C polymorphism modulates disease severity in hereditary angioedema |
| 001292 | E. Cataudella (Florence, Italy) |

15:00 - 16:30 L-OAS07 - ENT

(Room Munich, Oral Abstract Sessions)

Chair: **S. Agarwal** (Chennai, India), **A. Chaker** (Munich, Germany)

15:00 Allergic Conjunctivitis in Respiratory Allergy: Current Clinical Practice and Unmet Needs Among Allergists in Spain

100048 R. González Pérez (La Laguna, Spain)

15:12 Tas2Rs activation suppresses recurrent allergic rhinitis via a Tuft cell–CCL3 axis

100064 Y. W. Zhou (Nanjing, China)

15:24 An interpretable machine learning framework for screening psychological distress in hospitalized patients with chronic rhinosinusitis

100143 X. Feng (Jinan, China)

15:36 Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) meeting the POLINA Guidelines Criteria for Biologic Therapy experience Early and Sustained Benefit with Depemokimab: Subpopulation Analysis of Phase 3 ANCHOR-1/2 Trials

100145 J. Mullol (Barcelona, Spain)

15:48 S-Nitrosoglutathione inhibits ILC3-mediated inflammation in neutrophilic chronic rhinosinusitis

100190 Y. Peng (Guang Zhou Shi, China)

16:00 Response to Tezepelumab Treatment Among Adults with Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: Week 76 Off-Treatment Results from the Phase 3 WAYPOINT Study

100486 B. J. Lipworth (Dundee, United Kingdom)

16:12 Chronic and Recurrent Rhinosinusitis as Early Markers of Inborn Errors of Immunity: A Pediatric Observational Cohort

100668 L. Leonardi (Rome, Italy)

15:00 - 16:30 OAS14 - Pediatric drug allergy

(Room Gothenburg, Oral Abstract Sessions)

Chair: **F. Mori** (Florence, Italy), **J.-C. Caubet** (Geneva, Switzerland)

15:00 Testing a predictive diagnostic scale for NSAID hypersensitivity in pediatric patients

001651 P. Falabella (Esplugues de Llobregat, Spain)

15:12 Clinical Evaluation Of Suspected Hypersensitivity Reactions To Nonsteroidal Anti-Inflammatory Drugs in Pediatric Patients

001476 B. A. Toksoz (Ankara, Türkiye)

15:24 PEN-FAST in Pediatrics: Can an Adult Risk Score Predict Beta-Lactam Allergy in Children?

001671 M. Blanco-López (Madrid, Spain)

15:36 Evaluation of Direct Drug Provocation Tests in Children with Suspected Penicillin Allergy and the Role of the PEN-FAST Score

001988 A. Ursu (Lisboa, Portugal)

15:48 Direct Drug Provocation Test in the Diagnosis of Low-Risk Pediatric Beta-Lactam Allergy: A Retrospective Study Based on Risk Stratification

001532 S. Günder (İzmir, Türkiye)

16:00 Pediatric Severe Cutaneous Adverse Drug Reactions (SCARs) clinical characteristics and comparison of causality assessment tools and severity scoring systems in relation to clinical outcomes from a single center experience

001094 B. Cil Yılmaz (İstanbul, Türkiye)

16:12 The Implementation of Monocyte-Derived Dendritic Cell–Based Lymphocyte Transformation Testing in Pediatric SCAR Patients

001775 H. B. Gemici Karaaslan (İstanbul, Türkiye)

15:00 - 16:30 OAS15 - Climate and Aeroallergens: where are we going?

(Room Munich, Oral Abstract Sessions)

Chair: *I. Annesi-Maesano (Montpellier, France), I. Paciência (Oulu, Finland)*

15:00 Relationship between Bioaerosol Exposure and Respiratory Symptoms in an Allergic Rhinitis Cohort in Augsburg
000750 P. Tegni Sontia (Augsburg, Germany)

15:12 Epidemiological Profile of Allergen Sensitization in a Chinese Patient Cohort Based on ALEX2 Testing
000132 W. Luo (Guangzhou, China)

15:24 Exposure of nasal epithelial cells with pollen aerosols and coronaviruses in a near-physiological in vitro model
100340 S. Gilles (Augsburg, Germany)

15:00 - 16:30 SYM15 - Oral immunotherapy (OIT) for persistent food allergy

(Room Istanbul, 1- Istanbul, Symposium)

Chair: *M. Fernandez Rivas (Madrid, Spain), J.-F. Lopez (Davos, Switzerland)*

15:00 OIT from adolescence to adulthood
P. Rodríguez del Río (Madrid, Spain)

15:30 OIT for specific foods - milk and egg
S. Arasi (Rome, Italy)

16:00 Long term management with OIT
A. Anagnostou (Houston, United States of America)

15:00 - 16:30 SYM16 - Epithelial barriers and immune interactions

(Room Paris, 2- Paris, Symposium)

Chair: *L. O'Mahony (Cork, Ireland), I. Ogulur (Davos Dorf, Switzerland)*

15:00 Household detergents disrupts airway epithelial integrity and trigger type 2 inflammation
H. Morita (Tokyo, Japan)

15:30 Common food emulsifiers impair epithelial barrier integrity and trigger proinflammatory responses
D. Yazici (Rochester, NY, United States of America)

16:00 The regulation of epithelial barriers by Nectin-4
A.-S. Jang (Bucheon, Korea, Republic of)

15:00 - 16:30 TSY4 - Innovation in Allergen Immunotherapy: Novel Approaches, Mechanisms, and Outcomes That Matter

(Room Florence, 3- Florence, Thematic Symposium)

Chair: *M. van Zelm (Melbourne, Australia), L. Klimek (Wiesbaden, Germany)*

15:00 Allergen-Specific mRNA Immunotherapy for HDM-Induced Asthma: From Mechanism to Translational Potential
J. Sun (Beijing, China)

15:30 Breaking New Ground: How Novel Short-Course Allergen Immunotherapy Delivers High-Impact Results in Grass Allergy
M. Shamji (London, United Kingdom)

16:00 Are We Measuring What Matters? Correlating Clinical Trial Endpoints with Disease Burden in Allergic Rhinitis
M. Huffaker (Stanford, United States of America)

15:15 - 15:27 Türkiye - Turkish National Society of Allergy and Clinical Immunology
(EAACI Global Stage, NAIS Session)

15:15 Atopic dermatitis in pediatric studies from Türkiye
U. M. Sahiner (Ankara, Türkiye)

15:15 - 15:27 TEAACI Journals: Recent Developments in Respiratory Allergic Diseases and Prediction of the Future of Childhood Allergic Diseases
(Room Utrecht, 4- Utrecht, EAJ)

Chair: O. Palomares (Madrid, Spain), A. K. Azkur (Kırıkkale, Türkiye)

15:15 Epithelial Barrier Defect and Respiratory Inflammation
C. Akdis (Davos, Switzerland)

15:35 Current Views on Allergic Asthma and Respiratory Allergies
M. Escribese (Madrid, Spain)

15:55 Can We Predict the Future of Childhood Allergic Diseases?
A. Custovic (London, United Kingdom), S. Tsabouri (Ioannina, Greece)

15:15 - 16:15 SSS5 - EAACI APAPARI Sister Society Symposium: Challenges in the management of allergies - a global perspective
(Room Zurich, 5- Zurich, Sister Society Symposium)

Chair: H. Soo-Jong (Seoul, Korea, Republic of), G. Wong (Hong Kong, China)

15:15 Atopic dermatitis trajectories and asthma development
E. Lee (Gwangju, Korea, Republic of)

15:35 The Asian Pacific Anaphylaxis Registry: unusual suspects causing severe reactions
P. Pacharn (Bangkok, Thailand)

15:55 From policy to practice: bridging the gap in food allergy preparedness in schools
Y. Xing (Shenzhen, China)

15:27 - 15:39 UK - BSACI Oral Food Challenge – Clinical Practice Statement
(EAACI Global Stage, NAIS Session)

15:27 BSACI Oral Food Challenge – Clinical Practice Statement
I. Skypala (London, United Kingdom)

15:30 - 16:30 Satellite Symposium
(Room London, Sponsored Sessions)

15:30 - 16:30 Satellite Symposium
(Room Krakow, Sponsored Sessions)

15:39 - 15:51 Spain - Spanish Society of Allergology Clinical Immunology (SEAIC)
(EAACI Global Stage, NAIS Session)

15:39 Allergy in University in Spain

15:51 - 16:03 Albania - Albanian Society of Allergy, Asthma and Clinical Immunology
(EAACI Global Stage, NAIS Session)

15:51 Topic "Peculiarities of the sensitization trajectory of the Albanian population"
J. Asllani (Tirana, Albania)

16:03 - 16:15 Belgium - Association Belge de Formation Continue en Allergologie (ABEFORCAL)
(EAACI Global Stage, NAIS Session)

16:03 ABEFORCAL - history and activities
E.-S. Vaia (Valréas, France)

16:45 - 18:15 FT13 - Where allergy meets cancer
(Room Athens, Flash Talks)

Chair: *S. Karagiannis (London, United Kingdom), L. de las Vecillas Sanchez (Madrid, Spain)*

16:45 AllergoOncology: Circulating Immunoregulatory B and T cell Profiles in Patients with Melanoma Modulated with Checkpoint Inhibitor Immunotherapy
002114 L. Booth (London, United Kingdom)

16:52 State-Dependent Effects of Mast Cells on Adaptive and Innate Immune Cell Diversity in Hepatocellular Carcinoma
001427 N. Rohr-Udilova (Wien, Austria)

16:59 AllergoOncology: Basophil stimulation propensity in cancer and the basophil activation test (BAT) in the clinical development of anti-cancer IgE immunotherapies
000162 J. Chauhan (London, United Kingdom)

17:06 Management of Chemotherapeutic Drug Hypersensitivity Reactions Based on Skin Tests: Is Desensitization Essential?
000898 S. Maden (Ankara, Türkiye)

17:13 Rrapid desensitization following carboplatin hypersensitivity in recurrent ovarian cancer improves survival and delays platinum resistance
000845 O. Goksel (Izmir, Türkiye)

17:20 Human Serum Albumin Conjugation Is Essential For In Vitro Tests To Diagnose Hypersensitivity To Platinum Salts: Focus On The Basophil Activation Test
001665 J. Charpy (Bordeaux, France)

17:27 Basophil-Mediated Hypersensitivity to Olaparib: Diagnosis and Successful Desensitization
002018 L. Fabbri (Roma, Italy)

17:34 Initial Hypersensitivity Phenotypes as Predictors of Breakthrough Reactions During Taxane and Platinum Desensitization
000615 C. Camacho (Córdoba, Spain)

17:41 Stepwise Dose Escalation in the Final Bag Rather Than Excessive Dilution Improves Safety in the Castells Rapid Drug Desensitization Protocol
001173 M. Dursun (Istanbul, Türkiye)

17:48 Prevalence and Types of Cancer in Patients Receiving Omalizumab: Insights from a Ten-Year Cohort
000087 G. Tuncay (Berlin, Germany)

16:45 - 18:15 FT14 - Challenge of anaphylaxis phenotyping and adrenaline use (Room Glasgow, Flash Talks)

Chair: **M. Fernandez Rivas** (Madrid, Spain), **A. Akkor** (Istanbul, Türkiye)

- 16:45** **Assessment of Epinephrine autoinjector administration accuracy in an Italian pediatric cohort**
001591 M. Sciannamea (Roma, Italy)
- 16:52** **Comparative Ease-of-Use Assessment of a Nasal Adrenaline Spray with an Adrenaline Auto-Injectors in Children, Adults and Caregivers**
000890 D. Mack (Hamilton, Canada)
- 16:59** **Intranasal Adrenaline Associated with Lower Administration-Related Anxiety and Higher Willingness-to-Use vs. Adrenaline Auto-Injectors**
000889 D. Mack (Hamilton, Canada)
- 17:06** **Healthcare Professionals' Perspectives on Anaphylaxis Management: A Multi-Country Survey comparing Adrenaline Auto-Injectors and Nasal Adrenaline Sprays**
001283 A. T. Fox (London, United Kingdom)
- 17:13** **Percutaneous sensitisation route in wheat allergy - Demonstration of gliadin penetration in the epidermis by tape stripping**
000211 C. Kiani (Munich, Germany)
- 17:20** **Understanding anaphylaxis through phenotyping: a machine learning approach**
001835 M. Lebedkina (Moscow, Russia)
- 17:27** **Older Versus Younger Adults with Anaphylaxis: Findings from the Turkish Anaphylaxis Registry**
001738 Z. F. Ozseker (Istanbul, Türkiye)
- 17:34** **Natural history and predictors of persistence in pediatric lentil allergy in a Greek population**
000017 K. MILIORDOS (Panepistimioupoli Patron, Greece)
- 17:41** **Clinical predictors of severe anaphylaxis and management gaps: a retrospective cohort analysis**
001844 M. Lebedkina (Moscow, Russia)
- 17:48** **ORAL IMMUNOTHERAPY SUCCESS: AGE, SPECIFIC IgE, OR BOTH?**
000976 İ. Baş (İzmir, Türkiye)
- 17:55** **Deaths from anaphylaxis reported by coroners in England and Wales: a national observational study, 2013-2025**
002050 F. Bettsworth (Walsall, United Kingdom)
- 18:02** **Higher Basal Tryptase Levels Are Associated with Anaphylaxis in Children with Horse Allergy**
001066 S. Yavuz (Bonn, Germany)

16:45 - 18:15 IH 4 - Cell tests in allergology (Innovation Hub, Innovation Hub)

Chair: **E. Phillips** (Nashville, United States of America), **C. Mayorga** (Málaga, Spain)

- 16:45** **Advantages and limitations of basophil activation tests**
B. Eberlein (Munich, Germany)
- 17:15** **Is the MAT (mast cell activation test) the better BAT?**
A. Eggel (Bern, Switzerland)
- 17:45** **Lymphocyte transformation test: added value to the skin test with delayed reading?**
M. Ardern-Jones (Southampton, United Kingdom)

16:45 - 18:15 IWS7 - Dietary tools for prevention and management of food allergy (Room Utrecht, 4- Utrecht, Interactive Workshop)

Chair: *H. Hunter (London, United Kingdom), J. Hourihane (Dublin, Ireland)*

16:45 Breast feeding and complementary feeding practices

E. Vassilopoulou (Thessaloniki, Greece)

17:15 Approaches to food reintroduction - snakes and ladders

R. Meyer (Leuven, Belgium)

17:45 Dietary management - the importance of specialist dietetic advice

J. Eisenblätter (Bern, Switzerland)

16:45 - 18:15 OAS16 - Airway response and allergic sensitization (Room Gothenburg, Oral Abstract Sessions)

Chair: *T. Trikamjee (CAPE TOWN, South Africa), E. D'Auria (Milano, Italy)*

16:45 Age-Based Distribution of Allergen Sensitization According to Component-Based Multiplex Test Data From Istanbul, Turkey

001951 F. Kirbiyik (Istanbul, Türkiye)

16:57 Early-Life Atopic Dermatitis and Food Sensitization Increase the Risk of Inhalant Allergen Sensitization in Children via IL-2 Elevation: COCOA birth cohort

001460 E. Choi (Seoul, Korea, Republic of)

17:09 Clinical Characteristics and Progression Patterns of Pollen-Food Allergy Syndrome in Mugwort-Prevalent Northern China: A Population-Based Study

000836 S. Liu (Beijing, China)

16:45 - 18:15 OAS17 - Inflammation in the nose (Room Munich, Oral Abstract Sessions)

Chair: *I. Kaydashev (Poltava, Ukraine)*

16:45 Eosinophilic Inflammation Drives Squamous Metaplasia and Distinct Epithelial Remodeling in Chronic Rhinosinusitis with Nasal Polyps

000304 S. Xie (Changsha, China)

16:57 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT002, a Novel Bispecific IL-4Rα/IL-5 Antibody, in Healthy Volunteers: Results from the Single- and Multiple-Ascending Dose Portions of a Phase I Study

001772 T. Ho (Boston, United States of America)

17:09 Staphylococcal Superantigens-specific IgE Reveals Functional Superantigen Production Beyond Staphylococcus aureus in CRSwNP

001291 F. Lan (Beijing, China)

17:21 Improvement of Mixed Inflammatory Environment in Nasal Secretions of Diffuse Type 2 CRSwNP under Dupilumab

001776 F. Ryser (Bern, Switzerland)

17:33 Impact of 12 months of Dupilumab on Type 2 Spatial Immune Microenvironment in Chronic Rhinosinusitis with Nasal Polyposis

000637 E. M. Latis (Milan, Italy)

17:45 Clinical outcomes and biomarker levels after cessation of tezepelumab treatment in adults with severe CRSwNP from WAYPOINT

001507 O. Pfaar (Marburg, Germany)

16:45 - 18:15 SYM17 - AIT across the lifespan
(Room Istanbul, 1- Istanbul, Symposium)

Chair: **G. W. Canonica (Milan, Italy), G. Roberts (Southampton, United Kingdom)**

16:45 Aeroallergen immunotherapy in children: Preventing asthma and new sensitizations
U. M. Sahiner (Ankara, Türkiye)

17:15 Aeroallergen immunotherapy below 5 years of age: Evidence and controversies
M. Giovannini (Florence, Italy)

17:45 Allergen immunotherapy in elderly: Is age just a number?
C. M. Rondon (Málaga, Spain)

16:45 - 18:15 SYM18 - The double burden: How does obesity influence allergy?
(Room Paris, 2- Paris, Symposium)

Chair: **Z. Celebi sozener (Ankara, Türkiye), S. Saglani (London, United Kingdom)**

16:45 Asthma and Obesity: Clinical expressions of a broken environment
A. Moreira (Porto, Portugal)

17:15 Treatable treats in asthma – the role of the immunomodulatory diet
Ö. Soyer (Ankara, Türkiye)

17:45 Interlinked Inflammation: The immunological triad of asthma, obesity, and the microbiota
D. Mungan (Ankara, Türkiye)

16:45 - 18:15 SYM19 - The multidisciplinary approach to mastocytosis
(Room Florence, 3- Florence, Symposium)

Chair: **S. Broesby-Olsen (Odense, Denmark), C. Akin (Michigan, United States of America)**

16:45 The patients have skin lesions: when do suspect a systemic mastocytosis
S. Altrichter (Linz, Austria)

17:15 The patient has an indolent systemic mastocytosis: what is the risk of progression to an advanced disorder and how to follow-up
D. González-de-Olano (Madrid, Spain)

17:45 The patient has an indolent systemic mastocytosis: when is a candidate for mast cell depleting treatments?
M. Triggiani (Salerno, Italy)

16:45 - 18:15 YIR1 - YIR1
(Room Zurich, 5- Zurich, Year In Review)

Chair: **E. Khaleva (Southampton, United Kingdom), P. Gevaert (Gent, Belgium)**

16:45 Prevention of allergic diseases
S. Halken (Odense, Denmark)

17:15 ENT
A. Karavelia (Kalamata, Greece)

17:45 Asthma
Z. Diamant (Groningen, Netherlands)

07:45 - 08:30 MTE 9 - Global utilization of e-health apps: towards improved control
(Room Gothenburg, Meet The Expert)

07:45 Global utilization of e-health apps: towards improved control
J. Bousquet (Montpellier, France)

07:45 - 08:30 MTE 10 - Primary Immunodeficiencies: Laboratory tests for diagnosis and screening
(Room Munich, Meet The Expert)

07:45 Primary Immunodeficiencies: Laboratory tests for diagnosis and screening
G. Deniz (Istanbul, Türkiye)

07:45 - 08:30 MTE 11 - Oscillometry across the airway continuum: From nose to lung and beyond
(Room Athens, Meet The Expert)

07:45 Oscillometry across the airway continuum: From nose to lung and beyond
N. Gupta (Delhi, India)

07:45 - 08:30 MTE 12 - Skin and serum biomarkers in AD
(Room Glasgow, Meet The Expert)

07:45 Skin and serum biomarkers in AD
E. Knol (Utrecht, Netherlands)

08:30 - 10:00 IH 5 - Advanced immune profiling in health and inflammation
(Innovation Hub, Innovation Hub)

Chair: C. Akdis (Davos, Switzerland), H. Bayram (Istanbul, Türkiye)

08:30 High-dimensional profiling of the antibody repertoire in gastrointestinal inflammatory diseases
S. Boyd (Stanford, United States of America)

09:00 Immune microniches shape intestinal Treg
C. Coban (Bunkyo City, Japan)

09:30 Circulatory microinflammation and serum antibody repertoires in healthy individuals
I. Ogulur (Davos Dorf, Switzerland)

08:30 - 10:00 IWS8 - Management of indolent systemic mastocytosis: Identify, control, treat (Room Utrecht, 4- Utrecht, Interactive Workshop)

Chair: **M. Carter** (Bethesda, United States of America), **P. Pyatlova** (Berlin, Germany)

08:30 How to identify ISM in clinical practice: diagnostic challenges and evolving criteria
T. Gulen (Stockholm, Sweden)

09:00 Controlling symptoms in ISM: antihistamines, biologics, and individualized care
P. Bonadonna (Vicenza, Italy)

09:30 Treating the cause: KIT inhibition and disease-modifying approaches in ISM
C. Akin (Michigan, United States of America)

08:30 - 10:00 IWS9 - The unforgotten physiology of airways (Room Zurich, 5- Zurich, Interactive Workshop)

Chair: **P. Nair** (Hamilton, Ontario, Canada), **A. F. Kalpaklıoglu** (Ankara, Türkiye)

08:30 Bronchial hyperresponsiveness: a key feature of airways disease
S. Bavbek (Ankara, Türkiye)

09:00 IOS for measuring the response of therapy in the small airways
B. J. Lipworth (Dundee, United Kingdom)

09:30 The challenge of children: lung function testing in paediatrics
S. Foti Randazzese (Pavia, Italy)

08:30 - 10:00 JMA5 - Chronic spontaneous urticaria (CSU) and angioedema: Innovations in precision medicine (EAACI Global Stage, JMA)

Chair: **P. Kolkhir** (Berlin, Germany), **M. Metz** (Berlin, Germany)

08:30 Emerging biomarkers in CSU: Toward personalized patient management
R. Asero (Paderno Dugnano, Milano, Italy)

09:00 Difficult-to-treat CSU: Current clinical challenges and emerging therapeutic options
E. Kocatürk (Berlin, Germany)

09:30 Clinical phenotypes and advanced management of angioedema
M. Ferrer (Pamplona, Spain)

08:30 - 10:00 SYM20 - Biomarkers for food allergy diagnosis (Room Istanbul, 1- Istanbul, Symposium)

Chair: *M. Alvaro Lozano (Barcelona, Spain), C. Gomez-Casado (Düsseldorf, Germany)*

08:30 Promising biomarkers in FPIES: a multi-omic approach to non-IgE mediated food allergy
M. Pérez-Gordo (Madrid, Spain)

09:00 The microbiome as a predictive biomarker in IgE-mediated food allergy
C. Riggioni-Viquez (Toronto, Canada)

09:30 Fecal proteins as emerging tools in the diagnosis of food allergy: opportunities and challenges
C. Anania (Rome, Italy)

08:30 - 10:00 SYM21 - Biologics in ocular allergy (Room Paris, 2- Paris, Symposium)

Chair: *C. M. Rondon (Málaga, Spain), D. Silva (Porto, Portugal)*

08:30 Rationale for using biologics in severe ocular allergy
M. J. S. Vasconcelos (Porto, Portugal)

09:00 Which biologic for which ocular allergy?
S. Agarwal (Chennai, India)

09:30 How to manage dupilumab-induced ocular surface disease
B. Bozkurt (Konya, Türkiye)

08:30 - 10:00 SYM22 - Evolution and connectivity of allergen molecule sensitization (Room Florence, 3- Florence, Symposium)

Chair: *C. Hilger (Esch-sur-Alzette, Luxembourg), S. Dramburg (Berlin, Germany)*

08:30 The onset and plateau of sensitizations: A temporal perspective
A. Custovic (London, United Kingdom)

09:00 Defining the breadth of sensitization assessment across age groups
P. Matricardi (Berlin, Germany)

09:30 Interrelationships in sensitizations: Driven by allergen source, molecular structure, or comorbidity?
B. Sekerel (Ankara, Türkiye)

08:30 - 10:00 TSY5 - Neuroimmune interactions and innate immune cells in allergic disease (Room Krakow, 7- Krakow, Thematic Symposium)

Chair: *A. Eljaszewicz (Białystok, Poland), M. Pascal-Capdevila (Barcelona, Spain)*

08:30 Neuroimmune recognition of allergens and development of allergic disease
L. Deng (Boston, United States of America)

09:00 Innate lymphoid cells and allergy development
K. Moro (Osaka, Japan)

09:30 Basophils as effector cells of allergic reactions and anaphylaxis
A. Santos (London, United Kingdom)

08:45 - 09:45 SSS6 - EAACI GA2CI sister society symposium: Clinical Immunology in the Arabian Peninsula: Innovation, Evidence, and Diagnostic Insight
(Room London, 6- London, Sister Society Symposium)

Chair: **A. Alangari (Riyadh, Saudi Arabia)**

08:45 The impact of blocking IL4 / IL 13 pathway from clinical trials to real world evidence
R. Arnaout (Riyadh, Saudi Arabia)

09:05 Key challenges in the diagnosis and management of immunodeficiency in the Arabian Peninsula.

09:25 The rash that doesn't add up: when to think beyond allergy?
S. Elkhaila (United Arab Emirates)

08:45 - 10:15 L-FT15 - Immediate type hypersensitivity
(Room Athens, Flash Talks)

Chair: **J. A. Cornejo-Garcia (Málaga, Spain), T. Jimenez Rodriguez (Alicante, Spain)**

08:45 Hypersensitivity to Gadolinium-Based Contrast Media: Diagnostic and Re-Exposure Outcomes
002066 L. Manso Preto (Coimbra, Portugal)

08:52 Hypersensitivity Reactions to Anti-tuberculosis Drugs: Clinical Features, Risk factors, and Diagnostic Utility of The Graded Challenge Test
000921 P. Jansoontraporn (Bangkok, Thailand)

08:59 Preventable system-level gaps associated with diagnostic loss in perioperative hypersensitivity: evidence from national allergy and anaesthesiology surveys in Spain
000767 J. J. Laguna Martinez (Madrid, Spain)

09:06 NSAID Tolerance Can Be Restored in NECD With Adequate Disease Control, Even in the Absence of Complete Remission
001240 M. Hormet Igde (Istanbul, Türkiye)

09:13 Natural Evolution Of Hypersensitivity To NSAIDs In Children
001699 A. Prieto-Moreno Pfeifer (Madrid, Spain)

09:20 In the Absence of Penicillin Skin Test Kit, May Diagnostic Testing with Benzathine Penicillin G Be a Safe Alternative in Children with Suspected Penicillin Allergy in Acute Rheumatic Fever?
001510 C. Yildirimcakar (Denizli, Türkiye)

09:27 Selective Cephalosporin Allergy: A Retrospective Case Series
001406 L. Nogueras-Fuertes (Madrid, Spain)

09:34 Performance of the PEN-FAST Clinical Decision Rule in Patients with Suspected Aminopenicillin Hypersensitivity: A Real-World Cohort Study
002093 S. Flores Regalo (Coimbr, Portugal)

09:41 Beyond the Label: Persistent Misclassification and Enduring Quality-of-Life Gains After Penicillin Allergy Delabeling—Findings from the SPADE Cohort
001016 C.-H. Ho (Kowloon, Hong Kong)

09:48 Evaluation of the Association Between Reaction Severity and Cardiovascular Risk in Patients With Drug Hypersensitivity Reactions
000274 A. okumus guclu (İzmir, Türkiye)

09:55 Frequency Of Reported And Confirmed Drug Allergy In Patients Presenting To The Pediatric Emergency Department
000315 O. Yilmaz Topal (Ankara, Türkiye)

10:02 Do allergies breed antibiotic allergy labels? The dramatic rise of parent reported antibiotic allergies
001023 K. Rueter (Perth, Australia)

08:45 - 10:15 L-FT16 - Work and air pollution: out of the frying pan and into the fire (Room Glasgow, Flash Talks)

Chair: **D. Mijakoski** (Skopje, North Macedonia), **S. Gilles** (Augsburg, Germany)

08:45 Occupational Asthma – Reference Center Experience: The Intersection of Clinical Findings, Exposure, and Phenotype (2010–2025)

000382 O. Aydin (Ankara, Türkiye)

08:52 Improved diagnostics for occupational allergies to psyllium husks – a case series

000512 I. Sander (Bochum, Germany)

08:59 Occupational Exposure and Anaphylaxis to Hymenoptera Venom: A Real-World Study

001138 G. Martins (Lisboa, Portugal)

09:06 Beyond Exposure Limits: Allsens Captures Epithelial-Driven Immune Activation by Occupational Bioaerosols

000979 J. Samulin-Erdem (Oslo, Norway)

09:13 The complex role of air pollution on the association between greenness and the development of allergic rhinitis and asthma up to 27 years of age

001806 I. Paciência (Oulu, Finland)

09:20 Effect of PM_{2.5} Obtained from 2023 Turkey Earthquakes on Ferroptosis Signalling in Primary Human Bronchial Epithelial Cells and 3D Organoids with/without COPD

001703 Y. Vural (Istanbul, Türkiye)

09:27 Ozone Concentration as Strong Predictor of Symptom Load in Grass Allergic Patients in a Pivotal Phase III Study with PQ Grass

000774 M. Berger (Vienna, Austria)

09:34 Implementation of a New App to Provide Integrated Pollen Information in the Long-term Paediatric Study with PQ Grass

000782 M. Berger (Vienna, Austria)

09:41 Systemic inflammatory markers define the biological response to wildfire smoke exposure

100562 H. Babayev (Davos, Switzerland)

09:48 Altered morphological subsets of sputum neutrophils from patients with allergy with or without asthma during versus out of pollen season

100566 E. Tufvesson (Lund, Sweden)

08:45 - 10:15 L-FT07 - Allergy diagnosis

(Meeting room 3B01, Flash Talks)

Chair: J. L. Paris (Málaga, Spain), P. Rodríguez del Río (Madrid, Spain)

- | | |
|-------------------------------|---|
| 08:45
100022 | Evaluation of Reported Drug Allergy Labels in a Pediatric Outpatient Clinic: From Clinical Suspicion to Provocation
N. Nabiyeva Çevik (Istanbul, Türkiye) |
| 08:52
100038 | Development of a murine basophil activation test for modeling and prediction of human allergic mechanisms
L. Aglas (Helsinki, Finland) |
| 08:59
100050 | From Awareness to Assessment: Gaps in Olfactory Evaluation in Spanish Allergy Services
R. González Pérez (La Laguna, Spain) |
| 09:06
100164 | Hypersensitivity reactions to proton pump inhibitors: clinical features and tolerance to alternative agents in real-world practice
L. Neyra-Puell (Madrid, Spain) |
| 09:13
100220 | Beyond provocation: pulse-controlled ergometry as a tool to personalise diagnosis and exercise guidance in cholinergic urticaria
J. Guimarães (Setúbal, Portugal) |
| 09:20
100391 | Characterizing Pancake Syndrome: A Case Series from a Tertiary Allergy Centre
M. Bernardo (Ponta Delgada, Portugal) |
| 09:27
100418 | Clinical evaluation of patients presenting with a preliminary diagnosis of adverse reactions to antihypertensive drugs
I. D. Toprak (Istanbul, Türkiye) |
| 09:34
100442 | Regional Differences in Molecular Component Sensitization in Brazilian Patients with Insect Venom Allergy
K. Souza Santos (São Paulo, Brazil) |
| 09:41
100684 | One molecule, three phenotypes: age-driven clinical divergence of Tri a 19 (ω-5 gliadin) in a real-life Istanbul cohort
F. Kırbiyık (Istanbul, Türkiye) |
| 09:48
100721 | Transport of allergenic tropomyosins through the intestinal epithelium
P. Stoll (Vienna, Austria) |

08:45 - 10:15 OAS18 - Food allergy treatments: not just oral immunotherapy

(Room Gothenburg, Oral Abstract Sessions)

Chair: **M. Papadopoulos (Athens, Greece), A. Anagnostou (Houston, United States of America)**

08:45 Phase 2, Open-Label Study to Assess Consumption of Peanut in Infants Aged 6-12 Months With Peanut Allergy Treated With Epicutaneous Peanut Immunotherapy

001954 K. Perrett (Melbourne, Australia)

08:57 Confirmatory peanut oral food challenges in very young children are cost-effective

001164 M. Lloyd (Melbourne, Australia)

09:09 Long-term effectiveness and safety of paediatric cow's milk oral immunotherapy in real life: outcomes with and without omalizumab support

000911 M. Niegowska (Barcelona, Spain)

09:21 Component-Specific IgE and IgG4 Changes During 2 year follow up of Low-Dose Cashew Oral Immunotherapy

000955 K. Takahashi (Sagamihara, Japan)

09:33 Peanut allergoids conjugated to mannan as novel vaccine candidates for allergen-specific immunotherapy: unraveling their immunological mode of action

000764 M. del Campo-Grijalba (Madrid, Spain)

09:45 Nut-specific and cross-reactive immune modulation following prophylactic sublingual immunotherapy with walnut and pecan

001544 A. J. Jensen (Kongens Lyngby, Denmark)

09:57 An immune atlas of remission following peanut OIT

001158 S. Ashley (Parkville, Australia)

08:45 - 10:15 OASS19 - Childhood asthma under the lens

(Room Munich, Oral Abstract Sessions)

Chair: **B. Beken (Istanbul, Türkiye), W. Feleszko (Warszawa, Poland)**

08:45 Breastfeeding duration, plasma linoleic acid-derived oxylipins and risk of childhood asthma

001373 L. Chen (Gentofte, Denmark)

08:57 Aberrant Airway Fucosylation Impairs Epithelial Barrier Integrity and Drives Asthma Pathogenesis

000290 W. Gu (Suzhou, China)

09:09 Asthma Trajectory Shapes How Early Life Th1/Th2 Airway Immune Responses Influence the Duration of Asthma-Like Episodes

001342 J. Kyvsgaard (Gentofte, Denmark)

09:21 Does Asthma in Childhood increase the risk of Obesity in Adolescence?

001467 M. Rodrigues (Porto, Portugal)

09:33 Impedance Pneumography for Diagnosing and Monitoring Asthma in Young Children: A Systematic Review

000713 F. Kullberg (Copenhagen, Denmark)

09:45 Effect of SQ SLIT-tablets on asthma symptoms and safety in children with allergic rhinitis and with or without concomitant asthma across multiple trials

000781 O. Pfaar (Marburg, Germany)

09:57 Prospective Evaluation of GINA 2024 versus ATS/ERS 2021 Bronchodilator Responsiveness Criteria in Children: Agreement, Discordance, and Clinical Determinants

001472 G. Koken (Ankara, Türkiye)

10:30 - 12:00 PL7 - Epithelial biology from early development to repair mechanisms (Room Istanbul, 1- Istanbul, Plenary Lectures)

Chair: **M. Akdis** (davos wolfgang, Switzerland), **M. Torres** (Malaga, Spain)

10:30 Novel mechanism of pediatric eczema development
C. Flohr (London, United Kingdom)

11:00 Molecular mechanisms of tissue injury linked to epithelial barrier damage
C. Akdis (Davos, Switzerland)

11:30 Precision immunology in inflammatory lung diseases
Ö. Yildirim (Germany)

10:30 - 12:00 PL8 - Skin pruritus as a treatable trait (Room Paris, 2- Paris, Plenary Lectures)

Chair: **S. Tsabouri** (Ioannina, Greece), **I. Terreehorst** (Rotterdam, Netherlands)

10:30 Alpha - Delta T cells as drivers of skin itch in atopic eczema
C. Sokol (Boston, United States of America)

11:00 The burden of skin itch in chronic spontaneous urticaria
M. Pereira (Berlin, Germany)

11:30 Effect of novel biologicals on skin itch
K. Kabashima (Kyoto, Japan)

10:30 - 12:00 PL9 - EAACI goes global: Global trends in allergic diseases (Room Florence, 3- Florence, Plenary Lectures)

Chair: **I. Annesi-Maesano** (Montpellier, France), **A. Vega Castro** (Guadalajara, Spain)

10:30 Pollen allergy in China: Trends and the Impact of Climate Change
K. Guan (Beijing, China)

10:48 Respiratory allergies in Latin America
G. Wandalsen (Sao Paulo, Brazil)

11:06 Management of IgE-mediated food allergy in Latin America: challenges and opportunities
S. Monsell (Ciudad autonoma de Buenos Aires, Argentina)

11:24 Food allergy in India: Unique epidemiology, practices and protective factors
S. Arudi Nagarajan (Bengaluru, India)

11:42 Drug allergy in Asia: from epidemiology to risk stratification
P. Li (Hong Kong, Hong Kong)

12:15 - 13:15 PEAACI Special Session 1 - The Allergic Rhinitis and its Impact on Asthma (ARIA) - EAACI 2024-2025 guidelines
(EAACI Global Stage, EAACI Special Session)

12:15 Innovations in the ARIA-EAACI 2024-2025 guidelines

J. Bousquet (Montpellier, France)

12:35 ARIA-EAACI recommendations on the use of intranasal and oral treatments

B. Sousa-Pinto (Porto, Portugal)

12:55 ARIA-EAACI recommendations on the use of as-needed strategies and co-medication

L. Klimek (Wiesbaden, Germany)

12:15 - 13:15 FT17 - Educational tools to improve management and quality of life in allergic disease
(Room Athens, Flash Talks)

Chair: B. Buyuktiryaki (Istanbul, Türkiye), E. Vassilopoulou (Thessaloniki, Greece)

12:15 Opportunities to optimise the management of allergic rhinitis using the Respiratory Allergy Optimiser: results of the AERO study

000450 N. Nabiyeve Çevik (Istanbul, Türkiye)

12:22 Do Smartphone Images Predict the Risk of Skin Barrier Dysfunction in Infants? A Nested Analysis of Baseline Data from a Cohort Study

000659 C. Yamaguchi (Nagoya, Japan)

12:29 The Impact of Social Media on Parental Decision-Making in the Management of Pediatric Allergic Diseases

002026 C. Genis (Ankara, Türkiye)

12:36 Implementation of a urticaria care package in the general practitioner setting increased quality of chronic spontaneous urticaria management

000625 R. Asero (Paderno Dugnano, Milano, Italy)

12:43 Assessment of quality of life in Chronic Urticaria patients (2-18 Years of age)

000105 M. Ahmed (Hyderabad, India)

12:50 Breaking Myths in Childhood Eczema: Outcomes of a Community-Based Educational Program in Low-Resource Urban Settings of Pakistan

002117 A. M. Mustafa (Multan, Pakistan)

12:57 Food Allergy-Related Bullying in Children: Prevalence and Psychosocial Burden from a Mixed-Methods Study

001360 L. Carucci (Napoli, Italy)

13:04 Food Label Reading Behavior and Allergenic Protein Knowledge Among Parents of Children With Milk and Egg Allergy

000924 G. Yörüşün (Ankara, Türkiye)

12:15 - 13:15 FT18 - Tailoring allergy treatment: SLIT, Steroids, and targeted therapies in children (Room Glasgow, Flash Talks)

Chair: J. Schwarze (Edinburgh, United Kingdom), E. Khaleva (Southampton, United Kingdom)

- 12:15** Safety of a 300IR daily SLIT-liquid in patients 5-17 years old with birch pollen allergic rhinoconjunctivitis: results of the YOBI trial
001022 M. Gerstlauer (Augsburg, Germany)
- 12:22** SQ House Dust Mite SLIT-tablet is well-tolerated in children with and without asthma: Pooled safety analysis
000795 G. Roberts (Southampton, United Kingdom)
- 12:29** Symptom control and reduced intranasal corticosteroid use in children with allergic rhinitis/rhinoconjunctivitis treated with SQ house dust mite SLIT-tablet: A responder analysis
000815 D. Caimmi (Montpellier, France)
- 12:36** Too Much of a Good Thing? Lessons from Excessive Inhaled Corticosteroids, Persistent Cough, and Growth Suppression
001930 T. Kopiec (Warszawa, Poland)
- 12:43** Real-world status of early-life dietary allergen intake prior to the initial pediatric allergy specialist visit in Japan
000686 K. Toyokuni (Tokyo, Japan)
- 12:50** Changes in the volume of the cerebral cortex in children with allergies. Preliminary data
001609 L. Namazova-Baranova (Shenzhen, China), G. Karkashadze (Moscow, Russia), N. Shilko (Moscow, Russia), A. Firumyants (Moscow, Russia)
- 12:57** Reduction in symptom and medication scores in the first week of the first pollen season in children and adults treated with SQ SLIT-tablets across phase III trials
100185 S. R. Durham (London, United Kingdom)

12:15 - 13:15 L-FT08 - Dermatology (Meeting room 3B01, Flash Talks)

Chair: S. Altrichter (Linz, Austria), M. Triggiani (Salerno, Italy)

- 12:15** Azole antifungals as rare triggers of acute generalized exanthematous pustulosis: a systematic review
100018 J. Mahdavi (Arak, Iran, Islamic Republic of)
- 12:22** Correlation between Autoimmune Bullous Disease and Interstitial Lung Diseases: A Preliminary Study
100068 Z. Chen (Shanghai, China)
- 12:29** Long-term prophylaxis with plasma derived C1 inhibitor concentrate in hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH)
100174 L. Neyra-Puell (Madrid, Spain)
- 12:36** Do Wheal Features Predict Omalizumab Response in Chronic Spontaneous Urticaria?
100211 Z. Wang (Xi'an, China)
- 12:43** ITACA Survey: characteristics of patients with Hereditary Angioedema due to C1-inhibitor deficiency receiving long-term prophylaxis with subcutaneous C1-inhibitor
100571 R. Senter (Padua, Italy)
- 12:50** "Multidimensional evaluation of inducible versus spontaneous chronic urticaria in pediatrics"
100611 G. Yáñez Lema (Barcelona, Spain)
- 12:57** Baseline Immune Profile and Response-Based Stratification in Chronic Spontaneous Urticaria: Implications for Therapeutic Transition
100644 U. Yılmaz Ergün (Konya, Türkiye)
- 13:04** Serum 25-Hydroxyvitamin D Levels in Patients with Atopic Dermatitis: Seasonal Variability and Association with Disease Severity
100659 B. Cil Yılmaz (Ankara, Türkiye)

12:15 - 13:15 L-OAS08 - Food allergy

(Room Gothenburg, Oral Abstract Sessions)

Chair: C. Anania (Rome, Italy), A. Muraro (Padova, Italy)

12:15 Is The First Oral Food Challenge A Key To Predicting Follow-Up Challenge In Cow's Milk Allergy?

100080 T. Y. akın (İzmit, Türkiye)

12:27 Risk Factors for the Development of Food Allergy in Early Life

100352 A. Anagnostou (Houston, United States of America)

12:39 Safety of Omalizumab in Children 1 to 5 Years of Age with Multiple Food Allergies

100620 E. H. Kim (Chapel Hill, United States of America)

12:51 PRACTALL in Practice: A Multi-Centre Comparison of Updated and Original Food Challenge Stopping Criteria

100736 U. Ahmed (Cambridge, United Kingdom)

12:15 - 13:15 L-OAS09 - Anaphylaxis

(Room Munich, Oral Abstract Sessions)

Chair: P. Smith (SOUTHPORT, Australia)

12:15 Closer to nature, closer to risk: Exposure matters in Hymenoptera venom allergy

100157 G. Martins (Lisbon, Portugal)

12:27 Paediatric perioperative hypersensitivity reactions in France: Analysis of the GERAP network database

100167 L. MUCHEMBLED (Strasbourg, France)

12:39 Safety and Efficacy of Fixed Very-low-dose Intake in Infants and Toddlers with Severe Egg, Milk, and Wheat Allergy

100266 K. Kitamura (Obu, Japan)

12:51 Uterine cramping as a manifestation of anaphylaxis: a case series from the BIOGRIAL cohort

100591 F. Skrabski (Madrid, Spain)

13:03 Does hereditary alpha-tryptasemia really influence the frequency and severity of anaphylaxis?

100637 L. Carrasco Gómez (Madrid, Spain)

12:15 - 13:15 PiS01 - AI in diagnosing and treatment of asthma

(Innovation Hub, Pitch Session)

Chair: P. Smith (SOUTHPORT, Australia)

12:15 R. J. Vieira (Porto, Portugal), Z. Celebi sozener (Ankara, Türkiye)

001521 M. Zhou (Xi'an, China)

12:22 Development and validation of an interpretable whole slide imaging-based machine learning model for postoperative recurrence risk stratification in chronic rhinosinusitis with nasal polyps

001274 Z. Guo (Guangzhou, China)

12:29 Evolution of AI Chatbot Response Quality for Allergy Queries: A One-Year Follow-Up Study

001491 A. Bogomolov (Vinnytsia, Ukraine)

12:36 Artificial intelligence in allergology: physicians' readiness and barriers

001412 A. Bogomolov (Vinnytsia, Ukraine)

12:43 Predicting True Penicillin Hypersensitivity in Children Using Machine Learning Models: A Retrospective Cohort Study

100733 A. Kuzu Kuşaklı (Ankara, Türkiye)

12:50 Real-world evaluation of an Artificial Intelligence (AI)-assisted skin prick test readout method in children

100495 S. Seys (Hasselt, Belgium)

12:15 - 13:15 TPS - Poster Sessions
(Poster Area, Poster Walk)

12:15 - 13:15 SSS7 - EAACI APAAACI Sister Society symposium: Allergies and Sustainability in a Changing World
(Room Paris, 2- Paris, Sister Society Symposium)

12:15 Artificial Intelligence in Allergy & Immunology: Advancing Sustainable, Precision Care
R. Pawankar (Tokyo, Japan)

12:35 Integrating sustainability and resilience into laboratory medicine
A. Abdul Latiff (Kuala Lumpur, Malaysia)

12:55 Drug Allergy and Its Impact on Sustainability

12:15 - 13:15 SSS8 - EAACI ASBAI Sister Society Symposium: Vision Zero in Practice: Advances in Severe Pediatric Asthma, Drug Hypersensitivity, and Primary Immunodeficiencies Insights in Brazil
(Room Florence, 3- Florence, Sister Society Symposium)

Chair: F. Fernandes (São Paulo, Brazil), D. Solé (Brazil)

12:15 Severe Pediatric Asthma: Advances in Precision Diagnosis and Tailored Therapy
G. Wandalsen (Sao Paulo, Brazil)

12:35 Cross-Intolerance to NSAIDs: What Is Safe, What Is Not, and How to Prescribe Wisely
M. Felix (Rio de Janeiro, Brazil)

12:55 The BRAGID Registry: Insights into Inborn Errors of Immunity in Brazil
E. Goudouris (Rio de Janeiro, Brazil)

12:15 - 13:15 SSS9 - EAACI Hong Kong Institute of Allergy Joint SSS: East Meets EAACI: Translating Lessons from the East to Global Practice
(Room Utrecht, 4- Utrecht, Sister Society Symposium)

Chair: P. Li (Hong Kong, Hong Kong), J. Wong (Hong Kong, Hong Kong)

12:15 Local Shores to Global Guidelines: Hong Kong's Insights into Seafood Allergy
A. S. Y. Leung (Hong Kong, China)

12:35 Unusual Bugs, Universal Insights: Opportunistic Lessons into Acquired Immunodeficiency Syndromes
V. Chiang (Hong Kong, Hong Kong)

12:55 A Global Perspective of HAE: Inclusivity through diversity
D. Fomina (Moscow, Russia)

12:15 - 13:15 Satellite Symposium
(Room London, Sponsored Sessions)

12:15 - 13:15 Satellite Symposium
(Room Krakow, Sponsored Sessions)

12:15 - 13:15 L-TPS18 - Allergy diagnosis 21
(Poster Zone, Thematic Poster Session)

Chair: K. Bønnelykke (Lillerød, Denmark)

- D3.93** Clinical Efficacy of Tezepelumab in a Patient with Severe Refractory Mixed Asthma: A Case Report from Kazakhstan
M. Baidildaeva (Almaty, Kazakhstan)
-
- D3.94** Good Practice Recommendations for Basophil Activation Test (BAT) Data Analysis in Routine and High-Background Settings
M. Gerspach (Schönenbuch, Switzerland)
-
- D3.95** Hidden in everyday cosmetics: Facial allergic contact dermatitis to fragrances
R. Sá Teixeira (Vila Nova de Gaia, Portugal)
-
- D3.96** High burden of latent aeroallergen sensitization in healthy urban medical students: a blinded skin prick test study from South India
H. Billa Lakshmi (Hyderabad, India)
-
- D3.97** Allergic contact dermatitis confirmed by repeated open application test in a 68-year-old patient
M. Nisavic (Novi Sad, Serbia)
-
- D3.98** An extended study for the multiple detection of IgE-mediated allergic reactions using microarray technology
N. Offermann (Neuss, Germany)
-
- D3.100** Assessment of the impact of psychotropic drugs, antihistamines, and corticosteroids on the interpretation of skin tests in allergology
C. Egeley (Grenoble, France)
-
- D3.101** Etoricoxib Associated Fixed Drug Eruption: A Case Series from a Tertiary Allergy and Clinical Immunology Centre, United Arab Emirates
S. Elkhaila (Abu Dhabi, United Arab Emirates)
-
- D3.103** Comprehensive Allergen Characterization for Standardized Basophil Activation Testing
F. Richina (Schönenbuch, Switzerland)
-
- D3.104** Molecular Co-Sensitization Mapping Using a 192-Line Multiplex IgE Platform
H. J. LEE (Seoul, Korea, Republic of)
-
- D3.105** Analysis of post-vaccination immunity in children with dermatology diseases receiving biologic and immunosuppressive therapy
A. Kontorovich (Moscow, Russia)
-
- D3.106** Real-life outcomes of rapid drug desensitization to taxanes
C. Arrieta-Pey (Donostia / San Sebastián, Spain)
-

12:15 - 13:15 L-TPS19 - Asthma 15

(Poster Zone, Thematic Poster Session)

Chair: A. Spanevello (Milano, Italy), C. Schmidt-Weber (Munich, Germany)

D3.166 Attention-deficit/hyperactivity disorder (ADHD) in asthmatic children

M. Tavakol (Karaj, Iran, Islamic Republic of)

D3.168 Clinical Department of Allergy Center in Linköping

A. Graca (Linköping, Sweden)

D3.169 Paediatric Severe Acute Respiratory Infections in Malta: A Three-Year Review

G. Xuereb (Msida, Malta)

D3.171 Validation of the Kazakh Version of the Asthma Quality of Life Questionnaire (AQLQ) for Clinical Use in Adult Patients with Asthma

R. Bekmagambetova (Almaty, Kazakhstan)

D3.173 Switching from Dupilumab to Tezepelumab in a Child with Severe Asthma and Atopic Dermatitis: Clinical Considerations and Therapeutic Implications

M. Maia (Milano, Italy)

D3.174 Short-term tolerance of omlyclo, the omalizumab biosimilar

J. Arrieta Rodríguez (Sabadell, Spain)

D3.175 Algorithm for Biologics Selection in Severe Asthma

K. Pavlova (Moscow, Russia)

D3.178 Assessment of blood rheological properties in children with bronchial asthma

E. Aseeva (Moscow, Russia)

D3.179 Longitudinal breath profiling of exhaled volatile organic compounds differentiates viral-induced asthma exacerbation from clinical control

E. Hernández Lerma (Ciudad de México, Mexico)

12:15 - 13:15 L-TPS20 - Allergen immunotherapy 09 (Poster Zone, Thematic Poster Session)

Chair: A. Bozek (Katowice, Poland)

- D3.215** Shifting patterns of mite sensitization in Southern Europe: Real-World diagnostic and immunotherapy practices in Spain and Portugal (MITE-WISE Project)
J. Figueroa (Las Palmas de Gran Canaria, Spain)

- D3.216** Determination of Allergenic Activity of Native Mugwort Allergen Preparations by a Competitive IgE-Binding Test
P. Fiebig (Reinbek, Germany)

- D3.217** Development and validation of a monoclonal antibody-based competitive ELISA to accurate quantification of Blo t 2 in native Blomia tropicalis allergenic extracts
M. Viñuela (Alcalá de Henares, Spain)

- D3.218** When the sting is not the sensitizer: a vespid venom allergy case
D. Korshunova (Madrid, Spain)

- D3.220** Real-World Management of Pediatric Allergic Diseases: A Nationwide Physician Survey among Allergists and Pediatric Allergists in Turkey
N. N. Bahçeciler (Nicosia, Cyprus)

- D3.221** Cat Immunotherapy and Real-Life Data: A Single-Center Experience
Z. MEHTI (Ankara, Türkiye)

- D3.222** Monitoring the immune response during the first year of SCIT in Ragweed allergy
C. Uța (Timișoara, Romania)

- D3.223** Crossroads of Venom and Bite: A case of Horsefly - Wasp Cross - reactive Anaphylaxis
N. Petridou (Athina, Greece)

- D3.225** Two years Sublingual SQ-Grass Pollen Tablet Immunotherapy Combined with Dupilumab Induces Longterm Suppression of Immediate Cutaneous Allergen Sensitivity
A. Fedina (London, United Kingdom)

- D3.226** Prophylactic sublingual peanut immunotherapy alters antibody responses and downstream allergen reactivity in a Brown Norway rat model
M. Jalili (Kongens Lyngby, Denmark)

- D3.227** The effect of subcutaneous allergen immunotherapy after one year on the quality of life of children with perennial allergic rhinitis and rhinoconjunctivitis
T. Umanets (Kyiv, Ukraine)

- D3.228** One-Year Changes in Molecular sIgE Profiles During House Dust Mite Immunotherapy: A Pilot Study
L. Pilkytė (Kaunas, Lithuania)

- D3.229** Comparison of mold sensitization profiles in children (2021 and 2025): impact of environmental deterioration during martial law
E. Moskovenko (Kyiv, Ukraine)

12:15 - 13:15 L-TPS21 - Dermatology 08

(Poster Zone, Thematic Poster Session)

Chair: **M. Türk (Kayseri, Türkiye)**

D3.256 A Child with Mastocytosis presenting with generalized severe Pruritus: A Diagnostic Pitfall

U. Lippert (Göttingen, Germany)

D3.258 Not just a rash: a delayed diagnosis of allopurinol-induced dress syndrome

J. Coelho (Faro, Portugal)

D3.260 Shiitake-Induced Flagellate Dermatitis: Case Series from Kazakhstan

G. Tussupbekova (Astana, Kazakhstan)

D3.261 Orphan Diseases In Allergology - Melkersson-Rosenthal Syndrome

C. Toma (Chişinău, Moldova)

D3.264 Delayed Type Hypersensitivity Injection Site Reaction Induced By Liraglutide

C. Toma (Chişinău, Moldova)

D3.265 Gleish syndrome: A case report

H. Messaoudi (Algiers, Algeria)

D3.266 Component-Resolved Delayed Hypersensitivity to Piperacillin/Tazobactam and Clavulanic Acid Despite Structural Divergence

S. Arenas-Colmenares (Madrid, Spain)

D3.267 Statistics of Contributing Factors to Atopic Dermatitis in Children

R. Sepiashvili (Tskhaltubo, Georgia)

12:15 - 13:15 L-TPS22 - Food allergy 08

(Poster Zone, Thematic Poster Session)

Chair: K. Bluemchen (Frankfurt am Main, Germany), J. Upton (Toronto, Canada)

- D3.295** Comparing Real-World and AI-Enabled Market Research in Caregivers of Individuals with Peanut Allergy
S. Tardif (Hørsholm, Denmark)

- D3.296** Alpha-gal Syndrome with Concomitant Milk Sensitization in a Patient with Asthma and Allergic Rhinitis: A Case Report
M. Keren (İstanbul, Türkiye)

- D3.297** De-labelling peanut allergy in a 19-year-old woman with detectable Ara h 2 sensitization: a real-life, exercise-augmented oral food challenge
C. Siouta (Linköping, Sweden)

- D3.298** The Good, the Bad and the Ugly: Mugwort, Mango, and Pineapple
E. Lozes (Périgueux, France)

- D3.299** Don't miss the cannabis-associated food syndrome (CAFS)
S. Chantraine (Basel, Switzerland)

- D3.300** Wheat tolerance induction protocol
E. Armas Sosa (Santa Cruz de Tenerife, Spain)

- D3.301** Аллергия на белки коровьего молока у детей: сосредоточено на короткоцепочечных жирных кислотах
D. Bakirova (Tashkent, Uzbekistan)

- D3.302** Sesame as an under-recognized allergen: storage protein sensitization underlying food-induced anaphylaxis in a young adult
J. L. Alba-Rull (Córdoba, Spain)

- D3.303** Buckwheat Allergy in Bologna Metropolitan Area: Often Severe, Often Hidden
V. M. Scorcu (Bologna, Italy)

- D3.305** Isolated IgE-Mediated Anaphylaxis to Pine Nut in an adult
A. Alberto (Porto, Portugal)

- D3.304** Real-Life Evaluation of the Egg Ladder in a Tertiary Pediatric Allergy Center in Turkey
N. Umit (Antalya, Türkiye)

12:15 - 13:15 L-TPS23 - Anaphylaxis 07
(Poster Zone, Thematic Poster Session)

Chair: H. O. Skjerven (Oslo, Norway)

- D3.339** Severe β -lactam hypersensitivity phenotypes in routine care: anaphylaxis frequency in a 22-centre outpatient survey in China
L. Wang (shanghai, China)
- D3.340** The importance of de-labeling contrast allergy in cardiology department - clinical case
V. Brocovschii (Chişinău, Moldova)
- D3.341** Alignment with International Anaphylaxis Management Guidelines in a Tertiary Referral Center in Central Asia: A Retrospective Clinical Audit
A. Kulmanbetova (Almaty, Kazakhstan)
- D3.342** Adverse Events of Biologic Therapies: A One-Year Retrospective Study
N. Fathallah (Sousse, Tunisia)
- D3.343** Hereditary alpha-tryptasemia: clinical variability and anaphylaxis triggers in six genetically confirmed cases
A. Mugno (Burgos, Spain)
- D3.344** Rapid Desensitization to Iohexol Following Iopamidol-Induced Anaphylaxis Prior to Urgent Coronary Angiography
I. Boz (Antalya, Türkiye)
- D3.345** Anaphylactic Shock: Clinical Analysis of 8 Cases with Post-Hospital Outpatient Follow-Up
Z. Ispayeva (Almaty, Kazakhstan)
- D3.346** From Anaphylaxis to Oral Allergy Syndrome: Multiple Seed Hypersensitivity in a Single Pediatric Patient
B. Özkan Kırın (Ankara, Türkiye)
- D3.347** Idiopathic Anaphylaxis: A Diagnostic Challenge
I. Mrkić Kobal (Zagreb, Croatia)
- D3.348** Alpha-gal Syndrome in Young People: A Call for Public Health Awareness in Tick-Endemic Areas of Scotland and North East England
C. Zervas (Newcastle upon Tyne, United Kingdom)
- D3.349** Takotsubo cardiomyopathy triggered by anaphylaxis after a honey bee sting, forming ATAK complex: a rare case report
K. Festa (Athens, Greece)
- D3.352** Long-term analytical stability of ImmunoCAP tryptase supports enduring clinical interpretation thresholds
C. Mavrier (Les Ulis, France)
- D3.353** Clinical Characteristics and Triggers of Pediatric Anaphylaxis Cases: A Retrospective Single-Center Experience
D. Azkur (Kırıkkale, Türkiye)

12:15 - 13:15 L-TPS24 - Basic immunology 06

(Poster Zone, Thematic Poster Session)

Chair: **Ö. Alaz** (Zurich, Switzerland), **M. Muñoz-Ruiz** (Madrid, Spain)

- D3.398** Primary Care Physicians' Perspectives on Primary Immunodeficiency Diseases
Ö. Özdemir (Sakarya, Türkiye)

- D3.399** An SYK Variant with Variable Spectrum of Immunodeficiency and Immune Dysregulation: Case Series
M. Jefri (Riyadh, Saudi Arabia)

- D3.401** A mechanism for loss of biodiversity in the gut: Toxic effects and metabolic alterations of food additives on human fecal microbiome
B. Zhao (Davos, Switzerland)

- D3.402** Evaluation of Apigenin's Anti-Inflammatory and Wound Healing Effects Using Atopic Dermatitis Cell Culture Model
E. Birben (Ankara, Türkiye)

- D3.403** Protein Profiling of CAR-Engineered NK92-Derived Exosomes Using Western Blot
L. Zbircea (Timișoara, Romania)

- D3.404** From CVID to CTLA-4 Haploinsufficiency: The Impact of Genetic Diagnosis on Targeted Therapy
A. C. Coelho (Vila Nova de Gaia, Portugal)

- D3.405** X-Linked Agammaglobulinemia in Adulthood: 40 Years of Follow-Up
M. Imad (São Paulo, Brazil)

- D3.406** Novel bone materials selectively modulate the human immune response to favor remodeling over acute inflammation
H. Babayev (Davos, Switzerland)

- D3.407** Angioedema: cause or consequence?
L. Gonçalves (Lisboa, Portugal)

- D3.408** When Angioedema Is Not Angioedema: EBV-Associated Lymphocytic Inflammation Mimicking Hereditary Angioedema
C. Puente (Jesús María, Peru)

- D3.409** Immunological Mechanisms in Treatment-Resistant Depression
J. Zych (Częstochowa, Poland)

- D3.413** Basophil Activation Test Positivity and Response to Ciclosporin in Chronic Spontaneous Urticaria: A Real-World Exploratory Study
S. Flores Regalo (Coimbra, Portugal)

- D3.414** Clinical and Laboratory Predictors of Basophil Activation Test Positivity in Chronic Spontaneous Urticaria: A Real-World Exploratory Study
S. Flores Regalo (Coimbra, Portugal)

- D3.415** Galectin-10 Expression in Plasma-Derived Extracellular Vesicles of Patients with Eosinophilic Esophagitis: a Pilot Study
F. Mone (Baronissi, Italy)

- D3.416** PEG-CUR Reduces Oxidative Stress and Total Methylation Induced by Cigarette Smoke in Epithelial Cells: Development of PEG-Curcumin Loaded Fast-Dissolving Microneedle Patches
B. Kilic (Ankara, Türkiye)

12:15 - 13:15 L-TPS25 - Allied health and primary care 02

(Poster Zone, Thematic Poster Session)

Chair: I.-J. Wang (aipei Hospital Ministry of Health and Welfare, Taiwan)

- D3.488** Early Risk Assessment and Recognition of Allergies in Children: rationale, methodology, and proposed algorithms
E. Hamelmann (Bielefeld, Germany)
- D3.489** Anaphylaxis Diagnosis and Treatment from the Perspective of Primary Care Physicians
U. Dikici (Ankara, Türkiye)
- D3.490** AllergyIQ: An Interactive Virtual Educational Platform in Allergy and Immunology
F. AlYaqout (Kuwait, Kuwait)
- D3.491** Satisfaction with Sebetralstat as On-Demand Treatment of Hereditary Angioedema Attacks in KONFIDENT-S
A. Zanichelli (Milan, Italy)
- D3.492** Validation of the Portuguese version of the Food Allergy Quality of Life Questionnaire Adult Form (P-FAQLQ-AF)
P. Alves (Coimbra, Portugal)

12:15 - 13:15 TPS59 - Allergy diagnosis 11

(Poster Zone, Thematic Poster Session)

Chair: G. Karakaya (Ankara, Türkiye), J.-F. Lopez (Davos, Switzerland)

- D3.01** Association between allergen-related antibodies and clinical phenotypes of IgG4-related disease (IgG4-RD)
L. Lyu (Beijing, China)
- D3.02** A Well-Established Drug and A Rare Reaction: Successful Desensitization to Adalimumab
G. Fitoz Emeksiz (Ankara, Türkiye)
- D3.03** Titanium allergy – from anamnesis to diagnosis
N. Aliakhnovich (Vitebsk, Belarus)
- D3.04** Sensitization Pattern and Characteristics of IgE Repertoire in Allergic Children with Excessively High Serum IgE Levels
C.-M. Kang (Taipei, Taiwan)
- D3.06** Comparative Evaluation of Raw, Blanched, Individual and Composite Allergen Preparation for Basophil Activation Testing
M. Boussand (Marseille, France)
- D3.07** Low inter-lot variability and high long-term stability of ready-to-use and room temperature-stable dry reagents for Basophil Activation Testing against peanut extracts
M.-E. Castaing-Lasvignottes (Marseille, France)
- D3.08** Biomarker Profiles and Autoimmune Features in Patients with Chronic Urticaria: A Clinical–Laboratory Analysis
S. Dzhikova (Pleven, Bulgaria)
- D3.09** Cyto-LTT as a Diagnostic Tool in Acute Drug-Induced Interstitial Nephritis: A Case Report and Laboratory Case Series
O. Hausmann (Bern & Lucerne, Switzerland)
- D3.10** An exploratory assessment of biological inflammatory markers found in nasal epithelial cells from rhinitic patients as prospective predictors of rhinitis exacerbation status
E. F. Mateus Medina (Barcelona, Spain)
- D3.11** Identification of allergens in Chicken and Rabbit meat, a case report
M. L. Quiñones Obando (Madrid, Spain)
- D3.13** Molecular characterization of food allergens in a case of suspected honey and mustard allergy
M. L. Quiñones Obando (Cuenca, Spain)
- D3.14** IgE sensitisation to parvalbumin, Ani s 1, tropomyosin and arginine kinase delineates distinct molecular endotypes of seafood allergy
C. Casale (Modena, Italy)

12:15 - 13:15 TPS60 - Allergy diagnosis 12

(Poster Zone, Thematic Poster Session)

Chair: V. Esteban (Madrid, Spain), M. Muñoz (Berlin, Germany)

- D3.16** Increase of Post-SARS-CoV-2 Rashes Mimicking Penicillin Allergy in Children with Group A beta-hemolytic Streptococcus Infection: an emerging and challenging issue
F. Catamerò (Florence, Italy)

- D3.17** Outcomes of Anti-Tuberculosis Drug Reintroduction Following Adverse Drug Reactions among Adult Patients at a Tertiary Hospital in the Philippines (2022-2024)
V. L. Fider (Quezon City, Philippines)

- D3.18** Role of an Allergological Work-up in Antibiotic Allergy Delabeling in Mexican Pediatric Patients
L. M. Espinosa Méndez (Ciudad de México, Mexico)

- D3.20** Study of "in vitro" cross reactivity between nsLTP's comparing "in silico" results with a new specific IgE test based on immunoblot methodology
R. Lopez-Salgueiro (València, Spain)

- D3.21** When the Patient Diagnoses Herself: Amoxicillin-Induced Acute Pancreatitis as a Rare Manifestation of Drug Hypersensitivity
A. Abdurakhmanov (Manisa, Türkiye)

- D3.25** Machine learning models to differentiate cross-reactive and selective-hypersensitive patients to nonsteroidal anti-inflammatory drugs hypersensitivity
J. Triano-Cornejo (Málaga, Spain)

- D3.27** Nivolumab-Induced Psoriasiform Eruption: Diagnostic Challenge Between Immune-Related Toxicity and Drug Allergy
P. Letón-Cabanillas (Valladolid, Spain)

- D3.30** Automated generation of structured clinical databases in drug hypersensitivity: real-world validation in patients with proton pump inhibitor reactions
L. Carrasco Gómez (Madrid, Spain)

- D3.31** Real-world Practices in the Diagnosis and Evaluation of Allergic Rhinitis among Korean Specialists
S. C. Park (Seoul, Korea, Republic of)

12:15 - 13:15 TPS61 - Allergy diagnosis 13
(Poster Zone, Thematic Poster Session)

Chair: *T. Alfaya Arias (Madrid, Spain), J. Jagers (Cleveland, United States of America)*

- D3.35** The influence of birth month on allergen sensitization patterns: A comprehensive analysis of skin prick test results in a large patient cohort
M. Božan Aksentijević (Zagreb, Croatia)
- D3.36** Chronic type non-IgE-mediated gastrointestinal food allergies, Clinical features and unclassified subgroup in the recent cohort
T. Yaguchi (Setagaya City, Japan)
- D3.37** Optimal Single and Combinatorial Diagnostic Approaches for Wheat Allergy in Chinese Children
W. Zheng (Shatin, Hong Kong)
- D3.38** Elucidating the Causes of Discordant Results Between Two Specific IgE Assays Using Component-Resolved Diagnostics and Depletion Testing
M. Nagao (Tsu, Japan)
- D3.39** Allergic contact dermatitis to oxidized fragrance components: a case of sensitization to hydroperoxides of limonene
C.-T. Radu (București, Romania)
- D3.40** Evaluation of wheat allergy diagnostic methods in children and potential cross-reactivity to other cereal grains
H. W. C. Leung (Shatin, Hong Kong)
- D3.41** Population-based IgE profiling of adolescents using a multiplex allergen array
J. Rehr (Salzburg, Austria)
- D3.43** Classification of seasonal allergic rhinitis patients by prospective patient-recorded symptoms: the @IT.2020 project
S. Dramburg (Berlin, Germany)
- D3.45** Oral Food Challenge in children diagnosed with fish allergy. Our clinical experience
C. Moreno (Manresa, Spain)
- D3.46** Safety of the EAACI risk assessment in hypersensitivity reactions to chemotherapy
C. Mayorga (Málaga, Spain)
- D3.47** Changes in Poaceae and Betulaceae pollen seasons correlate with patient sensitization profiles: a single-centre study over 4 decades
F. Hannachi (Luxembourg, Luxembourg)

12:15 - 13:15 TPS62 - Allergy diagnosis 14
(Poster Zone, Thematic Poster Session)

Chair: B. Eberlein (Munich, Germany), A. Eggel (Bern, Switzerland)

- D3.49** Associations between the prevalence of sensitization of pets and symptoms of allergic rhinitis (AR) in children
M. Sung (GUMI, Korea, Republic of)

- D3.50** Molecular Characterization of Allergen Sensitization and Clinical Associations in a Romanian Cohort Using ALEX² Multiplex Assay
A. Chera (Bucharest, Romania)

- D3.51** Cardiovascular System Problems in Children Athletes with Allergic Diseases
L. Tchelidze (Tbilisi, Georgia)

- D3.52** Clinical spectrum and diagnostic challenges of paediatric angioedema without wheals
K. Umezawa (Setagaya City, Japan)

- D3.53** Prevalence of allergic sensitization to edible insects in exposed breeders from Thailand
A. Jacquet (Bangkok, Thailand)

- D3.55** Hereditary angioedema with normal C1-INH: DAB2IP mutation report
M. Lebedkina (Moscow, Russia)

- D3.56** Investigation of Serum Eosinophilic Granule Proteins Levels in Children with Chronic Spontaneous Urticaria
S. Y. Yilmaz (Konya, Türkiye)

- D3.57** Respiratory Manifestations Of Ascariasis Mimicking Allergic Disease: A Clinical Case
E. Vishneva (Moscow, Russia)

- D3.58** Eosinophilic ascites and extreme hypereosinophilia: differential diagnosis through medical treatment
P. Y. Uchupaille Torres (Guadalajara, Spain)

- D3.59** Occupational Cobalt Contact Dermatitis: Clinical Profile and Work implications
E. Baraketi (Tunis, Tunisia)

- D3.60** Allergic reaction in bisoprolol overdose
F. Dogjani (Tirana, Albania)

- D3.61** Acquired Food Allergy After Allogeneic Hematopoietic Stem Cell Transplantation From a Non-Allergic Unrelated Donor
S. Sartorio (Milan, Italy)

- D3.62** Application of a logistic regression model to predict the risk of allergic reactions in children with salmon sensitization (Sal s 1)
Y. Marushko (Kyiv, Ukraine)

12:15 - 13:15 TPS63 - Allergy diagnosis 15
(Poster Zone, Thematic Poster Session)

Chair: A. Dašić (Beograd, Serbia), S. Riemann (Ghent, Belgium)

- D3.63** Molecular Evidence of PR-10 in Cannabis Allergy
T. Galán Díez (Alcalá de Henares, Spain)
- D3.64** Alcohol-Soluble Wheat Proteins as the Likely Allergenic Trigger in a Patient With Reaction to Gin
F. Pineda de la Losa (Alcalá de Henares, Spain)
- D3.66** When dermatitis follows the menstrual cycle: two cases of endogenous progesterone hypersensitivity
M. Terzić (Belgrade, Serbia)
- D3.67** Retrospective Evaluation of IgE Panel Utility in Allergy Diagnostics: Insights from Baghdad, Iraq
D. Aljebouri (Baghdad, Iraq)
- D3.70** Structural and immunological insights into arginine kinases from house dust mites and related arthropods
N. Kulinskaya (Graz, Austria)
- D3.71** A research tool for development of in-house specific IgE immunoassays - comparison between different methods
Å. Marknell DeWitt (Uppsala, Sweden)
- D3.72** Effect of *Helicobacter pylori* Eradication on Disease Activity in Chronic Urticaria: Follow-Up Results
L. Bugadze (Tbilisi, Georgia)
- D3.73** Clinical Performance of Hycor NOVEOS–Based Specific IgE Measurements for the Screening of Respiratory Allergies
P. A. Apoil (Toulouse, France)
- D3.74** Age-related characteristics of children's sensitisation to timothy grass according to component diagnostics
M. Vafokulova (Tashkent, Uzbekistan)
- D3.75** Molecular sensitization profiles and clinical patterns in Albanian children with respiratory allergies
J. Asllani (Tirana, Albania)
- D3.76** Open-Label Clinical Trial To Evaluate The Effect Of Intranasal Olopatadine/Mometasone And Azelastine/ Mometasone On Histamine Reactivity In Skin Prick Tests
E. M. Navarrete Rodriguez (Ciudad de México, Mexico)
- D3.77** Tattoo Ink Allergy? Diagnostic Challenges in Cutaneous Reactions to Tattoo Ink Containing Metals
R. Curatolo (Basel, Switzerland)

12:15 - 13:15 TPS64 - Allergy diagnosis 16

(Poster Zone, Thematic Poster Session)

Chair: **L. Palacio-Garcia (Madrid, Spain), Z. Ü. Altinel (İstanbul, Türkiye)**

- D3.78 Association between lipocalin sensitization and clinical symptoms: Evidence for cross-reactivity**
T. Šmrhová (Plzeň, Czech Republic)

- D3.79 Patterns of House Dust Mite Hypersensitivity in Eastern Ukraine**
K. Gashynova (Dnipro, Ukraine)

- D3.80 Molecular allergy profiling of sensitization in adult patients with asthma in real practice**
A. Emelyanov (Sankt-Peterburg, Russia)

- D3.81 Allergic Contact Dermatitis Induced by Transdermal Estradiol Hormone Replacement Therapy in a Postmenopausal Patient: A Case Report**
M.-I. Stîngă (București, Romania)

- D3.82 Conceptualization of a questionnaire for clinical diagnosis of house dust mite's allergy**
A. Tiotiu (Brussels, Belgium)

- D3.83 A Case Report of Fenofibrate-Induced Fixed Drug Eruption Documented by Patch Testing and Oral Provocation**
O. Bratu (București, Romania)

- D3.84 Patterns of Sensitization to Artemisia and Ambrosia Pollen in Ukraine**
V. Rodinkova (Vinnytsia, Ukraine)

- D3.85 Estrogen-Induced Drug Hypersensitivity Syndrome in a Patient with HHV-6 Reactivation**
L. DuBuske (Gardner, United States of America)

- D3.86 ALEX versus ISAC. The same story or an improvement for allergologic molecular diagnostic?**
S. Palomo Álvarez (Pamplona, Spain)

- D3.87 Evaluation of CD63 as a Marker of Basophil Degranulation in the Assessment of IgE-mediated Allergic Immune Responses**
D. Milcheva (Sofia, Bulgaria)

- D3.88 Did the skin patch test sensitivity profiles change in young and middle-aged adult patients? Current data from a tertiary allergy clinic cohort**
B. Gorgulu Akin (Ankara, Türkiye)

- D3.89 Decoding a Triple Pediatric Food Allergy Phenotype Using Component-Resolved Diagnostics: Severe CMPA, Alpha-Gal, and PR-10-Mediated PFAS**
S. Samoud (Tunis, Tunisia)

- D3.90 Outcomes of Beta-Lactam Allergy Evaluation in Patients with Suspected Hypersensitivity: One-Year Experience**
A. Cros Alsina (Terrassa, Spain)

- D3.91 Molecular Profiling of Shrimp Allergy in Tunisia: The Role of Tropomyosin and Component-Resolved Diagnosis**
S. Samoud (Tunis, Tunisia)

- D3.92 Precision Allergy Diagnostics in Tunisia: Integrating Molecular Allergology into the Management of Respiratory and Food Allergies**
S. Samoud (Tunis, Tunisia)

12:15 - 13:15 TPS65 - Asthma 09

(Poster Zone, Thematic Poster Session)

Chair: **B. Beken (Istanbul, Türkiye)**

- D3.108** Heterogeneity of Remission Definitions in Asthma and Other Chronic Diseases: Evidence From Two Systematic Reviews
M. Lee Qiyu (Southampton, United Kingdom)
- D3.109** Clinical Characteristics of Asthma Patients with Fungal Sensitization: A Retrospective Cross-Sectional Study
E. Sahinoglu (Ankara, Türkiye)
- D3.110** Patterns of Opioid or Neuromodulator Use in Chronic Cough Patients with Newly Diagnosed Asthma
E.-J. Jo (Busan, Korea, Republic of)
- D3.111** The Impact of War on the Course of Asthma
A. Kovchun (Sumy, Ukraine)
- D3.112** Clinical Characteristics and Evaluation of Serum Inflammatory Markers in Patients Hospitalized Due to Asthma Exacerbations
G. I. Parlak Ozel (Ankara, Türkiye)
- D3.113** The Diagnostic Value of Exercise Bronchial Provocation Testing in Pediatric Asthma
F. Güvenir (ankara, Türkiye)
- D3.114** Characterization on genome-wide profile of H3K4me2 histone methylation in mouse asthmatic lung induced by Alt a 1
H. Berreiros-Hortala (Madrid, Spain)
- D3.115** Iloprost Attenuates Neutrophilic Airway Inflammation in a Murine Model of Type 2-Low Asthma
Y.-C. Wu (Kaohsiung, Taiwan)
- D3.119** Saving the Caregiver: Humanitarian Access to Dupilumab in a Physician with Severe Non-Allergic T2 Asthma in a Frontline Ukrainian City
A. Kovchun (Sumy, Ukraine)
- D3.120** Delivering Severe Asthma Care in the Real World: Insights into Anti-TSLP (Tezepelumab) Use from a Tertiary Allergy and Respiratory Centre
L. Pur Ozyigit (Leicester, United Kingdom)
- D3.121** Evaluation of small airway dysfunction in severe asthma treated with anti-IgE and anti-eosinophilic therapies: A prospective comparative study
C. Tuzer (istanbul, Türkiye)
- D3.122** Real-World Outcomes Of Tezepelumab In Severe Asthma After 12 Months Of Treatment
M. Polo López (Segovia, Spain)
- D3.123** The complementary role of impulse oscillometry in prediction of asthma persistence at school age among preschool children with recurrent wheezing
M. Aydın Mut (Mersin, Türkiye)
- D3.124** Effect of psycho-behavioural comorbidities on asthma symptom control scores: implications on asthma remission assessment
T. R. Tay (Singapore, Singapore)

12:15 - 13:15 TPS66 - Asthma 10

(Poster Zone, Thematic Poster Session)

Chair: **M. Mukherjee** (Hamilton, Canada)

- D3.126** Evaluation of Severe Pediatric Asthma Response to Biologics Using the Pediatric CONFIRM Score: A Real-Life Cohort Analysis
S. Foti Randazzese (Pavia, Italy)
- D3.127** Evaluation of Serum Ezrin Levels and Spirometric and Plethysmographic Tests in Patients with Allergic and Non-Allergic Asthma
B. Erdoğan (Kayseri, Türkiye)
- D3.128** Management of Nasal Polyposis in Moderate-Severe Asthma Patients With Aspirin Desensitization And Biologic Agent Combination: Our Real-Life Experience With Seven Cases
E. ASLAN (İzmir, Türkiye)
- D3.129** Evaluation of Cardiovascular Disease Risk and Associated Factors in Childhood Asthma
R. YILDIRIM (İzmir, Türkiye)
- D3.130** PGI2 Signaling Attenuates the Proliferation and Type 2 Cytokine Production of Group 2 Innate Lymphoid Cells
H.-H. Su (Kaohsiung, Taiwan)
- D3.131** Comparative Assessment of Exercise Provocation, and Impulse Oscillometry in Young Adults With Exercise-Induced Respiratory Symptoms
H. Jin (Daegu, Korea, Republic of)
- D3.132** The impact of biological therapy on the quality of life of patients with severe asthma
E. Basioli Kasap (Zadar, Croatia)
- D3.133** Clinical Impact of Cumulative Oral Corticosteroid Exposure in Patients with Severe Asthma: Data from the Korean Severe Asthma Registry
J.-H. Kim (Anyang, Korea, Republic of)
- D3.134** Pulmonary rehabilitation at altitude: Is there an optimal season?
N. van Zelst (Amsterdam, Netherlands)
- D3.135** Real World Efficacy of Benralizumab Treatment in Severe Eosinophilic Asthma: A Single-Center Experience
H. Yılmazlı (İzmir, Türkiye)
- D3.137** The “Street Cat” Paradox: Low Prevalence but High Disease Burden of Mouse Sensitization in Pediatric Asthma
G. Kiğılı (İstanbul, Türkiye)
- D3.138** Can FeNO predict lung function decline in asthma? A 5-year multicenter cohort study
P. Dominguez Ferrer (Madrid, Spain)
- D3.139** Asthma control and medication adherence in patients with asthma using preferred versus alternative GINA treatment tracks - a real-world observational study
M. Nunes (Lisbon, Portugal)

12:15 - 13:15 TPS67 - Asthma 11

(Poster Zone, Thematic Poster Session)

Chair: **E. Fuertes** (London, United Kingdom), **A. Bognanni** (Milan, Italy)

- D3.140** Transcriptomic profiling reveals distinct gene signatures and immune pathways in inhaled corticosteroid (ICS)-sensitive and resistant House Dust Mite (HDM)-induced asthma mouse models
F. Ruzzi (Parma, Italy)

- D3.141** Serum levels of IL-10 and IFN-GAMMA in adolescents diagnosed with asthma in clinical remission without treatment
M. T. Gonzales-Enriquez (Regina, Canada)

- D3.142** Adherence to Inhaled Corticosteroid Therapy in Patients with Severe Asthma at a Danish Tertiary Care Centre
O. Petersen (Aarhus, Denmark)

- D3.143** Immunomodulatory role of vitamin D in severe asthma: a potential biomarker of treatment response
M. Lampalo (Zagreb, Croatia)

- D3.144** Did allergic status change the quality of life in controlled severe asthma patients with triple therapy?
B. Gemicioglu (İstanbul, Türkiye)

- D3.145** Comparative particle size and distribution from fixed dose triple dry powder inhalers
B. J. Lipworth (Dundee, United Kingdom)

- D3.146** Attitudes and Knowledge Levels Regarding Physical Activity in Children with Asthma and Their Parents: A Comparison with Healthy Controls
M. C. Sifil (ankara, Türkiye)

- D3.147** A Survey of Approaches to Inhaled Therapy Management in Patients with Severe Asthma Treated with Biologics: Practices Among REIMAGINE Study Sites
P. Howarth (London, United Kingdom)

- D3.148** ANCA-Negative Systemic Vasculitis Developing Despite Anti-IL-5R Therapy and High Dose of Glucocorticosteroids: A Diagnostic and Therapeutic Challenge
K. Królak-Nowak (Łódź, Poland)

- D3.149** Nationwide Trends in Asthma-Related Mortality in Türkiye: Impact of the Sex-Specific Differences (2018–2024)
F. E. Gunaydin (Frimley, United Kingdom)

- D3.150** Clinical characterization of patients affected by asthma and psoriasis or psoriatic arthritis: an observational retrospective study
V. Maggiolo (Monserato, Italy)

- D3.151** Anti-IL5 biologics in eosinophilic granulomatosis with polyangiitis patients followed in a severe asthma multidisciplinary unit: functional and clinical outcomes
N. Abdurrachid (Lisboa, Portugal)

- D3.152** The quality of life in severe asthma patients treated with biologics is better than those with triple inhaler therapy
B. Gemicioglu (İstanbul, Türkiye)

12:15 - 13:15 TPS68 - Asthma 12

(Poster Zone, Thematic Poster Session)

Chair: A. F. Kalyoncu (Ankara, Türkiye), D. Karaguzel (Ankara, Türkiye)

- D3.153** Add-on Dupilumab therapy significantly reduces severe asthma exacerbations and emergency visits in patients with severe persistent asthma requiring oral corticosteroids for maintenance therapy: our experience in Réunion Island
B. Omarjee (Saint-Denis, Réunion)

- D3.154** Trends in Bronchial Asthma Incidence in Crimea: Analysis from 2017-2024 with Age-Specific Insights
L. DuBuske (Gardner, United States of America)

- D3.155** Th2–Th17 immune shift following dupilumab therapy
L. Rodríguez Calderón (Guadalajara, Spain)

- D3.156** Pulmonary embolism in a young asthma patient
A. Csuth (Linköping, Sweden)

- D3.157** Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region
D. De Zubiria (Cali, Colombia)

- D3.158** Dupilumab Response in a Patient with Severe Asthma Refractory to Anti-IL5 Therapy: A Case Report
Y. Bozkurt (ISTANBUL, Türkiye)

- D3.159** Early Bronchodilator Response in Asthma: When Is Testing Really Necessary?
S. B. Kaya (Malatya, Türkiye)

- D3.160** Study of the allergic sensitization profile in asthmatic patients consulting at ignace deen university hospital, conakry
I. T. Diallo (Conakry, Guinea)

- D3.161** Efficacy and Safety of Ciclesonide in Achieving Asthma Control: Results of an Observational Multicenter Study in Real-World Clinical Practice
O. Belik (Moscow, Russia)

- D3.164** Early and Sustained Effect of Zupilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma
A. Kamboj (San Francisco, United States of America)

- D3.165** Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor
M. Valentine (Tempe, AZ, United States of America)

12:15 - 13:15 TPS69 - Allergen immunotherapy 06
(Poster Zone, Thematic Poster Session)

Chair: *H. Duman Senol (İzmir, Türkiye), N. N. Bahçeciler (Nicosia, Cyprus)*

- D3.181** Oral Immunotherapy for food allergy through a personalised approach
A. Moracho Pascual (Leganés, Spain)
- D3.182** Initiating Sublingual Immunotherapy in Pre-Adolescence (<12 Years) Maximizes Adherence Potential: Analysis of Subjective Burden and Local Reactions
P. Kunc (High Tatras, Slovakia)
- D3.183** Determination of IgE antibodies against recombinant allergens (Phl p 1 and Phl p 5) in a random sample of patients from Madrid with pollinosis before and after one year of subcutaneous immunotherapy
A. De Noia (Madrid, Spain)
- D3.184** Comparative immunogenicity of mixed versus individual extracts from the storage mites *Acarus siro* and *Tyrophagus putrescentiae*
R. Moya (Tres Cantos, Spain)
- D3.185** Clinical Characteristics of Patients with Hymenoptera Venom Allergy Treated with Venom Immunotherapy: A Retrospective Study
K. Kırdök (İzmir, Türkiye)
- D3.187** Sustained Clinical Benefit of Allergen Immunotherapy in Allergic Rhinitis: A Real-Life Study
P. Novakova (Sofia, Bulgaria)
- D3.188** Real-Life Effectiveness of Subcutaneous Allergen Immunotherapy Assessed by Medication Consumption: A Retrospective Cohort Study
S. Flores Regalo (Coimbra, Portugal)
- D3.189** Oral Immunotherapy–Associated Eosinophilic Esophagitis: A Pediatric Case Report
A. Miletić Gospić (Zagreb, Croatia)
- D3.190** Protocol for a real-world Study to Track Response to Oralair in Naïve patients with Grass pollen allergy (STRONG) in the Netherlands
M. Busch (Arnhem, Netherlands)
- D3.191** Demonstrating the Stability of Allergoids, the Next Generation of Allergen Therapy
S. Hewings (Worthing, United Kingdom)
- D3.192** Safety of AIT with Depigmented-polymerized extracts in patients with severe allergic asthma. A subanalysis of the SAGITAL study
G. Salamanca Fernández (Tres Cantos, Spain)
- D3.193** Dual Blockade of TSLP and IL11 with a bispecific antibody: A Promising Strategy for the Treatment of Asthma and Other Airway Disorders
Z. Zhu (Wilmington, DE, United States of America)
- D3.194** Carry-Over Effect of House Dust Mite (HDM) Immunotherapy for Allergic Respiratory Conditions in Pediatric and Adolescent Populations: A Systematic Review and Narrative Synthesis
N. Tran (Hanoi, Vietnam)
- D3.195** Building expert consensus on the positioning of allergen immunotherapy (AIT) within a treatment paradigm for allergic rhinitis/rhinoconjunctivitis led by disease remission: A Delphi consensus
G. W. Canonica (Rozzano, Italy)
- D3.196** Safety of subcutaneous immunotherapy with purified native protein Cup a 1, a major allergen of *Cupressus arizonica*: 6-year real-world data
B. López-Cauce (Leganés, Spain)

12:15 - 13:15 TPS70 - Allergen immunotherapy 07
(Poster Zone, Thematic Poster Session)

Chair: **B. Bohle (Vienna, Austria), C. Panaïtescu (Timisoara, Romania)**

- D3.198** Challenges of using clinical scores as primary endpoints in allergology trials
R. Mösges (Köln, Germany)
-
- D3.199** Severe systemic allergic reaction following violation of elimination diet in a patient with sensitization despite achieved remission on allergen-specific immunotherapy
Y. Dytyatkovska (Dnipro, Ukraine)
-
- D3.200** Broad profile of olive pollen sensitisation as a key factor in immunotherapy failure
P. López De Los Santos (Palma de Mallorca, Spain)
-
- D3.201** Subcutaneous immunotherapy with a depigmented cat allergoid is safe in patients with cat allergy and beneficial for mental health in adolescents
A. Sager (Witten, Germany)
-
- D3.202** Characterising relevant major allergens beyond modification: from allergen to allergoid
I. Martino (Worthing, United Kingdom)
-
- D3.203** Characterisation of relevant allergens in grass pollen extracts
H. Young (Worthing, United Kingdom)
-
- D3.205** Two-year Outcomes of Multiple Low-Dose Oral Immunotherapies for combination of Tree Nuts or Peanut for Severe Allergy Patients
C. Nobuto (Sagamihara, Japan)
-
- D3.206** Pollen-Food Allergy Syndrome (PFAS): A New Paradigm in Allergy Practice – Results of a Survey Among Allergists
R. Montagne (Antony, France)
-
- D3.207** Symptomatology and Sensitization Profiles of Patients Undergoing Subcutaneous Immunotherapy for Aeroallergens in Greece
F. Kapsouli (Athens, Greece)
-
- D3.208** Security of initiation of SCIT in the day hospital
N. Cerdeira (Madrid, Spain)
-
- D3.209** Subcutaneous Allergen Immunotherapy in Children: Frequency of Local and Systemic Adverse Reactions and Associated Risk Factors
S. Aslan (Eskişehir, Türkiye)
-
- D3.213** Sustained effectiveness of the 300 IR house dust mite sublingual tablet over 2 treatment years in a real-world data setting – results of a non-interventional study
U. Reineke (Herford, Germany)
-
- D3.214** A multi-epitope protein promotes regulatory T-cell responses in PBLs from HDM-allergic patients
E. Egea-Bermejo (Barranquilla, Colombia)
-

12:15 - 13:15 TPS71 - Dermatology 05

(Poster Zone, Thematic Poster Session)

Chair: K. Jamalyan (Yerevan, Armenia), N. Douladiris (Nea Kallikratia, Chalkidiki, Greece)

- D3.231** Gut Microbiome Dysbiosis in Antihistamine-Refractory Chronic Spontaneous Urticaria and Its Association with Disease Characteristics- A Cross-Sectional Case–Control Analysis
I. Podder (Kolkata, India)
- D3.232** The AhR agonist tapinarof suppresses human skin inflammation by inducing metabolic reprogramming and reducing production of mitochondrial pro-inflammatory DAMPs
M.-A. Lefevre (Lyon, France)
- D3.233** Polypharmacy-Associated Lichenoid Eruption Simulating Keratosis Lichenoides Chronica
G. G. Atay (Istanbul, Türkiye)
- D3.234** Successful Use of Ritlecitinib in Long-Standing Alopecia Areata with Previous JAK Inhibitor Failure
A. De (Kolkata, India)
- D3.235** Trends in Sensitization to Preservatives and Epoxy Resins among occupationally exposed workers: A 31-Year Patch Test analysis from Tunisia
C. Sridi (Sousse, Tunisia)
- D3.236** Does Night Work Influence the Severity of Allergic Contact Dermatitis?
I. Kacem (Sousse, Tunisia)
- D3.237** Specific Features of Allergic Contact Dermatitis in Diabetic Patients in a Dermato-Allergology Unit in Tunisia
I. Kacem (Sousse, Tunisia)
- D3.238** Allergic Contact Dermatitis to Formaldehyde: A 31-Year Experience in a Dermato-Allergology Consultation
I. Kacem (Sousse, Tunisia)
- D3.239** Foot Allergic Contact Dermatitis in Workers: Prevalence and Allergen Patterns
I. Kacem (Sousse, Tunisia)

12:15 - 13:15 TPS72 - Dermatology 06

(Poster Zone, Thematic Poster Session)

Chair: **I. D. Toprak (İstanbul, Türkiye)**

- D3.240** Differential microRNA expression in chronic spontaneous urticaria in relation to treatment response
Y. M. Ye (Suwon, Korea, Republic of)

- D3.241** How Clinical Control of Chronic Urticaria influence in mental health
J. I. Larco (Lima, Peru)

- D3.242** SDRIFE induced by multiple systemic corticosteroids
J. Ramirez-Cortes (Majadahonda, Spain)

- D3.243** Food allergy in children with inherited epidermolysis bullosa: possible role of transcutaneous sensitization and features of the clinical course
A. Galimova (Moscow, Russia)

- D3.244** STK4 Deficiency Presenting with Epidermodysplasia Verruciformis
H. Artac (Konya, Türkiye)

- D3.245** Complete Resolution of Systemic Delayed Hypersensitivity following Removal of a Titanium Fixation Screw: A Case Report
H.-K. Won (Cheongju, Korea, Republic of)

- D3.246** A Novel Mutation in a Case of Deficiency of Interleukin-1 Receptor Antagonist in a Filipino Male Child
A. Lee (Manila, Philippines)

- D3.247** Skin Involvement Is One Of The Common Signs In Children With Inborn Errors Of Immunity
H. Artac (Konya, Türkiye)

- D3.248** Prospective Evaluation Of The Efficacy Of Janus Kinase Inhibitor Therapy In Children With Alopecia Areata And Atopic Dermatitis
E. Vishneva (Moscow, Russia)

- D3.249** Late-onset toxic epidermal necrolysis (TEN) associated with nivolumab: attention to possible cofactors
R. Picos Baliña (Sevilla, Spain)

- D3.250** Changes in eating behavior in children with psoriasis during biological therapy depending on epicardial adipose tissue thickness
E. Vishneva (Moscow, Russia)

- D3.251** Prevention of Irritant Contact Dermatitis Among Dental Students
I. Kacem (Sousse, Tunisia)

- D3.252** Water-induced localized urticaria: A rare case of aquagenic urticaria
P. S. Figueiredo (Lisboa, Portugal)

- D3.253** Two Infant Cases Diagnosed with Bullous Mastocytosis, a Rare Variant of Diffuse Cutaneous Mastocytosis
M. Kurtuluş (Konya, Türkiye)

12:15 - 13:15 TPS73 - Food allergy 05

(Poster Zone, Thematic Poster Session)

Chair: **S. Arudi Nagarajan** (Bengaluru, India), **A. Fiocchi** (Roma, Italy)

- D3.270** Recent Trends in Food Allergy among Schoolchildren in a South Korean City (2018–2022)
G.-S. Choi (Busan, Korea, Republic of)

- D3.271** Development of a multiplex assay to assess the risk of IgE cross-reactivity to new protein sources
Y. Awad (Gif-sur-Yvette, France)

- D3.272** Selective Sensitization to Prawn with Absence of Cross-Reactivity to Fish: Molecular Identification of Hemocyanin (Pen m 7) and Sarcoplasmic Calcium-Binding Protein (Pen m 4) in a Patient with Recurrent Urticaria
M. Fernandez Izquierdo (Madrid, Spain)

- D3.273** Longitudinal Changes in Severity in Children with Severe, Refractory Cow's Milk Allergy
M. Omori (Obu, Japan)

- D3.274** Feasibility of Digestive Enzyme Supplementation for Cow's Milk Allergy in Exclusively Breastfed Infants
A. Fulmali (Cambridge, UK, United Kingdom)

- D3.275** In silico based assessment of intrinsic protein features for ranking clinical relevance of plant-based food allergens
A. Hussain (Kongens Lyngby, Denmark)

- D3.277** Tolerance to canned fish in patients allergic to β -parvalbumins
A. Grilo Mendes (Vila Nova de Gaia, Portugal)

- D3.278** Tropomyosin-Driven Cross-Reactivity Between Shellfish and House Dust Mites: A Case Report
E. KARAÇURA (Istanbul, Türkiye)

- D3.279** Sweet Honey And Sour Allergies: Pollen-Food Defensin Cross-Reactivity - a case series
A. Ivasko (Târgu Mureş, Romania)

- D3.280** Severe Anaphylaxis Induced by Turkey Egg with Tolerance to Hen's Egg and Poultry Meat: A First Report
P. Korkmaz (Şanlıurfa, Türkiye)

- D3.281** A Challenging Case of Paediatric Potato Allergy with Discordant Diagnostic Findings
N. Rao (Manchester, United Kingdom)

- D3.282** A Case of Nonsteroidal Anti-Inflammatory Drug-Exacerbated Food Allergy
E. Sahinoglu (Ankara, Türkiye)

12:15 - 13:15 TPS74 - Food allergy 06

(Poster Zone, Thematic Poster Session)

Chair: H. Breiteneder (Vienna, Austria), G. Zanoni (Verona, Italy)

D3.283 Oat-Induced Anaphylaxis: Allergenic Characterization in a Clinical Case

K. C. Paucar Vidal (Majadahonda, Spain)

D3.284 Milk Aversion After Successful Desensitization in a Milk-Allergic Child

A. Miletić Gospić (Zagreb, Croatia)

D3.286 Infant feeding patterns, perinatal history and the development of food allergy in early childhood

K. Efendieva (Moscow, Russia)

D3.287 Tick Bite-Induced Alpha-Gal Syndrome: A Report of Two Cases and Literature Review Focusing on Clinical Characteristics of Asian Patients

X. Gao (Tsingdao, China)

D3.288 Evaluating the role of dust mite sensitization in the development of edible insect allergies

L. Aparicio Armengol (Madrid, Spain)

D3.289 Tolerance Assessment in Children with IgE-Mediated Cow's Milk Allergy Using Different Cutoff Values of Cow's Milk Specific IgE

C. Kavukcu Horosan (Denizli, Türkiye)

D3.290 Generalized Urticaria Induced from Prick-by-Prick Test in Food Allergy Diagnosis

E. Lekli (Tirana, Albania)

D3.291 Molecular Identification of Heat-Stable β -Parvalbumin in megrim (*Lepidorhombus boscii*) as the Likely Allergen in a Child With Selective Fish Reactivity

A. Ventosa (Córdoba, Spain)

D3.292 Safety profile of the yellow fever vaccine in egg-allergic children

S. Regina Abu Jamra (Ribeirao Preto, Brazil)

D3.293 Selective Quail Egg Allergy Without Cross-Reactivity to Hen's Egg: Molecular Characterization of a Pediatric Case

E. Abel-Fernandez (Alcalá de Henares, Spain)

12:15 - 13:15 TPS75 - Anaphylaxis 04

(Poster Zone, Thematic Poster Session)

Chair: A. Anagnostou (Houston, United States of America), D. İlğün Gürel (Ankara, Türkiye)

D3.306 Venous-Venous ECMO For Aprotinin-Induced Perioperative Anaphylaxis

I. Calik (Istanbul, Türkiye), L. Pur Ozyigit (Leicester, United Kingdom), P. Romero (Leicester, United Kingdom)

D3.307 Chlorhexidine-triggered anaphylaxis in a child with multisystem allergy and sickle cell disease: a diagnostic pitfall

Z. E. Hamed (Newcastle upon Tyne, United Kingdom)

D3.308 Kounis Syndrome: the allergic myocardial infarction

C. Maçães (Porto, Portugal)

D3.309 Basophil Activation Test Detects Rocuronium Allergy During the Post-Anaphylactic Refractory Period: A PAMA Case Report

N. Kotnik (Golnik, Slovenia)

D3.313 Recurrent Anaphylaxis with Elevated Baseline Tryptase Revealing Hereditary Alpha-Tryptasemia with Mast Cell Activation

J. Silva (Porto, Portugal)

D3.314 Rapid desensitization to intravenous risankizumab after anaphylaxis in a patient with Crohn's disease: a case report

M. Nenova (Sofia, Bulgaria)

D3.317 Linguistic Validation of the Turkish Version of the Mastocytosis Control Test (MCT)

D. Unal (Istanbul, Türkiye)

D3.318 Evaluation of Clinical Predictors and Serum Tryptase Levels in Systemic Mastocytosis

A. Pehlivanlar Ustaoglu (Ankara, Türkiye)

D3.319 Clinical Data of Drug Induced Anaphylaxis according to the standardized European Anaphylaxis Registry (NORA)

F. Kapsouli (Athens, Greece)

D3.320 Anaphylaxis by Chlorhexidine: A case series

M. Zavala (Pamplona, Spain)

D3.321 Cardiac arrest after Iodixanol: a case of non-IgE mediated mast cell activation

V. Vatnani Moolchandani (Las Palmas de Gran Canaria, Spain)

D3.322 Successful management with Omalizumab and high-dose venom immunotherapy in a patient with Kounis Syndrome and Clonal Mast Cell Activation Syndrome

P. Viedma Ayllon (Castellon de la Plana, Spain)

12:15 - 13:15 TPS76 - Anaphylaxis 05

(Poster Zone, Thematic Poster Session)

Chair: T. Dribin (Cincinnati, United States of America), M. D. L. A. Gonzalez-Labrador (Alcorcón, Spain)

- D3.323** SBK007: A Novel Oral H1 Antihistamine with Rapid Onset (30min): Preclinical Pharmacodynamics in Acute Urticaria
M. Chen (Chengdu, China)
- D3.324** Hereditary Angioedema Attack Frequency and Severity According to Individuals Taking Berotralstat for Long-Term Prophylaxis
T. Khuu (Durham, United States of America)
- D3.325** Immediate-type allergic reactions associated with thiuram mix sensitization in an adolescent with atopic dermatitis: a case report
R. Pozerskyte (Vilnius, Lithuania)
- D3.326** Markedly Elevated Basal Serum Tryptase Revealing Smoldering Multiple Myeloma After Nonsteroidal Anti-Inflammatory Drug-Induced Anaphylaxis
S. Çolak (Ankara, Türkiye)
- D3.328** Paediatric Anaphylaxis: The Importance Of Recognition
V. Mateo-Frances (Madrid, Spain)
- D3.329** Real-world shelf-life of adrenaline auto-injectors (AAls) at pharmacy dispensing: Insights from six countries
M. Vang Lybech (Hørsholm, Denmark), J. Nørregaard (Kungsbacka, Sweden), K. Malottki (Reading, United Kingdom), J. Finney (London, United Kingdom), J. H. Kamstrup (Copenhagen, Denmark), A. Danø (Rungsted Kyst, Denmark), D. Grabowski (Toronto, Canada), S. Hussein (Hørsholm, Denmark)
- D3.331** Real-World Challenges in Pediatric Anaphylaxis: The Role of Epinephrine
L. Nogueras-Fuertes (Madrid, Spain)
- D3.332** Patient Preferences for Nasal Adrenaline Spray versus Adrenaline Auto-Injectors in Anaphylaxis: A Multi-Country Discrete Choice Experiment
M. Worm (Berlin, Germany), A. T. Fox (London, United Kingdom), M. Ben-Shoshan (Montreal, Canada), M. Bachmann (Cape Town, South Africa), K. Werner (Cape Town, South Africa), A. Danø (Rungsted Kyst, Denmark), M. Vang Lybech (Hørsholm, Denmark), G. Pouessel (Roubaix, France), S. Hussein (Hørsholm, Denmark)
- D3.333** Clinical Characteristics of Anaphylaxis in Infants and Toddlers
A. Toksoz (Ankara, Türkiye)
- D3.334** Severe Early-Onset Atopy With Recurrent Anaphylaxis and Infections as Indicators of CADINS Disease
A. Alexandru (Târgu Mureş, Romania)
- D3.335** Anaphylaxis After Eating Sushi - Emergent allergies with new food habits?
L. Pereira (Coimbra, Portugal)

12:15 - 13:15 TPS77 - Immune deficiencies and autoimmunity 05

(Poster Zone, Thematic Poster Session)

Chair: E. Efstathiou (London, United Kingdom)

- D3.357** Revealing an Underlying Inborn Error of Immunity in Pediatric Granulomatous Disease: A Case of STAT1 Loss-of-Function–Associated Mendelian Susceptibility to Mycobacterial Disease after BCG Vaccination
M. Movahedi (Tehran, Iran, Islamic Republic of)
-
- D3.361** Pulmonary Embolism in a Patient with Hyper IgE (Job) Syndrome Associated with Genetic Thrombophilia: A Rare Case
M. Dursun (Istanbul, Türkiye)
-
- D3.362** Ulcerative Colitis Developing in an Immunodeficiency Patient with CD19 Gene Mutation: A Case Report
L. KILINÇKAYA (Sakarya, Türkiye)
-
- D3.363** Systemic Lupus Erythematosus in a Patient with Hyper IgM Syndrome
T. Potluri (Preston, United Kingdom)
-
- D3.366** Experience With Berotralstat In The First Turkish Patients
E. TÜSÜZ ÖNATA (Sakarya, Türkiye)
-
- D3.367** Clinical and immunological heterogeneity of 22q11.2 deletion syndrome in children from the Republic of Moldova
S. Sciucu (Chisinau, Moldova)
-
- D3.368** Selective IgE Deficiency in Children: 10-Year Experience
B. uzunoğlu (izmir, Türkiye)
-

12:15 - 13:15 TPS78 - Drug Allergy 04

(Poster Zone, Thematic Poster Session)

Chair: A. Haccuria (Brussels, Belgium), R. Madrigal-Burgaleta (London, United Kingdom)

- D3.370** Three cases of erdosteine-induced delayed drug hypersensitivity
Y.-I. Koh (Gwangju, Korea, Republic of)
-
- D3.372** Rapid Intramuscular Penicillin Desensitization: A Promising Future
A. Capelo (Rio De Janeiro, Brazil)
-
- D3.373** Non-immediate Hypersensitivity Reactions To Both Penicillin and Aminopenicillin and Diagnostic approach – A Real Life Retrospective Study
M. Jensen (Aalborg, Denmark)
-
- D3.374** Recall urticaria to dalteparin sodium in a patient with previous systemic reaction to nadroparin calcium
M. Terzić (Beograd, Serbia)
-
- D3.375** Delayed-Type Drug Reactions in Pediatric Patients: Clinical Features and Management
S. Akyuz Oktay (Ankara, Türkiye)
-
- D3.376** Drug Allergy Related to Chemotherapy and Premedication: Anaphylaxis Induced by Carboplatin and Methylprednisolone
Ö. ARGİN (Istanbul, Türkiye)
-
- D3.377** Causes of a morbilliform rash: when the most frequent answer is not
B. Mora Gálvez-Cañero (Madrid, Spain)
-
- D3.378** Drug hypersensitivity in children in a frontline setting: interim results of a pilot epidemiological project
D. Yartseva (Zaporizhzhia, Ukraine)
-
- D3.379** Varenicline's DRESS Syndrome
B. Mora Gálvez-Cañero (Madrid, Spain)
-
- D3.380** The Most Serious Threat in Perioperative Hypersensitivity Reactions (PHRs): Neuromuscular Blocking Agent (NMBA) Hypersensitivity and Cisatracurium as a Safe Haven in the Setting of Cross-Reactivity
H. F. Avcı (Istanbul, Türkiye)
-
- D3.381** The paradox of treatment: H1-antihistamines-induced urticaria in a patient with chronic spontaneous urticaria
A. Velickovic (Belgrade, Serbia)
-
- D3.382** Safety and outcomes of penicillin desensitization during pregnancy: experience from a tertiary referral center
A. Capelo (Rio De Janeiro, Brazil)
-
- D3.383** Delayed T-cell-mediated hypersensitivity to dimethyl fumarate: clinical presentation and diagnostic considerations
M. Seoane-Rodriguez (Valdemoro, Spain)
-
- D3.384** Assessment of the role of Rapid Drug Desensitization to treat cancer patient with infusion-related allergic reactions. Italian experience
G. Cortellini (Rimini, Italy)
-

12:15 - 13:15 TPS79 - Basic immunology 04
(Poster Zone, Thematic Poster Session)

Chair: *S. Boyd (Stanford, United States of America), T. Chatila (Boston, United States of America)*

- D3.385** A Synthetic Serum Comprising Human IgE Monoclonal Antibodies to Peanut Allergens
B. SMITH (Charlottesville, United States of America)
-
- D3.386** Prevalence and immune mechanisms of rheumatoid arthritis in Kyrgyz highland residents
R. Khanferyan (Moscow, Russia)
-
- D3.387** Assessment of safety of cryopreserved mesenchymal stem cells in the treatment of atopic dermatitis
L. DuBuske (Gardner, United States of America)
-
- D3.388** Association of HLA and cytokine production as risk factors for prostate cancer
L. DuBuske (Gardner, United States of America)
-
- D3.389** The Role Of Metabolic Endotoxemia In The Development Of Systemic Inflammation In Patients With Type 1 And Type 2 Diabetes Mellitus
L. DuBuske (Gardner, United States of America)
-
- D3.390** Lipopolysaccharide-Binding Protein And sCd14 In Patients With Type 1 Diabetes Mellitus And Diabetic Nephropathy
L. DuBuske (Gardner, United States of America)
-
- D3.391** The Effect of Bicarbonate Mineral Water on Endotoxemia Markers in Patients with Type 1 Diabetes Mellitus
L. DuBuske (Gardner, United States of America)
-
- D3.392** Associations Between Markers Of Endotoxin-Binding Systems And Vasoactive Agents In Patients With Rheumatoid Arthritis
L. DuBuske (Gardner, United States of America)
-
- D3.393** Immunological Profiling of the Kras-Driven Microenvironment in a Murine Model of Endometriosis
S.-T. Wu (Kaohsiung City, Taiwan)
-
- D3.394** Assessment of safety and tolerability of mesenchymal stem cells and tolerogenic dendritic cells as a therapy for type 1 diabetes
L. DuBuske (Gardner, United States of America)
-
- D3.395** Analysis of single cell multiome data (transcriptomics + ATAC) from human nasal polyp mast cells
Y. Jang (London, United Kingdom)
-
- D3.396** A new B-cell epitope profiling of glutathione S-transferase allergens supports mite-specific cross-reactivity within different species
E. Egea-Bermejo (Barranquilla, Colombia)
-
- D3.397** MOG Antibody-Associated Bilateral Optic Neuritis in a Child Following Mycoplasma Infection
A. Iqbal (Boston, United Kingdom)
-

12:15 - 13:15 TPS80 - Biologicals 03

(Poster Zone, Thematic Poster Session)

Chair: Z. Alsalloom (Manama, Bahrain), H. Al Bahri (Bahrain)

- D3.418** A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
Y. M. Ye (Suwon, Korea, Republic of)
- D3.419** Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
E. Atayik (Konya, Türkiye)
- D3.420** Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
B. Hijazi (Riyadh, Saudi Arabia)
- D3.421** Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
A. Kucharczyk (Warsaw, Poland)
- D3.422** Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
J. Levina (Moscow, Russia)
- D3.423** Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
H. Bonnekoh (Berlin, Germany)
- D3.424** Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
H. Kayıkcı (Ankara, Türkiye)
- D3.425** Comparative Effects of Subcutaneous Allergen Immunotherapy and Biological Agents on Olfactory Function: Preliminary results
M. Taş (Kırıkkale, Türkiye)
- D3.426** Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D. Gialama (Berlin, Germany)
- D3.427** Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
I. López-Fletcher (Ciudad de Guatemala, Guatemala)
- D3.428** Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
M. Adamczewska (Łódź, Poland)

12:15 - 13:15 TPS81 - Biologicals 04

(Poster Zone, Thematic Poster Session)

- D3.430** The effect of biological treatment of atopic dermatitis in children
V. Novotová (Bratislava, Slovakia)
- D3.431** Dupilumab therapy of patients with chronic rhinosinusitis with nasal polyps: long-term observational study
Á. Kiricsi (Szeged, Hungary)
- D3.432** Severe chronic rhinosinusitis - diagnostic and therapeutic challenges, personalized approach and place of biological treatment: a clinical case
E. Petkova (Sofia, Bulgaria)
- D3.433** An effect on lipid profile of biologic therapy independent from weight variation
M. Bullita (Cagliari, Italy)
- D3.434** Effectiveness of Biologic Therapies in Adults With Chronic Rhinosinusitis With Nasal Polyps: Real-World Data
M. Akarsu (Ankara, Türkiye)
- D3.435** "Looking Twice in Atopic Dermatitis Therapy: Pruritus Is Not Always the Same, and Eczema Is Not Always Atopic Dermatitis"
S. Isik (Göttingen, Germany)

12:15 - 13:15 TPS82 - Clinical Trials 02

(Poster Zone, Thematic Poster Session)

- D3.437** The effect of biological treatment of atopic dermatitis in children
P. Lacwik (Kielce, Poland)

- D3.438** Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
T. Khuu (Durham, United States of America)

- D3.439** Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort
E. N. Mete Gokmen (İzmir, Türkiye)

- D3.440** Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
M. Stobiecki (Kraków, Poland)

- D3.441** Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
E. N. Mete Gokmen (İzmir, Türkiye)

- D3.442** Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort
S. Trainotti (Munich, Germany)

- D3.443** Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort
S. Trainotti (Munich, Germany)

- D3.444** Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
M. Stobiecki (Kraków, Poland)

- D3.445** Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
N. Samson (London, United Kingdom)

- D3.446** PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants
J. A. Layhadi (London, United Kingdom)

- D3.447** Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut
S. Starchenka (Worthing, United Kingdom)

- D3.448** Use of Sebetralstat as Short-term Prophylaxis for Patients with Hereditary Angioedema: Results from the KONFIDENT-S Study
M. Cancian (Padua, Italy)

12:15 - 13:15 TPS83 - ENT 02

(Poster Zone, Thematic Poster Session)

Chair: Z. Alsalloom (Manama, Bahrain), H. Al Bahri (Bahrain)

- D3.451** Long-term follow-up of ASA therapy after desensitization in patients with chronic rhinosinusitis with nasal polyps indicates high rate of treatment discontinuation
T. Pullerits (Gothenburg, Sweden)
- D3.454** Do we still need aspirin desensitization therapy for nasal polyposis?
K. Seifert (Ulm, Germany)
- D3.455** Comparative Characterization of Olfactory Dysfunction in Mouse Models of Eosinophilic Chronic Rhinosinusitis
A. Dekeyser (Brussels, Belgium)
- D3.456** BEAMER: A multidisciplinary model for disease-agnostic adherence integrating chronic rhinosinusitis: development and prospective study
K. Scheckenbach (Düsseldorf, Germany)
- D3.457** Does the Way We Ask Matter? Comparing Self- and Interviewer-Administered RQLQ in Allergic Rhinoconjunctivitis
T. Nicola-Varo (Târgu Mureş, Romania)
- D3.462** Polysorbate 80 (E433) sensitisation predicts and explains part of the variability of the Chronic Cough and Opposing Defiant Behaviour (ODB) in sensitised children: how the industrialised nutrition impacts the gut-brain axis and favours neuro-inflammation
K. Kefala (Paris, France)

12:15 - 13:15 TPS84 - Environmental allergy and climate change + One Health 02

(Poster Zone, Thematic Poster Session)

Chair: A. Bossios (Stockholm, Sweden)

- D3.464** Influences of Climate and Environmental Exposures on Atopic Dermatitis Persistence and Asthma Development in Early Childhood: 6-Year Follow-up of Longitudinal Study
S. Kim (Seoul, Korea, Republic of)
- D3.465** Climate Change Anxiety Scale (HAES-13) in assessing the emotional impact of extreme weather events
M. Urrutia Pereira (Uruguaiiana, Brazil)
- D3.466** Quantitative assessment of environmental exposure to Der p1, Der p 2 and Der p 23 in European and South African house dust samples
M. Oliver (Cardiff, United Kingdom)
- D3.467** When urban green spaces meet human allergies – Evidence from an urban pine park in Thessaloniki, Greece
G. Varsamis (Thessaloniki, Greece)
- D3.468** Effect of Microplastic Inhalation on Allergic and Nonallergic Rhinitis
Y. Itmec (Kirikkale, Türkiye)
- D3.469** Interaction between Meteorological Variables and Atmospheric Pollutants in the Dynamics of Alternaria Spores in Bragança, Portugal
T. Ribeiro (Porto, Portugal)
- D3.471** Invisible Ventilation Gaps: Continuous Low-Cost Indoor Air Quality Monitoring in a Northern Portuguese Hospital
G. Silva (Porto, Portugal)
- D3.473** Symptom burden and sensitization patterns in allergic rhinitis: real-world data
A.-V. Gorbatsvski (Târgu Mureş, Romania)
- D3.474** Non-IgE-mediated rhinitis in sub-Saharan Africa: an underdiagnosed condition?
L. Mouangue-Mbonjo (Yaounde, Cameroon)
- D3.475** Long-term retention of mouse blood proteins in Ixodes ricinus suggests residual host blood as a potential source of α -Gal
J. Petry (Esch-sur-Alzette, Luxembourg)

12:15 - 13:15 TPS85 - Biomarkers 02

(Poster Zone, Thematic Poster Session)

Chair: K. F. Chung (London, United Kingdom), A. Maldonado (Madrid, Spain)

- D3.477** IgE Sialylation as a Potential Biomarker of Allergy: Evidence from Patients with Diverse Allergic Conditions
J. Alvarez (Tres Cantos, Spain)
- D3.478** Microsplenia: Spleen Size Reduction as a Comprehensive Biomarker for Immune-Related Diseases, Disease Monitoring, and Treatment Response
L. Petrenko (Kyiv, Ukraine)
- D3.479** Association between Mitochondrial DNA Copy Number and Lung Function in Schoolchildren
H.-F. Kao (Tainan, West- Central, Taiwan)
- D3.480** Protamine Hypersensitivity Risk in an Elderly Patient with Recurrent Food Anaphylaxis and High Cardiovascular Risk- Case Report
A. Łata (Wrocław, Poland)
- D3.481** Machine Learning–Based Plasma Proteomic Signatures for Prediction of Chronic Rhinosinusitis
D. Kim (Seoul, Korea, Republic of)
- D3.482** Harnessing the Baseline Nasal Microbiome to Predict Pollen Related Symptom Expression
M. Gökkaya (Augsburg, Germany)
- D3.483** Wearable Energy-efficient Device development for Real-time Evaluation, Analysis, and Monitoring platform
G. Eom (Seoul, Korea, Republic of)
- D3.484** Non-Invasive Detection of Airborne Fungal Exposure Using Machine Learning–Assisted Volatile Biomarker Sensing
D. Kim (Seoul, Korea, Republic of)
- D3.485** Prevalence of *Ambrosia artemisiifolia* in Italy: Bioinformatics and Botanical Aerobiology Analysis
M. Albanesi (Bari, Italy)
- D3.486** Acute hepatitis B with atypical serological markers in a previously vaccinated patient receiving anti-CD20 obinutuzumab
J. Vitte (Reims, France)
- D3.487** Intersection of Micronutrient Malabsorption Symptoms and Iron Deficiency in a Diet interaction in East African Population
S. Abdoukader Houmed (Istanbul, Türkiye)

12:15 - 13:15 TPS86 - Occupational allergy
(Poster Zone, Thematic Poster Session)

Chair: **M. Raulf** (Bochum, Germany)

- D3.493 Identification of Two IgE-Reactive Proteins in *Planococcus citri* Larvae: A Novel Case of Occupational Respiratory Allergy in a Pest-Control Laboratory Worker**
A. E. Fernandez Fernandez (Alcalá de Henares, Spain)
-
- D3.495 Validation of a 4-steps single-concentration dosimeter test for measuring bronchial hyperresponsiveness with methacholine**
V. van Kampen (Bochum, Germany)
-
- D3.496 When music makes you bleed: suspected mould-triggered hypersensitivity pneumonitis from a contaminated trumpet in a 17-year-old professional player**
A. Adamiec (Warszawa, Poland)
-
- D3.497 Allergic Contact Dermatitis with Multiple Sensitizations in a Professional Viola Player**
A. Bostanoğlu Karaçin (Ankara, Türkiye)
-
- D3.498 Indoor environmental quality in university settings: identifying opportunities for promoting health, comfort, and academic performance among medical students**
P. Carvalho (Porto, Portugal)
-
- D3.499 Allergic Contact Dermatitis to Lanolin in an Occupational Allergological Dermatology Unit in Tunisia**
I. Kacem (Sousse, Tunisia)
-
- D3.503 Occupational Respiratory Allergies in Tunisia: Professional Outcomes and Risk Factors Among Workers**
I. Kacem (Sousse, Tunisia)
-
- D3.504 Allergic Diseases as a Leading Cause of Early Retirement in Occupational Settings**
I. Kacem (Sousse, Tunisia)
-
- D3.505 Problem-Based Learning on Allergic Contact Dermatitis Enhances Competency Development in Occupational Medicine**
I. Kacem (Sousse, Tunisia)
-
- D3.506 Assessment of exposure profiles and allergic outcomes in veterinary workers: findings from a standardized questionnaire**
A. BROGGIO (Padova, Italy)
-
- D3.507 Impact of chemical warfare agents on immune response**
K. Gashynova (Dnipro, Ukraine)
-
- D3.508 Management of Severe Occupational Allergic Rhinitis and Asthma in a Veterinary Student: A Molecular-Guided Approach**
B. Çelik Eroğlu (Ankara, Türkiye)
-

12:15 - 13:15 TPS87 - Aerobiology and pollution
(Poster Zone, Thematic Poster Session)

Chair: A. Damialis (Thessaloniki, Greece), A. Charalampopoulos (Thessaloniki, Greece)

- D3.509** Predicting Fungal and Bacterial Bioaerosol Concentrations Across Distinct Building Types: A Generalized Additive Model and Machine Learning Framework
S. Seo (Seoul, Korea, Republic of)
- D3.510** Correlation between Emergency visits and Platanus ssp pollen levels in a child population
I. Garcia-Nunez (Córdoba, Spain)
- D3.511** Correlation between Emergency visits and Platanus ssp pollen levels
I. Garcia-Nunez (Córdoba, Spain)
- D3.512** Objective Ambulatory Assessment of Indoor Air Quality and Cough Frequency
K.-M. Ahn (Seoul, Korea, Republic of)
- D3.513** Atmospheric Pollen Content in Arid Climate: One-year Seasonal Trends in Doha, Qatar
Y. M. Elkhatib (Doha, Qatar)
- D3.514** Atmospheric fungal spore content in an Arid Climate: One-year Seasonal Patterns in Doha, Qatar
Y. M. Elkhatib (Doha, Qatar)
- D3.515** PM2.5 exposure shapes monocyte and T cell immune reprogramming in allergic airway disease
D. Song (Seoul, Korea, Republic of)
- D3.516** Airborne pollen where and when it should not exist – Towards ‘allergy-safe’ environments or adopting a Planetary Health approach?
E. Papakonstantinou (Thessaloniki, Greece)
- D3.517** Design of an AI-Based Decision Support System for Field-Tailored Personal Protective Equipment Using Multi-Layer Protective Composites
S. PARK (Seoul, Korea, Republic of)
- D3.518** Environmentally relevant irregular polystyrene particles exert stronger biological effects than spherical model particles in human bronchial smooth muscle cells
M. Pietrzak (Wroclaw, Poland)

12:15 - 13:15 TPS88 - COVID19

(Poster Zone, Thematic Poster Session)

Chair: **D. Kocacik Uygun (Antalya, Türkiye)**

- D3.519** Post-COVID-19 Reshaping of Molecular IgE Sensitization Profiles to Seasonal and Indoor Allergens
N. Zakhidova (Tashkent, Uzbekistan)

- D3.520** Post-COVID Olfactory and Taste Dysfunction in Students at a South African Medical School
R. Seedat (Bloemfontein, South Africa)

- D3.521** Dermatologic adverse effects of COVID-19 vaccination
I. Kacem (Sousse, Tunisia)

- D3.522** Post-Vaccination SARS-CoV-2 Infections: Evidence, Severity, and Outcomes
I. Kacem (Sousse, Tunisia)

- D3.523** Early childhood: a risk predictor for post-COVID-19 pulmonary sequelae in children
S. Sciuca (Chisinau, Moldova)

- D3.524** Clinical use of procalcitonin and IL-6 in diagnosis of bacterial superinfection in COVID-19
B. Prnjavorac (Tešanj, Bosnia and Herzegovina)

- D3.525** One- year hospital readmission after pediatric COVID- 19 hospitalization: a single- center cohort study
C. Vladulescu (Craiova, Romania)

- D3.526** Baseline demographic characteristics and early-life exposures in infants born during and after the COVID-19 pandemic: A comparison of the CORAL and FLORAL birth cohorts
A. Sokay (Dublin, Ireland)

- D3.527** Multisystem Inflammatory Syndrome in Children (MIS-C) as a Condition Resulting from Immune Dysregulation: What has Coronavirus Infection Taught Us? (Case Study)
L. Tchelidze (Tbilisi, Georgia)

12:15 - 13:15 TPS89 - Infections

(Poster Zone, Thematic Poster Session)

- D3.529** Altered Virulence of *Pseudomonas aeruginosa* from Polystyrene-Fed *Zophobas atratus* Larvae and Immunological Effects of Microplastics on Murine Lungs
I. Kaydashev (Poltava, Ukraine)

- D3.530** Nonresponsiveness to Hepatitis B Vaccine Is Characterized by Reduced T Stem Cell Memory (TSCM) Cells
H. Molavi (shiraz, Iran, Islamic Republic of)

- D3.531** Diverse Infectious Disease Outcomes After SARS CoV 2 Infection in Children and Adolescents: A Nationwide Matched Cohort Study
H.-J. Yang (Seoul, Korea, Republic of)

- D3.532** Influence of sensitization on persistent symptoms of chronic fatigue
D. Hristova (Sofia, Bulgaria)

- D3.533** Prevalence of dysplasia and cervical cancer of papillomavirus origin in women of different age groups
M. Lomikovska (L'viv, Ukraine)

- D3.536** *Staphylococcus aureus* bacteria as a causative agent of upper respiratory tract allergies
G. Yeryomenko (Kharkiv, Ukraine)

- D3.537** Immunologic and other factors influencing clearance of viral hepatitis infections
G. Kamkamidze (Tbilisi, Georgia)

12:15 - 13:15 TPS90 - Eosinophilic esophagitis (Poster Zone, Thematic Poster Session)

Chair: **A. Bakirtas (Ankara, Türkiye), C. Zeyneloglu (Davos, Switzerland)**

- D3.538** Aeroallergen sensitisation as a risk factor for paediatric eosinophilic esophagitis
R. Zermati (Paris, France)

- D3.539** Evaluation of Treatment Selection and Response in Patients with Eosinophilic Esophagitis Based on Clinical Findings and Allergy Testing
M. S. Ensari (Ankara, Türkiye)

- D3.540** Sources of IL-13 in Acute Versus Chronic Models of Eosinophilic Esophagitis
A. Doyle (Scottsdale, United States of America)

- D3.541** Who takes the patient with eosinophilic esophagitis (EoE) and acute laryngeal edema?
N. O. Berghi (Bucureşti, Romania)

- D3.542** Prevalence of sensitization to panallergens and IgG4 profiles against specific foods in patients with allergic-phenotype eosinophilic esophagitis
J. Domenech Witek (Cádiz, Spain)

12:15 - 13:15 TPS91 - AllergoOncology (Poster Zone, Thematic Poster Session)

Chair: **S. Karagiannis (London, United Kingdom), H. Kayıkcı (Ankara, Türkiye)**

- D3.544** Allergic biomarkers and clinical outcomes in lung cancer patients treated with immune checkpoint inhibitors: a pilot study
I. Dávila (Salamanca, Spain)

- D3.545** Natural Killer and Dendritic Cells Leverage Synergistic Interactions to Enhance Treatment of Non-Small Cell Lung Cancer
B.-Y. Tsai (Taipei, Taiwan)

- D3.546** AllergoOncology: Basophil number and subpopulation proportions may offer potential as predictive biomarkers in non-small cell lung cancer
M. Lasa-Lazaro (Barcelona, Spain)

- D3.547** Clinical Outcomes and Safety of Drug Desensitization in Chemotherapy-Induced Hypersensitivity
S. Rodríguez Cano (Córdoba, Spain)

- D3.548** Refractory and persistent pruritus in an atopic patient: A red flag for underlying malignancy?
T. M. De Vicente Jiménez (San Sebastián de los Reyes (Madrid), Spain)

13:30 - 14:00 EAACI Special Session 2 - EAACI Meet and greet the EAACI Leadership (EAACI Global Stage, EAACI Special Session)

13:30 Meet and Greet the Leadership

M. Torres (Malaga, Spain), M. Shamji (London, United Kingdom), P. Bonadonna (Vicenza, Italy), A. Moreira (Porto, Portugal), J. Walusiak-Skorupa (Lodz, Poland), O. Pfaar (Marburg, Germany), O. Palomares (Madrid, Spain), S. Del Giacco (Cagliari, Italy)

13:30 - 14:30 Enlightenment talk (Innovation Hub, EAACI Enlightening Talk)

Chair: C. Pitsios (Nicosia, Cyprus)

13:30 Living with reactions no one can see

I. Terreehorst (Rotterdam, Netherlands)

14:00 Medicine is a lifetime story

A. Karavelia (Kalamata, Greece)

13:30 - 14:30 SSS10 - EAACI ACAAI Sister Symposium: Bringing it back to our patients (Room London, 6- London, Sister Society Symposium)

13:30 How the ACAAI bridges the gap

T. Mahr (LaCrosse, United States of America)

13:50 Insight into asthma on a daily basis

C. Zachary (Minnesota, United States of America)

14:10 How to influence our patients in a world of influencers

D. Stukus (Ohio, United States of America)

13:30 - 15:00 FT19 - Precision medicine in Allergy: targeted biologic therapies (Room Athens, Flash Talks)

Chair: E. Terzioglu (Antalya, Türkiye)

- 13:30** Real-world dosing interval extension of biologics in severe asthma in the Dutch RAPSODI registry: can this be successfully applied?
001612 C. J. M. Marijnissen (Leiden, Netherlands)
-
- 13:37** Twice-Yearly Depemokimab Maintains Exacerbation Reduction Over 2 Years in Patients with Asthma Regardless of Prior Exacerbation History: An Integrated Analysis of the SWIFT-1/-2 and AGILE Studies
000770 E. Heffler (Milano, Italy)
-
- 13:44** Evaluation of remission in a cohort of Italian patients with severe asthma and CRSwNP who experienced switching of biologics
001985 E. Piano (Cagliari, Italy)
-
- 13:51** Dose-related efficacy of omalizumab in food-allergic children with severe asthma: OSAFA observational study
001937 S. Arasi (Rome, Italy)
-
- 13:58** Reduction in OCS cumulative dose while improving asthma control and quality of life in severe eosinophilic asthma treated with Benralizumab. Real-World Evidence from the AURORA study
000798 A. Kucharczyk (Warszawa, Poland)
-
- 14:05** A New Design and Functional Characterization of an IL-4 Receptor-Targeted Immunotoxin as an Immunomodulatory Strategy in Allergy
000164 N. Batres Casero (Madrid, Spain)
-
- 14:12** Interleukin-1 Inhibition in Hereditary Periodic Fever Syndromes: Single-Center Experience from Slovakia
001277 B. Šlenker (Martin, Slovakia)
-
- 14:19** Hereditary Alpha-Trypsinemia: a case series including Omalizumab treatment outcomes
000076 J. Guimarães (Setúbal, Portugal)
-
- 14:26** Efficacy of dupilumab vs omalizumab on symptom and quality of life burden in patients with severe chronic rhinosinusitis with nasal polyps and coexisting asthma: Results from the EVEREST study
001647 E. Heffler (Milano, Italy)
-
- 14:33** Differential Clinical Outcomes And Modulation Of Cd62l^{low} Ieos With Mepolizumab 100 Mg Versus 300 Mg In Egpa Patients
001040 M. E. Milanese (Florence, Italy)
-

13:30 - 15:00 FT20 - Emerging concepts in basic immunology

(Room Glasgow, Flash Talks)

Chair: G. Deniz (Istanbul, Türkiye), H. Morita (Tokyo, Japan)

- 13:30** Feasibility of lentiviral transduction in resting primary human basophils and CD34+-derived progenitors: overcoming limitations of current in vitro allergy basophil-based cellular models
001441 C. Frecha (Malaga, Spain)
-
- 13:37** Elucidating the Pathogenesis of Eosinophilic Chronic Rhinosinusitis via Ferroptosis
000672 K. Miyamura (Minato City, Japan)
-
- 13:44** Fish-oil-derived furan metabolites modulate early life immunometabolic responses and infection risk in childhood
001457 O. Bæk (Gentofte, Denmark)
-
- 13:51** Polyphenols reduce activation of monocyte derived dendritic cells (moDCs) in type-2 polarizing conditions
001453 C. den Elzen (Utrecht, Netherlands)
-
- 13:58** Altered cord blood immune reactivity as a potential early marker of non-IgE mediated allergy
001847 J. Hrdý (Prague, Czech Republic)
-
- 14:05** Anti-IL-5R α therapy and sustained multilevel disease control in refractory eosinophilic colitis: a case report
000906 L. Bruno (Roma, Italy)
-
- 14:12** Distinct Gene Variations Associated with Severity of Infection in COVID-19 Patients
000591 N. Oruklu (Ankara, Türkiye)
-
- 14:19** Donor-Dependent Transfer or Resolution of Allergic Diseases After Allogeneic Hematopoietic Stem Cell Transplantation
000237 Z. Bayazit (Kayseri, Türkiye)
-
- 14:26** Efficacy and Safety of Histaglobulin as an Adjunctive Therapy in Chronic Spontaneous Urticaria: A prospective, single-arm, self-controlled, interventional study
000242 A. De (Kolkata, India)
-
- 14:33** IgE Deficiency in Childhood: A Predictor of Autoimmunity and Recurrent Respiratory Tract Infections
000355 K. Miliordos (Panepistimioupoli Patron, Greece)
-
- 14:40** Isoquercetin Mimics Pioglitazone in Suppressing LPS-Induced Airway Inflammation Through Ferroptosis-Associated Mechanisms
001779 R. S. Yanikoglu (Istanbul, Türkiye)
-
- 14:47** Multiple Hypersensitivity Reactions to Chemically Unrelated H1 Antihistamines: Two Case Reports
001370 K. Gojny (Wrocław, Poland)
-
- 14:54** The use of immunotoxins against allergy. An immunotoxin targeted against Fc ϵ RI, and its improved trimeric design
000136 J. Narbona Corral (Madrid, Spain)
-

13:30 - 15:00 L- FT09 - Immune modulatory therapies for allergic diseases (Meeting room 3B01, Flash Talks)

Chair: R. van Ree (Amsterdam, Netherlands)

13:30 The drop of Allergen Immunotherapy in Italy: a direct assessment of sales

100062 G. Costanzo (Milan, Italy)

13:37 Quality of Life Improvement with 300 IR Liquid Sublingual Immunotherapy in Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomised and Non-randomised Studies

100066 D. Di Bona (Foggia, Italy)

13:44 Potential for clinical remission in house dust mite allergic rhinitis with the 300IR house dust mite sublingual immunotherapy tablet

100070 R. Brehler (Münster, Germany)

13:51 Potential for clinical remission in birch pollen-induced allergic rhinoconjunctivitis with a 300IR birch liquid sublingual immunotherapy

100071 M. Gerstlauer (Augsburg, Germany)

13:58 Treatment with mannan-conjugated birch pollen allergoids is safe and well tolerated in adult and adolescent birch pollen allergic patients – results from a Phase III DBPC trial

100182 E. Raskopf (Cologne, Germany)

14:05 Safety, adherence, and effectiveness of a short-course preseasonal subcutaneous immunotherapy with allergoid pollen extract of grass and/or olive adjuvanted with monophosphoryl lipid A (MPL) in real-world practice

100200 A. González Jáimez (Madrid, Spain)

14:12 Real-world effectiveness of tezepelumab in severe asthma: comparison between naive and switch patients

100419 V. Villalobos-Violan (Madrid, Spain)

14:19 Innovation in Trial Design of a Combined Short-and Long-term DBPC Phase III Study with PQ Grass and the First-Year Safety Data

100472 L. DuBuske (Washington, United States of America)

14:26 Systemic aluminum exposure during subcutaneous cluster allergen immunotherapy: pharmacokinetic analysis from a randomized phase II–III trial

100631 E. Aghayev (Hamburg, Germany)

13:30 - 15:00 JMA6 - Treatment options in chronic rhinosinusitis: best time, best procedure (Room Zurich, JMA)

Chair: *M. Schiappoli (Verona, Italy), J. Hagemann (Wiesbaden, Germany)*

13:30 The current relevance of surgery in the management of CRSwNP

J. Maza Solano (Sevilla, Spain)

14:00 Best management of CRSwNP exacerbation under biological treatment

Z. Tsinaslanidou (Thessaloniki, Greece)

14:30 Biologics in CRSwNP: tackle the inflammation at its origin

F. Ryser (Bern, Switzerland)

13:30 - 15:00 OAS20 - Molecular Allergology applied in clinics (Room Gothenburg, Oral Abstract Sessions)

Chair: *R. Bahri (Manchester, United Kingdom), P. Matricardi (Berlin, Germany)*

13:30 Clinical Relevance of Sensitization to Rare Allergen Sources

000473 S. Woehrl (Vienna, Austria)

13:42 Clinical characterization of the first subjects diagnosed with hereditary alpha-tryptasemia in Switzerland

001726 H. Wassmer (Basel, Switzerland)

13:54 Novel Calcium-Binding Allergens in Blue Swimmer Crab: Molecular Characterization of Sarcoplasmic Calcium-Binding Protein and Troponin C

000391 S. Heidari (Townsville, Australia)

14:06 Comparison of Molecular Tests and Skin Tests in Patients With Food Allergy and/or Polysensitization

001045 F. Tadik (İstanbul, Türkiye)

14:18 Assessing the Correlation between Molecular Sensitization to High-Risk Food Allergens and Clinical History: A Real-Life Adult Cohort Study

001331 M.-C. Cernat (Bucharest, Romania)

14:30 Outcomes of double-blind, placebo-controlled challenges with edible shrimps and their diagnosis by conventional and functional IgE-based allergy tests

000419 T. F. Leung (Shatin, Hong Kong)

14:42 Molecular sensitization profiles in house dust mite-allergic patients: a comparison of serum and nasal secretions

001635 P. Janssen (Ghent, Belgium)

13:30 - 15:00 OAS21 - Clinical biomarkers in pediatric and adult onset asthma (Room Munich, Oral Abstract Sessions)

Chair: **S. Foti Randazzese** (Pavia, Italy), **C. Janson** (Uppsala, Sweden)

13:30 Blood Eosinophils Alone Will Not Cut It: A Real-World, Multi-Biomarker Map of Type 2 Inflammation Across Chronic Airway Diseases

001171 R. Chen (Guangzhou, China)

13:42 Exhaled nitric oxide in pediatric asthma: clinical and functional associations

001998 A. Ursu (Lisbon, Portugal)

13:54 Body composition and airway inflammation in children: sex-specific associations between lean and muscle mass with FeNO

001797 J. Jesus (Porto, Portugal)

14:06 Asthma Control in the Context of Novel IOS Ratios, Systemic Inflammatory Indices, and Sensitization Status

001687 A. Suleyman (İstanbul, Türkiye)

14:18 Childhood exhaled nitric oxide predicts persistence of allergic sensitization into adolescence and young adulthood

000592 H. Chang (Taoyuan, Taiwan)

14:30 Respiratory oscillometry in children: feasibility and preliminary data from a national population-based study supporting future asthma care

000803 E. Wasilewska (Gdańsk, Poland)

13:30 - 15:00 SYM23 - New Insights into pediatric drug hypersensitivity (Room Istanbul, 1- Istanbul, Symposium)

Chair: **J.-C. Caubet** (Geneva, Switzerland), **Ö. Soyer** (Ankara, Türkiye)

13:30 The dilemma of viruses in pediatric drug hypersensitivity reactions

F. Mori (Florence, Italy)

14:00 A contemporary approach to diagnosis and management of DRESS in children

S. Kuyucu (Mersin, Türkiye)

14:30 Delabelling betalactam allergies in infants with non severe cutaneous reactions

E. Gomes (Porto, Portugal)

13:30 - 15:00 SYM24 - Planetary health - Allergic disease and the multi-exposome (Room Paris, 2- Paris, Symposium)

Chair: **R. Pawankar** (Tokyo, Japan), **O. Goksel** (Izmir, Türkiye)

13:30 From climate change to unpredictable planetary health: impacts on allergic and non-allergic diseases

C. Antunes (Évora, Portugal)

14:00 Allergens and pathogens (pollen and fungi and viruses) interactions with airway epithelium

S. Gilles (Augsburg, Germany)

14:30 Indoor air quality: Hidden sources and (un)controlled allergens

M. Raulf (Bochum, Germany)

15:00 - 16:30 TSY6 - Neutrophils in allergy and inflammation
(Room Florence, 3- Florence, Thematic Symposium)

Chair: **D. Dwyer (Boston, United States of America), C. Sokol (Boston, United States of America)**

13:30 Regulation of neutrophil function in inflammation and organ injury
A. Margraf (Münster, Germany)

14:00 Neutrophil response mechanisms in allergy and immunity
Ö. Alaz (Zurich, Switzerland)

14:30 Neutrophil extracellular traps and respiratory diseases
G. Marone (Naples, Italy)

13:45 - 14:15 Satellite Symposium
(Room Krakow, Sponsored Sessions)

13:45 - 15:15 GBD2 - Groundbreaking Discoveries in Skin Allergy
(Room Utrecht, 4- Utrecht, Ground Breaking Discoveries)

Chair: **C. Panaiteescu (Timisoara, Romania), K. Kabashima (Kyoto, Japan)**

13:45 Diagnostic approach to severe cutaneous adverse reactions
A. Barbaud (Paris, France)

14:15 Chronic urticaria treatment: unmet needs and future opportunities
T. Zuberbier (Berlin, Germany)

14:45 Atopic dermatitis treatment: from orphanhood to explosion
P. Schmid-Grendelmeier (Davos, Switzerland)

14:15 - 15:15 SRegulation of allergen-based products
(Room Krakow, 7- Krakow, Symposium)

14:15 Regulatory framework of allergen products to diagnose type I allergies
V. Mahler (Langen, Germany)

14:45 Regulatory framework of allergen products for AIT
J. Zimmer (Hessen, Germany)

14:40 - 15:40 SSS11 - EAACI KAAACI Joint symposium: Allergic and airway diseases across the life course
(Room London, 6- London, Sister Society Symposium)

Chair: **D. H. Lim (Incheon, Korea, Republic of)**

14:40 Severe asthma in Korea: Real-World clinical profiles, treatment strategies, and outcomes
J.-H. Kim (Anyang, Korea, Republic of)

15:00 Childhood asthma trajectories: Phenotypes and remission (KAS Cohort)
J. Yoon (Seoul, Korea, Republic of)

14:45 - 15:00 Highlight Session

(Innovation Hub, EAACI Special Session)

15:00 - 15:45 P & C 6 - PRO CON 6: Intramuscular adrenaline is preferable to nasal adrenaline

(EAACI Global Stage, Pro Con)

Chair: **G. Roberts (Southampton, United Kingdom)**

15:00 Pro

P. J. Turner (London, United Kingdom)

15:23 Con

M. Alvaro Lozano (Esplugues de Llobregat, Spain)

15:15 - 16:45 FT21 - Mechanistic insight in AIT

(Room Athens, Flash Talks)

Chair: **D. Barber (Madrid, Spain), J. A. Layhadi (London, United Kingdom)**

15:15 A consensus nsLTP allergen in mRNA-LNPs reduces Th2 and enhances Th1 responses in samples from nsLTP-allergic patients

001395 J. Corneliussen (Kongens Lyngby, Denmark)

15:22 A consensus nsLTP allergen induces cross-reactive IgG responses using mRNA-LNP immunization

000408 E. Rivera-De-Torre (Kongens Lyngby, Denmark)

15:29 Study on the role of RNA m6A methylation modification in subcutaneous immunotherapy for dust mite allergy in children with asthma

001616 X. Gao (Tsingdao, China)

15:36 Allergen-laden VNP decorated with IL-12 show enhanced Th1 priming activity and reduce Th2 immune responses in a preclinical humanized mouse model of mugwort allergy

000717 B. Kratzer (Wien, Austria)

15:43 Prophylactic T-cell modulation by an engineered full-length Art v 1 analogue shielded in a virus-like nanoparticle attenuates mugwort pollen allergy in a humanized mouse model

001694 A. N. A. Sehgal (Wien, Austria)

15:50 Dose-dependent anaphylaxis induced by subcutaneously administered Ara h 2 in a humanized mouse model for peanut allergy

000727 K. Hellström (Espoo, Finland)

15:57 Does oral and skin sensitisation to peanut lead to differences in the humoral response in Brown Norway rats?

000715 J. M. Puerta-Pertínez (Kongens Lyngby, Denmark)

16:04 Harnessing the power of high-affinity Siglec-9 ligands for allergen immunotherapy by site-specific glyco-tagging

000999 A. Ehlers (Utrecht, Netherlands)

16:11 Impact of the definition of the standardization unit on the biological potency of grass pollen extracts

000789 T. Batard (Antony, France)

16:18 Short-course treatment with mannan-conjugated birch pollen allergoids reduces allergic symptoms and medication need during the birch pollen season and induces immunological responses

100184 E. Raskopf (Cologne, Germany)

16:25 Clinical and Immunological Changes in Patients with Respiratory Allergies Undergoing Allergen Immunotherapy for Cat Dander: A Prospective, Real-World Study

100330 H. Chen (Wuhan, China)

16:32 Pioneering Intratonsillar Immunotherapy (ITIT): Inducing Rapid Clinical Remission via Dual Remodeling of Follicular T-Cell Subsets and Effector Granulocyte Function in Allergic Rhinitis

100338 T. Gu (Wuhan, China)

15:15 - 16:45 FT22 - Nasal polyps and beyond (Room Glasgow, Flash Talks)

Chair: J. Maza Solano (Sevilla, Spain)

15:15 **Rupatadine inhibits Platelet-Activating Factor-induced Prostaglandin D2 in Nasal Polyps from CRSwNP patients**
100204 J. Mullol (Barcelona, Spain)

15:22 **Standardized data collection via the German National Chronic Rhinosinusitis Registry (GENRE CRS) facilitates future research projects**
000599 F. Bärhold (Wiesbaden, Germany)

15:29 **Treatment Patterns and Healthcare Resource Utilisation: A Real-World Survey of Patients with Chronic Rhinosinusitis with Nasal Polyps in Europe and the US**
000494 F. Hennesy (Bollington, United Kingdom)

15:36 **Rapid Reduction with Dupilumab in Total Symptom Score over 28 Days in Patients with Chronic Rhinosinusitis with Nasal Polyps: Interim Analysis from the ProGNOSE Study in Germany**
000563 A. Chaker (München, Germany)

15:43 **Dupilumab Rapidly Reduces IgE and Eosinophils in Kimura Disease: Sustained Remission Achieved**
000340 H. Wang (Hangzhou, China)

15:50 **The impact of biologic therapies on corticosteroid use in EGPA remission maintenance: a monocentric retrospective study**
001812 B. Lauro (Cagliari, Italy)

15:57 **Investigation of Single-Cell Transcriptional Heterogeneity in the Olfactory Mucosa of Patients with Chronic Rhinosinusitis and Olfactory Dysfunction**
000934 H. Zhang (Guang Zhou Shi, China)

16:04 **Male Predominance and Pubertal Resolution in Vernal Keratoconjunctivitis: Is Sex Steroid Intracrinology the Underlying Mechanism?**
000160 S. Agarwal (Chennai, India)

16:11 **Reduced Work Engagement in Patients With Chronic Rhinosinusitis: A Cross-Sectional Study**
100366 H. Zhao (Jinan, China)

16:18 **"Prevalence of Anxiety as an Invisible Burden and Its Relationship with Clinical Parameters in Patients with Chronic Rhinosinusitis with Nasal Polyps: A Cross-Sectional Study"**
100608 Ş. IŞIK (Kayseri, Türkiye)

15:15 - 16:45 L- FT10 - Drug allergy

(Meeting room 3B01, Flash Talks)

Chair: **A. Ariza** (Málaga, Spain), **E. Gomes** (porto, Portugal)

- | | |
|---------------|--|
| 15:15 | Deciphering the clinical and genetic heterogeneity within drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with drug-induced liver injury |
| 100065 | S. He (Shanghai, China) |
| 15:22 | An in vitro diagnostic activation-induced marker (AIM) test to identify delayed hypersensitivity reactions to antibiotics |
| 100129 | R. Brooimans (Rotterdam, Netherlands) |
| 15:29 | Peri-operative anaphylaxis in Cape Town South Africa, a 2018-2025 Retrospective cohort |
| 100275 | C. Day (Cape Town, South Africa) |
| 15:36 | Suspected Hypersensitivity Reactions to Gadolinium-Based Contrast Agents: A Case Series |
| 100291 | C. Mações (Vila Nova de Gaia, Portugal) |
| 15:43 | Penicillin Allergy De-Labeling in Children: An Irish Secondary Care Framework for Low-Risk Patients |
| 100297 | M. Alim (Clonmel, Ireland) |
| 15:50 | Quality of life in Drug Allergy – Results from the BIOGRAL study |
| 100305 | N. P. Freundt-Serpa (Madrid, Spain) |
| 15:57 | DRESS Syndrome in pediatric population: Insights from a 9 reported cases |
| 100331 | N. Fathallah (Sousse, Tunisia) |
| 16:04 | International validation of a digital self-assessment tool (SELF-FAST) to identify low-risk penicillin and sulfa antibiotic allergies in adults |
| 100356 | M. Rose (Heidelberg, Australia) |
| 16:11 | Differential vascular inflammatory programs linked to kallikrein dynamics in African ACE inhibitor-associated angioedema |
| 100369 | S. Pedretti (Cape Town, South Africa) |
| 16:18 | Distinctive Features of Paracetamol- and Ibuprofen-Induced Reactions in Childhood |
| 100540 | S. Aksoy Girgiç (Istanbul, Türkiye) |
| 16:25 | PALM Study: Penicillin Allergy Labels and Management in the United Arab Emirates |
| 100715 | S. Elkhaila (Abu Dhabi, United Arab Emirates) |

15:15 - 16:45 IWS10 - Influence of co-morbidities in the management of atopic dermatitis

(Room Utrecht, 4- Utrecht, Interactive Workshop)

Chair: **P. Uysal** (Aydın, Türkiye), **M. De Graaf** (Utrecht, Netherlands)

- | | |
|--------------|---|
| 15:15 | Infections in patients with atopic dermatitis and the influence of treatment |
| | M.-C. Brüggen (Zürich, Switzerland) |
| 15:45 | Management of asthma associated with atopic dermatitis |
| | S. Del Giacco (Cagliari, Italy) |
| 16:15 | When to look for a contact dermatitis in patients with atopic dermatitis |
| | N. Douladiris (Nea Kallikratia, Chalkidiki, Greece) |

15:15 - 16:45 IWS11 - Frontiers in aerobiology: Automation, innovation, and clinical integration (Room Zurich, 5- Zurich, Interactive Workshop)

Chair: **C. Antunes** (Évora, Portugal), **J. Oteros** (Córdoba, Spain)

15:15 Clinical Relevance of automated aerobiology in allergy diagnosis and treatment

H. Bayram (Istanbul, Türkiye)

15:45 Advances in automatic methods for aerobiological monitoring

J. Buters (München, Germany)

16:15 Exploring alternative automated bioaerosol sampling methods in aerobiology

C. Skjøth (Roskilde, Denmark)

15:15 - 16:45 IWS12 - Feeding difficulties and adaptive behaviours in EoE (Room Krakow, 7- Krakow, Interactive Workshop)

Chair: **E. Savarino** (Padua, Italy), **T. Greuter** (Lugano, Switzerland)

15:15 Feeding difficulties in pediatric EoE: Systematic insights and clinical challenges

C. Pitsios (Nicosia, Cyprus)

15:45 Behavioural and symptom-based monitoring in pediatric EoE: From children to adolescents and parents

A. Bakirtas (Ankara, Türkiye)

16:15 The relationship between eating behaviours and esophageal remodeling: What can they tell us about disease state?

H. Duman Senol (İzmir, Türkiye)

15:15 - 16:45 OAS22 - Tissue structural cells in the control of inflammation (Room Gothenburg, Oral Abstract Sessions)

Chair: **A. L. Aral** (Istanbul, Türkiye), **A. Eljaszewicz** (Białystok, Poland)

15:15 Cell-type-selective immune remodeling and immunometabolic reprogramming in psoriatic arthritis after anti-interleukin-17 therapy

001159 A. Sherri (Łódź, Poland)

15:27 Earthquake-Derived PM_{2.5} from the 2023 Türkiye Earthquakes Induces Apoptosis and Oxidative Stress in Primary Human Bronchial Epithelial Cells and Bronchial Organoids

001650 Z. Shahpar (Istanbul, Türkiye)

15:39 Lipocalin 2 Participates in the Pathogenesis of Vitiligo by Regulating the iNOS-Nrf2 Signaling Axis

000940 K. Ren (Xi'an, China)

15:15 - 16:45 OAS23 - Transforming disease course: clinical outcomes and remission with biologics (Room Munich, Oral Abstract Sessions)

Chair: Z. Tsinaslanidou (Thessaloniki, Greece), T. Eiwegger (St. Poelten, Austria)

15:15 Achieving Remission in Chronic Rhinosinusitis with Nasal Polyps Depends on Application of Current Criteria and Existing Comorbidities: Results from a Bi-National Cohort

000441 J. Hagemann (Wiesbaden, Germany)

15:27 Clinically meaningful improvements in upper airway outcomes with dupilumab vs omalizumab by prior surgery status in severe chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST study)

001393 S. Reitsma (Amsterdam, Netherlands)

15:39 Pediatric IPEX-Associated Dermatitis Responds to Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling

000191 J. Yang (Shanghai, China)

15:51 Predictors of response to omalizumab treatment in patients with chronic spontaneous urticaria: a post hoc analysis of a double-blind, randomized, phase 3 study

000555 M. Metz (Berlin, Germany)

16:03 Quality of life outcomes of omalizumab biosimilar CT-P39 compared to reference omalizumab in patients with chronic spontaneous urticaria: a post hoc analysis of a double-blind, randomized, phase 3 study

000477 E. Heffler (Rozzano, Italy)

16:15 Efficacy of omalizumab in patients with chronic spontaneous urticaria with and without angioedema: a post hoc analysis of a double-blind, randomized, phase 3 study of omalizumab biosimilar CT-P39

000556 M. Metz (Berlin, Germany)

16:27 Verekitug, a novel TSLP receptor antagonist antibody, in participants with chronic rhinosinusitis with nasal polyps in VIBRANT: responder analysis using clinically meaningful efficacy outcome thresholds

000221 J. Mullol (Barcelona, Spain)

15:15 - 16:45 SYM25 - Microplastics and epithelial barriers (Room Istanbul, 1- Istanbul, Symposium)

Chair: D. Yazici (Rochester, NY, United States of America), C. Traidl-Hoffmann (Augsburg, Germany)

15:15 Effects of microplastics on lung epithelial cells

Y. Pat (Boston, United States of America)

15:45 Effects of microplastics on gut epithelial cells

S. Ardicli (Türkiye)

16:15 Pulmonary epithelial cells and the effects of microplastics on the respiratory system

M. Wang (Beijing, China)

15:15 - 16:45 SYM26 - Latest advancement in hymenoptera venom allergy (Room Paris, 2- Paris, Symposium)

Chair: T. Alfaya Arias (Madrid, Spain), E. Boni (Bologna, Italy)

15:15 Insights into early immunological responses in VIT

M. Ollert (Esch-sur-Alzette, Luxembourg)

15:45 Advances in the diagnosis of hymenoptera venom hypersensitivity

G. Sturm (Graz, Austria)

16:15 Longterm efficacy of venom immunotherapy

M. B. Bilò (Ancona, Italy)

15:15 - 16:45 SYM27 - Asthma heterogeneity and precision medicine (Room Florence, 3- Florence, Symposium)

Chair: A. Custovic (London, United Kingdom), O. Can Bostan (Istanbul, Türkiye)

15:15 Defining asthma molecular phenotypes – the road to effective therapies
I. Adcock (London, United Kingdom)

15:45 Asthma genomics, susceptibility and severity; polygenic clinical risk assessment
E. Bleecker (Tucson, United States of America)

16:15 The importance of local biomarkers
M. Mukherjee (Hamilton, Canada)

16:00 - 16:45 P & C 5 - PRO CON 5 - Should drug challenge precede desensitization in immediate hypersensitivity reactions to biologicals? (EAACI Global Stage, Pro Con)

Chair: D. González-de-Olano (Madrid, Spain)

16:00 Pro
R. Madrigal-Burgaleta (London, United Kingdom)

16:23 Con
M. Castells (Boston, United States of America)

17:00 - 18:30 FT23 - Urticaria contact dermatitis (Room Athens, Flash Talks)

Chair: D. Can (İzmir, Türkiye), M. Ferrer (Pamplona, Spain)

17:00 Complement C5 defines two immunological endotypes in CSU, with distinct autoantibody profiles and omalizumab responses: The INCA study
000384 J. Marcelino (Berlin, Germany)

17:07 Cyclosporine in Antihistamine-Refractory Chronic Spontaneous Urticaria: Clinical Outcomes and Biomarker Changes
000936 A. De (Kolkata, India)

17:14 Dyspnea and joint pain are the most common additional symptoms in chronic spontaneous urticaria and are associated with poor disease control and quality of life
001281 P. Pyatlova (Berlin, Germany)

17:21 Prevalence of sleep disturbance and obstructive sleep apnoea in chronic spontaneous urticaria and associated risk-factors – an institution-based analytical cross-sectional study
000249 I. Podder (Kolkata, India)

17:28 Long-term Barzolvolimab Treatment Results in Sustained Off-treatment Improvement in Angioedema in Patients with CSU Refractory to Antihistamines
000816 M. Metz (Berlin, Germany)

17:35 Development and Validation of the Symptomatic Dermographism Activity Score (SDAS)
000749 M. Muñoz (Berlin, Germany)

17:42 Psychometric Validation of the Worst Itch Numeric Rating Scale (WI-NRS) as a Patient-Reported Outcome (PRO) in Cold Urticaria: Data from a Clinical Trial of Barzolvolimab
000825 M. Metz (Berlin, Germany)

17:49 Regional differences in chronic inducible urticaria
001454 E. Kruger (Cape Town, South Africa)

17:56 REASSERT: A global, prospective, non-interventional, patient-centric study evaluating the effectiveness and safety of remibrutinib and quality of life (QoL) in patients with chronic spontaneous urticaria (CSU)
000333 M. Metz (Berlin, Germany)

18:03 Unmet needs in treatment escalation for chronic spontaneous urticaria: Findings from the CURE Registry
000769 P. Kolchir (Berlin, Germany)

17:00 - 18:30 FT24 - Systems immunology across the spectrum: from inborn errors to therapy in pediatrics (Room Glasgow, Flash Talks)

Chair: J. Torres Borrego (Córdoba, Spain), S. S. Kilic (BURSA, Türkiye)

- 17:00** Nasal lavage–derived extracellular vesicles reflect allergic inflammation, IgE-related activity and epithelial remodeling in children with asthma
001357 D. Ambrozej (Warsaw, Poland)
-
- 17:07** Dietary Advancement Therapy using Milk and Egg Ladders: Preliminary Findings from a Pilot Observational Study
000912 C. Cronin (Cork, Ireland)
-
- 17:14** Causative Foods that change over time in childhood Food Protein–Induced Enterocolitis Syndrome
001873 M. B. İstanbullu (Denizli, Türkiye)
-
- 17:21** Distinct Tfh and Treg Signatures in Patients with Inborn Errors of Immunity
001242 F. Bayram Çatak (Istanbul, Türkiye)
-
- 17:28** Hematopoietic Stem Cell Transplantation for EBV-Associated Disease in Children with Inborn Errors of Immunity: A Case Series
000664 E. Kahveci (Istanbul, Türkiye)
-
- 17:35** Benralizumab as an effective steroid-sparing therapy in a child with steroid-dependent hypereosinophilic syndrome and multi-organ involvement
001048 J. S. Park (Seoul, Korea, Republic of)
-
- 17:42** Effectiveness, Safety Profile, and Patient Satisfaction of Subcutaneous Immunoglobulin Replacement Therapy in Primary Immunodeficiency
001085 C. Caka (Ankara, Türkiye)
-
- 17:49** Gender-Based Differences in Clinical and Immunological Profiles of Pediatric Vernal Keratoconjunctivitis
001778 B. Bozkurt (Konya, Türkiye)
-
- 17:56** The National Allergy Centre Of Excellence - Addressing Australia's Allergy Crisis
002088 K. Perrett (Parkville, Australia)
-

17:00 - 18:30 L-FT11 - Asthma

(Meeting room 3B01, Flash Talks)

Chair: K. Bønnelykke (Lillerød, Denmark), S. Quirce (Madrid, Spain)

17:00 IL-5/IL-5R blockade enables safe non-steroidal anti-inflammatory agent reintroduction in non-steroidal anti-inflammatory exacerbated respiratory disease

100173 P. Korkmaz (Istanbul, Türkiye)

17:07 Ultra-Processed Food Consumption as a Risk Factor in Childhood Asthma

100198 E. Topyildiz (Istanbul, Türkiye)

17:14 Real-world clinical characteristics and outcomes of severe asthma patients treated with tezepelumab: a multicenter retrospective cohort study

100288 L. de las Vecillas Sanchez (Madrid, Spain)

17:21 Lipolysis–microlipophagy cascade regulated by ATGL drives pathogenic adaptive type 2 immunity

100372 H. Yagyu (Yokohama, Japan)

17:28 Symptoms severity and molecular patterns of animal sensitization in veterinary workers

100400 A. Broggio (Padova, Italy)

17:35 Uncontrolled Asthma Significantly Increases Postoperative Respiratory Risk: A Prospective Study

100612 S. B. Kaya (Malatya, Türkiye)

17:42 Early clinical and inflammatory outcomes after initiation of tezepelumab in severe uncontrolled asthma: real-world data from the multicenter TRIGGER study

100660 K. Festa (Athens, Greece)

17:49 Chronobiologic Variation in Th1, Th2, and Th17 Cytokines in Severe Asthma

100722 A. Akenroye (Boston, United States of America)

17:56 Effectiveness of Broncho-Vaxom® in Preventing Recurrent Respiratory Tract Infections: Results from the REACH Study, a Multi-Country Real-World Study

100283 G. W. Canonica (Milan, Italy)

18:03 IL-33 modulates cytotoxic NK Cell Subsets in Severe Eosinophilic Asthma

000601 L. Bergantini (Siena, Italy)

17:00 - 18:30 IWS13 - Update on lipid transfer protein allergy

(Room Utrecht, 4- Utrecht, Interactive Workshop)

Chair: R. Asero (Paderno Dugnano, Milano, Italy)

17:00 LTP allergy - similarities and differences between children and adults

B. Pessina (Milano, Italy)

17:30 LTP allergy diagnosis - food triggers, allergic co-morbidities, co-factors and diagnostic options

I. Skypala (London, United Kingdom)

18:00 Immunotherapy and other management options

M. Fernandez Rivas (Madrid, Spain)

17:00 - 18:30 JMA7 - Allergen immunotherapy in special populations, what aspects should be taken into account? (Room London, JMA)

Chair: **E. Karakoç Aydiner** (İstanbul, Türkiye), **Z. Liu** (Wuhan, China)

17:00 AIT in immunodeficient patients: What do we know?
F. Cinetto (Treviso, Italy)

17:30 Insights from immune responses in allergy, immunotherapy and tolerance to cancer
S. Karagiannis (London, United Kingdom)

18:00 Clinical decision making in complex cases
D. Eyice Karabacak (Istanbul, Türkiye)

17:00 - 18:30 JMA8 - JMA Case Report Session (Room Krakow, JMA)

Chair: **B. Olivieri** (Verona, Italy), **G. Silva** (Porto, Portugal)

17:00 Fixed Drug Eruption Induced by Ferric Carboxymaltose with Positive Lymphocyte Transformation Test
N. C. Peña-González (Madrid, Spain)

17:08 When the excipient strikes: Mannitol-induced anaphylaxis. A case report
001088 D. M. Tello Montúfar (Santiago de Compostela, Spain)

17:16 Donor-Acquired Peanut Allergy After Lung Transplantation Despite Negative Skin and Serum IgE Testing
000199 K. Sohng (Toronto, Canada)

17:24 Severe Eczema: Presenting feature for Prolidase Deficiency
001326 A. K. Baskin (Ankara, Türkiye)

17:32 Selective Immediate Hypersensitivity to Triamcinolone: Identifying Safe Alternatives
001534 D. Harguindeguy Blanco (Valladolid, Spain)

17:40 Persistent egg yolk allergy after egg white oral immunotherapy: identification of YGP40
000472 M. D. L. A. Gonzalez-Labrador (Madrid, Spain)

100388 Hypersensitivity Reactions to Cardiac Resynchronization Therapy Devices: A Case Report
M. Bernardo (Ponta Delgada, Portugal)

100219 Season-dependent cholinergic urticaria with discordant exercise provocation: implications for diagnosis
J. Guimarães (Setúbal, Portugal)

100410 Autosomal Recessive Agammaglobulinemia caused by a FNIP1 mutation
D. İlgün Gürel (Ankara, Türkiye)

17:00 - 18:30 OAS24 - From risk to resilience: prevention of allergic diseases in childhood (Room Gothenburg, Oral Abstract Sessions)

Chair: S. Arasi (Rome, Italy)

17:00 Cat exposure and asthma outcomes in children with asthma and allergy

001284 R. Putri (Stockholm, Sweden)

17:12 Systematic review of maternal dietary patterns during pregnancy and offspring eczema/atopic dermatitis

001165 W. Tan (Cambridge, United Kingdom)

17:24 Multidimensional risk prediction model for infant atopic dermatitis: A prospective cohort study

000656 X. Gao (Tsingdao, China)

17:36 Therapeutic Efficacy of Cutaneous Application of Postbiotic N-(1-carbamoyl-2-phenyl-ethyl) Butyramide (FBA) in Pediatric Patients Affected by Atopic Dermatitis: The BuPAD Trial

002056 P. D'alessio (Naples, Italy)

17:48 Real-Life Outcomes from Nine Years of Allergen-Supervised Vaccination in Children at Risk for Hypersensitivity

000531 S. Foti Randazzese (Pavia, Italy)

18:00 Etiological and Prognostic Evaluation of Acute Urticaria in Childhood: A Multicenter Study

001112 D. Azkur (Kırıkkale, Türkiye)

18:12 Determining the Minimal Clinically Important Difference of the Urticaria Control Test in Children

001334 O. Y. Ulutas (Istanbul, Türkiye)

17:00 - 18:30 OAS25 - Epithelial barrier and systemic inflammation: from nose to gut (Room Munich, Oral Abstract Sessions)

Chair: A. L. Aral (Istanbul, Türkiye), I. Ogulur (Davos, Switzerland)

17:00 Early-Life Epithelial Immune Programming and Barrier Integrity Are Associated with Distinct Asthma Trajectories in Preschool Wheezers

001658 H. Charles (München, Germany)

17:12 Pathomechanisms of type-2 epithelial (E2) cells in allergy and asthma

001626 C. Schmidt-Weber (Munich, Germany)

17:24 Key Artemisia Pollen Components in the Progression from Allergic Rhinitis to Asthma: Mechanisms and Role Identification

001315 Y. Ru (Beijing, China)

17:36 Intranasal OM-85 Attenuates Allergen- and Virus-Induced Airway Inflammation by Restoring Epithelial-Macrophage Homeostasis

001669 A. Kouklas (Épalinges, Switzerland)

17:48 Single-Cell Profiling Reveals Enhanced Mast Cell - Epithelial Communication in CRSwNP and Its Modulation by Mepolizumab

002028 P. Yu (Gent, Belgium)

18:00 Transcriptomic comparison of nasal tissue and brushing samples in eosinophilic CRSwNP

000240 D. Nakashima (Tokyo, Japan)

18:12 Food emulsifier Polysorbate 80 Drives Gut Barrier Dysfunction and Systemic Inflammation Through Oxidative Stress

001618 C. Zeyneloglu (Davos, Switzerland)

17:00 - 18:30 SYM28 - Exposome and microbiome in immune regulation (Room Istanbul, 1- Istanbul, Symposium)

Chair: **Y. Pat** (Boston, United States of America), **W. Feleszko** (Warszawa, Poland)

17:00 The impact of air pollution on the immune system

O. Goksel (Izmir, Türkiye)

17:30 Immune response to airborne viruses and fungi

C. Karaaslan (Ankara, Türkiye)

18:00 IL-6 responses to virus and asthma exacerbations

M. Wegmann (Borstel, Germany)

17:00 - 18:30 TSY7 - From arachidonic acid and bioactive lipids to airway inflammation (Room Florence, 3- Florence, Thematic Symposium)

Chair: **A. Villasenar Solis** (Madrid, Spain), **M. Sanak** (Krakow, Poland)

17:00 Towards personalized asthma care: Metabolic profiling and the discovery of metabotypes

C. Wheelock (Stockholm, Sweden)

17:30 Targeting arachidonic acid signalling in different asthma inflammatory phenotypes

M. Tynecka (Białystok, Poland)

18:00 Multi-omics approaches towards studying the role of bioactive lipids in asthma and allergic diseases

U. Radzikowska (Davos, Switzerland)

17:00 - 18:30 YIR2 - YIR2 (Room Zurich, 5- Zurich, Year In Review)

Chair: **C. Panaitescu** (Timisoara, Romania)

17:00 Mechanisms of airway allergy

J. Schwarze (Edinburgh, United Kingdom)

17:30 Allergomics

H. Breiteneder (Vienna, Austria)

18:00 Allergen Immunotherapy

R. Zhu (Wuhan, China)

17:00 - 18:45 SYM29 - From clinic to classroom: Advancing allergy education across sectors Room Paris, 2- Paris, Symposium)

Chair: **C. Ozdemir** (İstanbul, Türkiye), **R. Gawlik** (Gliwice, Poland)

17:00 Allergy knowledge deficits in primary and school care: A European outlook

B. Buyuktiryaki (Istanbul, Türkiye)

17:30 Curriculum innovation for allergy management in primary health and education

G. Feketea (Patra, Greece)

18:00 Safer schools, better care: Measuring impact of allergy education

D. Ryan (Kegworth, United Kingdom)

07:45 - 08:30 MTE 9 - Global utilization of e-health apps: towards improved control
(Room Gothenburg, Meet The Expert)

07:45 Global utilization of e-health apps: towards improved control
J. Bousquet (Montpellier, France)

07:45 - 08:30 MTE 10 - Primary Immunodeficiencies: Laboratory tests for diagnosis and screening
(Room Munich, Meet The Expert)

07:45 Primary Immunodeficiencies: Laboratory tests for diagnosis and screening
G. Deniz (Istanbul, Türkiye)

07:45 - 08:30 MTE 11 - Oscillometry across the airway continuum: From nose to lung and beyond
(Room Athens, Meet The Expert)

07:45 Oscillometry across the airway continuum: From nose to lung and beyond
N. Gupta (Delhi, India)

07:45 - 08:30 MTE 12 - Skin and serum biomarkers in AD
(Room Glasgow, Meet The Expert)

07:45 Skin and serum biomarkers in AD
E. Knol (Utrecht, Netherlands)

08:30 - 10:00 IH 5 - Advanced immune profiling in health and inflammation
(Innovation Hub, Innovation Hub)

Chair: C. Akdis (Davos, Switzerland), H. Bayram (Istanbul, Türkiye)

08:30 High-dimensional profiling of the antibody repertoire in gastrointestinal inflammatory diseases
S. Boyd (Stanford, United States of America)

09:00 Immune microniches shape intestinal Treg
C. Coban (Bunkyo City, Japan)

09:30 Circulatory microinflammation and serum antibody repertoires in healthy individuals
I. Ogulur (Davos Dorf, Switzerland)

08:30 - 10:00 IWS8 - Management of indolent systemic mastocytosis: Identify, control, treat (Room Utrecht, 4- Utrecht, Interactive Workshop)

Chair: **M. Carter** (Bethesda, United States of America), **P. Pyatlova** (Berlin, Germany)

08:30 How to identify ISM in clinical practice: diagnostic challenges and evolving criteria
T. Gulen (Stockholm, Sweden)

09:00 Controlling symptoms in ISM: antihistamines, biologics, and individualized care
P. Bonadonna (Vicenza, Italy)

09:30 Treating the cause: KIT inhibition and disease-modifying approaches in ISM
C. Akin (Michigan, United States of America)

08:30 - 10:00 IWS9 - The unforgotten physiology of airways (Room Zurich, 5- Zurich, Interactive Workshop)

Chair: **P. Nair** (Hamilton, Ontario, Canada), **A. F. Kalpaklıoglu** (Ankara, Türkiye)

08:30 Bronchial hyperresponsiveness: a key feature of airways disease
S. Bavbek (Ankara, Türkiye)

09:00 IOS for measuring the response of therapy in the small airways
B. J. Lipworth (Dundee, United Kingdom)

09:30 The challenge of children: lung function testing in paediatrics
S. Foti Randazzese (Pavia, Italy)

08:30 - 10:00 JMA5 - Chronic spontaneous urticaria (CSU) and angioedema: Innovations in precision medicine (EAACI Global Stage, JMA)

Chair: **P. Kolkhir** (Berlin, Germany), **M. Metz** (Berlin, Germany)

08:30 Emerging biomarkers in CSU: Toward personalized patient management
R. Asero (Paderno Dugnano, Milano, Italy)

09:00 Difficult-to-treat CSU: Current clinical challenges and emerging therapeutic options
E. Kocatürk (Berlin, Germany)

09:30 Clinical phenotypes and advanced management of angioedema
M. Ferrer (Pamplona, Spain)

08:30 - 10:00 SYM20 - Biomarkers for food allergy diagnosis (Room Istanbul, 1- Istanbul, Symposium)

Chair: *M. Alvaro Lozano (Barcelona, Spain), C. Gomez-Casado (Düsseldorf, Germany)*

08:30 Promising biomarkers in FPIES: a multi-omic approach to non-IgE mediated food allergy
M. Pérez-Gordo (Madrid, Spain)

09:00 The microbiome as a predictive biomarker in IgE-mediated food allergy
C. Riggioni-Viquez (Toronto, Canada)

09:30 Fecal proteins as emerging tools in the diagnosis of food allergy: opportunities and challenges
C. Anania (Rome, Italy)

08:30 - 10:00 SYM21 - Biologics in ocular allergy (Room Paris, 2- Paris, Symposium)

Chair: *C. M. Rondon (Málaga, Spain), D. Silva (Porto, Portugal)*

08:30 Rationale for using biologics in severe ocular allergy
M. J. S. Vasconcelos (Porto, Portugal)

09:00 Which biologic for which ocular allergy?
S. Agarwal (Chennai, India)

09:30 How to manage dupilumab-induced ocular surface disease
B. Bozkurt (Konya, Türkiye)

08:30 - 10:00 SYM22 - Evolution and connectivity of allergen molecule sensitization (Room Florence, 3- Florence, Symposium)

Chair: *C. Hilger (Esch-sur-Alzette, Luxembourg), S. Dramburg (Berlin, Germany)*

08:30 The onset and plateau of sensitizations: A temporal perspective
A. Custovic (London, United Kingdom)

09:00 Defining the breadth of sensitization assessment across age groups
P. Matricardi (Berlin, Germany)

09:30 Interrelationships in sensitizations: Driven by allergen source, molecular structure, or comorbidity?
B. Sekerel (Ankara, Türkiye)

08:30 - 10:00 TSY5 - Neuroimmune interactions and innate immune cells in allergic disease (Room Krakow, 7- Krakow, Thematic Symposium)

Chair: *A. Eljaszewicz (Białystok, Poland), M. Pascal-Capdevila (Barcelona, Spain)*

08:30 Neuroimmune recognition of allergens and development of allergic disease
L. Deng (Boston, United States of America)

09:00 Innate lymphoid cells and allergy development
K. Moro (Osaka, Japan)

09:30 Basophils as effector cells of allergic reactions and anaphylaxis
A. Santos (London, United Kingdom)

08:45 - 09:45 SSS6 - EAACI GA2CI sister society symposium: Clinical Immunology in the Arabian Peninsula: Innovation, Evidence, and Diagnostic Insight
(Room London, 6- London, Sister Society Symposium)

Chair: **A. Alangari (Riyadh, Saudi Arabia)**

08:45 The impact of blocking IL4 / IL 13 pathway from clinical trials to real world evidence
R. Arnaout (Riyadh, Saudi Arabia)

09:05 Key challenges in the diagnosis and management of immunodeficiency in the Arabian Peninsula.

09:25 The rash that doesn't add up: when to think beyond allergy?
S. Elkhaila (United Arab Emirates)

08:45 - 10:15 L-FT15 - Immediate type hypersensitivity
(Room Athens, Flash Talks)

Chair: **J. A. Cornejo-Garcia (Málaga, Spain), T. Jimenez Rodriguez (Alicante, Spain)**

08:45 Hypersensitivity to Gadolinium-Based Contrast Media: Diagnostic and Re-Exposure Outcomes
002066 L. Manso Preto (Coimbra, Portugal)

08:52 Hypersensitivity Reactions to Anti-tuberculosis Drugs: Clinical Features, Risk factors, and Diagnostic Utility of The Graded Challenge Test
000921 P. Jansoontraporn (Bangkok, Thailand)

08:59 Preventable system-level gaps associated with diagnostic loss in perioperative hypersensitivity: evidence from national allergy and anaesthesiology surveys in Spain
000767 J. J. Laguna Martinez (Madrid, Spain)

09:06 NSAID Tolerance Can Be Restored in NECD With Adequate Disease Control, Even in the Absence of Complete Remission
001240 M. Hormet Igde (Istanbul, Türkiye)

09:13 Natural Evolution Of Hypersensitivity To NSAIDs In Children
001699 A. Prieto-Moreno Pfeifer (Madrid, Spain)

09:20 In the Absence of Penicillin Skin Test Kit, May Diagnostic Testing with Benzathine Penicillin G Be a Safe Alternative in Children with Suspected Penicillin Allergy in Acute Rheumatic Fever?
001510 C. Yildirimcakar (Denizli, Türkiye)

09:27 Selective Cephalosporin Allergy: A Retrospective Case Series
001406 L. Nogueras-Fuertes (Madrid, Spain)

09:34 Performance of the PEN-FAST Clinical Decision Rule in Patients with Suspected Aminopenicillin Hypersensitivity: A Real-World Cohort Study
002093 S. Flores Regalo (Coimbr, Portugal)

09:41 Beyond the Label: Persistent Misclassification and Enduring Quality-of-Life Gains After Penicillin Allergy Delabeling—Findings from the SPADE Cohort
001016 C.-H. Ho (Kowloon, Hong Kong)

09:48 Evaluation of the Association Between Reaction Severity and Cardiovascular Risk in Patients With Drug Hypersensitivity Reactions
000274 A. okumus guclu (İzmir, Türkiye)

09:55 Frequency Of Reported And Confirmed Drug Allergy In Patients Presenting To The Pediatric Emergency Department
000315 O. Yilmaz Topal (Ankara, Türkiye)

10:02 Do allergies breed antibiotic allergy labels? The dramatic rise of parent reported antibiotic allergies
001023 K. Rueter (Perth, Australia)

08:45 - 10:15 L-FT16 - Work and air pollution: out of the frying pan and into the fire (Room Glasgow, Flash Talks)

Chair: **D. Mijakoski** (Skopje, North Macedonia), **S. Gilles** (Augsburg, Germany)

08:45 Occupational Asthma – Reference Center Experience: The Intersection of Clinical Findings, Exposure, and Phenotype (2010–2025)

000382 O. Aydin (Ankara, Türkiye)

08:52 Improved diagnostics for occupational allergies to psyllium husks – a case series

000512 I. Sander (Bochum, Germany)

08:59 Occupational Exposure and Anaphylaxis to Hymenoptera Venom: A Real-World Study

001138 G. Martins (Lisboa, Portugal)

09:06 Beyond Exposure Limits: Allsens Captures Epithelial-Driven Immune Activation by Occupational Bioaerosols

000979 J. Samulin-Erdem (Oslo, Norway)

09:13 The complex role of air pollution on the association between greenness and the development of allergic rhinitis and asthma up to 27 years of age

001806 I. Paciência (Oulu, Finland)

09:20 Effect of PM_{2.5} Obtained from 2023 Turkey Earthquakes on Ferroptosis Signalling in Primary Human Bronchial Epithelial Cells and 3D Organoids with/without COPD

001703 Y. Vural (Istanbul, Türkiye)

09:27 Ozone Concentration as Strong Predictor of Symptom Load in Grass Allergic Patients in a Pivotal Phase III Study with PQ Grass

000774 M. Berger (Vienna, Austria)

09:34 Implementation of a New App to Provide Integrated Pollen Information in the Long-term Paediatric Study with PQ Grass

000782 M. Berger (Vienna, Austria)

09:41 Systemic inflammatory markers define the biological response to wildfire smoke exposure

100562 H. Babayev (Davos, Switzerland)

09:48 Altered morphological subsets of sputum neutrophils from patients with allergy with or without asthma during versus out of pollen season

100566 E. Tufvesson (Lund, Sweden)

08:45 - 10:15 L-FT07 - Allergy diagnosis

(Meeting room 3B01, Flash Talks)

Chair: J. L. Paris (Málaga, Spain), P. Rodríguez del Río (Madrid, Spain)

- | | |
|-------------------------------|---|
| 08:45
100022 | Evaluation of Reported Drug Allergy Labels in a Pediatric Outpatient Clinic: From Clinical Suspicion to Provocation
N. Nabyeva Çevik (Istanbul, Türkiye) |
| 08:52
100038 | Development of a murine basophil activation test for modeling and prediction of human allergic mechanisms
L. Aglas (Helsinki, Finland) |
| 08:59
100050 | From Awareness to Assessment: Gaps in Olfactory Evaluation in Spanish Allergy Services
R. González Pérez (La Laguna, Spain) |
| 09:06
100164 | Hypersensitivity reactions to proton pump inhibitors: clinical features and tolerance to alternative agents in real-world practice
L. Neyra-Puell (Madrid, Spain) |
| 09:13
100220 | Beyond provocation: pulse-controlled ergometry as a tool to personalise diagnosis and exercise guidance in cholinergic urticaria
J. Guimarães (Setúbal, Portugal) |
| 09:20
100391 | Characterizing Pancake Syndrome: A Case Series from a Tertiary Allergy Centre
M. Bernardo (Ponta Delgada, Portugal) |
| 09:27
100418 | Clinical evaluation of patients presenting with a preliminary diagnosis of adverse reactions to antihypertensive drugs
I. D. Toprak (Istanbul, Türkiye) |
| 09:34
100442 | Regional Differences in Molecular Component Sensitization in Brazilian Patients with Insect Venom Allergy
K. Souza Santos (São Paulo, Brazil) |
| 09:41
100684 | One molecule, three phenotypes: age-driven clinical divergence of Tri a 19 (ω-5 gliadin) in a real-life Istanbul cohort
F. Kırbiyık (Istanbul, Türkiye) |
| 09:48
100721 | Transport of allergenic tropomyosins through the intestinal epithelium
P. Stoll (Vienna, Austria) |

08:45 - 10:15 OAS18 - Food allergy treatments: not just oral immunotherapy

(Room Gothenburg, Oral Abstract Sessions)

Chair: **M. Papadopoulos (Athens, Greece), A. Anagnostou (Houston, United States of America)**

08:45 Phase 2, Open-Label Study to Assess Consumption of Peanut in Infants Aged 6-12 Months With Peanut Allergy Treated With Epicutaneous Peanut Immunotherapy

001954 K. Perrett (Melbourne, Australia)

08:57 Confirmatory peanut oral food challenges in very young children are cost-effective

001164 M. Lloyd (Melbourne, Australia)

09:09 Long-term effectiveness and safety of paediatric cow's milk oral immunotherapy in real life: outcomes with and without omalizumab support

000911 M. Niegowska (Barcelona, Spain)

09:21 Component-Specific IgE and IgG4 Changes During 2 year follow up of Low-Dose Cashew Oral Immunotherapy

000955 K. Takahashi (Sagamihara, Japan)

09:33 Peanut allergoids conjugated to mannan as novel vaccine candidates for allergen-specific immunotherapy: unraveling their immunological mode of action

000764 M. del Campo-Grijalba (Madrid, Spain)

09:45 Nut-specific and cross-reactive immune modulation following prophylactic sublingual immunotherapy with walnut and pecan

001544 A. J. Jensen (Kongens Lyngby, Denmark)

09:57 An immune atlas of remission following peanut OIT

001158 S. Ashley (Parkville, Australia)

08:45 - 10:15 OASS19 - Childhood asthma under the lens

(Room Munich, Oral Abstract Sessions)

Chair: **B. Beken (Istanbul, Türkiye), W. Feleszko (Warszawa, Poland)**

08:45 Breastfeeding duration, plasma linoleic acid-derived oxylipins and risk of childhood asthma

001373 L. Chen (Gentofte, Denmark)

08:57 Aberrant Airway Fucosylation Impairs Epithelial Barrier Integrity and Drives Asthma Pathogenesis

000290 W. Gu (Suzhou, China)

09:09 Asthma Trajectory Shapes How Early Life Th1/Th2 Airway Immune Responses Influence the Duration of Asthma-Like Episodes

001342 J. Kyvsgaard (Gentofte, Denmark)

09:21 Does Asthma in Childhood increase the risk of Obesity in Adolescence?

001467 M. Rodrigues (Porto, Portugal)

09:33 Impedance Pneumography for Diagnosing and Monitoring Asthma in Young Children: A Systematic Review

000713 F. Kullberg (Copenhagen, Denmark)

09:45 Effect of SQ SLIT-tablets on asthma symptoms and safety in children with allergic rhinitis and with or without concomitant asthma across multiple trials

000781 O. Pfaar (Marburg, Germany)

09:57 Prospective Evaluation of GINA 2024 versus ATS/ERS 2021 Bronchodilator Responsiveness Criteria in Children: Agreement, Discordance, and Clinical Determinants

001472 G. Koken (Ankara, Türkiye)

10:30 - 12:00 PL7 - Epithelial biology from early development to repair mechanisms (Room Istanbul, 1- Istanbul, Plenary Lectures)

Chair: **M. Akdis** (davos wolfgang, Switzerland), **M. Torres** (Malaga, Spain)

10:30 Novel mechanism of pediatric eczema development
C. Flohr (London, United Kingdom)

11:00 Molecular mechanisms of tissue injury linked to epithelial barrier damage
C. Akdis (Davos, Switzerland)

11:30 Precision immunology in inflammatory lung diseases
Ö. Yildirim (Germany)

10:30 - 12:00 PL8 - Skin pruritus as a treatable trait (Room Paris, 2- Paris, Plenary Lectures)

Chair: **S. Tsabouri** (Ioannina, Greece), **I. Terreehorst** (Rotterdam, Netherlands)

10:30 Alpha - Delta T cells as drivers of skin itch in atopic eczema
C. Sokol (Boston, United States of America)

11:00 The burden of skin itch in chronic spontaneous urticaria
M. Pereira (Berlin, Germany)

11:30 Effect of novel biologicals on skin itch
K. Kabashima (Kyoto, Japan)

10:30 - 12:00 PL9 - EAACI goes global: Global trends in allergic diseases (Room Florence, 3- Florence, Plenary Lectures)

Chair: **I. Annesi-Maesano** (Montpellier, France), **A. Vega Castro** (Guadalajara, Spain)

10:30 Pollen allergy in China: Trends and the Impact of Climate Change
K. Guan (Beijing, China)

10:48 Respiratory allergies in Latin America
G. Wandalsen (Sao Paulo, Brazil)

11:06 Management of IgE-mediated food allergy in Latin America: challenges and opportunities
S. Monsell (Ciudad autonoma de Buenos Aires, Argentina)

11:24 Food allergy in India: Unique epidemiology, practices and protective factors
S. Arudi Nagarajan (Bengaluru, India)

11:42 Drug allergy in Asia: from epidemiology to risk stratification
P. Li (Hong Kong, Hong Kong)

12:15 - 13:15 PEAACI Special Session 1 - The Allergic Rhinitis and its Impact on Asthma (ARIA) - EAACI 2024-2025 guidelines
(EAACI Global Stage, EAACI Special Session)

12:15 Innovations in the ARIA-EAACI 2024-2025 guidelines

J. Bousquet (Montpellier, France)

12:35 ARIA-EAACI recommendations on the use of intranasal and oral treatments

B. Sousa-Pinto (Porto, Portugal)

12:55 ARIA-EAACI recommendations on the use of as-needed strategies and co-medication

L. Klimek (Wiesbaden, Germany)

12:15 - 13:15 FT17 - Educational tools to improve management and quality of life in allergic disease
(Room Athens, Flash Talks)

Chair: B. Buyuktiryaki (Istanbul, Türkiye), E. Vassilopoulou (Thessaloniki, Greece)

12:15 Opportunities to optimise the management of allergic rhinitis using the Respiratory Allergy Optimiser: results of the AERO study

000450 N. Nabiyeve Çevik (Istanbul, Türkiye)

12:22 Do Smartphone Images Predict the Risk of Skin Barrier Dysfunction in Infants? A Nested Analysis of Baseline Data from a Cohort Study

000659 C. Yamaguchi (Nagoya, Japan)

12:29 The Impact of Social Media on Parental Decision-Making in the Management of Pediatric Allergic Diseases

002026 C. Genis (Ankara, Türkiye)

12:36 Implementation of a urticaria care package in the general practitioner setting increased quality of chronic spontaneous urticaria management

000625 R. Asero (Paderno Dugnano, Milano, Italy)

12:43 Assessment of quality of life in Chronic Urticaria patients (2-18 Years of age)

000105 M. Ahmed (Hyderabad, India)

12:50 Breaking Myths in Childhood Eczema: Outcomes of a Community-Based Educational Program in Low-Resource Urban Settings of Pakistan

002117 A. M. Mustafa (Multan, Pakistan)

12:57 Food Allergy-Related Bullying in Children: Prevalence and Psychosocial Burden from a Mixed-Methods Study

001360 L. Carucci (Napoli, Italy)

13:04 Food Label Reading Behavior and Allergenic Protein Knowledge Among Parents of Children With Milk and Egg Allergy

000924 G. Yörüşün (Ankara, Türkiye)

12:15 - 13:15 FT18 - Tailoring allergy treatment: SLIT, Steroids, and targeted therapies in children (Room Glasgow, Flash Talks)

Chair: J. Schwarze (Edinburgh, United Kingdom), E. Khaleva (Southampton, United Kingdom)

- 12:15** Safety of a 300IR daily SLIT-liquid in patients 5-17 years old with birch pollen allergic rhinoconjunctivitis: results of the YOBI trial
001022 M. Gerstlauer (Augsburg, Germany)
- 12:22** SQ House Dust Mite SLIT-tablet is well-tolerated in children with and without asthma: Pooled safety analysis
000795 G. Roberts (Southampton, United Kingdom)
- 12:29** Symptom control and reduced intranasal corticosteroid use in children with allergic rhinitis/rhinoconjunctivitis treated with SQ house dust mite SLIT-tablet: A responder analysis
000815 D. Caimmi (Montpellier, France)
- 12:36** Too Much of a Good Thing? Lessons from Excessive Inhaled Corticosteroids, Persistent Cough, and Growth Suppression
001930 T. Kopiec (Warszawa, Poland)
- 12:43** Real-world status of early-life dietary allergen intake prior to the initial pediatric allergy specialist visit in Japan
000686 K. Toyokuni (Tokyo, Japan)
- 12:50** Changes in the volume of the cerebral cortex in children with allergies. Preliminary data
001609 L. Namazova-Baranova (Shenzhen, China), G. Karkashadze (Moscow, Russia), N. Shilko (Moscow, Russia), A. Firumyants (Moscow, Russia)
- 12:57** Reduction in symptom and medication scores in the first week of the first pollen season in children and adults treated with SQ SLIT-tablets across phase III trials
100185 S. R. Durham (London, United Kingdom)

12:15 - 13:15 L-FT08 - Dermatology (Meeting room 3B01, Flash Talks)

Chair: S. Altrichter (Linz, Austria), M. Triggiani (Salerno, Italy)

- 12:15** Azole antifungals as rare triggers of acute generalized exanthematous pustulosis: a systematic review
100018 J. Mahdavi (Arak, Iran, Islamic Republic of)
- 12:22** Correlation between Autoimmune Bullous Disease and Interstitial Lung Diseases: A Preliminary Study
100068 Z. Chen (Shanghai, China)
- 12:29** Long-term prophylaxis with plasma derived C1 inhibitor concentrate in hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH)
100174 L. Neyra-Puell (Madrid, Spain)
- 12:36** Do Wheal Features Predict Omalizumab Response in Chronic Spontaneous Urticaria?
100211 Z. Wang (Xi'an, China)
- 12:43** ITACA Survey: characteristics of patients with Hereditary Angioedema due to C1-inhibitor deficiency receiving long-term prophylaxis with subcutaneous C1-inhibitor
100571 R. Senter (Padua, Italy)
- 12:50** "Multidimensional evaluation of inducible versus spontaneous chronic urticaria in pediatrics"
100611 G. Yáñez Lema (Barcelona, Spain)
- 12:57** Baseline Immune Profile and Response-Based Stratification in Chronic Spontaneous Urticaria: Implications for Therapeutic Transition
100644 U. Yılmaz Ergün (Konya, Türkiye)
- 13:04** Serum 25-Hydroxyvitamin D Levels in Patients with Atopic Dermatitis: Seasonal Variability and Association with Disease Severity
100659 B. Cil Yılmaz (Ankara, Türkiye)

12:15 - 13:15 L-OAS08 - Food allergy

(Room Gothenburg, Oral Abstract Sessions)

Chair: C. Anania (Rome, Italy), A. Muraro (Padova, Italy)

12:15 Is The First Oral Food Challenge A Key To Predicting Follow-Up Challenge In Cow's Milk Allergy?

100080 T. Y. akın (İzmit, Türkiye)

12:27 Risk Factors for the Development of Food Allergy in Early Life

100352 A. Anagnostou (Houston, United States of America)

12:39 Safety of Omalizumab in Children 1 to 5 Years of Age with Multiple Food Allergies

100620 E. H. Kim (Chapel Hill, United States of America)

12:51 PRACTALL in Practice: A Multi-Centre Comparison of Updated and Original Food Challenge Stopping Criteria

100736 U. Ahmed (Cambridge, United Kingdom)

12:15 - 13:15 L-OAS09 - Anaphylaxis

(Room Munich, Oral Abstract Sessions)

Chair: P. Smith (SOUTHPORT, Australia)

12:15 Closer to nature, closer to risk: Exposure matters in Hymenoptera venom allergy

100157 G. Martins (Lisbon, Portugal)

12:27 Paediatric perioperative hypersensitivity reactions in France: Analysis of the GERAP network database

100167 L. MUCHEMBLED (Strasbourg, France)

12:39 Safety and Efficacy of Fixed Very-low-dose Intake in Infants and Toddlers with Severe Egg, Milk, and Wheat Allergy

100266 K. Kitamura (Obu, Japan)

12:51 Uterine cramping as a manifestation of anaphylaxis: a case series from the BIOGRIAL cohort

100591 F. Skrabski (Madrid, Spain)

13:03 Does hereditary alpha-tryptasemia really influence the frequency and severity of anaphylaxis?

100637 L. Carrasco Gómez (Madrid, Spain)

12:15 - 13:15 PiS01 - AI in diagnosing and treatment of asthma

(Innovation Hub, Pitch Session)

Chair: P. Smith (SOUTHPORT, Australia)

12:15 R. J. Vieira (Porto, Portugal), Z. Celebi sozener (Ankara, Türkiye)

001521 M. Zhou (Xi'an, China)

12:22 Development and validation of an interpretable whole slide imaging-based machine learning model for postoperative recurrence risk stratification in chronic rhinosinusitis with nasal polyps

001274 Z. Guo (Guangzhou, China)

12:29 Evolution of AI Chatbot Response Quality for Allergy Queries: A One-Year Follow-Up Study

001491 A. Bogomolov (Vinnytsia, Ukraine)

12:36 Artificial intelligence in allergology: physicians' readiness and barriers

001412 A. Bogomolov (Vinnytsia, Ukraine)

12:43 Predicting True Penicillin Hypersensitivity in Children Using Machine Learning Models: A Retrospective Cohort Study

100733 A. Kuzu Kuşaklı (Ankara, Türkiye)

12:50 Real-world evaluation of an Artificial Intelligence (AI)-assisted skin prick test readout method in children

100495 S. Seys (Hasselt, Belgium)

12:15 - 13:15 TPS - Poster Sessions
(Poster Area, Poster Walk)

12:15 - 13:15 SSS7 - EAACI APAAACI Sister Society symposium: Allergies and Sustainability in a Changing World
(Room Paris, 2- Paris, Sister Society Symposium)

12:15 Artificial Intelligence in Allergy & Immunology: Advancing Sustainable, Precision Care
R. Pawankar (Tokyo, Japan)

12:35 Integrating sustainability and resilience into laboratory medicine
A. Abdul Latiff (Kuala Lumpur, Malaysia)

12:55 Drug Allergy and Its Impact on Sustainability

12:15 - 13:15 SSS8 - EAACI ASBAI Sister Society Symposium: Vision Zero in Practice: Advances in Severe Pediatric Asthma, Drug Hypersensitivity, and Primary Immunodeficiencies Insights in Brazil
(Room Florence, 3- Florence, Sister Society Symposium)

Chair: F. Fernandes (São Paulo, Brazil), D. Solé (Brazil)

12:15 Severe Pediatric Asthma: Advances in Precision Diagnosis and Tailored Therapy
G. Wandalsen (Sao Paulo, Brazil)

12:35 Cross-Intolerance to NSAIDs: What Is Safe, What Is Not, and How to Prescribe Wisely
M. Felix (Rio de Janeiro, Brazil)

12:55 The BRAGID Registry: Insights into Inborn Errors of Immunity in Brazil
E. Goudouris (Rio de Janeiro, Brazil)

12:15 - 13:15 SSS9 - EAACI Hong Kong Institute of Allergy Joint SSS: East Meets EAACI: Translating Lessons from the East to Global Practice
(Room Utrecht, 4- Utrecht, Sister Society Symposium)

Chair: P. Li (Hong Kong, Hong Kong), J. Wong (Hong Kong, Hong Kong)

12:15 Local Shores to Global Guidelines: Hong Kong's Insights into Seafood Allergy
A. S. Y. Leung (Hong Kong, China)

12:35 Unusual Bugs, Universal Insights: Opportunistic Lessons into Acquired Immunodeficiency Syndromes
V. Chiang (Hong Kong, Hong Kong)

12:55 A Global Perspective of HAE: Inclusivity through diversity
D. Fomina (Moscow, Russia)

12:15 - 13:15 Satellite Symposium
(Room London, Sponsored Sessions)

12:15 - 13:15 Satellite Symposium
(Room Krakow, Sponsored Sessions)

12:15 - 13:15 L-TPS18 - Allergy diagnosis 21
(Poster Zone, Thematic Poster Session)

Chair: K. Bønnelykke (Lillerød, Denmark)

- D3.93** Clinical Efficacy of Tezepelumab in a Patient with Severe Refractory Mixed Asthma: A Case Report from Kazakhstan
M. Baidildaeva (Almaty, Kazakhstan)
-
- D3.94** Good Practice Recommendations for Basophil Activation Test (BAT) Data Analysis in Routine and High-Background Settings
M. Gerspach (Schönenbuch, Switzerland)
-
- D3.95** Hidden in everyday cosmetics: Facial allergic contact dermatitis to fragrances
R. Sá Teixeira (Vila Nova de Gaia, Portugal)
-
- D3.96** High burden of latent aeroallergen sensitization in healthy urban medical students: a blinded skin prick test study from South India
H. Billa Lakshmi (Hyderabad, India)
-
- D3.97** Allergic contact dermatitis confirmed by repeated open application test in a 68-year-old patient
M. Nisavic (Novi Sad, Serbia)
-
- D3.98** An extended study for the multiple detection of IgE-mediated allergic reactions using microarray technology
N. Offermann (Neuss, Germany)
-
- D3.100** Assessment of the impact of psychotropic drugs, antihistamines, and corticosteroids on the interpretation of skin tests in allergology
C. Egeley (Grenoble, France)
-
- D3.101** Etoricoxib Associated Fixed Drug Eruption: A Case Series from a Tertiary Allergy and Clinical Immunology Centre, United Arab Emirates
S. Elkhaila (Abu Dhabi, United Arab Emirates)
-
- D3.103** Comprehensive Allergen Characterization for Standardized Basophil Activation Testing
F. Richina (Schönenbuch, Switzerland)
-
- D3.104** Molecular Co-Sensitization Mapping Using a 192-Line Multiplex IgE Platform
H. J. LEE (Seoul, Korea, Republic of)
-
- D3.105** Analysis of post-vaccination immunity in children with dermatology diseases receiving biologic and immunosuppressive therapy
A. Kontorovich (Moscow, Russia)
-
- D3.106** Real-life outcomes of rapid drug desensitization to taxanes
C. Arrieta-Pey (Donostia / San Sebastián, Spain)
-

12:15 - 13:15 L-TPS19 - Asthma 15

(Poster Zone, Thematic Poster Session)

Chair: A. Spanevello (Milano, Italy), C. Schmidt-Weber (Munich, Germany)

D3.166 Attention-deficit/hyperactivity disorder (ADHD) in asthmatic children

M. Tavakol (Karaj, Iran, Islamic Republic of)

D3.168 Clinical Department of Allergy Center in Linköping

A. Graca (Linköping, Sweden)

D3.169 Paediatric Severe Acute Respiratory Infections in Malta: A Three-Year Review

G. Xuereb (Msida, Malta)

D3.171 Validation of the Kazakh Version of the Asthma Quality of Life Questionnaire (AQLQ) for Clinical Use in Adult Patients with Asthma

R. Bekmagambetova (Almaty, Kazakhstan)

D3.173 Switching from Dupilumab to Tezepelumab in a Child with Severe Asthma and Atopic Dermatitis: Clinical Considerations and Therapeutic Implications

M. Maia (Milano, Italy)

D3.174 Short-term tolerance of omlyclo, the omalizumab biosimilar

J. Arrieta Rodríguez (Sabadell, Spain)

D3.175 Algorithm for Biologics Selection in Severe Asthma

K. Pavlova (Moscow, Russia)

D3.178 Assessment of blood rheological properties in children with bronchial asthma

E. Aseeva (Moscow, Russia)

D3.179 Longitudinal breath profiling of exhaled volatile organic compounds differentiates viral-induced asthma exacerbation from clinical control

E. Hernández Lerma (Ciudad de México, Mexico)

12:15 - 13:15 L-TPS20 - Allergen immunotherapy 09 (Poster Zone, Thematic Poster Session)

Chair: A. Bozek (Katowice, Poland)

- D3.215** Shifting patterns of mite sensitization in Southern Europe: Real-World diagnostic and immunotherapy practices in Spain and Portugal (MITE-WISE Project)
J. Figueroa (Las Palmas de Gran Canaria, Spain)
- D3.216** Determination of Allergenic Activity of Native Mugwort Allergen Preparations by a Competitive IgE-Binding Test
P. Fiebig (Reinbek, Germany)
- D3.217** Development and validation of a monoclonal antibody-based competitive ELISA to accurate quantification of Blo t 2 in native Blomia tropicalis allergenic extracts
M. Viñuela (Alcalá de Henares, Spain)
- D3.218** When the sting is not the sensitizer: a vespid venom allergy case
D. Korshunova (Madrid, Spain)
- D3.220** Real-World Management of Pediatric Allergic Diseases: A Nationwide Physician Survey among Allergists and Pediatric Allergists in Turkey
N. N. Bahçeciler (Nicosia, Cyprus)
- D3.221** Cat Immunotherapy and Real-Life Data: A Single-Center Experience
Z. MEHTI (Ankara, Türkiye)
- D3.222** Monitoring the immune response during the first year of SCIT in Ragweed allergy
C. Uța (Timișoara, Romania)
- D3.223** Crossroads of Venom and Bite: A case of Horsefly - Wasp Cross - reactive Anaphylaxis
N. Petridou (Athina, Greece)
- D3.225** Two years Sublingual SQ-Grass Pollen Tablet Immunotherapy Combined with Dupilumab Induces Longterm Suppression of Immediate Cutaneous Allergen Sensitivity
A. Fedina (London, United Kingdom)
- D3.226** Prophylactic sublingual peanut immunotherapy alters antibody responses and downstream allergen reactivity in a Brown Norway rat model
M. Jalili (Kongens Lyngby, Denmark)
- D3.227** The effect of subcutaneous allergen immunotherapy after one year on the quality of life of children with perennial allergic rhinitis and rhinoconjunctivitis
T. Umanets (Kyiv, Ukraine)
- D3.228** One-Year Changes in Molecular sIgE Profiles During House Dust Mite Immunotherapy: A Pilot Study
L. Pilkytė (Kaunas, Lithuania)
- D3.229** Comparison of mold sensitization profiles in children (2021 and 2025): impact of environmental deterioration during martial law
E. Moskovenko (Kyiv, Ukraine)

12:15 - 13:15 L-TPS21 - Dermatology 08

(Poster Zone, Thematic Poster Session)

Chair: **M. Türk (Kayseri, Türkiye)**

D3.256 A Child with Mastocytosis presenting with generalized severe Pruritus: A Diagnostic Pitfall

U. Lippert (Göttingen, Germany)

D3.258 Not just a rash: a delayed diagnosis of allopurinol-induced dress syndrome

J. Coelho (Faro, Portugal)

D3.260 Shiitake-Induced Flagellate Dermatitis: Case Series from Kazakhstan

G. Tussupbekova (Astana, Kazakhstan)

D3.261 Orphan Diseases In Allergology - Melkersson-Rosenthal Syndrome

C. Toma (Chişinău, Moldova)

D3.264 Delayed Type Hypersensitivity Injection Site Reaction Induced By Liraglutide

C. Toma (Chişinău, Moldova)

D3.265 Gleish syndrome: A case report

H. Messaoudi (Algiers, Algeria)

D3.266 Component-Resolved Delayed Hypersensitivity to Piperacillin/Tazobactam and Clavulanic Acid Despite Structural Divergence

S. Arenas-Colmenares (Madrid, Spain)

D3.267 Statistics of Contributing Factors to Atopic Dermatitis in Children

R. Sepiashvili (Tskhaltubo, Georgia)

12:15 - 13:15 L-TPS22 - Food allergy 08

(Poster Zone, Thematic Poster Session)

Chair: K. Bluemchen (Frankfurt am Main, Germany), J. Upton (Toronto, Canada)

- D3.295** Comparing Real-World and AI-Enabled Market Research in Caregivers of Individuals with Peanut Allergy
S. Tardif (Hørsholm, Denmark)

- D3.296** Alpha-gal Syndrome with Concomitant Milk Sensitization in a Patient with Asthma and Allergic Rhinitis: A Case Report
M. Keren (İstanbul, Türkiye)

- D3.297** De-labelling peanut allergy in a 19-year-old woman with detectable Ara h 2 sensitization: a real-life, exercise-augmented oral food challenge
C. Siouta (Linköping, Sweden)

- D3.298** The Good, the Bad and the Ugly: Mugwort, Mango, and Pineapple
E. Lozes (Périgueux, France)

- D3.299** Don't miss the cannabis-associated food syndrome (CAFS)
S. Chantraine (Basel, Switzerland)

- D3.300** Wheat tolerance induction protocol
E. Armas Sosa (Santa Cruz de Tenerife, Spain)

- D3.301** Аллергия на белки коровьего молока у детей: сосредоточено на короткоцепочечных жирных кислотах
D. Bakirova (Tashkent, Uzbekistan)

- D3.302** Sesame as an under-recognized allergen: storage protein sensitization underlying food-induced anaphylaxis in a young adult
J. L. Alba-Rull (Córdoba, Spain)

- D3.303** Buckwheat Allergy in Bologna Metropolitan Area: Often Severe, Often Hidden
V. M. Scorcu (Bologna, Italy)

- D3.305** Isolated IgE-Mediated Anaphylaxis to Pine Nut in an adult
A. Alberto (Porto, Portugal)

- D3.304** Real-Life Evaluation of the Egg Ladder in a Tertiary Pediatric Allergy Center in Turkey
N. Umit (Antalya, Türkiye)

12:15 - 13:15 L-TPS23 - Anaphylaxis 07
(Poster Zone, Thematic Poster Session)

Chair: H. O. Skjerven (Oslo, Norway)

- D3.339** Severe β -lactam hypersensitivity phenotypes in routine care: anaphylaxis frequency in a 22-centre outpatient survey in China
L. Wang (shanghai, China)
- D3.340** The importance of de-labeling contrast allergy in cardiology department - clinical case
V. Brocovschii (Chişinău, Moldova)
- D3.341** Alignment with International Anaphylaxis Management Guidelines in a Tertiary Referral Center in Central Asia: A Retrospective Clinical Audit
A. Kulmanbetova (Almaty, Kazakhstan)
- D3.342** Adverse Events of Biologic Therapies: A One-Year Retrospective Study
N. Fathallah (Sousse, Tunisia)
- D3.343** Hereditary alpha-tryptasemia: clinical variability and anaphylaxis triggers in six genetically confirmed cases
A. Mugno (Burgos, Spain)
- D3.344** Rapid Desensitization to Iohexol Following Iopamidol-Induced Anaphylaxis Prior to Urgent Coronary Angiography
I. Boz (Antalya, Türkiye)
- D3.345** Anaphylactic Shock: Clinical Analysis of 8 Cases with Post-Hospital Outpatient Follow-Up
Z. Ispayeva (Almaty, Kazakhstan)
- D3.346** From Anaphylaxis to Oral Allergy Syndrome: Multiple Seed Hypersensitivity in a Single Pediatric Patient
B. Özkan Kırın (Ankara, Türkiye)
- D3.347** Idiopathic Anaphylaxis: A Diagnostic Challenge
I. Mrkić Kobal (Zagreb, Croatia)
- D3.348** Alpha-gal Syndrome in Young People: A Call for Public Health Awareness in Tick-Endemic Areas of Scotland and North East England
C. Zervas (Newcastle upon Tyne, United Kingdom)
- D3.349** Takotsubo cardiomyopathy triggered by anaphylaxis after a honey bee sting, forming ATAK complex: a rare case report
K. Festa (Athens, Greece)
- D3.352** Long-term analytical stability of ImmunoCAP tryptase supports enduring clinical interpretation thresholds
C. Mavrier (Les Ulis, France)
- D3.353** Clinical Characteristics and Triggers of Pediatric Anaphylaxis Cases: A Retrospective Single-Center Experience
D. Azkur (Kırıkkale, Türkiye)

12:15 - 13:15 L-TPS24 - Basic immunology 06

(Poster Zone, Thematic Poster Session)

Chair: **Ö. Alaz** (Zurich, Switzerland), **M. Muñoz-Ruiz** (Madrid, Spain)

- D3.398** Primary Care Physicians' Perspectives on Primary Immunodeficiency Diseases
Ö. Özdemir (Sakarya, Türkiye)

- D3.399** An SYK Variant with Variable Spectrum of Immunodeficiency and Immune Dysregulation: Case Series
M. Jefri (Riyadh, Saudi Arabia)

- D3.401** A mechanism for loss of biodiversity in the gut: Toxic effects and metabolic alterations of food additives on human fecal microbiome
B. Zhao (Davos, Switzerland)

- D3.402** Evaluation of Apigenin's Anti-Inflammatory and Wound Healing Effects Using Atopic Dermatitis Cell Culture Model
E. Birben (Ankara, Türkiye)

- D3.403** Protein Profiling of CAR-Engineered NK92-Derived Exosomes Using Western Blot
L. Zbircea (Timișoara, Romania)

- D3.404** From CVID to CTLA-4 Haploinsufficiency: The Impact of Genetic Diagnosis on Targeted Therapy
A. C. Coelho (Vila Nova de Gaia, Portugal)

- D3.405** X-Linked Agammaglobulinemia in Adulthood: 40 Years of Follow-Up
M. Imad (São Paulo, Brazil)

- D3.406** Novel bone materials selectively modulate the human immune response to favor remodeling over acute inflammation
H. Babayev (Davos, Switzerland)

- D3.407** Angioedema: cause or consequence?
L. Gonçalves (Lisboa, Portugal)

- D3.408** When Angioedema Is Not Angioedema: EBV-Associated Lymphocytic Inflammation Mimicking Hereditary Angioedema
C. Puente (Jesús María, Peru)

- D3.409** Immunological Mechanisms in Treatment-Resistant Depression
J. Zych (Częstochowa, Poland)

- D3.413** Basophil Activation Test Positivity and Response to Ciclosporin in Chronic Spontaneous Urticaria: A Real-World Exploratory Study
S. Flores Regalo (Coimbra, Portugal)

- D3.414** Clinical and Laboratory Predictors of Basophil Activation Test Positivity in Chronic Spontaneous Urticaria: A Real-World Exploratory Study
S. Flores Regalo (Coimbra, Portugal)

- D3.415** Galectin-10 Expression in Plasma-Derived Extracellular Vesicles of Patients with Eosinophilic Esophagitis: a Pilot Study
F. Mone (Baronissi, Italy)

- D3.416** PEG-CUR Reduces Oxidative Stress and Total Methylation Induced by Cigarette Smoke in Epithelial Cells: Development of PEG-Curcumin Loaded Fast-Dissolving Microneedle Patches
B. Kilic (Ankara, Türkiye)

12:15 - 13:15 L-TPS25 - Allied health and primary care 02

(Poster Zone, Thematic Poster Session)

Chair: I.-J. Wang (aipei Hospital Ministry of Health and Welfare, Taiwan)

- D3.488** Early Risk Assessment and Recognition of Allergies in Children: rationale, methodology, and proposed algorithms
E. Hamelmann (Bielefeld, Germany)
- D3.489** Anaphylaxis Diagnosis and Treatment from the Perspective of Primary Care Physicians
U. Dikici (Ankara, Türkiye)
- D3.490** AllergyIQ: An Interactive Virtual Educational Platform in Allergy and Immunology
F. AlYaqout (Kuwait, Kuwait)
- D3.491** Satisfaction with Sebetralstat as On-Demand Treatment of Hereditary Angioedema Attacks in KONFIDENT-S
A. Zanichelli (Milan, Italy)
- D3.492** Validation of the Portuguese version of the Food Allergy Quality of Life Questionnaire Adult Form (P-FAQLQ-AF)
P. Alves (Coimbra, Portugal)

12:15 - 13:15 TPS59 - Allergy diagnosis 11

(Poster Zone, Thematic Poster Session)

Chair: G. Karakaya (Ankara, Türkiye), J.-F. Lopez (Davos, Switzerland)

- D3.01** Association between allergen-related antibodies and clinical phenotypes of IgG4-related disease (IgG4-RD)
L. Lyu (Beijing, China)
- D3.02** A Well-Established Drug and A Rare Reaction: Successful Desensitization to Adalimumab
G. Fitoz Emeksiz (Ankara, Türkiye)
- D3.03** Titanium allergy – from anamnesis to diagnosis
N. Aliakhnovich (Vitebsk, Belarus)
- D3.04** Sensitization Pattern and Characteristics of IgE Repertoire in Allergic Children with Excessively High Serum IgE Levels
C.-M. Kang (Taipei, Taiwan)
- D3.06** Comparative Evaluation of Raw, Blanched, Individual and Composite Allergen Preparation for Basophil Activation Testing
M. Boussand (Marseille, France)
- D3.07** Low inter-lot variability and high long-term stability of ready-to-use and room temperature-stable dry reagents for Basophil Activation Testing against peanut extracts
M.-E. Castaing-Lasvignottes (Marseille, France)
- D3.08** Biomarker Profiles and Autoimmune Features in Patients with Chronic Urticaria: A Clinical–Laboratory Analysis
S. Dzhikova (Pleven, Bulgaria)
- D3.09** Cyto-LTT as a Diagnostic Tool in Acute Drug-Induced Interstitial Nephritis: A Case Report and Laboratory Case Series
O. Hausmann (Bern & Lucerne, Switzerland)
- D3.10** An exploratory assessment of biological inflammatory markers found in nasal epithelial cells from rhinitic patients as prospective predictors of rhinitis exacerbation status
E. F. Mateus Medina (Barcelona, Spain)
- D3.11** Identification of allergens in Chicken and Rabbit meat, a case report
M. L. Quiñones Obando (Madrid, Spain)
- D3.13** Molecular characterization of food allergens in a case of suspected honey and mustard allergy
M. L. Quiñones Obando (Cuenca, Spain)
- D3.14** IgE sensitisation to parvalbumin, Ani s 1, tropomyosin and arginine kinase delineates distinct molecular endotypes of seafood allergy
C. Casale (Modena, Italy)

12:15 - 13:15 TPS60 - Allergy diagnosis 12

(Poster Zone, Thematic Poster Session)

Chair: V. Esteban (Madrid, Spain), M. Muñoz (Berlin, Germany)

- D3.16** Increase of Post-SARS-CoV-2 Rashes Mimicking Penicillin Allergy in Children with Group A beta-hemolytic Streptococcus Infection: an emerging and challenging issue
F. Catamerò (Florence, Italy)

- D3.17** Outcomes of Anti-Tuberculosis Drug Reintroduction Following Adverse Drug Reactions among Adult Patients at a Tertiary Hospital in the Philippines (2022-2024)
V. L. Fider (Quezon City, Philippines)

- D3.18** Role of an Allergological Work-up in Antibiotic Allergy Delabeling in Mexican Pediatric Patients
L. M. Espinosa Méndez (Ciudad de México, Mexico)

- D3.20** Study of "in vitro" cross reactivity between nsLTP's comparing "in silico" results with a new specific IgE test based on immunoblot methodology
R. Lopez-Salgueiro (València, Spain)

- D3.21** When the Patient Diagnoses Herself: Amoxicillin-Induced Acute Pancreatitis as a Rare Manifestation of Drug Hypersensitivity
A. Abdurakhmanov (Manisa, Türkiye)

- D3.25** Machine learning models to differentiate cross-reactive and selective-hypersensitive patients to nonsteroidal anti-inflammatory drugs hypersensitivity
J. Triano-Cornejo (Málaga, Spain)

- D3.27** Nivolumab-Induced Psoriasiform Eruption: Diagnostic Challenge Between Immune-Related Toxicity and Drug Allergy
P. Letón-Cabanillas (Valladolid, Spain)

- D3.30** Automated generation of structured clinical databases in drug hypersensitivity: real-world validation in patients with proton pump inhibitor reactions
L. Carrasco Gómez (Madrid, Spain)

- D3.31** Real-world Practices in the Diagnosis and Evaluation of Allergic Rhinitis among Korean Specialists
S. C. Park (Seoul, Korea, Republic of)

12:15 - 13:15 TPS61 - Allergy diagnosis 13
(Poster Zone, Thematic Poster Session)

Chair: *T. Alfaya Arias (Madrid, Spain), J. Jagers (Cleveland, United States of America)*

- D3.35** The influence of birth month on allergen sensitization patterns: A comprehensive analysis of skin prick test results in a large patient cohort
M. Božan Aksentijević (Zagreb, Croatia)
- D3.36** Chronic type non-IgE-mediated gastrointestinal food allergies, Clinical features and unclassified subgroup in the recent cohort
T. Yaguchi (Setagaya City, Japan)
- D3.37** Optimal Single and Combinatorial Diagnostic Approaches for Wheat Allergy in Chinese Children
W. Zheng (Shatin, Hong Kong)
- D3.38** Elucidating the Causes of Discordant Results Between Two Specific IgE Assays Using Component-Resolved Diagnostics and Depletion Testing
M. Nagao (Tsu, Japan)
- D3.39** Allergic contact dermatitis to oxidized fragrance components: a case of sensitization to hydroperoxides of limonene
C.-T. Radu (București, Romania)
- D3.40** Evaluation of wheat allergy diagnostic methods in children and potential cross-reactivity to other cereal grains
H. W. C. Leung (Shatin, Hong Kong)
- D3.41** Population-based IgE profiling of adolescents using a multiplex allergen array
J. Rehr (Salzburg, Austria)
- D3.43** Classification of seasonal allergic rhinitis patients by prospective patient-recorded symptoms: the @IT.2020 project
S. Dramburg (Berlin, Germany)
- D3.45** Oral Food Challenge in children diagnosed with fish allergy. Our clinical experience
C. Moreno (Manresa, Spain)
- D3.46** Safety of the EAACI risk assessment in hypersensitivity reactions to chemotherapy
C. Mayorga (Málaga, Spain)
- D3.47** Changes in Poaceae and Betulaceae pollen seasons correlate with patient sensitization profiles: a single-centre study over 4 decades
F. Hannachi (Luxembourg, Luxembourg)

12:15 - 13:15 TPS62 - Allergy diagnosis 14
(Poster Zone, Thematic Poster Session)

Chair: B. Eberlein (Munich, Germany), A. Eggel (Bern, Switzerland)

- D3.49** Associations between the prevalence of sensitization of pets and symptoms of allergic rhinitis (AR) in children
M. Sung (GUMI, Korea, Republic of)

- D3.50** Molecular Characterization of Allergen Sensitization and Clinical Associations in a Romanian Cohort Using ALEX² Multiplex Assay
A. Chera (Bucharest, Romania)

- D3.51** Cardiovascular System Problems in Children Athletes with Allergic Diseases
L. Tchelidze (Tbilisi, Georgia)

- D3.52** Clinical spectrum and diagnostic challenges of paediatric angioedema without wheals
K. Umezawa (Setagaya City, Japan)

- D3.53** Prevalence of allergic sensitization to edible insects in exposed breeders from Thailand
A. Jacquet (Bangkok, Thailand)

- D3.55** Hereditary angioedema with normal C1-INH: DAB2IP mutation report
M. Lebedkina (Moscow, Russia)

- D3.56** Investigation of Serum Eosinophilic Granule Proteins Levels in Children with Chronic Spontaneous Urticaria
S. Y. Yilmaz (Konya, Türkiye)

- D3.57** Respiratory Manifestations Of Ascariasis Mimicking Allergic Disease: A Clinical Case
E. Vishneva (Moscow, Russia)

- D3.58** Eosinophilic ascites and extreme hypereosinophilia: differential diagnosis through medical treatment
P. Y. Uchupaille Torres (Guadalajara, Spain)

- D3.59** Occupational Cobalt Contact Dermatitis: Clinical Profile and Work implications
E. Baraketi (Tunis, Tunisia)

- D3.60** Allergic reaction in bisoprolol overdose
F. Dogjani (Tirana, Albania)

- D3.61** Acquired Food Allergy After Allogeneic Hematopoietic Stem Cell Transplantation From a Non-Allergic Unrelated Donor
S. Sartorio (Milan, Italy)

- D3.62** Application of a logistic regression model to predict the risk of allergic reactions in children with salmon sensitization (Sal s 1)
Y. Marushko (Kyiv, Ukraine)

12:15 - 13:15 TPS63 - Allergy diagnosis 15
(Poster Zone, Thematic Poster Session)

Chair: A. Dašić (Beograd, Serbia), S. Riemann (Ghent, Belgium)

- D3.63** **Molecular Evidence of PR-10 in Cannabis Allergy**
T. Galán Díez (Alcalá de Henares, Spain)

- D3.64** **Alcohol-Soluble Wheat Proteins as the Likely Allergenic Trigger in a Patient With Reaction to Gin**
F. Pineda de la Losa (Alcalá de Henares, Spain)

- D3.66** **When dermatitis follows the menstrual cycle: two cases of endogenous progestogen hypersensitivity**
M. Terzić (Belgrade, Serbia)

- D3.67** **Retrospective Evaluation of IgE Panel Utility in Allergy Diagnostics: Insights from Baghdad, Iraq**
D. Aljebouri (Baghdad, Iraq)

- D3.70** **Structural and immunological insights into arginine kinases from house dust mites and related arthropods**
N. Kulminkaya (Graz, Austria)

- D3.71** **A research tool for development of in-house specific IgE immunoassays - comparison between different methods**
Å. Marknell DeWitt (Uppsala, Sweden)

- D3.72** **Effect of Helicobacter pylori Eradication on Disease Activity in Chronic Urticaria: Follow-Up Results**
L. Bugadze (T'bilisi, Georgia)

- D3.73** **Clinical Performance of Hycor NOVEOS–Based Specific IgE Measurements for the Screening of Respiratory Allergies**
P. A. Apoil (Toulouse, France)

- D3.74** **Age-related characteristics of children's sensitisation to timothy grass according to component diagnostics**
M. Vafokulova (Tashkent, Uzbekistan)

- D3.75** **Molecular sensitization profiles and clinical patterns in Albanian children with respiratory allergies**
J. Asllani (Tirana, Albania)

- D3.76** **Open-Label Clinical Trial To Evaluate The Effect Of Intranasal Olopatadine/Mometasone And Azelastine/ Mometasone On Histamine Reactivity In Skin Prick Tests**
E. M. Navarrete Rodriguez (Ciudad de México, Mexico)

- D3.77** **Tattoo Ink Allergy? Diagnostic Challenges in Cutaneous Reactions to Tattoo Ink Containing Metals**
R. Curatolo (Basel, Switzerland)

12:15 - 13:15 TPS64 - Allergy diagnosis 16

(Poster Zone, Thematic Poster Session)

Chair: **L. Palacio-Garcia** (Madrid, Spain), **Z. Ü. Altinel** (İstanbul, Türkiye)

- D3.78** Association between lipocalin sensitization and clinical symptoms: Evidence for cross-reactivity
T. Šmrhová (Plzeň, Czech Republic)

- D3.79** Patterns of House Dust Mite Hypersensitivity in Eastern Ukraine
K. Gashynova (Dnipro, Ukraine)

- D3.80** Molecular allergy profiling of sensitization in adult patients with asthma in real practice
A. Emelyanov (Sankt-Peterburg, Russia)

- D3.81** Allergic Contact Dermatitis Induced by Transdermal Estradiol Hormone Replacement Therapy in a Postmenopausal Patient: A Case Report
M.-I. Stîngă (București, Romania)

- D3.82** Conceptualization of a questionnaire for clinical diagnosis of house dust mite's allergy
A. Tiotiu (Brussels, Belgium)

- D3.83** A Case Report of Fenofibrate-Induced Fixed Drug Eruption Documented by Patch Testing and Oral Provocation
O. Bratu (București, Romania)

- D3.84** Patterns of Sensitization to Artemisia and Ambrosia Pollen in Ukraine
V. Rodinkova (Vinnytsia, Ukraine)

- D3.85** Estrogen-Induced Drug Hypersensitivity Syndrome in a Patient with HHV-6 Reactivation
L. DuBuske (Gardner, United States of America)

- D3.86** ALEX versus ISAC. The same story or an improvement for allergologic molecular diagnostic?
S. Palomo Álvarez (Pamplona, Spain)

- D3.87** Evaluation of CD63 as a Marker of Basophil Degranulation in the Assessment of IgE-mediated Allergic Immune Responses
D. Milcheva (Sofia, Bulgaria)

- D3.88** Did the skin patch test sensitivity profiles change in young and middle-aged adult patients? Current data from a tertiary allergy clinic cohort
B. Gorgulu Akin (Ankara, Türkiye)

- D3.89** Decoding a Triple Pediatric Food Allergy Phenotype Using Component-Resolved Diagnostics: Severe CMPA, Alpha-Gal, and PR-10-Mediated PFAS
S. Samoud (Tunis, Tunisia)

- D3.90** Outcomes of Beta-Lactam Allergy Evaluation in Patients with Suspected Hypersensitivity: One-Year Experience
A. Cros Alsina (Terrassa, Spain)

- D3.91** Molecular Profiling of Shrimp Allergy in Tunisia: The Role of Tropomyosin and Component-Resolved Diagnosis
S. Samoud (Tunis, Tunisia)

- D3.92** Precision Allergy Diagnostics in Tunisia: Integrating Molecular Allergology into the Management of Respiratory and Food Allergies
S. Samoud (Tunis, Tunisia)

12:15 - 13:15 TPS65 - Asthma 09

(Poster Zone, Thematic Poster Session)

Chair: **B. Beken (Istanbul, Türkiye)**

- D3.108** Heterogeneity of Remission Definitions in Asthma and Other Chronic Diseases: Evidence From Two Systematic Reviews
M. Lee Qiyu (Southampton, United Kingdom)
- D3.109** Clinical Characteristics of Asthma Patients with Fungal Sensitization: A Retrospective Cross-Sectional Study
E. Sahinoglu (Ankara, Türkiye)
- D3.110** Patterns of Opioid or Neuromodulator Use in Chronic Cough Patients with Newly Diagnosed Asthma
E.-J. Jo (Busan, Korea, Republic of)
- D3.111** The Impact of War on the Course of Asthma
A. Kovchun (Sumy, Ukraine)
- D3.112** Clinical Characteristics and Evaluation of Serum Inflammatory Markers in Patients Hospitalized Due to Asthma Exacerbations
G. I. Parlak Ozel (Ankara, Türkiye)
- D3.113** The Diagnostic Value of Exercise Bronchial Provocation Testing in Pediatric Asthma
F. Güvenir (ankara, Türkiye)
- D3.114** Characterization on genome-wide profile of H3K4me2 histone methylation in mouse asthmatic lung induced by Alt a 1
H. Berreiros-Hortala (Madrid, Spain)
- D3.115** Iloprost Attenuates Neutrophilic Airway Inflammation in a Murine Model of Type 2-Low Asthma
Y.-C. Wu (Kaohsiung, Taiwan)
- D3.119** Saving the Caregiver: Humanitarian Access to Dupilumab in a Physician with Severe Non-Allergic T2 Asthma in a Frontline Ukrainian City
A. Kovchun (Sumy, Ukraine)
- D3.120** Delivering Severe Asthma Care in the Real World: Insights into Anti-TSLP (Tezepelumab) Use from a Tertiary Allergy and Respiratory Centre
L. Pur Ozyigit (Leicester, United Kingdom)
- D3.121** Evaluation of small airway dysfunction in severe asthma treated with anti-IgE and anti-eosinophilic therapies: A prospective comparative study
C. Tuzer (istanbul, Türkiye)
- D3.122** Real-World Outcomes Of Tezepelumab In Severe Asthma After 12 Months Of Treatment
M. Polo López (Segovia, Spain)
- D3.123** The complementary role of impulse oscillometry in prediction of asthma persistence at school age among preschool children with recurrent wheezing
M. Aydın Mut (Mersin, Türkiye)
- D3.124** Effect of psycho-behavioural comorbidities on asthma symptom control scores: implications on asthma remission assessment
T. R. Tay (Singapore, Singapore)

12:15 - 13:15 TPS66 - Asthma 10

(Poster Zone, Thematic Poster Session)

Chair: **M. Mukherjee** (Hamilton, Canada)

- D3.126** Evaluation of Severe Pediatric Asthma Response to Biologics Using the Pediatric CONFIRM Score: A Real-Life Cohort Analysis
S. Foti Randazzese (Pavia, Italy)
- D3.127** Evaluation of Serum Ezrin Levels and Spirometric and Plethysmographic Tests in Patients with Allergic and Non-Allergic Asthma
B. Erdoğan (Kayseri, Türkiye)
- D3.128** Management of Nasal Polyposis in Moderate-Severe Asthma Patients With Aspirin Desensitization And Biologic Agent Combination: Our Real-Life Experience With Seven Cases
E. ASLAN (İzmir, Türkiye)
- D3.129** Evaluation of Cardiovascular Disease Risk and Associated Factors in Childhood Asthma
R. YILDIRIM (İzmir, Türkiye)
- D3.130** PGI2 Signaling Attenuates the Proliferation and Type 2 Cytokine Production of Group 2 Innate Lymphoid Cells
H.-H. Su (Kaohsiung, Taiwan)
- D3.131** Comparative Assessment of Exercise Provocation, and Impulse Oscillometry in Young Adults With Exercise-Induced Respiratory Symptoms
H. Jin (Daegu, Korea, Republic of)
- D3.132** The impact of biological therapy on the quality of life of patients with severe asthma
E. Basioli Kasap (Zadar, Croatia)
- D3.133** Clinical Impact of Cumulative Oral Corticosteroid Exposure in Patients with Severe Asthma: Data from the Korean Severe Asthma Registry
J.-H. Kim (Anyang, Korea, Republic of)
- D3.134** Pulmonary rehabilitation at altitude: Is there an optimal season?
N. van Zelst (Amsterdam, Netherlands)
- D3.135** Real World Efficacy of Benralizumab Treatment in Severe Eosinophilic Asthma: A Single-Center Experience
H. Yılmazlı (İzmir, Türkiye)
- D3.137** The “Street Cat” Paradox: Low Prevalence but High Disease Burden of Mouse Sensitization in Pediatric Asthma
G. Kiğılı (İstanbul, Türkiye)
- D3.138** Can FeNO predict lung function decline in asthma? A 5-year multicenter cohort study
P. Dominguez Ferrer (Madrid, Spain)
- D3.139** Asthma control and medication adherence in patients with asthma using preferred versus alternative GINA treatment tracks - a real-world observational study
M. Nunes (Lisbon, Portugal)

12:15 - 13:15 TPS67 - Asthma 11

(Poster Zone, Thematic Poster Session)

Chair: E. Fuertes (London, United Kingdom), A. Bognanni (Milan, Italy)

- D3.140** Transcriptomic profiling reveals distinct gene signatures and immune pathways in inhaled corticosteroid (ICS)-sensitive and resistant House Dust Mite (HDM)-induced asthma mouse models
F. Ruzzi (Parma, Italy)

- D3.141** Serum levels of IL-10 and IFN-GAMMA in adolescents diagnosed with asthma in clinical remission without treatment
M. T. Gonzales-Enriquez (Regina, Canada)

- D3.142** Adherence to Inhaled Corticosteroid Therapy in Patients with Severe Asthma at a Danish Tertiary Care Centre
O. Petersen (Aarhus, Denmark)

- D3.143** Immunomodulatory role of vitamin D in severe asthma: a potential biomarker of treatment response
M. Lampalo (Zagreb, Croatia)

- D3.144** Did allergic status change the quality of life in controlled severe asthma patients with triple therapy?
B. Gemicioglu (İstanbul, Türkiye)

- D3.145** Comparative particle size and distribution from fixed dose triple dry powder inhalers
B. J. Lipworth (Dundee, United Kingdom)

- D3.146** Attitudes and Knowledge Levels Regarding Physical Activity in Children with Asthma and Their Parents: A Comparison with Healthy Controls
M. C. Sifil (ankara, Türkiye)

- D3.147** A Survey of Approaches to Inhaled Therapy Management in Patients with Severe Asthma Treated with Biologics: Practices Among REIMAGINE Study Sites
P. Howarth (London, United Kingdom)

- D3.148** ANCA-Negative Systemic Vasculitis Developing Despite Anti-IL-5R Therapy and High Dose of Glucocorticosteroids: A Diagnostic and Therapeutic Challenge
K. Królak-Nowak (Łódź, Poland)

- D3.149** Nationwide Trends in Asthma-Related Mortality in Türkiye: Impact of the Sex-Specific Differences (2018–2024)
F. E. Gunaydin (Frimley, United Kingdom)

- D3.150** Clinical characterization of patients affected by asthma and psoriasis or psoriatic arthritis: an observational retrospective study
V. Maggiolo (Monserato, Italy)

- D3.151** Anti-IL5 biologics in eosinophilic granulomatosis with polyangiitis patients followed in a severe asthma multidisciplinary unit: functional and clinical outcomes
N. Abdurrachid (Lisboa, Portugal)

- D3.152** The quality of life in severe asthma patients treated with biologics is better than those with triple inhaler therapy
B. Gemicioglu (İstanbul, Türkiye)

12:15 - 13:15 TPS68 - Asthma 12

(Poster Zone, Thematic Poster Session)

Chair: A. F. Kalyoncu (Ankara, Türkiye), D. Karaguzel (Ankara, Türkiye)

- D3.153** Add-on Dupilumab therapy significantly reduces severe asthma exacerbations and emergency visits in patients with severe persistent asthma requiring oral corticosteroids for maintenance therapy: our experience in Réunion Island
B. Omarjee (Saint-Denis, Réunion)

- D3.154** Trends in Bronchial Asthma Incidence in Crimea: Analysis from 2017-2024 with Age-Specific Insights
L. DuBuske (Gardner, United States of America)

- D3.155** Th2–Th17 immune shift following dupilumab therapy
L. Rodríguez Calderón (Guadalajara, Spain)

- D3.156** Pulmonary embolism in a young asthma patient
A. Csuth (Linköping, Sweden)

- D3.157** Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region
D. De Zubiria (Cali, Colombia)

- D3.158** Dupilumab Response in a Patient with Severe Asthma Refractory to Anti-IL5 Therapy: A Case Report
Y. Bozkurt (ISTANBUL, Türkiye)

- D3.159** Early Bronchodilator Response in Asthma: When Is Testing Really Necessary?
S. B. Kaya (Malatya, Türkiye)

- D3.160** Study of the allergic sensitization profile in asthmatic patients consulting at ignace deen university hospital, conakry
I. T. Diallo (Conakry, Guinea)

- D3.161** Efficacy and Safety of Ciclesonide in Achieving Asthma Control: Results of an Observational Multicenter Study in Real-World Clinical Practice
O. Belik (Moscow, Russia)

- D3.164** Early and Sustained Effect of Zupilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma
A. Kamboj (San Francisco, United States of America)

- D3.165** Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor
M. Valentine (Tempe, AZ, United States of America)

12:15 - 13:15 TPS69 - Allergen immunotherapy 06
(Poster Zone, Thematic Poster Session)

Chair: *H. Duman Senol (İzmir, Türkiye), N. N. Bahçeciler (Nicosia, Cyprus)*

- D3.181** Oral Immunotherapy for food allergy through a personalised approach
A. Moracho Pascual (Leganés, Spain)
- D3.182** Initiating Sublingual Immunotherapy in Pre-Adolescence (<12 Years) Maximizes Adherence Potential: Analysis of Subjective Burden and Local Reactions
P. Kunc (High Tatras, Slovakia)
- D3.183** Determination of IgE antibodies against recombinant allergens (Phl p 1 and Phl p 5) in a random sample of patients from Madrid with pollinosis before and after one year of subcutaneous immunotherapy
A. De Noia (Madrid, Spain)
- D3.184** Comparative immunogenicity of mixed versus individual extracts from the storage mites *Acarus siro* and *Tyrophagus putrescentiae*
R. Moya (Tres Cantos, Spain)
- D3.185** Clinical Characteristics of Patients with Hymenoptera Venom Allergy Treated with Venom Immunotherapy: A Retrospective Study
K. Kirdök (İzmir, Türkiye)
- D3.187** Sustained Clinical Benefit of Allergen Immunotherapy in Allergic Rhinitis: A Real-Life Study
P. Novakova (Sofia, Bulgaria)
- D3.188** Real-Life Effectiveness of Subcutaneous Allergen Immunotherapy Assessed by Medication Consumption: A Retrospective Cohort Study
S. Flores Regalo (Coimbra, Portugal)
- D3.189** Oral Immunotherapy–Associated Eosinophilic Esophagitis: A Pediatric Case Report
A. Miletić Gospić (Zagreb, Croatia)
- D3.190** Protocol for a real-world Study to Track Response to Oralair in Naïve patients with Grass pollen allergy (STRONG) in the Netherlands
M. Busch (Arnhem, Netherlands)
- D3.191** Demonstrating the Stability of Allergoids, the Next Generation of Allergen Therapy
S. Hewings (Worthing, United Kingdom)
- D3.192** Safety of AIT with Depigmented-polymerized extracts in patients with severe allergic asthma. A subanalysis of the SAGITAL study
G. Salamanca Fernández (Tres Cantos, Spain)
- D3.193** Dual Blockade of TSLP and IL11 with a bispecific antibody: A Promising Strategy for the Treatment of Asthma and Other Airway Disorders
Z. Zhu (Wilmington, DE, United States of America)
- D3.194** Carry-Over Effect of House Dust Mite (HDM) Immunotherapy for Allergic Respiratory Conditions in Pediatric and Adolescent Populations: A Systematic Review and Narrative Synthesis
N. Tran (Hanoi, Vietnam)
- D3.195** Building expert consensus on the positioning of allergen immunotherapy (AIT) within a treatment paradigm for allergic rhinitis/rhinoconjunctivitis led by disease remission: A Delphi consensus
G. W. Canonica (Rozzano, Italy)
- D3.196** Safety of subcutaneous immunotherapy with purified native protein Cup a 1, a major allergen of *Cupressus arizonica*: 6-year real-world data
B. López-Cauce (Leganés, Spain)

12:15 - 13:15 TPS70 - Allergen immunotherapy 07
(Poster Zone, Thematic Poster Session)

Chair: **B. Bohle (Vienna, Austria), C. Panaïtescu (Timisoara, Romania)**

- D3.198** Challenges of using clinical scores as primary endpoints in allergology trials
R. Mösges (Köln, Germany)
-
- D3.199** Severe systemic allergic reaction following violation of elimination diet in a patient with sensitization despite achieved remission on allergen-specific immunotherapy
Y. Dytyatkovska (Dnipro, Ukraine)
-
- D3.200** Broad profile of olive pollen sensitisation as a key factor in immunotherapy failure
P. López De Los Santos (Palma de Mallorca, Spain)
-
- D3.201** Subcutaneous immunotherapy with a depigmented cat allergoid is safe in patients with cat allergy and beneficial for mental health in adolescents
A. Sager (Witten, Germany)
-
- D3.202** Characterising relevant major allergens beyond modification: from allergen to allergoid
I. Martino (Worthing, United Kingdom)
-
- D3.203** Characterisation of relevant allergens in grass pollen extracts
H. Young (Worthing, United Kingdom)
-
- D3.205** Two-year Outcomes of Multiple Low-Dose Oral Immunotherapies for combination of Tree Nuts or Peanut for Severe Allergy Patients
C. Nobuto (Sagamihara, Japan)
-
- D3.206** Pollen-Food Allergy Syndrome (PFAS): A New Paradigm in Allergy Practice – Results of a Survey Among Allergists
R. Montagne (Antony, France)
-
- D3.207** Symptomatology and Sensitization Profiles of Patients Undergoing Subcutaneous Immunotherapy for Aeroallergens in Greece
F. Kapsouli (Athens, Greece)
-
- D3.208** Security of initiation of SCIT in the day hospital
N. Cerdeira (Madrid, Spain)
-
- D3.209** Subcutaneous Allergen Immunotherapy in Children: Frequency of Local and Systemic Adverse Reactions and Associated Risk Factors
S. Aslan (Eskişehir, Türkiye)
-
- D3.213** Sustained effectiveness of the 300 IR house dust mite sublingual tablet over 2 treatment years in a real-world data setting – results of a non-interventional study
U. Reineke (Herford, Germany)
-
- D3.214** A multi-epitope protein promotes regulatory T-cell responses in PBLs from HDM-allergic patients
E. Egea-Bermejo (Barranquilla, Colombia)
-

12:15 - 13:15 TPS71 - Dermatology 05

(Poster Zone, Thematic Poster Session)

Chair: K. Jamalyan (Yerevan, Armenia), N. Douladiris (Nea Kallikratia, Chalkidiki, Greece)

- D3.231** Gut Microbiome Dysbiosis in Antihistamine-Refractory Chronic Spontaneous Urticaria and Its Association with Disease Characteristics- A Cross-Sectional Case–Control Analysis
I. Podder (Kolkata, India)
- D3.232** The AhR agonist tapinarof suppresses human skin inflammation by inducing metabolic reprogramming and reducing production of mitochondrial pro-inflammatory DAMPs
M.-A. Lefevre (Lyon, France)
- D3.233** Polypharmacy-Associated Lichenoid Eruption Simulating Keratosis Lichenoides Chronica
G. G. Atay (Istanbul, Türkiye)
- D3.234** Successful Use of Ritlecitinib in Long-Standing Alopecia Areata with Previous JAK Inhibitor Failure
A. De (Kolkata, India)
- D3.235** Trends in Sensitization to Preservatives and Epoxy Resins among occupationally exposed workers: A 31-Year Patch Test analysis from Tunisia
C. Sridi (Sousse, Tunisia)
- D3.236** Does Night Work Influence the Severity of Allergic Contact Dermatitis?
I. Kacem (Sousse, Tunisia)
- D3.237** Specific Features of Allergic Contact Dermatitis in Diabetic Patients in a Dermato-Allergology Unit in Tunisia
I. Kacem (Sousse, Tunisia)
- D3.238** Allergic Contact Dermatitis to Formaldehyde: A 31-Year Experience in a Dermato-Allergology Consultation
I. Kacem (Sousse, Tunisia)
- D3.239** Foot Allergic Contact Dermatitis in Workers: Prevalence and Allergen Patterns
I. Kacem (Sousse, Tunisia)

12:15 - 13:15 TPS72 - Dermatology 06

(Poster Zone, Thematic Poster Session)

Chair: **I. D. Toprak (İstanbul, Türkiye)**

- D3.240** Differential microRNA expression in chronic spontaneous urticaria in relation to treatment response
Y. M. Ye (Suwon, Korea, Republic of)

- D3.241** How Clinical Control of Chronic Urticaria influence in mental health
J. I. Larco (Lima, Peru)

- D3.242** SDRIFE induced by multiple systemic corticosteroids
J. Ramirez-Cortes (Majadahonda, Spain)

- D3.243** Food allergy in children with inherited epidermolysis bullosa: possible role of transcutaneous sensitization and features of the clinical course
A. Galimova (Moscow, Russia)

- D3.244** STK4 Deficiency Presenting with Epidermodysplasia Verruciformis
H. Artac (Konya, Türkiye)

- D3.245** Complete Resolution of Systemic Delayed Hypersensitivity following Removal of a Titanium Fixation Screw: A Case Report
H.-K. Won (Cheongju, Korea, Republic of)

- D3.246** A Novel Mutation in a Case of Deficiency of Interleukin-1 Receptor Antagonist in a Filipino Male Child
A. Lee (Manila, Philippines)

- D3.247** Skin Involvement Is One Of The Common Signs In Children With Inborn Errors Of Immunity
H. Artac (Konya, Türkiye)

- D3.248** Prospective Evaluation Of The Efficacy Of Janus Kinase Inhibitor Therapy In Children With Alopecia Areata And Atopic Dermatitis
E. Vishneva (Moscow, Russia)

- D3.249** Late-onset toxic epidermal necrolysis (TEN) associated with nivolumab: attention to possible cofactors
R. Picos Baliña (Sevilla, Spain)

- D3.250** Changes in eating behavior in children with psoriasis during biological therapy depending on epicardial adipose tissue thickness
E. Vishneva (Moscow, Russia)

- D3.251** Prevention of Irritant Contact Dermatitis Among Dental Students
I. Kacem (Sousse, Tunisia)

- D3.252** Water-induced localized urticaria: A rare case of aquagenic urticaria
P. S. Figueiredo (Lisboa, Portugal)

- D3.253** Two Infant Cases Diagnosed with Bullous Mastocytosis, a Rare Variant of Diffuse Cutaneous Mastocytosis
M. Kurtuluş (Konya, Türkiye)

12:15 - 13:15 TPS73 - Food allergy 05

(Poster Zone, Thematic Poster Session)

Chair: **S. Arudi Nagarajan** (Bengaluru, India), **A. Fiocchi** (Roma, Italy)

- D3.270** Recent Trends in Food Allergy among Schoolchildren in a South Korean City (2018–2022)
G.-S. Choi (Busan, Korea, Republic of)

- D3.271** Development of a multiplex assay to assess the risk of IgE cross-reactivity to new protein sources
Y. Awad (Gif-sur-Yvette, France)

- D3.272** Selective Sensitization to Prawn with Absence of Cross-Reactivity to Fish: Molecular Identification of Hemocyanin (Pen m 7) and Sarcoplasmic Calcium-Binding Protein (Pen m 4) in a Patient with Recurrent Urticaria
M. Fernandez Izquierdo (Madrid, Spain)

- D3.273** Longitudinal Changes in Severity in Children with Severe, Refractory Cow's Milk Allergy
M. Omori (Obu, Japan)

- D3.274** Feasibility of Digestive Enzyme Supplementation for Cow's Milk Allergy in Exclusively Breastfed Infants
A. Fulmali (Cambridge, UK, United Kingdom)

- D3.275** In silico based assessment of intrinsic protein features for ranking clinical relevance of plant-based food allergens
A. Hussain (Kongens Lyngby, Denmark)

- D3.277** Tolerance to canned fish in patients allergic to β -parvalbumins
A. Grilo Mendes (Vila Nova de Gaia, Portugal)

- D3.278** Tropomyosin-Driven Cross-Reactivity Between Shellfish and House Dust Mites: A Case Report
E. KARAÇURA (Istanbul, Türkiye)

- D3.279** Sweet Honey And Sour Allergies: Pollen-Food Defensin Cross-Reactivity - a case series
A. Ivasko (Târgu Mureş, Romania)

- D3.280** Severe Anaphylaxis Induced by Turkey Egg with Tolerance to Hen's Egg and Poultry Meat: A First Report
P. Korkmaz (Şanlıurfa, Türkiye)

- D3.281** A Challenging Case of Paediatric Potato Allergy with Discordant Diagnostic Findings
N. Rao (Manchester, United Kingdom)

- D3.282** A Case of Nonsteroidal Anti-Inflammatory Drug-Exacerbated Food Allergy
E. Sahinoglu (Ankara, Türkiye)

12:15 - 13:15 TPS74 - Food allergy 06

(Poster Zone, Thematic Poster Session)

Chair: H. Breiteneder (Vienna, Austria), G. Zanoni (Verona, Italy)

D3.283 Oat-Induced Anaphylaxis: Allergenic Characterization in a Clinical Case

K. C. Paucar Vidal (Majadahonda, Spain)

D3.284 Milk Aversion After Successful Desensitization in a Milk-Allergic Child

A. Miletić Gospić (Zagreb, Croatia)

D3.286 Infant feeding patterns, perinatal history and the development of food allergy in early childhood

K. Efendieva (Moscow, Russia)

D3.287 Tick Bite-Induced Alpha-Gal Syndrome: A Report of Two Cases and Literature Review Focusing on Clinical Characteristics of Asian Patients

X. Gao (Tsingdao, China)

D3.288 Evaluating the role of dust mite sensitization in the development of edible insect allergies

L. Aparicio Armengol (Madrid, Spain)

D3.289 Tolerance Assessment in Children with IgE-Mediated Cow's Milk Allergy Using Different Cutoff Values of Cow's Milk Specific IgE

C. Kavukcu Horosan (Denizli, Türkiye)

D3.290 Generalized Urticaria Induced from Prick-by-Prick Test in Food Allergy Diagnosis

E. Lekli (Tirana, Albania)

D3.291 Molecular Identification of Heat-Stable β -Parvalbumin in megrim (*Lepidorhombus boscii*) as the Likely Allergen in a Child With Selective Fish Reactivity

A. Ventosa (Córdoba, Spain)

D3.292 Safety profile of the yellow fever vaccine in egg-allergic children

S. Regina Abu Jamra (Ribeirao Preto, Brazil)

D3.293 Selective Quail Egg Allergy Without Cross-Reactivity to Hen's Egg: Molecular Characterization of a Pediatric Case

E. Abel-Fernandez (Alcalá de Henares, Spain)

12:15 - 13:15 TPS75 - Anaphylaxis 04

(Poster Zone, Thematic Poster Session)

Chair: A. Anagnostou (Houston, United States of America), D. İlğün Gürel (Ankara, Türkiye)

D3.306 Veno-Venous ECMO For Aprotinin-Induced Perioperative Anaphylaxis

I. Calik (Istanbul, Türkiye), L. Pur Ozyigit (Leicester, United Kingdom), P. Romero (Leicester, United Kingdom)

D3.307 Chlorhexidine-triggered anaphylaxis in a child with multisystem allergy and sickle cell disease: a diagnostic pitfall

Z. E. Hamed (Newcastle upon Tyne, United Kingdom)

D3.308 Kounis Syndrome: the allergic myocardial infarction

C. Maçães (Porto, Portugal)

D3.309 Basophil Activation Test Detects Rocuronium Allergy During the Post-Anaphylactic Refractory Period: A PAMA Case Report

N. Kotnik (Golnik, Slovenia)

D3.313 Recurrent Anaphylaxis with Elevated Baseline Tryptase Revealing Hereditary Alpha-Trypsinemia with Mast Cell Activation

J. Silva (Porto, Portugal)

D3.314 Rapid desensitization to intravenous risankizumab after anaphylaxis in a patient with Crohn's disease: a case report

M. Nenova (Sofia, Bulgaria)

D3.317 Linguistic Validation of the Turkish Version of the Mastocytosis Control Test (MCT)

D. Unal (Istanbul, Türkiye)

D3.318 Evaluation of Clinical Predictors and Serum Tryptase Levels in Systemic Mastocytosis

A. Pehlivanlar Ustaoglu (Ankara, Türkiye)

D3.319 Clinical Data of Drug Induced Anaphylaxis according to the standardized European Anaphylaxis Registry (NORA)

F. Kapsouli (Athens, Greece)

D3.320 Anaphylaxis by Chlorhexidine: A case series

M. Zavala (Pamplona, Spain)

D3.321 Cardiac arrest after Iodixanol: a case of non-IgE mediated mast cell activation

V. Vatnani Moolchandani (Las Palmas de Gran Canaria, Spain)

D3.322 Successful management with Omalizumab and high-dose venom immunotherapy in a patient with Kounis Syndrome and Clonal Mast Cell Activation Syndrome

P. Viedma Ayllon (Castellon de la Plana, Spain)

12:15 - 13:15 TPS76 - Anaphylaxis 05

(Poster Zone, Thematic Poster Session)

Chair: T. Dribin (Cincinnati, United States of America), M. D. L. A. Gonzalez-Labrador (Alcorcón, Spain)

- D3.323** SBK007: A Novel Oral H1 Antihistamine with Rapid Onset (30min): Preclinical Pharmacodynamics in Acute Urticaria
M. Chen (Chengdu, China)
- D3.324** Hereditary Angioedema Attack Frequency and Severity According to Individuals Taking Berotralstat for Long-Term Prophylaxis
T. Khuu (Durham, United States of America)
- D3.325** Immediate-type allergic reactions associated with thiuram mix sensitization in an adolescent with atopic dermatitis: a case report
R. Pozerskyte (Vilnius, Lithuania)
- D3.326** Markedly Elevated Basal Serum Tryptase Revealing Smoldering Multiple Myeloma After Nonsteroidal Anti-Inflammatory Drug-Induced Anaphylaxis
S. Çolak (Ankara, Türkiye)
- D3.328** Paediatric Anaphylaxis: The Importance Of Recognition
V. Mateo-Frances (Madrid, Spain)
- D3.329** Real-world shelf-life of adrenaline auto-injectors (AAIs) at pharmacy dispensing: Insights from six countries
M. Vang Lybech (Hørsholm, Denmark), J. Nørregaard (Kungsbacka, Sweden), K. Malottki (Reading, United Kingdom), J. Finney (London, United Kingdom), J. H. Kamstrup (Copenhagen, Denmark), A. Danø (Rungsted Kyst, Denmark), D. Grabowski (Toronto, Canada), S. Hussein (Hørsholm, Denmark)
- D3.331** Real-World Challenges in Pediatric Anaphylaxis: The Role of Epinephrine
L. Nogueras-Fuertes (Madrid, Spain)
- D3.332** Patient Preferences for Nasal Adrenaline Spray versus Adrenaline Auto-Injectors in Anaphylaxis: A Multi-Country Discrete Choice Experiment
M. Worm (Berlin, Germany), A. T. Fox (London, United Kingdom), M. Ben-Shoshan (Montreal, Canada), M. Bachmann (Cape Town, South Africa), K. Werner (Cape Town, South Africa), A. Danø (Rungsted Kyst, Denmark), M. Vang Lybech (Hørsholm, Denmark), G. Pouessel (Roubaix, France), S. Hussein (Hørsholm, Denmark)
- D3.333** Clinical Characteristics of Anaphylaxis in Infants and Toddlers
A. Toksoz (Ankara, Türkiye)
- D3.334** Severe Early-Onset Atopy With Recurrent Anaphylaxis and Infections as Indicators of CADINS Disease
A. Alexandru (Târgu Mureş, Romania)
- D3.335** Anaphylaxis After Eating Sushi - Emergent allergies with new food habits?
L. Pereira (Coimbra, Portugal)

12:15 - 13:15 TPS77 - Immune deficiencies and autoimmunity 05

(Poster Zone, Thematic Poster Session)

Chair: E. Efstathiou (London, United Kingdom)

- D3.357** Revealing an Underlying Inborn Error of Immunity in Pediatric Granulomatous Disease: A Case of STAT1 Loss-of-Function–Associated Mendelian Susceptibility to Mycobacterial Disease after BCG Vaccination
M. Movahedi (Tehran, Iran, Islamic Republic of)

- D3.361** Pulmonary Embolism in a Patient with Hyper IgE (Job) Syndrome Associated with Genetic Thrombophilia: A Rare Case
M. Dursun (Istanbul, Türkiye)

- D3.362** Ulcerative Colitis Developing in an Immunodeficiency Patient with CD19 Gene Mutation: A Case Report
L. KILINÇKAYA (Sakarya, Türkiye)

- D3.363** Systemic Lupus Erythematosus in a Patient with Hyper IgM Syndrome
T. Potluri (Preston, United Kingdom)

- D3.366** Experience With Berotralstat In The First Turkish Patients
E. TÜSÜZ ÖNATA (Sakarya, Türkiye)

- D3.367** Clinical and immunological heterogeneity of 22q11.2 deletion syndrome in children from the Republic of Moldova
S. Sciucu (Chisinau, Moldova)

- D3.368** Selective IgE Deficiency in Children: 10-Year Experience
B. uzunoğlu (izmir, Türkiye)

12:15 - 13:15 TPS78 - Drug Allergy 04

(Poster Zone, Thematic Poster Session)

Chair: A. Haccuria (Brussels, Belgium), R. Madrigal-Burgaleta (London, United Kingdom)

- D3.370** Three cases of erdosteine-induced delayed drug hypersensitivity
Y.-I. Koh (Gwangju, Korea, Republic of)

- D3.372** Rapid Intramuscular Penicillin Desensitization: A Promising Future
A. Capelo (Rio De Janeiro, Brazil)

- D3.373** Non-immediate Hypersensitivity Reactions To Both Penicillin and Aminopenicillin and Diagnostic approach – A Real Life Retrospective Study
M. Jensen (Aalborg, Denmark)

- D3.374** Recall urticaria to dalteparin sodium in a patient with previous systemic reaction to nadroparin calcium
M. Terzić (Beograd, Serbia)

- D3.375** Delayed-Type Drug Reactions in Pediatric Patients: Clinical Features and Management
S. Akyuz Oktay (Ankara, Türkiye)

- D3.376** Drug Allergy Related to Chemotherapy and Premedication: Anaphylaxis Induced by Carboplatin and Methylprednisolone
Ö. ARGİN (Istanbul, Türkiye)

- D3.377** Causes of a morbilliform rash: when the most frequent answer is not
B. Mora Gálvez-Cañero (Madrid, Spain)

- D3.378** Drug hypersensitivity in children in a frontline setting: interim results of a pilot epidemiological project
D. Yartseva (Zaporizhzhia, Ukraine)

- D3.379** Varenicline's DRESS Syndrome
B. Mora Gálvez-Cañero (Madrid, Spain)

- D3.380** The Most Serious Threat in Perioperative Hypersensitivity Reactions (PHRs): Neuromuscular Blocking Agent (NMBA) Hypersensitivity and Cisatracurium as a Safe Haven in the Setting of Cross-Reactivity
H. F. Avcı (Istanbul, Türkiye)

- D3.381** The paradox of treatment: H1-antihistamines-induced urticaria in a patient with chronic spontaneous urticaria
A. Velickovic (Belgrade, Serbia)

- D3.382** Safety and outcomes of penicillin desensitization during pregnancy: experience from a tertiary referral center
A. Capelo (Rio De Janeiro, Brazil)

- D3.383** Delayed T-cell-mediated hypersensitivity to dimethyl fumarate: clinical presentation and diagnostic considerations
M. Seoane-Rodriguez (Valdemoro, Spain)

- D3.384** Assessment of the role of Rapid Drug Desensitization to treat cancer patient with infusion-related allergic reactions. Italian experience
G. Cortellini (Rimini, Italy)

12:15 - 13:15 TPS79 - Basic immunology 04
(Poster Zone, Thematic Poster Session)

Chair: *S. Boyd (Stanford, United States of America), T. Chatila (Boston, United States of America)*

- D3.385** A Synthetic Serum Comprising Human IgE Monoclonal Antibodies to Peanut Allergens
B. SMITH (Charlottesville, United States of America)
-
- D3.386** Prevalence and immune mechanisms of rheumatoid arthritis in Kyrgyz highland residents
R. Khanferyan (Moscow, Russia)
-
- D3.387** Assessment of safety of cryopreserved mesenchymal stem cells in the treatment of atopic dermatitis
L. DuBuske (Gardner, United States of America)
-
- D3.388** Association of HLA and cytokine production as risk factors for prostate cancer
L. DuBuske (Gardner, United States of America)
-
- D3.389** The Role Of Metabolic Endotoxemia In The Development Of Systemic Inflammation In Patients With Type 1 And Type 2 Diabetes Mellitus
L. DuBuske (Gardner, United States of America)
-
- D3.390** Lipopolysaccharide-Binding Protein And sCd14 In Patients With Type 1 Diabetes Mellitus And Diabetic Nephropathy
L. DuBuske (Gardner, United States of America)
-
- D3.391** The Effect of Bicarbonate Mineral Water on Endotoxemia Markers in Patients with Type 1 Diabetes Mellitus
L. DuBuske (Gardner, United States of America)
-
- D3.392** Associations Between Markers Of Endotoxin-Binding Systems And Vasoactive Agents In Patients With Rheumatoid Arthritis
L. DuBuske (Gardner, United States of America)
-
- D3.393** Immunological Profiling of the Kras-Driven Microenvironment in a Murine Model of Endometriosis
S.-T. Wu (Kaohsiung City, Taiwan)
-
- D3.394** Assessment of safety and tolerability of mesenchymal stem cells and tolerogenic dendritic cells as a therapy for type 1 diabetes
L. DuBuske (Gardner, United States of America)
-
- D3.395** Analysis of single cell multiome data (transcriptomics + ATAC) from human nasal polyp mast cells
Y. Jang (London, United Kingdom)
-
- D3.396** A new B-cell epitope profiling of glutathione S-transferase allergens supports mite-specific cross-reactivity within different species
E. Egea-Bermejo (Barranquilla, Colombia)
-
- D3.397** MOG Antibody-Associated Bilateral Optic Neuritis in a Child Following Mycoplasma Infection
A. Iqbal (Boston, United Kingdom)
-

12:15 - 13:15 TPS80 - Biologicals 03

(Poster Zone, Thematic Poster Session)

Chair: Z. Alsalloom (Manama, Bahrain), H. Al Bahri (Bahrain)

- D3.418** A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
Y. M. Ye (Suwon, Korea, Republic of)
- D3.419** Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
E. Atayik (Konya, Türkiye)
- D3.420** Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
B. Hijazi (Riyadh, Saudi Arabia)
- D3.421** Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
A. Kucharczyk (Warsaw, Poland)
- D3.422** Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
J. Levina (Moscow, Russia)
- D3.423** Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
H. Bonnekoh (Berlin, Germany)
- D3.424** Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
H. Kayıkcı (Ankara, Türkiye)
- D3.425** Comparative Effects of Subcutaneous Allergen Immunotherapy and Biological Agents on Olfactory Function: Preliminary results
M. Taş (Kırıkkale, Türkiye)
- D3.426** Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D. Gialama (Berlin, Germany)
- D3.427** Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
I. López-Fletcher (Ciudad de Guatemala, Guatemala)
- D3.428** Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
M. Adamczewska (Łódź, Poland)

12:15 - 13:15 TPS81 - Biologicals 04

(Poster Zone, Thematic Poster Session)

- D3.430** The effect of biological treatment of atopic dermatitis in children
V. Novotová (Bratislava, Slovakia)
- D3.431** Dupilumab therapy of patients with chronic rhinosinusitis with nasal polyps: long-term observational study
Á. Kiricsi (Szeged, Hungary)
- D3.432** Severe chronic rhinosinusitis - diagnostic and therapeutic challenges, personalized approach and place of biological treatment: a clinical case
E. Petkova (Sofia, Bulgaria)
- D3.433** An effect on lipid profile of biologic therapy independent from weight variation
M. Bullita (Cagliari, Italy)
- D3.434** Effectiveness of Biologic Therapies in Adults With Chronic Rhinosinusitis With Nasal Polyps: Real-World Data
M. Akarsu (Ankara, Türkiye)
- D3.435** "Looking Twice in Atopic Dermatitis Therapy: Pruritus Is Not Always the Same, and Eczema Is Not Always Atopic Dermatitis"
S. Isik (Göttingen, Germany)

12:15 - 13:15 TPS82 - Clinical Trials 02

(Poster Zone, Thematic Poster Session)

- D3.437** The effect of biological treatment of atopic dermatitis in children
P. Lacwik (Kielce, Poland)

- D3.438** Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
T. Khuu (Durham, United States of America)

- D3.439** Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort
E. N. Mete Gokmen (İzmir, Türkiye)

- D3.440** Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
M. Stobiecki (Kraków, Poland)

- D3.441** Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
E. N. Mete Gokmen (İzmir, Türkiye)

- D3.442** Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort
S. Trainotti (Munich, Germany)

- D3.443** Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort
S. Trainotti (Munich, Germany)

- D3.444** Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
M. Stobiecki (Kraków, Poland)

- D3.445** Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
N. Samson (London, United Kingdom)

- D3.446** PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants
J. A. Layhadi (London, United Kingdom)

- D3.447** Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut
S. Starchenka (Worthing, United Kingdom)

- D3.448** Use of Sebetralstat as Short-term Prophylaxis for Patients with Hereditary Angioedema: Results from the KONFIDENT-S Study
M. Cancian (Padua, Italy)

12:15 - 13:15 TPS83 - ENT 02

(Poster Zone, Thematic Poster Session)

Chair: Z. Alsalloom (Manama, Bahrain), H. Al Bahri (Bahrain)

- D3.451** Long-term follow-up of ASA therapy after desensitization in patients with chronic rhinosinusitis with nasal polyps indicates high rate of treatment discontinuation
T. Pullerits (Gothenburg, Sweden)
- D3.454** Do we still need aspirin desensitization therapy for nasal polyposis?
K. Seifert (Ulm, Germany)
- D3.455** Comparative Characterization of Olfactory Dysfunction in Mouse Models of Eosinophilic Chronic Rhinosinusitis
A. Dekeyser (Brussels, Belgium)
- D3.456** BEAMER: A multidisciplinary model for disease-agnostic adherence integrating chronic rhinosinusitis: development and prospective study
K. Scheckenbach (Düsseldorf, Germany)
- D3.457** Does the Way We Ask Matter? Comparing Self- and Interviewer-Administered RQLQ in Allergic Rhinoconjunctivitis
T. Nicola-Varo (Târgu Mureş, Romania)
- D3.462** Polysorbate 80 (E433) sensitisation predicts and explains part of the variability of the Chronic Cough and Opposing Defiant Behaviour (ODB) in sensitised children: how the industrialised nutrition impacts the gut-brain axis and favours neuro-inflammation
K. Kefala (Paris, France)

12:15 - 13:15 TPS84 - Environmental allergy and climate change + One Health 02

(Poster Zone, Thematic Poster Session)

Chair: A. Bossios (Stockholm, Sweden)

- D3.464** Influences of Climate and Environmental Exposures on Atopic Dermatitis Persistence and Asthma Development in Early Childhood: 6-Year Follow-up of Longitudinal Study
S. Kim (Seoul, Korea, Republic of)
- D3.465** Climate Change Anxiety Scale (HAES-13) in assessing the emotional impact of extreme weather events
M. Urrutia Pereira (Uruguaiiana, Brazil)
- D3.466** Quantitative assessment of environmental exposure to Der p1, Der p 2 and Der p 23 in European and South African house dust samples
M. Oliver (Cardiff, United Kingdom)
- D3.467** When urban green spaces meet human allergies – Evidence from an urban pine park in Thessaloniki, Greece
G. Varsamis (Thessaloniki, Greece)
- D3.468** Effect of Microplastic Inhalation on Allergic and Nonallergic Rhinitis
Y. Itmec (Kirikkale, Türkiye)
- D3.469** Interaction between Meteorological Variables and Atmospheric Pollutants in the Dynamics of Alternaria Spores in Bragança, Portugal
T. Ribeiro (Porto, Portugal)
- D3.471** Invisible Ventilation Gaps: Continuous Low-Cost Indoor Air Quality Monitoring in a Northern Portuguese Hospital
G. Silva (Porto, Portugal)
- D3.473** Symptom burden and sensitization patterns in allergic rhinitis: real-world data
A.-V. Gorbatovschi (Târgu Mureş, Romania)
- D3.474** Non-IgE-mediated rhinitis in sub-Saharan Africa: an underdiagnosed condition?
L. Mouangue-Mbonjo (Yaounde, Cameroon)
- D3.475** Long-term retention of mouse blood proteins in Ixodes ricinus suggests residual host blood as a potential source of α -Gal
J. Petry (Esch-sur-Alzette, Luxembourg)

12:15 - 13:15 TPS85 - Biomarkers 02

(Poster Zone, Thematic Poster Session)

Chair: **K. F. Chung** (London, United Kingdom), **A. Maldonado** (Madrid, Spain)

- D3.477** IgE Sialylation as a Potential Biomarker of Allergy: Evidence from Patients with Diverse Allergic Conditions
J. Alvarez (Tres Cantos, Spain)

- D3.478** Microsplenia: Spleen Size Reduction as a Comprehensive Biomarker for Immune-Related Diseases, Disease Monitoring, and Treatment Response
L. Petrenko (Kyiv, Ukraine)

- D3.479** Association between Mitochondrial DNA Copy Number and Lung Function in Schoolchildren
H.-F. Kao (Tainan, West- Central, Taiwan)

- D3.480** Protamine Hypersensitivity Risk in an Elderly Patient with Recurrent Food Anaphylaxis and High Cardiovascular Risk- Case Report
A. Łata (Wrocław, Poland)

- D3.481** Machine Learning–Based Plasma Proteomic Signatures for Prediction of Chronic Rhinosinusitis
D. Kim (Seoul, Korea, Republic of)

- D3.482** Harnessing the Baseline Nasal Microbiome to Predict Pollen Related Symptom Expression
M. Gökkaya (Augsburg, Germany)

- D3.483** Wearable Energy-efficient Device development for Real-time Evaluation, Analysis, and Monitoring platform
G. Eom (Seoul, Korea, Republic of)

- D3.484** Non-Invasive Detection of Airborne Fungal Exposure Using Machine Learning–Assisted Volatile Biomarker Sensing
D. Kim (Seoul, Korea, Republic of)

- D3.485** Prevalence of *Ambrosia artemisiifolia* in Italy: Bioinformatics and Botanical Aerobiology Analysis
M. Albanesi (Bari, Italy)

- D3.486** Acute hepatitis B with atypical serological markers in a previously vaccinated patient receiving anti-CD20 obinutuzumab
J. Vitte (Reims, France)

- D3.487** Intersection of Micronutrient Malabsorption Symptoms and Iron Deficiency in a Diet interaction in East African Population
S. Abdoukader Houmed (Istanbul, Türkiye)

12:15 - 13:15 TPS86 - Occupational allergy
(Poster Zone, Thematic Poster Session)

Chair: **M. Raulf** (Bochum, Germany)

- D3.493 Identification of Two IgE-Reactive Proteins in *Planococcus citri* Larvae: A Novel Case of Occupational Respiratory Allergy in a Pest-Control Laboratory Worker**
A. E. Fernandez Fernandez (Alcalá de Henares, Spain)
-
- D3.495 Validation of a 4-steps single-concentration dosimeter test for measuring bronchial hyperresponsiveness with methacholine**
V. van Kampen (Bochum, Germany)
-
- D3.496 When music makes you bleed: suspected mould-triggered hypersensitivity pneumonitis from a contaminated trumpet in a 17-year-old professional player**
A. Adamiec (Warszawa, Poland)
-
- D3.497 Allergic Contact Dermatitis with Multiple Sensitizations in a Professional Viola Player**
A. Bostanoğlu Karaçin (Ankara, Türkiye)
-
- D3.498 Indoor environmental quality in university settings: identifying opportunities for promoting health, comfort, and academic performance among medical students**
P. Carvalho (Porto, Portugal)
-
- D3.499 Allergic Contact Dermatitis to Lanolin in an Occupational Allergological Dermatology Unit in Tunisia**
I. Kacem (Sousse, Tunisia)
-
- D3.503 Occupational Respiratory Allergies in Tunisia: Professional Outcomes and Risk Factors Among Workers**
I. Kacem (Sousse, Tunisia)
-
- D3.504 Allergic Diseases as a Leading Cause of Early Retirement in Occupational Settings**
I. Kacem (Sousse, Tunisia)
-
- D3.505 Problem-Based Learning on Allergic Contact Dermatitis Enhances Competency Development in Occupational Medicine**
I. Kacem (Sousse, Tunisia)
-
- D3.506 Assessment of exposure profiles and allergic outcomes in veterinary workers: findings from a standardized questionnaire**
A. BROGGIO (Padova, Italy)
-
- D3.507 Impact of chemical warfare agents on immune response**
K. Gashynova (Dnipro, Ukraine)
-
- D3.508 Management of Severe Occupational Allergic Rhinitis and Asthma in a Veterinary Student: A Molecular-Guided Approach**
B. Çelik Eroğlu (Ankara, Türkiye)
-

12:15 - 13:15 TPS87 - Aerobiology and pollution
(Poster Zone, Thematic Poster Session)

Chair: *A. Damialis (Thessaloniki, Greece), A. Charalampopoulos (Thessaloniki, Greece)*

- D3.509** Predicting Fungal and Bacterial Bioaerosol Concentrations Across Distinct Building Types: A Generalized Additive Model and Machine Learning Framework
S. Seo (Seoul, Korea, Republic of)
-
- D3.510** Correlation between Emergency visits and Platanus ssp pollen levels in a child population
I. Garcia-Nunez (Córdoba, Spain)
-
- D3.511** Correlation between Emergency visits and Platanus ssp pollen levels
I. Garcia-Nunez (Córdoba, Spain)
-
- D3.512** Objective Ambulatory Assessment of Indoor Air Quality and Cough Frequency
K.-M. Ahn (Seoul, Korea, Republic of)
-
- D3.513** Atmospheric Pollen Content in Arid Climate: One-year Seasonal Trends in Doha, Qatar
Y. M. Elkhatib (Doha, Qatar)
-
- D3.514** Atmospheric fungal spore content in an Arid Climate: One-year Seasonal Patterns in Doha, Qatar
Y. M. Elkhatib (Doha, Qatar)
-
- D3.515** PM2.5 exposure shapes monocyte and T cell immune reprogramming in allergic airway disease
D. Song (Seoul, Korea, Republic of)
-
- D3.516** Airborne pollen where and when it should not exist – Towards ‘allergy-safe’ environments or adopting a Planetary Health approach?
E. Papakonstantinou (Thessaloniki, Greece)
-
- D3.517** Design of an AI-Based Decision Support System for Field-Tailored Personal Protective Equipment Using Multi-Layer Protective Composites
S. PARK (Seoul, Korea, Republic of)
-
- D3.518** Environmentally relevant irregular polystyrene particles exert stronger biological effects than spherical model particles in human bronchial smooth muscle cells
M. Pietrzak (Wroclaw, Poland)
-

12:15 - 13:15 TPS88 - COVID19

(Poster Zone, Thematic Poster Session)

Chair: **D. Kocacik Uygun (Antalya, Türkiye)**

- D3.519** Post-COVID-19 Reshaping of Molecular IgE Sensitization Profiles to Seasonal and Indoor Allergens
N. Zakhidova (Tashkent, Uzbekistan)

- D3.520** Post-COVID Olfactory and Taste Dysfunction in Students at a South African Medical School
R. Seedat (Bloemfontein, South Africa)

- D3.521** Dermatologic adverse effects of COVID-19 vaccination
I. Kacem (Sousse, Tunisia)

- D3.522** Post-Vaccination SARS-CoV-2 Infections: Evidence, Severity, and Outcomes
I. Kacem (Sousse, Tunisia)

- D3.523** Early childhood: a risk predictor for post-COVID-19 pulmonary sequelae in children
S. Sciuca (Chisinau, Moldova)

- D3.524** Clinical use of procalcitonin and IL-6 in diagnosis of bacterial superinfection in COVID-19
B. Prnjavorac (Tešanj, Bosnia and Herzegovina)

- D3.525** One- year hospital readmission after pediatric COVID- 19 hospitalization: a single- center cohort study
C. Vladulescu (Craiova, Romania)

- D3.526** Baseline demographic characteristics and early-life exposures in infants born during and after the COVID-19 pandemic: A comparison of the CORAL and FLORAL birth cohorts
A. Sokay (Dublin, Ireland)

- D3.527** Multisystem Inflammatory Syndrome in Children (MIS-C) as a Condition Resulting from Immune Dysregulation: What has Coronavirus Infection Taught Us? (Case Study)
L. Tchelidze (Tbilisi, Georgia)

12:15 - 13:15 TPS89 - Infections

(Poster Zone, Thematic Poster Session)

- D3.529** Altered Virulence of Pseudomonas aeruginosa from Polystyrene-Fed Zophobas atratus Larvae and Immunological Effects of Microplastics on Murine Lungs
I. Kaydashev (Poltava, Ukraine)

- D3.530** Nonresponsiveness to Hepatitis B Vaccine Is Characterized by Reduced T Stem Cell Memory (TSCM) Cells
H. Molavi (shiraz, Iran, Islamic Republic of)

- D3.531** Diverse Infectious Disease Outcomes After SARS CoV 2 Infection in Children and Adolescents: A Nationwide Matched Cohort Study
H.-J. Yang (Seoul, Korea, Republic of)

- D3.532** Influence of sensitization on persistent symptoms of chronic fatigue
D. Hristova (Sofia, Bulgaria)

- D3.533** Prevalence of dysplasia and cervical cancer of papillomavirus origin in women of different age groups
M. Lomikovska (L'viv, Ukraine)

- D3.536** Staphylococcus aureus bacteria as a causative agent of upper respiratory tract allergies
G. Yeryomenko (Kharkiv, Ukraine)

- D3.537** Immunologic and other factors influencing clearance of viral hepatitis infections
G. Kamkamidze (Tbilisi, Georgia)

12:15 - 13:15 TPS90 - Eosinophilic esophagitis (Poster Zone, Thematic Poster Session)

Chair: **A. Bakirtas (Ankara, Türkiye), C. Zeyneloglu (Davos, Switzerland)**

- D3.538** Aeroallergen sensitisation as a risk factor for paediatric eosinophilic esophagitis
R. Zermati (Paris, France)

- D3.539** Evaluation of Treatment Selection and Response in Patients with Eosinophilic Esophagitis Based on Clinical Findings and Allergy Testing
M. S. Ensari (Ankara, Türkiye)

- D3.540** Sources of IL-13 in Acute Versus Chronic Models of Eosinophilic Esophagitis
A. Doyle (Scottsdale, United States of America)

- D3.541** Who takes the patient with eosinophilic esophagitis (EoE) and acute laryngeal edema?
N. O. Berghi (Bucureşti, Romania)

- D3.542** Prevalence of sensitization to panallergens and IgG4 profiles against specific foods in patients with allergic-phenotype eosinophilic esophagitis
J. Domenech Witek (Cádiz, Spain)

12:15 - 13:15 TPS91 - AllergoOncology (Poster Zone, Thematic Poster Session)

Chair: **S. Karagiannis (London, United Kingdom), H. Kayıkcı (Ankara, Türkiye)**

- D3.544** Allergic biomarkers and clinical outcomes in lung cancer patients treated with immune checkpoint inhibitors: a pilot study
I. Dávila (Salamanca, Spain)

- D3.545** Natural Killer and Dendritic Cells Leverage Synergistic Interactions to Enhance Treatment of Non-Small Cell Lung Cancer
B.-Y. Tsai (Taipei, Taiwan)

- D3.546** AllergoOncology: Basophil number and subpopulation proportions may offer potential as predictive biomarkers in non-small cell lung cancer
M. Lasa-Lazaro (Barcelona, Spain)

- D3.547** Clinical Outcomes and Safety of Drug Desensitization in Chemotherapy-Induced Hypersensitivity
S. Rodríguez Cano (Córdoba, Spain)

- D3.548** Refractory and persistent pruritus in an atopic patient: A red flag for underlying malignancy?
T. M. De Vicente Jiménez (San Sebastián de los Reyes (Madrid), Spain)

13:30 - 14:00 EAACI Special Session 2 - EAACI Meet and greet the EAACI Leadership (EAACI Global Stage, EAACI Special Session)

13:30 Meet and Greet the Leadership

M. Torres (Malaga, Spain), M. Shamji (London, United Kingdom), P. Bonadonna (Vicenza, Italy), A. Moreira (Porto, Portugal), J. Walusiak-Skorupa (Lodz, Poland), O. Pfaar (Marburg, Germany), O. Palomares (Madrid, Spain), S. Del Giacco (Cagliari, Italy)

13:30 - 14:30 Enlightenment talk (Innovation Hub, EAACI Enlightening Talk)

Chair: C. Pitsios (Nicosia, Cyprus)

13:30 Living with reactions no one can see

I. Terreehorst (Rotterdam, Netherlands)

14:00 Medicine is a lifetime story

A. Karavelia (Kalamata, Greece)

13:30 - 14:30 SSS10 - EAACI ACAAI Sister Symposium: Bringing it back to our patients (Room London, 6- London, Sister Society Symposium)

13:30 How the ACAAI bridges the gap

T. Mahr (LaCrosse, United States of America)

13:50 Insight into asthma on a daily basis

C. Zachary (Minnesota, United States of America)

14:10 How to influence our patients in a world of influencers

D. Stukus (Ohio, United States of America)

13:30 - 15:00 FT19 - Precision medicine in Allergy: targeted biologic therapies (Room Athens, Flash Talks)

Chair: E. Terzioglu (Antalya, Türkiye)

- 13:30** Real-world dosing interval extension of biologics in severe asthma in the Dutch RAPSODI registry: can this be successfully applied?
001612 C. J. M. Marijnissen (Leiden, Netherlands)
-
- 13:37** Twice-Yearly Depemokimab Maintains Exacerbation Reduction Over 2 Years in Patients with Asthma Regardless of Prior Exacerbation History: An Integrated Analysis of the SWIFT-1/-2 and AGILE Studies
000770 E. Heffler (Milano, Italy)
-
- 13:44** Evaluation of remission in a cohort of Italian patients with severe asthma and CRSwNP who experienced switching of biologics
001985 E. Piano (Cagliari, Italy)
-
- 13:51** Dose-related efficacy of omalizumab in food-allergic children with severe asthma: OSAFA observational study
001937 S. Arasi (Rome, Italy)
-
- 13:58** Reduction in OCS cumulative dose while improving asthma control and quality of life in severe eosinophilic asthma treated with Benralizumab. Real-World Evidence from the AURORA study
000798 A. Kucharczyk (Warszawa, Poland)
-
- 14:05** A New Design and Functional Characterization of an IL-4 Receptor-Targeted Immunotoxin as an Immunomodulatory Strategy in Allergy
000164 N. Batres Casero (Madrid, Spain)
-
- 14:12** Interleukin-1 Inhibition in Hereditary Periodic Fever Syndromes: Single-Center Experience from Slovakia
001277 B. Šlenker (Martin, Slovakia)
-
- 14:19** Hereditary Alpha-Trypsinemia: a case series including Omalizumab treatment outcomes
000076 J. Guimarães (Setúbal, Portugal)
-
- 14:26** Efficacy of dupilumab vs omalizumab on symptom and quality of life burden in patients with severe chronic rhinosinusitis with nasal polyps and coexisting asthma: Results from the EVEREST study
001647 E. Heffler (Milano, Italy)
-
- 14:33** Differential Clinical Outcomes And Modulation Of Cd62llow Ieos With Mepolizumab 100 Mg Versus 300 Mg In Egpa Patients
001040 M. E. Milanese (Florence, Italy)
-

13:30 - 15:00 FT20 - Emerging concepts in basic immunology

(Room Glasgow, Flash Talks)

Chair: G. Deniz (Istanbul, Türkiye), H. Morita (Tokyo, Japan)

- 13:30** Feasibility of lentiviral transduction in resting primary human basophils and CD34+-derived progenitors: overcoming limitations of current in vitro allergy basophil-based cellular models
001441 C. Frecha (Malaga, Spain)
- 13:37** Elucidating the Pathogenesis of Eosinophilic Chronic Rhinosinusitis via Ferroptosis
000672 K. Miyamura (Minato City, Japan)
- 13:44** Fish-oil-derived furan metabolites modulate early life immunometabolic responses and infection risk in childhood
001457 O. Bæk (Gentofte, Denmark)
- 13:51** Polyphenols reduce activation of monocyte derived dendritic cells (moDCs) in type-2 polarizing conditions
001453 C. den Elzen (Utrecht, Netherlands)
- 13:58** Altered cord blood immune reactivity as a potential early marker of non-IgE mediated allergy
001847 J. Hrdý (Prague, Czech Republic)
- 14:05** Anti-IL-5Rα therapy and sustained multilevel disease control in refractory eosinophilic colitis: a case report
000906 L. Bruno (Roma, Italy)
- 14:12** Distinct Gene Variations Associated with Severity of Infection in COVID-19 Patients
000591 N. Oruklu (Ankara, Türkiye)
- 14:19** Donor-Dependent Transfer or Resolution of Allergic Diseases After Allogeneic Hematopoietic Stem Cell Transplantation
000237 Z. Bayazit (Kayseri, Türkiye)
- 14:26** Efficacy and Safety of Histaglobulin as an Adjunctive Therapy in Chronic Spontaneous Urticaria: A prospective, single-arm, self-controlled, interventional study
000242 A. De (Kolkata, India)
- 14:33** IgE Deficiency in Childhood: A Predictor of Autoimmunity and Recurrent Respiratory Tract Infections
000355 K. Miliordos (Panepistimioupoli Patron, Greece)
- 14:40** Isoquercetin Mimics Pioglitazone in Suppressing LPS-Induced Airway Inflammation Through Ferroptosis-Associated Mechanisms
001779 R. S. Yanikoglu (Istanbul, Türkiye)
- 14:47** Multiple Hypersensitivity Reactions to Chemically Unrelated H1 Antihistamines: Two Case Reports
001370 K. Gojny (Wrocław, Poland)
- 14:54** The use of immunotoxins against allergy. An immunotoxin targeted against FcεRI, and its improved trimeric design
000136 J. Narbona Corral (Madrid, Spain)

13:30 - 15:00 L- FT09 - Immune modulatory therapies for allergic diseases (Meeting room 3B01, Flash Talks)

Chair: R. van Ree (Amsterdam, Netherlands)

13:30 The drop of Allergen Immunotherapy in Italy: a direct assessment of sales

100062 G. Costanzo (Milan, Italy)

13:37 Quality of Life Improvement with 300 IR Liquid Sublingual Immunotherapy in Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomised and Non-randomised Studies

100066 D. Di Bona (Foggia, Italy)

13:44 Potential for clinical remission in house dust mite allergic rhinitis with the 300IR house dust mite sublingual immunotherapy tablet

100070 R. Brehler (Münster, Germany)

13:51 Potential for clinical remission in birch pollen-induced allergic rhinoconjunctivitis with a 300IR birch liquid sublingual immunotherapy

100071 M. Gerstlauer (Augsburg, Germany)

13:58 Treatment with mannan-conjugated birch pollen allergoids is safe and well tolerated in adult and adolescent birch pollen allergic patients – results from a Phase III DBPC trial

100182 E. Raskopf (Cologne, Germany)

14:05 Safety, adherence, and effectiveness of a short-course preseasonal subcutaneous immunotherapy with allergoid pollen extract of grass and/or olive adjuvanted with monophosphoryl lipid A (MPL) in real-world practice

100200 A. González Jáimez (Madrid, Spain)

14:12 Real-world effectiveness of tezepelumab in severe asthma: comparison between naive and switch patients

100419 V. Villalobos-Violan (Madrid, Spain)

14:19 Innovation in Trial Design of a Combined Short-and Long-term DBPC Phase III Study with PQ Grass and the First-Year Safety Data

100472 L. DuBuske (Washington, United States of America)

14:26 Systemic aluminum exposure during subcutaneous cluster allergen immunotherapy: pharmacokinetic analysis from a randomized phase II–III trial

100631 E. Aghayev (Hamburg, Germany)

13:30 - 15:00 JMA6 - Treatment options in chronic rhinosinusitis: best time, best procedure (Room Zurich, JMA)

Chair: *M. Schiappoli (Verona, Italy), J. Hagemann (Wiesbaden, Germany)*

13:30 The current relevance of surgery in the management of CRSwNP

J. Maza Solano (Sevilla, Spain)

14:00 Best management of CRSwNP exacerbation under biological treatment

Z. Tsinaslanidou (Thessaloniki, Greece)

14:30 Biologics in CRSwNP: tackle the inflammation at its origin

F. Ryser (Bern, Switzerland)

13:30 - 15:00 OAS20 - Molecular Allergology applied in clinics (Room Gothenburg, Oral Abstract Sessions)

Chair: *R. Bahri (Manchester, United Kingdom), P. Matricardi (Berlin, Germany)*

13:30 Clinical Relevance of Sensitization to Rare Allergen Sources

000473 S. Woehrl (Vienna, Austria)

13:42 Clinical characterization of the first subjects diagnosed with hereditary alpha-tryptasemia in Switzerland

001726 H. Wassmer (Basel, Switzerland)

13:54 Novel Calcium-Binding Allergens in Blue Swimmer Crab: Molecular Characterization of Sarcoplasmic Calcium-Binding Protein and Troponin C

000391 S. Heidari (Townsville, Australia)

14:06 Comparison of Molecular Tests and Skin Tests in Patients With Food Allergy and/or Polysensitization

001045 F. Tadik (İstanbul, Türkiye)

14:18 Assessing the Correlation between Molecular Sensitization to High-Risk Food Allergens and Clinical History: A Real-Life Adult Cohort Study

001331 M.-C. Cernat (Bucharest, Romania)

14:30 Outcomes of double-blind, placebo-controlled challenges with edible shrimps and their diagnosis by conventional and functional IgE-based allergy tests

000419 T. F. Leung (Shatin, Hong Kong)

14:42 Molecular sensitization profiles in house dust mite-allergic patients: a comparison of serum and nasal secretions

001635 P. Janssen (Ghent, Belgium)

13:30 - 15:00 OAS21 - Clinical biomarkers in pediatric and adult onset asthma (Room Munich, Oral Abstract Sessions)

Chair: **S. Foti Randazzese** (Pavia, Italy), **C. Janson** (Uppsala, Sweden)

13:30 Blood Eosinophils Alone Will Not Cut It: A Real-World, Multi-Biomarker Map of Type 2 Inflammation Across Chronic Airway Diseases

001171 R. Chen (Guangzhou, China)

13:42 Exhaled nitric oxide in pediatric asthma: clinical and functional associations

001998 A. Ursu (Lisbon, Portugal)

13:54 Body composition and airway inflammation in children: sex-specific associations between lean and muscle mass with FeNO

001797 J. Jesus (Porto, Portugal)

14:06 Asthma Control in the Context of Novel IOS Ratios, Systemic Inflammatory Indices, and Sensitization Status

001687 A. Suleyman (İstanbul, Türkiye)

14:18 Childhood exhaled nitric oxide predicts persistence of allergic sensitization into adolescence and young adulthood

000592 H. Chang (Taoyuan, Taiwan)

14:30 Respiratory oscillometry in children: feasibility and preliminary data from a national population-based study supporting future asthma care

000803 E. Wasilewska (Gdańsk, Poland)

13:30 - 15:00 SYM23 - New Insights into pediatric drug hypersensitivity (Room Istanbul, 1- Istanbul, Symposium)

Chair: **J.-C. Caubet** (Geneva, Switzerland), **Ö. Soyer** (Ankara, Türkiye)

13:30 The dilemma of viruses in pediatric drug hypersensitivity reactions

F. Mori (Florence, Italy)

14:00 A contemporary approach to diagnosis and management of DRESS in children

S. Kuyucu (Mersin, Türkiye)

14:30 Delabelling betalactam allergies in infants with non severe cutaneous reactions

E. Gomes (Porto, Portugal)

13:30 - 15:00 SYM24 - Planetary health - Allergic disease and the multi-exposome (Room Paris, 2- Paris, Symposium)

Chair: **R. Pawankar** (Tokyo, Japan), **O. Goksel** (Izmir, Türkiye)

13:30 From climate change to unpredictable planetary health: impacts on allergic and non-allergic diseases

C. Antunes (Évora, Portugal)

14:00 Allergens and pathogens (pollen and fungi and viruses) interactions with airway epithelium

S. Gilles (Augsburg, Germany)

14:30 Indoor air quality: Hidden sources and (un)controlled allergens

M. Raulf (Bochum, Germany)

15:00 - 16:30 TSY6 - Neutrophils in allergy and inflammation
(Room Florence, 3- Florence, Thematic Symposium)

Chair: **D. Dwyer (Boston, United States of America), C. Sokol (Boston, United States of America)**

13:30 Regulation of neutrophil function in inflammation and organ injury
A. Margraf (Münster, Germany)

14:00 Neutrophil response mechanisms in allergy and immunity
Ö. Alaz (Zurich, Switzerland)

14:30 Neutrophil extracellular traps and respiratory diseases
G. Marone (Naples, Italy)

13:45 - 14:15 Satellite Symposium
(Room Krakow, Sponsored Sessions)

13:45 - 15:15 GBD2 - Groundbreaking Discoveries in Skin Allergy
(Room Utrecht, 4- Utrecht, Ground Breaking Discoveries)

Chair: **C. Panaiteescu (Timisoara, Romania), K. Kabashima (Kyoto, Japan)**

13:45 Diagnostic approach to severe cutaneous adverse reactions
A. Barbaud (Paris, France)

14:15 Chronic urticaria treatment: unmet needs and future opportunities
T. Zuberbier (Berlin, Germany)

14:45 Atopic dermatitis treatment: from orphanhood to explosion
P. Schmid-Grendelmeier (Davos, Switzerland)

14:15 - 15:15 SRegulation of allergen-based products
(Room Krakow, 7- Krakow, Symposium)

14:15 Regulatory framework of allergen products to diagnose type I allergies
V. Mahler (Langen, Germany)

14:45 Regulatory framework of allergen products for AIT
J. Zimmer (Hessen, Germany)

14:40 - 15:40 SSS11 - EAACI KAAACI Joint symposium: Allergic and airway diseases across the life course
(Room London, 6- London, Sister Society Symposium)

Chair: **D. H. Lim (Incheon, Korea, Republic of)**

14:40 Severe asthma in Korea: Real-World clinical profiles, treatment strategies, and outcomes
J.-H. Kim (Anyang, Korea, Republic of)

15:00 Childhood asthma trajectories: Phenotypes and remission (KAS Cohort)
J. Yoon (Seoul, Korea, Republic of)

14:45 - 15:00 Highlight Session

(Innovation Hub, EAACI Special Session)

15:00 - 15:45 P & C 6 - PRO CON 6: Intramuscular adrenaline is preferable to nasal adrenaline

(EAACI Global Stage, Pro Con)

Chair: **G. Roberts (Southampton, United Kingdom)**

15:00 Pro

P. J. Turner (London, United Kingdom)

15:23 Con

M. Alvaro Lozano (Esplugues de Llobregat, Spain)

15:15 - 16:45 FT21 - Mechanistic insight in AIT

(Room Athens, Flash Talks)

Chair: **D. Barber (Madrid, Spain), J. A. Layhadi (London, United Kingdom)**

15:15 A consensus nsLTP allergen in mRNA-LNPs reduces Th2 and enhances Th1 responses in samples from nsLTP-allergic patients

001395 J. Corneliussen (Kongens Lyngby, Denmark)

15:22 A consensus nsLTP allergen induces cross-reactive IgG responses using mRNA-LNP immunization

000408 E. Rivera-De-Torre (Kongens Lyngby, Denmark)

15:29 Study on the role of RNA m6A methylation modification in subcutaneous immunotherapy for dust mite allergy in children with asthma

001616 X. Gao (Tsingdao, China)

15:36 Allergen-laden VNP decorated with IL-12 show enhanced Th1 priming activity and reduce Th2 immune responses in a preclinical humanized mouse model of mugwort allergy

000717 B. Kratzer (Wien, Austria)

15:43 Prophylactic T-cell modulation by an engineered full-length Art v 1 analogue shielded in a virus-like nanoparticle attenuates mugwort pollen allergy in a humanized mouse model

001694 A. N. A. Sehgal (Wien, Austria)

15:50 Dose-dependent anaphylaxis induced by subcutaneously administered Ara h 2 in a humanized mouse model for peanut allergy

000727 K. Hellström (Espoo, Finland)

15:57 Does oral and skin sensitisation to peanut lead to differences in the humoral response in Brown Norway rats?

000715 J. M. Puerta-Pertínez (Kongens Lyngby, Denmark)

16:04 Harnessing the power of high-affinity Siglec-9 ligands for allergen immunotherapy by site-specific glyco-tagging

000999 A. Ehlers (Utrecht, Netherlands)

16:11 Impact of the definition of the standardization unit on the biological potency of grass pollen extracts

000789 T. Batard (Antony, France)

16:18 Short-course treatment with mannan-conjugated birch pollen allergoids reduces allergic symptoms and medication need during the birch pollen season and induces immunological responses

100184 E. Raskopf (Cologne, Germany)

16:25 Clinical and Immunological Changes in Patients with Respiratory Allergies Undergoing Allergen Immunotherapy for Cat Dander: A Prospective, Real-World Study

100330 H. Chen (Wuhan, China)

16:32 Pioneering Intratonsillar Immunotherapy (ITIT): Inducing Rapid Clinical Remission via Dual Remodeling of Follicular T-Cell Subsets and Effector Granulocyte Function in Allergic Rhinitis

100338 T. Gu (Wuhan, China)

15:15 - 16:45 FT22 - Nasal polyps and beyond (Room Glasgow, Flash Talks)

Chair: J. Maza Solano (Sevilla, Spain)

15:15 Rupatadine inhibits Platelet-Activating Factor-induced Prostaglandin D2 in Nasal Polyps from CRSwNP patients
100204 J. Mullol (Barcelona, Spain)

15:22 Standardized data collection via the German National Chronic Rhinosinusitis Registry (GENRE CRS) facilitates future research projects
000599 F. Bärhold (Wiesbaden, Germany)

15:29 Treatment Patterns and Healthcare Resource Utilisation: A Real-World Survey of Patients with Chronic Rhinosinusitis with Nasal Polyps in Europe and the US
000494 F. Hennesy (Bollington, United Kingdom)

15:36 Rapid Reduction with Dupilumab in Total Symptom Score over 28 Days in Patients with Chronic Rhinosinusitis with Nasal Polyps: Interim Analysis from the ProGNOSE Study in Germany
000563 A. Chaker (München, Germany)

15:43 Dupilumab Rapidly Reduces IgE and Eosinophils in Kimura Disease: Sustained Remission Achieved
000340 H. Wang (Hangzhou, China)

15:50 The impact of biologic therapies on corticosteroid use in EGPA remission maintenance: a monocentric retrospective study
001812 B. Lauro (Cagliari, Italy)

15:57 Investigation of Single-Cell Transcriptional Heterogeneity in the Olfactory Mucosa of Patients with Chronic Rhinosinusitis and Olfactory Dysfunction
000934 H. Zhang (Guang Zhou Shi, China)

16:04 Male Predominance and Pubertal Resolution in Vernal Keratoconjunctivitis: Is Sex Steroid Intracrinology the Underlying Mechanism?
000160 S. Agarwal (Chennai, India)

16:11 Reduced Work Engagement in Patients With Chronic Rhinosinusitis: A Cross-Sectional Study
100366 H. Zhao (Jinan, China)

16:18 "Prevalence of Anxiety as an Invisible Burden and Its Relationship with Clinical Parameters in Patients with Chronic Rhinosinusitis with Nasal Polyps: A Cross-Sectional Study"
100608 Ş. IŞIK (Kayseri, Türkiye)

15:15 - 16:45 L- FT10 - Drug allergy

(Meeting room 3B01, Flash Talks)

Chair: **A. Ariza** (Málaga, Spain), **E. Gomes** (porto, Portugal)

- | | |
|---------------|--|
| 15:15 | Deciphering the clinical and genetic heterogeneity within drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with drug-induced liver injury |
| 100065 | S. He (Shanghai, China) |
| 15:22 | An in vitro diagnostic activation-induced marker (AIM) test to identify delayed hypersensitivity reactions to antibiotics |
| 100129 | R. Brooimans (Rotterdam, Netherlands) |
| 15:29 | Peri-operative anaphylaxis in Cape Town South Africa, a 2018-2025 Retrospective cohort |
| 100275 | C. Day (Cape Town, South Africa) |
| 15:36 | Suspected Hypersensitivity Reactions to Gadolinium-Based Contrast Agents: A Case Series |
| 100291 | C. Mações (Vila Nova de Gaia, Portugal) |
| 15:43 | Penicillin Allergy De-Labeling in Children: An Irish Secondary Care Framework for Low-Risk Patients |
| 100297 | M. Alim (Clonmel, Ireland) |
| 15:50 | Quality of life in Drug Allergy – Results from the BIOGRAL study |
| 100305 | N. P. Freundt-Serpa (Madrid, Spain) |
| 15:57 | DRESS Syndrome in pediatric population: Insights from a 9 reported cases |
| 100331 | N. Fathallah (Sousse, Tunisia) |
| 16:04 | International validation of a digital self-assessment tool (SELF-FAST) to identify low-risk penicillin and sulfa antibiotic allergies in adults |
| 100356 | M. Rose (Heidelberg, Australia) |
| 16:11 | Differential vascular inflammatory programs linked to kallikrein dynamics in African ACE inhibitor-associated angioedema |
| 100369 | S. Pedretti (Cape Town, South Africa) |
| 16:18 | Distinctive Features of Paracetamol- and Ibuprofen-Induced Reactions in Childhood |
| 100540 | S. Aksoy Girgiç (Istanbul, Türkiye) |
| 16:25 | PALM Study: Penicillin Allergy Labels and Management in the United Arab Emirates |
| 100715 | S. Elkhaila (Abu Dhabi, United Arab Emirates) |

15:15 - 16:45 IWS10 - Influence of co-morbidities in the management of atopic dermatitis

(Room Utrecht, 4- Utrecht, Interactive Workshop)

Chair: **P. Uysal** (Aydın, Türkiye), **M. De Graaf** (Utrecht, Netherlands)

- | | |
|--------------|---|
| 15:15 | Infections in patients with atopic dermatitis and the influence of treatment |
| | M.-C. Brüggen (Zürich, Switzerland) |
| 15:45 | Management of asthma associated with atopic dermatitis |
| | S. Del Giacco (Cagliari, Italy) |
| 16:15 | When to look for a contact dermatitis in patients with atopic dermatitis |
| | N. Douladiris (Nea Kallikratia, Chalkidiki, Greece) |

15:15 - 16:45 IWS11 - Frontiers in aerobiology: Automation, innovation, and clinical integration (Room Zurich, 5- Zurich, Interactive Workshop)

Chair: **C. Antunes** (Évora, Portugal), **J. Oteros** (Córdoba, Spain)

15:15 Clinical Relevance of automated aerobiology in allergy diagnosis and treatment

H. Bayram (Istanbul, Türkiye)

15:45 Advances in automatic methods for aerobiological monitoring

J. Buters (München, Germany)

16:15 Exploring alternative automated bioaerosol sampling methods in aerobiology

C. Skjøth (Roskilde, Denmark)

15:15 - 16:45 IWS12 - Feeding difficulties and adaptive behaviours in EoE (Room Krakow, 7- Krakow, Interactive Workshop)

Chair: **E. Savarino** (Padua, Italy), **T. Greuter** (Lugano, Switzerland)

15:15 Feeding difficulties in pediatric EoE: Systematic insights and clinical challenges

C. Pitsios (Nicosia, Cyprus)

15:45 Behavioural and symptom-based monitoring in pediatric EoE: From children to adolescents and parents

A. Bakirtas (Ankara, Türkiye)

16:15 The relationship between eating behaviours and esophageal remodeling: What can they tell us about disease state?

H. Duman Senol (İzmir, Türkiye)

15:15 - 16:45 OAS22 - Tissue structural cells in the control of inflammation (Room Gothenburg, Oral Abstract Sessions)

Chair: **A. L. Aral** (Istanbul, Türkiye), **A. Eljaszewicz** (Białystok, Poland)

15:15 Cell-type-selective immune remodeling and immunometabolic reprogramming in psoriatic arthritis after anti-interleukin-17 therapy

001159 A. Sherri (Łódź, Poland)

15:27 Earthquake-Derived PM_{2.5} from the 2023 Türkiye Earthquakes Induces Apoptosis and Oxidative Stress in Primary Human Bronchial Epithelial Cells and Bronchial Organoids

001650 Z. Shahpar (Istanbul, Türkiye)

15:39 Lipocalin 2 Participates in the Pathogenesis of Vitiligo by Regulating the iNOS-Nrf2 Signaling Axis

000940 K. Ren (Xi'an, China)

15:15 - 16:45 OAS23 - Transforming disease course: clinical outcomes and remission with biologics (Room Munich, Oral Abstract Sessions)

Chair: Z. Tsinaslanidou (Thessaloniki, Greece), T. Eiwegger (St. Poelten, Austria)

15:15 Achieving Remission in Chronic Rhinosinusitis with Nasal Polyps Depends on Application of Current Criteria and Existing Comorbidities: Results from a Bi-National Cohort

000441 J. Hagemann (Wiesbaden, Germany)

15:27 Clinically meaningful improvements in upper airway outcomes with dupilumab vs omalizumab by prior surgery status in severe chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST study)

001393 S. Reitsma (Amsterdam, Netherlands)

15:39 Pediatric IPEX-Associated Dermatitis Responds to Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling

000191 J. Yang (Shanghai, China)

15:51 Predictors of response to omalizumab treatment in patients with chronic spontaneous urticaria: a post hoc analysis of a double-blind, randomized, phase 3 study

000555 M. Metz (Berlin, Germany)

16:03 Quality of life outcomes of omalizumab biosimilar CT-P39 compared to reference omalizumab in patients with chronic spontaneous urticaria: a post hoc analysis of a double-blind, randomized, phase 3 study

000477 E. Heffler (Rozzano, Italy)

16:15 Efficacy of omalizumab in patients with chronic spontaneous urticaria with and without angioedema: a post hoc analysis of a double-blind, randomized, phase 3 study of omalizumab biosimilar CT-P39

000556 M. Metz (Berlin, Germany)

16:27 Verekitug, a novel TSLP receptor antagonist antibody, in participants with chronic rhinosinusitis with nasal polyps in VIBRANT: responder analysis using clinically meaningful efficacy outcome thresholds

000221 J. Mullol (Barcelona, Spain)

15:15 - 16:45 SYM25 - Microplastics and epithelial barriers (Room Istanbul, 1- Istanbul, Symposium)

Chair: D. Yazici (Rochester, NY, United States of America), C. Traidl-Hoffmann (Augsburg, Germany)

15:15 Effects of microplastics on lung epithelial cells

Y. Pat (Boston, United States of America)

15:45 Effects of microplastics on gut epithelial cells

S. Ardicli (Türkiye)

16:15 Pulmonary epithelial cells and the effects of microplastics on the respiratory system

M. Wang (Beijing, China)

15:15 - 16:45 SYM26 - Latest advancement in hymenoptera venom allergy (Room Paris, 2- Paris, Symposium)

Chair: T. Alfaya Arias (Madrid, Spain), E. Boni (Bologna, Italy)

15:15 Insights into early immunological responses in VIT

M. Ollert (Esch-sur-Alzette, Luxembourg)

15:45 Advances in the diagnosis of hymenoptera venom hypersensitivity

G. Sturm (Graz, Austria)

16:15 Longterm efficacy of venom immunotherapy

M. B. Bilò (Ancona, Italy)

15:15 - 16:45 SYM27 - Asthma heterogeneity and precision medicine (Room Florence, 3- Florence, Symposium)

Chair: A. Custovic (London, United Kingdom), O. Can Bostan (Istanbul, Türkiye)

15:15 Defining asthma molecular phenotypes – the road to effective therapies
I. Adcock (London, United Kingdom)

15:45 Asthma genomics, susceptibility and severity; polygenic clinical risk assessment
E. Bleecker (Tucson, United States of America)

16:15 The importance of local biomarkers
M. Mukherjee (Hamilton, Canada)

16:00 - 16:45 P & C 5 - PRO CON 5 - Should drug challenge precede desensitization in immediate hypersensitivity reactions to biologicals? (EAACI Global Stage, Pro Con)

Chair: D. González-de-Olano (Madrid, Spain)

16:00 Pro
R. Madrigal-Burgaleta (London, United Kingdom)

16:23 Con
M. Castells (Boston, United States of America)

17:00 - 18:30 FT23 - Urticaria contact dermatitis (Room Athens, Flash Talks)

Chair: D. Can (İzmir, Türkiye), M. Ferrer (Pamplona, Spain)

17:00 Complement C5 defines two immunological endotypes in CSU, with distinct autoantibody profiles and omalizumab responses: The INCA study
000384 J. Marcelino (Berlin, Germany)

17:07 Cyclosporine in Antihistamine-Refractory Chronic Spontaneous Urticaria: Clinical Outcomes and Biomarker Changes
000936 A. De (Kolkata, India)

17:14 Dyspnea and joint pain are the most common additional symptoms in chronic spontaneous urticaria and are associated with poor disease control and quality of life
001281 P. Pyatlova (Berlin, Germany)

17:21 Prevalence of sleep disturbance and obstructive sleep apnoea in chronic spontaneous urticaria and associated risk-factors – an institution-based analytical cross-sectional study
000249 I. Podder (Kolkata, India)

17:28 Long-term Barzolvolimab Treatment Results in Sustained Off-treatment Improvement in Angioedema in Patients with CSU Refractory to Antihistamines
000816 M. Metz (Berlin, Germany)

17:35 Development and Validation of the Symptomatic Dermographism Activity Score (SDAS)
000749 M. Muñoz (Berlin, Germany)

17:42 Psychometric Validation of the Worst Itch Numeric Rating Scale (WI-NRS) as a Patient-Reported Outcome (PRO) in Cold Urticaria: Data from a Clinical Trial of Barzolvolimab
000825 M. Metz (Berlin, Germany)

17:49 Regional differences in chronic inducible urticaria
001454 E. Kruger (Cape Town, South Africa)

17:56 REASSERT: A global, prospective, non-interventional, patient-centric study evaluating the effectiveness and safety of remibrutinib and quality of life (QoL) in patients with chronic spontaneous urticaria (CSU)
000333 M. Metz (Berlin, Germany)

18:03 Unmet needs in treatment escalation for chronic spontaneous urticaria: Findings from the CURE Registry
000769 P. Kolkhir (Berlin, Germany)

17:00 - 18:30 FT24 - Systems immunology across the spectrum: from inborn errors to therapy in pediatrics (Room Glasgow, Flash Talks)

Chair: J. Torres Borrego (Córdoba, Spain), S. S. Kilic (BURSA, Türkiye)

- 17:00** Nasal lavage–derived extracellular vesicles reflect allergic inflammation, IgE-related activity and epithelial remodeling in children with asthma
001357 D. Ambrozej (Warsaw, Poland)
-
- 17:07** Dietary Advancement Therapy using Milk and Egg Ladders: Preliminary Findings from a Pilot Observational Study
000912 C. Cronin (Cork, Ireland)
-
- 17:14** Causative Foods that change over time in childhood Food Protein–Induced Enterocolitis Syndrome
001873 M. B. İstanbullu (Denizli, Türkiye)
-
- 17:21** Distinct Tfh and Treg Signatures in Patients with Inborn Errors of Immunity
001242 F. Bayram Çatak (Istanbul, Türkiye)
-
- 17:28** Hematopoietic Stem Cell Transplantation for EBV-Associated Disease in Children with Inborn Errors of Immunity: A Case Series
000664 E. Kahveci (Istanbul, Türkiye)
-
- 17:35** Benralizumab as an effective steroid-sparing therapy in a child with steroid-dependent hypereosinophilic syndrome and multi-organ involvement
001048 J. S. Park (Seoul, Korea, Republic of)
-
- 17:42** Effectiveness, Safety Profile, and Patient Satisfaction of Subcutaneous Immunoglobulin Replacement Therapy in Primary Immunodeficiency
001085 C. Caka (Ankara, Türkiye)
-
- 17:49** Gender-Based Differences in Clinical and Immunological Profiles of Pediatric Vernal Keratoconjunctivitis
001778 B. Bozkurt (Konya, Türkiye)
-
- 17:56** The National Allergy Centre Of Excellence - Addressing Australia's Allergy Crisis
002088 K. Perrett (Parkville, Australia)
-

17:00 - 18:30 L-FT11 - Asthma

(Meeting room 3B01, Flash Talks)

Chair: K. Bønnelykke (Lillerød, Denmark), S. Quirce (Madrid, Spain)

17:00 IL-5/IL-5R blockade enables safe non-steroidal anti-inflammatory agent reintroduction in non-steroidal anti-inflammatory exacerbated respiratory disease

100173 P. Korkmaz (Istanbul, Türkiye)

17:07 Ultra-Processed Food Consumption as a Risk Factor in Childhood Asthma

100198 E. Topyildiz (Istanbul, Türkiye)

17:14 Real-world clinical characteristics and outcomes of severe asthma patients treated with tezepelumab: a multicenter retrospective cohort study

100288 L. de las Vecillas Sanchez (Madrid, Spain)

17:21 Lipolysis–microlipophagy cascade regulated by ATGL drives pathogenic adaptive type 2 immunity

100372 H. Yagyu (Yokohama, Japan)

17:28 Symptoms severity and molecular patterns of animal sensitization in veterinary workers

100400 A. Broggio (Padova, Italy)

17:35 Uncontrolled Asthma Significantly Increases Postoperative Respiratory Risk: A Prospective Study

100612 S. B. Kaya (Malatya, Türkiye)

17:42 Early clinical and inflammatory outcomes after initiation of tezepelumab in severe uncontrolled asthma: real-world data from the multicenter TRIGGER study

100660 K. Festa (Athens, Greece)

17:49 Chronobiologic Variation in Th1, Th2, and Th17 Cytokines in Severe Asthma

100722 A. Akenroye (Boston, United States of America)

17:56 Effectiveness of Broncho-Vaxom® in Preventing Recurrent Respiratory Tract Infections: Results from the REACH Study, a Multi-Country Real-World Study

100283 G. W. Canonica (Milan, Italy)

18:03 IL-33 modulates cytotoxic NK Cell Subsets in Severe Eosinophilic Asthma

000601 L. Bergantini (Siena, Italy)

17:00 - 18:30 IWS13 - Update on lipid transfer protein allergy

(Room Utrecht, 4- Utrecht, Interactive Workshop)

Chair: R. Asero (Paderno Dugnano, Milano, Italy)

17:00 LTP allergy - similarities and differences between children and adults

B. Pessina (Milano, Italy)

17:30 LTP allergy diagnosis - food triggers, allergic co-morbidities, co-factors and diagnostic options

I. Skypala (London, United Kingdom)

18:00 Immunotherapy and other management options

M. Fernandez Rivas (Madrid, Spain)

17:00 - 18:30 JMA7 - Allergen immunotherapy in special populations, what aspects should be taken into account? (Room London, JMA)

Chair: **E. Karakoç Aydiner** (İstanbul, Türkiye), **Z. Liu** (Wuhan, China)

17:00 AIT in immunodeficient patients: What do we know?
F. Cinetto (Treviso, Italy)

17:30 Insights from immune responses in allergy, immunotherapy and tolerance to cancer
S. Karagiannis (London, United Kingdom)

18:00 Clinical decision making in complex cases
D. Eyice Karabacak (Istanbul, Türkiye)

17:00 - 18:30 JMA8 - JMA Case Report Session (Room Krakow, JMA)

Chair: **B. Olivieri** (Verona, Italy), **G. Silva** (Porto, Portugal)

17:00 Fixed Drug Eruption Induced by Ferric Carboxymaltose with Positive Lymphocyte Transformation Test
N. C. Peña-González (Madrid, Spain)

17:08 When the excipient strikes: Mannitol-induced anaphylaxis. A case report
001088 D. M. Tello Montúfar (Santiago de Compostela, Spain)

17:16 Donor-Acquired Peanut Allergy After Lung Transplantation Despite Negative Skin and Serum IgE Testing
000199 K. Sohng (Toronto, Canada)

17:24 Severe Eczema: Presenting feature for Prolidase Deficiency
001326 A. K. Baskin (Ankara, Türkiye)

17:32 Selective Immediate Hypersensitivity to Triamcinolone: Identifying Safe Alternatives
001534 D. Harguindeguy Blanco (Valladolid, Spain)

17:40 Persistent egg yolk allergy after egg white oral immunotherapy: identification of YGP40
000472 M. D. L. A. Gonzalez-Labrador (Madrid, Spain)

100388 Hypersensitivity Reactions to Cardiac Resynchronization Therapy Devices: A Case Report
M. Bernardo (Ponta Delgada, Portugal)

100219 Season-dependent cholinergic urticaria with discordant exercise provocation: implications for diagnosis
J. Guimarães (Setúbal, Portugal)

100410 Autosomal Recessive Agammaglobulinemia caused by a FNIP1 mutation
D. İlgün Gürel (Ankara, Türkiye)

17:00 - 18:30 OAS24 - From risk to resilience: prevention of allergic diseases in childhood (Room Gothenburg, Oral Abstract Sessions)

Chair: **S. Arasi (Rome, Italy)**

17:00 Cat exposure and asthma outcomes in children with asthma and allergy

001284 R. Putri (Stockholm, Sweden)

17:12 Systematic review of maternal dietary patterns during pregnancy and offspring eczema/atopic dermatitis

001165 W. Tan (Cambridge, United Kingdom)

17:24 Multidimensional risk prediction model for infant atopic dermatitis: A prospective cohort study

000656 X. Gao (Tsingdao, China)

17:36 Therapeutic Efficacy of Cutaneous Application of Postbiotic N-(1-carbamoyl-2-phenyl-ethyl) Butyramide (FBA) in Pediatric Patients Affected by Atopic Dermatitis: The BuPAD Trial

002056 P. D'alessio (Naples, Italy)

17:48 Real-Life Outcomes from Nine Years of Allergen-Supervised Vaccination in Children at Risk for Hypersensitivity

000531 S. Foti Randazzese (Pavia, Italy)

18:00 Etiological and Prognostic Evaluation of Acute Urticaria in Childhood: A Multicenter Study

001112 D. Azkur (Kırıkkale, Türkiye)

18:12 Determining the Minimal Clinically Important Difference of the Urticaria Control Test in Children

001334 O. Y. Ulutas (Istanbul, Türkiye)

17:00 - 18:30 OAS25 - Epithelial barrier and systemic inflammation: from nose to gut (Room Munich, Oral Abstract Sessions)

Chair: **A. L. Aral (Istanbul, Türkiye), I. Ogulur (Davos, Switzerland)**

17:00 Early-Life Epithelial Immune Programming and Barrier Integrity Are Associated with Distinct Asthma Trajectories in Preschool Wheezers

001658 H. Charles (München, Germany)

17:12 Pathomechanisms of type-2 epithelial (E2) cells in allergy and asthma

001626 C. Schmidt-Weber (Munich, Germany)

17:24 Key Artemisia Pollen Components in the Progression from Allergic Rhinitis to Asthma: Mechanisms and Role Identification

001315 Y. Ru (Beijing, China)

17:36 Intranasal OM-85 Attenuates Allergen- and Virus-Induced Airway Inflammation by Restoring Epithelial-Macrophage Homeostasis

001669 A. Kouklas (Épalinges, Switzerland)

17:48 Single-Cell Profiling Reveals Enhanced Mast Cell - Epithelial Communication in CRSwNP and Its Modulation by Mepolizumab

002028 P. Yu (Gent, Belgium)

18:00 Transcriptomic comparison of nasal tissue and brushing samples in eosinophilic CRSwNP

000240 D. Nakashima (Tokyo, Japan)

18:12 Food emulsifier Polysorbate 80 Drives Gut Barrier Dysfunction and Systemic Inflammation Through Oxidative Stress

001618 C. Zeyneloglu (Davos, Switzerland)

17:00 - 18:30 SYM28 - Exposome and microbiome in immune regulation (Room Istanbul, 1- Istanbul, Symposium)

Chair: **Y. Pat** (Boston, United States of America), **W. Feleszko** (Warszawa, Poland)

17:00 The impact of air pollution on the immune system
O. Goksel (Izmir, Türkiye)

17:30 Immune response to airborne viruses and fungi
C. Karaaslan (Ankara, Türkiye)

18:00 IL-6 responses to virus and asthma exacerbations
M. Wegmann (Borstel, Germany)

17:00 - 18:30 TSY7 - From arachidonic acid and bioactive lipids to airway inflammation (Room Florence, 3- Florence, Thematic Symposium)

Chair: **A. Villasenar Solis** (Madrid, Spain), **M. Sanak** (Krakow, Poland)

17:00 Towards personalized asthma care: Metabolic profiling and the discovery of metabotypes
C. Wheelock (Stockholm, Sweden)

17:30 Targeting arachidonic acid signalling in different asthma inflammatory phenotypes
M. Tynecka (Białystok, Poland)

18:00 Multi-omics approaches towards studying the role of bioactive lipids in asthma and allergic diseases
U. Radzikowska (Davos, Switzerland)

17:00 - 18:30 YIR2 - YIR2 (Room Zurich, 5- Zurich, Year In Review)

Chair: **C. Panaitescu** (Timisoara, Romania)

17:00 Mechanisms of airway allergy
J. Schwarze (Edinburgh, United Kingdom)

17:30 Allergomics
H. Breiteneder (Vienna, Austria)

18:00 Allergen Immunotherapy
R. Zhu (Wuhan, China)

17:00 - 18:45 SYM29 - From clinic to classroom: Advancing allergy education across sectors Room Paris, 2- Paris, Symposium)

Chair: **C. Ozdemir** (İstanbul, Türkiye), **R. Gawlik** (Gliwice, Poland)

17:00 Allergy knowledge deficits in primary and school care: A European outlook
B. Buyuktiryaki (Istanbul, Türkiye)

17:30 Curriculum innovation for allergy management in primary health and education
G. Feketea (Patra, Greece)

18:00 Safer schools, better care: Measuring impact of allergy education
D. Ryan (Kegworth, United Kingdom)

07:45 - 08:45 GA - EAACI General Assembly
(Room London, 6- London)

- 07:45** Presidential report (vote for approval)
- 07:51** Secretary General and Vice-Presidents reports (vote for approval)
- 08:13** Treasurer report and EAACI Budget 2026 (vote for approval)
- 08:19** Reappointment of the Auditor (vote for approval)
- 08:23** Presentation and approval of 2026-2028 elections for the members of the Executive Committee (vote for approval)
- 08:29** EAACI President 2026-2028 address
- 08:39** Q&A Session

09:00 - 10:30 PL10 - Mast cell regulation across the body boundaries
(Room Istanbul, 1- Istanbul, Plenary Lectures)

Chairs: A. Santos (London, United Kingdom), I. Eguiluz (Malaga, Spain)

- 09:00** Targeting Bruton's Tyrosine Kinase in mast cells: From bench to bedside M. Dispenza
(Baltimore, United States of America)
- 09:30** Airway intraepithelial mast cells: differentiation and effector functions
D. Dwyer (Boston, United States of America)
- 10:00** Intraepithelial mast cells drive gasdermin C-mediated type 2 immunity

09:00 - 10:30 PL11 - Climate change on planetary health
(Room Paris, 2- Paris, Plenary Lectures)

Chairs: C. Ozdemir (İstanbul, Türkiye), C. Pitsios (Nicosia, Cyprus)

- 09:00** Allergy and climate: health impacts across a changing planet
I. Annesi-Maesano (Montpellier, France)
- 09:30** Environmental change and its effect the airway microbiome: Implications for respiratory health
A. Bossios (Stockholm, Sweden)
- 10:00** Climate driven trends in aerobiology
A. Damialis (Thessaloniki, Greece)

10:45 - 12:15 FT25 - Mastocytosis (Room Athens, Flash Talks)

Chairs: S. Altrichter (Linz, Austria), T. Gulen (Stockholm, Sweden)

10:45 001000	Effectiveness and tolerability of avapritinib in indolent systemic mastocytosis: first results from the French nationwide real-world AIMS study C. Gourguechon (Amiens, France)
10:52 000609	Durable Symptom and Quality of Life Improvement in Patients with Indolent Systemic Mastocytosis Treated with Avapritinib: Updated 4-Year Results from the PIONEER Trial V. Sabato (Antwerp, Belgium)
10:59 000966	Food-induced anaphylaxis in patients with mastocytosis: a clinical perspective from Verona G. Sfriso (Verona, Italy)
11:06 000534	Hereditary α -Tryptasemia, Tryptase Levels, and Mast Cell Burden in Nonadvanced Systemic Mastocytosis: Data from the Summit Trial of Bezucastinib N. A. Boggs (Bethesda, United States of America)
11:13 001999	Interpreting Baseline Serum Tryptase During Screening for Clonal Mast Cell Disease in the Presence or Absence of Hereditary Alpha-Tryptasemia V. Sabato (Edegem, Belgium)
11:20 001982	Incidence of hereditary alpha-tryptasemia diagnoses in a French university hospital: clinical and biological profile associated with a positive diagnosis C. Chatain (Grenoble, France)
11:27 001130	Baseline Tryptase >8 ng/mL Identifies a High-Risk Pediatric Subgroup for Anaphylaxis in Mastocytosis and Isolated Hypertryptasemia: A Single-Center Cross-Sectional Study N. Mól (Kraków, Poland)
11:34 001593	Phenotyping of a prospective cohort with elevated basal tryptasemia: prevalence of hereditary alpha-tryptasemia U. Jacquier (Nice, France)
11:41 001526	Hereditary Alpha-Tryptasemia in Children: Clinical and Laboratory Characterization of a Pediatric Cohort T. Bogs (Bonn, Germany)
11:48 000358	Urinary Lipid Metabolite Profiling in Pediatric Cutaneous Mastocytosis by Lipidomics R. Fukuda (Tokyo, Japan)
11:55 000938	ATH-004 potently inhibits MRGPRX2-mediated mast cell degranulation in vitro and in vivo F. Zhou (Shanghai, China)
12:02 001974	Targeting p84-dependent PI3Ky attenuates mast cell-driven inflammation without compromising host immunity R. Silveira (Basel, Switzerland)
12:09 100303	Avapritinib improves symptoms and quality of life in indolent systemic mastocytosis: 12-month outcome of the real-world AVATAR study P. Pyatlova (Berlin, Germany)

10:45 - 12:15 FT26 - Too little, too much: primary immunodeficiency and autoimmunity (Room Glasgow)

Chair: R. Castagnoli (Pavia, Italy)

10:45 000972	Clinical Spectrum of Cutaneous, Ocular and Hair Manifestations in Patients with Inborn Errors of Immunity: Insights from a Single Center in Turkey B. Cil Yılmaz (İstanbul, Türkiye),
10:52 000467	Malignancy Characteristics in Adults with Inborn Errors of Immunity: A Single-Center Experience O. Efe (Ankara, Türkiye)
10:59 001736	Evaluation of Frequency of Immunodeficiency, Clinical Characteristics, and Mortality-Associated Factors Among Patients in a Tertiary Pediatric Intensive Care Unit C. Genis (Ankara, Türkiye)
11:06 000995	National Experience in Adenosine Deaminase Deficiency: ADA-TR Study Group - A Multicenter Observational Cohort S. Bozkurt (İstanbul, Türkiye)
11:13 001300	Screening for Primary Immunodeficiency in Adults Attending Pulmonary and Allergy Clinics: A JMF-10–Based Study M. Akarsu (Ankara, Türkiye),
11:20 000671	Monogenic atopic disorders as an emerging category within primary immunodeficiencies A. Sediva (Praha 5, Czech Republic)
11:27 001389	Low Total IgE Identifies an Immune Dysregulation Phenotype in Adult Common Variable Immunodeficiency E. Çetin Başaran (Ankara, Türkiye),
11:34 001872	Infusion-Related Reactions During Immunoglobulin Replacement Therapy in Children with Primary Immunodeficiency: A Single-Center Experience Y. Kavas Yıldız (Ankara, Türkiye)
11:41 002057	Immunological and Functional Genomic Evaluation in ARPC1B Deficiency A. Bulutoglu (İstanbul, Türkiye)
11:48 002051	Assessing Humoral and Cellular Immunity Using Recombinant Zoster and Tetanus Vaccination in Adults with Antibody Deficiencies C. Tsoukas (Montréal, Canada)
11:55 000488	Assessment of Disease Severity in Common Variable Immunodeficiency Using Ameratunga and Grimbacher Scoring Systems G. Fitoz Emeksiz (Ankara, Türkiye)
12:02 001260	Clinical and Laboratory Characteristics in Patients with X-Linked Agammaglobulinemia at Vietnam National Children's Hospital Over 15 Years (2010–2025) T. X. D. Nguyen (Hanoi, Vietnam)

10:45 - 12:15 IWS14 - Management of severe cutaneous drug reaction (Room Utrecht, 4- Utrecht, Interactive Workshop)

Chairs: J. A. Trubiano (Parkville, Australia), A. Barbaud (Paris, France)

10:45 DRESS

E. Phillips (Nashville, United States of America)

11:15 Stevens-Johnson syndrome

C. Wen Hung (Taoyuan, Taiwan)

11:45 Acute generalized pustular exanthema

G. Karakaya (Ankara, Türkiye)

10:45 - 12:15 IWS15 - AIT : From decision making to adherence (Room Zurich, 5- Zurich, Interactive Workshop)

Chairs: P. Rodríguez del Río (Madrid, Spain), A. Nakonechna (London, United Kingdom)

10:45 Organ-specific challenges in airway allergy: How they shape AIT decisions

S. R. Durham (London, United Kingdom)

11:15 Placebo and Nocebo in allergen immunotherapy: More than a control arm

D. Antolin-Amerigo (Madrid, Spain)

11:45 Adherence to AIT in real life: Lessons from the clinic

S. Tsabouri (Ioannina, Greece)

10:45 - 12:15 IWS16 - Which sampling methods for which biomarkers in chronic airway disease? (Room London, 6- London, Interactive Workshop)

Chair: K. F. Chung (London, United Kingdom)

10:45 Systemic biomarkers: which and for which?

I. Dávila (Salamanca, Spain)

11:15 Lower airway sampling methods: which and for which biomarkers?

A. Spanevello (Varese, Italy)

11:45 Non-invasive methods for biomarkers assessment

S. Siddiqui (London, United Kingdom)

10:45 - 12:15 IWS17 - Searching for the balance: How (Dys)regulated proteolytic activity and cellular responses shape airway inflammation and remodeling (Room Krakow, 7- Krakow, Interactive Workshop)

Chair: B. Karaatmaca (Ankara, Türkiye), O. Kalayci (Ankara, Türkiye)

10:45 Unraveling serpin dynamics in asthma: Cross-talk between inflammation and cell death

D. Karaguzel (Ankara, Türkiye)

11:15 Breaking barriers: The role of proteolytic allergens in airway inflammation and remodeling

A. Eljaszewicz (Bialystok, Poland)

11:45 Fueling fibrosis: How aging bone marrow drives profibrotic macrophage activity in the lung

R. Gawish (Vienna, Austria)

09:00 - 10:30 OAS26 - It's pollen time!

(Room Gothenburg, Oral Abstract Sessions)

Chair: A. Damialis (Thessaloniki, Greece), C. Antunes (Évora, Portugal)

10:45 Artificial Intelligence in Aerobiology: Opportunities and Challenges for Personalized Pollen Information
001573 L. Dirr (Stockerau, Austria)

10:57 Pollen-specific optical and biochemical profiles for environmental aeroallergen monitoring
000716 O. Goksel (İzmir, Türkiye)

11:09 Pollen exposure and allergic respiratory diseases: a multicentric retrospective time series analysis in Bavaria, Germany
000230 M. Boser (Augsburg, Germany)

11:21 Clustering and Phylogenetic Analysis of Tree Pollen Sensitization Patterns to Optimize Allergen Immunotherapy
001848 M. Yasniuk (Vinnytsia, Ukraine), V. Rodinkova (Vinnytsia, Ukraine)

11:33 Prevalence of Sensitization to Ambrosia Pollen among Ukrainian Military Personnel on the Front Line (2022–2025)
001946 D. Gerasymchuk (Helsinki, Finland),

11:45 MRGPRX2-Mediated Mast Cell Activation by Artemisia Pollen Drives CCL2-Dependent Macrophage Polarization and Aggravates Asthma Airway Inflammation
001017 L. Yun (Xi'an, China)

11:57 LTP4 and TPL2: new IgE recognized components of Lolium perenne pollen induced by urban air pollution
100497 J. Fernandez (Alicante, Spain)

10:45 - 12:15 OAS27 - From biologics to cold steel

(Room Munich, Oral Abstract Sessions)

Chair: S. Reitsma (Ede, Netherlands), P. Li (Hong Kong, Hong Kong)

10:45 Aspirin-Exacerbated Respiratory Disease Diminishes Real-World Effectiveness of Mepolizumab in Severe Type 2 Chronic Rhinosinusitis with Nasal Polyps
001121 M. E. T. Zanetti (Ribeirao Preto, Brazil)

10:57 Real-World Comparison of Mepolizumab and Omalizumab in CRSwNP: Impact of Baseline Phenotypic Complexity
000857 O. T. Seren (İzmir, Türkiye)

11:09 Twice-Yearly Depemokimab Improves Symptoms and Quality of Life in Patients with CRSwNP with Post-Surgical Recurrence and Multiple Indicators of Type 2 Inflammation: Post Hoc Analysis of ANCHOR-1/-2
000584 E. De Corso (Rome, Italy),

11:21 Efficacy of Stapokibar in Chronic Rhinosinusitis with Nasal Polyps in South China: A Real-World Study from SYSU
001041 H. Zhong (Guangzhou, China)

11:33 Evaluation of simultaneous dual biological therapy in CRSwNP and concomitant type 2 diseases
000607 F. Bärhold (Wiesbaden, Germany)

11:45 Posterior nasal nerve neurectomy with mucosal flap coverage of the sphenopalatine foramen for treatment of allergic rhinitis: 12-month outcomes after treatment in a prospective cohort study
000633 L. Wang (Guangzhou, China)

11:57 Radical Endoscopic Sinus Surgery (with DrafIII Frontal Sinus Surgery) Combined with Bioabsorbable Steroid-eluting Sinus Stents for Recurrent Eosinophilic Sinusitis with Nasal Polyps
001018 H. Zheng (Fuzhou, China)

10:45 - 12:15 SYM30 - Trajectories of asthma and lung function (Room Istanbul, 1- Istanbul, Symposium)

Chairs: *I. Eguiluz (Malaga, Spain), M. Serbes (Adana, Türkiye)*

10:45 Asthma inception and trajectory through life course
E. Melén (Stockholm, Sweden)

11:15 Monitoring asthma in children
B. Beken (Istanbul, Türkiye)

11:45 Childhood lung function trajectories: implementation at clinical and population level
N. Papadopoulos (Athens, Greece)

10:45 - 12:15 SYM31 - SYM 31: Clinical trials and Real-world evidence in allergy (Room Paris, 2- Paris, Symposium)

Chairs: *S. Sindher (Stanford, United States of America), Z. Liu (Wuhan, China)*

10:45 Applying GRADE in clinical guideline: from evidence to actionable recommendations

11:15 How to integrate RWE in clinical guidelines
D. Di Bona (Foggia, Italy)

11:45 Shaping therapeutic goals by digital tools, trials and RWE
T. Chivato (Alcorcon, Spain)

10:45 - 12:15 SYM32 - Ultra-Processed Foods (UPF) and the onset of adverse food reactions (Room Florence, 3- Florence, Symposium)

Chairs: *C. Venter (Aurora, United States of America), E. Vassilopoulou (Thessaloniki, Greece)*

10:45 What are the most relevant detrimental UPF compounds?
C. Sackesen (Istanbul, Türkiye)

11:15 Deciphering the mechanisms and the effects of UPF interaction with human cells and microbiome
R. Berni Canani (Naples, Italy)

11:45 How to limit the UPF exposure in the paediatric age
P. Smith (Southport, Australia)

10:45 - 12:15 EAACI Special Session 3 - Presidential Symposium - Science in the era of disinformation: The responsibility of medical societies (Room Istanbul, 1- Istanbul, EAACI Special Session)

12:30 Opening Remarks

12:35 Presidential Keynote 1: Framing the global context: why defending scientific integrity is now a strategic priority for EAACI and allied societies.
G. W. Canonica (Milan, Italy)

12:50 Presidential Keynote 2: Evidence-based medicine under scrutiny: Maintaining standards in a fragmented information landscape
M. Torres (Malaga, Spain)

13:05 Presidential Panel Discussion: From misinformation to leadership: How medical societies must respond

12:30 - 14:00 FT27 - Biomarkers in food allergy and skin allergy

(Room Athens, Flash Talks)

Chair: Ö. Soyer (Ankara, Türkiye)

12:30
000745 **Systemic metabolic biomarkers identifying clinical tolerance in lipid transfer protein (LTP) allergy after pectin intervention**

J. Morillas-Armenta (Boadilla del Monte, Spain),

12:37
001136 **Optimising the diagnosis of sesame seed allergy with the basophil activation test**

R.-X. Foong (London, United Kingdom)

12:44
000176 **Alpha-Hairpinin (Pap s 1.0101) Sensitization and Optimized Prick-to-Prick Testing Define Clinical Poppy Seed Allergy in Children**

C. Caka (Ankara, Türkiye)

12:51
001839 **What Happens in the Long Term to Pediatric Patients with Unexplained Elevated IgE?**

Ç. Torun Özel (Ankara, Türkiye)

12:58
000059 **Tryptophan, kynurenine levels and indoleamine 2,3-dioxygenase activity in patients with chronic spontaneous urticaria**

E. Burygina (Saint Petersburg, Russia)

13:05
001155 **Is low IgE a potential marker for type IIb autoimmunity: findings from a large international cohort**

S. Ornek Ozdemir (London, United Kingdom)

13:12
001230 **Remibrutinib-induced decreases in B cell biomarkers are associated with complete and sustained response in chronic spontaneous urticaria patients**

M. Metz (Berlin, Germany)

13:19
001442 **The correlation between serum lactate dehydrogenase activity and disease severity in children with moderate-to-severe atopic dermatitis**

T. T. T. TRAN (Hanoi, Vietnam)

13:26
002002 **Non-invasive Multiomics Skin Profiling of Atopic Dermatitis via Tape Strip Sampling**

A.-M. Schoos (Copenhagen, Denmark)

13:33
100509 **Clinical and molecular cross-sensitization phenotypes of non-specific lipid transfer proteins (nsLTP) in a Portuguese cohort**

M. I. Garcia (Funchal, Portugal)

13:40
100648 **Salivary Proteomic in Atopic Dermatitis: Identifying Non-Invasive Biomarkers of Glandular Dysfunction and Oxidative Stress**

L. Franchi (Monsezzato, Italy)

12:30 - 14:00 FT28 - New clinical and immunologic insights in AIT for Food and Respiratory Allergy (Room Glasgow, Flash Talks)

Chair: D. Eyice Karabacak (Istanbul, Türkiye)

- | | |
|------------------------|---|
| 12:30
002020 | Clinical description of a pediatric cohort with severe and persistent IgE-mediated cow's milk protein allergy managed at a tertiary university hospita
L. Bohbot (Stras, France), C. Metz-Favre (Strasbourg, France) |
| 12:37
000480 | Impact of Food Form on Eliciting Dose Relative to Habitual Intake During Cow's Milk Oral Food Challenge: A Real-World Analysis
S. Hamaguchi (Tokyo, Japan) |
| 12:44
000931 | Component-Specific IgE and IgG4 Changes During Low-Dose Oral Immunotherapy for Walnut Allergy in Children
Y. Shimaoka (Sagamihara, Japan), |
| 12:51
000720 | Clinical Proof of Concept of VLP Peanut for Treatment of Peanut Allergy
A. Santos (London, United Kingdom) |
| 12:58
001709 | A Hypoallergenic Ara h 2-VLP Peanut Vaccine: Tolerogenic Immune Features in Healthy Volunteers
J. A. Layhadi (London, United Kingdom) |
| 13:05
001497 | Contribution of the individual allergens Ara h 1, 2, 3 and 6 and post-translational proline hydroxylation modifications of Ara h 1, 2 and 3 differs in intraperitoneal, oral and skin sensitisation to peanut in Brown Norway rats
J. M. Larsen (Kongens Lyngby, Denmark), K. Bøgh (Kgs. Lyngby, Denmark) |
| 13:12
000653 | Hypoallergenic probiotic vaccine for shrimp allergy treatment: Induction of shrimp tropomyosin-specific blocking antibodies
C. Y. Y. Wai (Shatin, Hong Kong) |
| 13:19
000732 | Effectiveness and Safety Study of Subcutaneous Immunotherapy for Respiratory Allergy to Dermatophagoides and Grass Pollen
Y. Ruiz García (Alcalá de Henares, Spain) |
| 13:26
001938 | Effectiveness of Allergen-Specific Immunotherapy in Bronchial Asthma and allergy rinitis Triggered by Tree and Grass Pollen Allergens"
L. Bugadze (T'bilisi, Georgia) |
| 13:33
000513 | Impact of liquid sublingual immunotherapy on sleep and mental health issues in patients with allergic rhinitis with or without asthma in the real-world EfficAPSI study
E. Fromentin (Lille, France) |
| 13:40
001006 | Revisiting Subcutaneous Aeroallergen Immunotherapy: A Single-Center Experience
S. Yalçın (Ankara, Türkiye) |
| 13:47
100161 | Consistency of treatment efficacy across main comorbidity subgroups in pediatric birch-induced allergic rhinoconjunctivitis in the YOBI trial
M. Gerstlauer (Augsburg, Germany) |

12:30 - 14:00 IWS18 - Managing venom allergy (Room Utrecht, 4- Utrecht, Interactive Workshop)

Chair: *G. Sturm (Graz, Austria), P. Kopac (Golnik, Slovenia)*

12:30 Challenges in the diagnosis and treatment of hymenoptera venom hypersensitivity

A. Vega Castro (Guadalajara, Spain)

13:00 From induction protocols to maintenance management

E. Boni (Bologna, Italy)

13:30 Sting challenge test

T. Alfaya Arias (Madrid, Spain)

12:30 - 14:00 IWS19 - Beyond Type 2 inflammation in asthma (Room Zurich, 5- Zurich, Interactive Workshop)

Chair: *L. DuBuske (Washington, DC, United States of America), S. Del Giacco (Cagliari, Italy)*

12:30 Does type 2 low asthma exist as a clinical phenotype?

K. F. Chung (London, United Kingdom)

13:00 The need for novel non-invasive biomarkers for clinical practice

J. Dominguez-Ortega (Madrid, Spain)

13:30 Are infection or comorbidities drivers of asthma?

P. Nair (Hamilton, Ontario, Canada)

12:30 - 14:00 IWS20 - Multidisciplinary approaches in allergy care (Room London, 6- London, Interactive Workshop)

Chair: *J. Hourihane (Dublin, Ireland), B. Sekerel (Ankara, Türkiye)*

12:30 Empowering primary and allied health in allergy diagnosis and patient support

C. Ozdemir (İstanbul, Türkiye)

13:00 Molecular profiling of food allergens: Clinical relevance in nutrition planning

R. van Ree (Amsterdam, Netherlands)

13:30 Safe food planning for children with multiple allergies: Beyond elimination

C. Berghea (București, Romania)

12:30 - 14:00 OAS28 - From mechanisms to meaningful outcomes: Biologics in respiratory disease (Room Gothenburg, Oral Abstract Sessions)

Chair: I. Kaydashev (Poltava, Ukraine)

- 12:30**
000142 **Dupilumab + AIT: CD8⁺ T Cells Uncover a Potent Immune Reset in Severe Allergic patients**
J. López-Rodríguez (Alcorcón, Spain)
- 12:42**
000125 **Comparative longitudinal immunoproteomics in asthma patients treated with three different biologic agents**
C. Rosales-Ariza (Madrid, Spain)
- 12:54**
000860 **Arachidonic Acid Metabolite Profiling for Biologic Selection and Treatment Monitoring in Severe Asthma**
M. Liu (Guangzhou, China)
- 13:06**
000673 **Dupilumab Significantly Improves the Likelihood of Achieving Clinical Remission Components in Patients With Moderate-to-Severe Asthma and Markedly Elevated Eosinophils and FeNO: Win Ratio Analysis of QUEST**
B. J. Lipworth (Dundee, United Kingdom)
- 13:18**
001266 **Off-label Use of Type 2 Targeted Biologic Therapies in Pediatric Pulmonology and Allergy: A National Multicenter Cohort Study (France, 2005–2025)**
C. Josserand (Nice, France)
- 13:30**
000923 **Impact of initiation timing on the efficacy of biologics in seasonal allergic rhinitis: A prospective observational study**
Z. Pan (Beijing, China), X. Zhou (Beijing, China)

12:30 - 14:00 OAS29 - Pediatric food allergy: from diet to disease modulation (Room Munich, Oral Abstract Sessions)

Chair: S. Tsabouri (Ioannina, Greece)

- 12:30**
001131 **Investigation of Factors Determining Tolerance and Reactivity to Sesame in Patients with Sesame Sensitization**
G. Yaylak (İstanbul, Türkiye)
- 12:42**
000879 **A Fifteen-Year Multicentre Experience of Egg Ladder Management for IgE-Mediated Egg Allergy in Young Children in Ireland**
J. E. Trujillo Wurttele (Cork, Ireland)
- 12:54**
000870 **Biscotti-Twice-Baked-Cake is a New Method to Reintroduce Milk in Cow's Milk Protein Allergy**
C. Bülbüloğlu (İstanbul, Türkiye)
- 13:06**
001598 **Could Ultraprocessed Foods Contribute to Food Protein-Induced Allergic Proctocolitis in Breastfed Infants?**
L. Carucci (Napoli, Italy),
- 13:18**
001623 **How Dietary Advanced Glycation End Products (AGEs) could increase the eosinophils in human esophagus: new insights in pediatric eosinophilic esophagitis pathogenesis**
L. Carucci (Naples, Italy)
- 13:30**
001211 **A novel dietary therapy, the Rainbow Diet, induces consistent histologic and clinical remission in pediatric non-EoE eosinophilic gastrointestinal diseases: a proof-of-concept study**
I. Nomura (Tokyo, Japan)
- 13:42**
001338 **Formula Choice Shapes Epigenetic, Immunological and Gut Microbiota trajectories toward Immune Tolerance in Children with IgE-Mediated Cow's Milk Allergy: Mechanistic Insights from the EPICMA Study**
L. Carucci (naples, Italy)

12:30 - 14:00 TSY8 - IL-33 role in different tissue targets mediating inflammatory responses
(Room London, 6- London, Thematic Symposium)

Chair: **H. Morita (Tokyo, Japan), C. Akdis (Davos, Switzerland)**

12:30 How IL-33 and the microbiota shape immune responses in the lung
B. Opitz (Berlin, Germany)

13:00 IL-33 role in the gut immune system
T. Pizarro (Cleveland, United States of America)

13:30 IL-33 role in mast cell mediated cutaneous diseases
G. Nilsson (Stockholm, Sweden)

12:30 - 14:15 SYM34 - Update In angioedema therapy
(Room Paris, 2- Paris, Symposium)

Chairs: **M. Guilarte (Barcelona, Spain), A. Akkor (Istanbul, Türkiye)**

12:30 New therapies: is it time to hypothesize tailored therapies?
A. Valerieva (Sofia, Bulgaria)

13:00 The new landscape of hereditary angioedema treatment: 25 years of advancement
T. Caballero (Madrid, Spain)

13:30 Treat-to-target approach in HAE
M. Cancian (Padova, Italy)

12:30 - 14:15 SYM35 - Food allergy prevention
(Room Florence, 3- Florence, Symposium)

Chairs: **R. Berni Canani (Naples, Italy), O. Kalayci (Ankara, Türkiye)**


12:30 Overview of the prevention of food allergy
G. Roberts (Southampton, United Kingdom)

13:00 A nutritional approach to food allergy prevention
C. Venter (Aurora, United States of America)

13:30 The prevention of food allergy - a dual approach
H. O. Skjerven (Oslo, Norway)

14:15 - 14:45 Closing Ceremony
(Room Istanbul, 1- Istanbul, Ceremony)

The National Allergy Society Village is open throughout the entire Congress and features the virtual booths of our NAS from all over Europe. At each booth you will be able to visualise brochures, watch videos, consult important national resources and much more. You will also have the chance to interact with respective members of the NAS through an e-mail form. We encourage you to visit this area to learn more about your country's very own society dedicated to allergy, asthma, and immunology, or explore developments in the field from other countries.

	Armenia Armenian Association of Allergologists and Immunologists (AAAI)		Italy Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO)
	Azerbaijan Azerbaijan Society of Allergologists and Immunologists (ASAI)		Italy Italian Society of Pediatric Allergy and Immunology (SIAIP)
	Belgium Association Belge de Formation Continue en Allergologie (ABEFORCAL)		Italy Italian Society of Allergology, Asthma and Clinical Immunology (SIAAIC)
	Croatia Croatian Society for Allergology and Clinical Immunology (CSACI)		Kazakhstan Kazakhstan Association of Allergology and Clinical Immunology (KAACI)
	France French Society of Allergology and Clinical Immunology (SFA)		North Macedonia Macedonian Respiratory Society (MRS)
	Georgia Georgian Association of Allergology and Clinical Immunology (GAACI)		North Macedonia Pediatric Respiratory Society (PEDIARES)
	Germany German Society for Allergology and Clinical Immunology (DGAKI)		North Macedonia Society of Pulmonologists of the Republic of Macedonia (SPRM)
	Germany German Society of Allergology (AeDA)		Poland Polish Society of Allergology (PTA)
	Greece Hellenic Society of Allergology and Clinical Immunology (EAAKA)		Romania Romanian Society of Allergology and Clinical Immunology (RSACI)
	Greece Greek Paediatric Allergy Society (GPAS)		Spain Spanish Society of Allergology and Clinical Immunology (SEAIC)
	Hungary Hungarian Society of Allergology and Clinical Immunology (MAKIT)		Spain Spanish Pediatric Society of Clinical Immunology, allergy and Asthma (SEICAP)



Serbia

Serbian Association of Allergology and Clinical Immunology (SAACI)



Türkiye

Society of Pediatric Allergy Immunology and Asthma (CAİAD)



Türkiye

Turkish National Society of Allergy and Clinical Immunology (TNSACI)



Türkiye

Turkish Society of Immunology (TSI)



Türkiye

Turkish Thoracic Society (TTS)



United Kingdom

British Society for Allergy & Clinical Immunology (BSACI)



Commonwealth of Independent States (CIS)
Society of Allergology and Immunology



Algeria

Algerian Society of Allergy and Clinical Immunology (ASACI)



Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI)



Hong Kong Special Administrative Region of China

Hong Kong Institute of Allergy (HKIA)



India

Indian Academy of Pediatrics (IAP)
Allergy Chapter



Japan

Japanese Society of Allergology (JSA)



Korea

Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI)



United Arab Emirates

Gulf Academy of Allergy and Clinical Immunology (GA2CI)



Patient Organisations Committee (POC)

Sponsorship and Exhibition

This section contains information that is promotional in nature, distinct from the scientific / educational elements of the EAACI Congress 2026.





Join us for the ALK-sponsored EAACI 2026 symposia

From evidence to practice: Real-world use and clinical implementation of nasal adrenaline in anaphylaxis

When

Friday 12 June, 12:00–13:00

Where

Room: Paris

Introduction: Aikaterini Anagnostou, US

- *Addressing the unmet needs in paediatric and adult anaphylaxis management: The role of nasal adrenaline*
Nick Makwana, UK
- *Real-world evidence of nasal adrenaline in anaphylaxis management*
Knut Brockow, DE
- *Patient preference and clinical implementation of nasal adrenaline*
Doug Mack, CA

Panel discussion

20 years of SQ SLIT-tablet experience: Key learnings and new horizons

When

Saturday 13 June, 12:00–13:00

Where

Room: Paris

Introduction: Moisés Calderón Zapata, Costa Rica

- *Disease modifying & preventative benefits: The ultimate goal of allergy immunotherapy*
Stephen Durham, UK
- *Connecting the airways: Clinical benefits beyond allergic rhinitis*
Anna von Bülow, DK
- *Next steps: Peanut SLIT-tablet Phase 2 efficacy & safety outcomes*
Edwin Kim, US

Panel discussion

Founder Sponsors



EAACI and the Local Organising Committee gratefully acknowledge the support of the 2025 Founder Sponsors.



Platinum Level



Gold Level



Silver Level



Corporate Level



Please [CLICK HERE](#) to view the full list of the EAACI Founder Sponsors.



Join us for our company sponsored
satellite symposium at **EAACI 2026**

From Nobel-prize discovery to AIT clinical evidence:

Shaping pathways to respiratory allergy remission

S P E A K E R S



Turning off allergy at its source: The potential of AIT

Prof Mübeccel Akdiş (Chair),

Head of the Immune Regulation research group at the Swiss
Institute for Allergy and Asthma Research, Davos, Switzerland



Birch SLIT: What's new in the evidence?

Prof Oliver Pfaar,

Head of the Section of Rhinology and Allergology,
University Hospital, Philipps-University Marburg, Germany



**From consensus to clinical impact: AIT outcomes
through the lens of remission**

Prof Johann Christian Virchow,

Head of the Department of Pulmonology,
University Hospital Rostock, Germany

12 June 2026 | 13:30–14:30, Room Utrecht, Level B2

You can also join us virtually at the EAACI Hybrid Congress

Friday 12 June 2026

12:00 - 13:00 SAT1-1 - ALK - From evidence to practice: Real-world use and clinical implementation of nasal adrenaline in anaphylaxis (Room Paris, Sponsored Sessions)

Chairs: A. Anagnostou (Houston, United States of America)

Objectives:

- Addressing the unmet needs across children and adults at risk of anaphylaxis
- Real-world evidence of nasal adrenaline – what have we learned
- Clinical usability and implementation of nasal adrenaline

12:00 Introduction

A. Anagnostou (Houston, United States of America)

12:05 Addressing the unmet needs in paediatric and adult anaphylaxis management: The role of nasal adrenaline

N. Makwana (Birmingham, United Kingdom)

12:20 Real-world evidence of nasal adrenaline in anaphylaxis management

12:35 Patient preference and clinical implementation of nasal adrenaline

D. Mack (Hamilton, Canada)

12:50 Panel discussion

A. Anagnostou (Houston, United States of America)

12:00 - 13:00 SAT1-2 - Siemens Healthineers - Precision in High-Risk Allergy: Navigating Patient Impact (Room Utrecht, Sponsored Sessions)

Chair: Alexandra Santos (United Kingdom, London)

Objectives:

At the end of this symposium, participants will be able to:

- Describe current guideline-based approaches to food allergy and apply principles of precision diagnostics to support more confident clinical decision-making in high-risk allergy, balancing diagnostic accuracy with meaningful patient impact.
- Discuss peanut allergy as a model of high-risk food allergy, using real-world data to illustrate how discrepant diagnostic results, component testing, CCD interference, and oral food challenges can impact clinical decision making.
- Explain how diagnostic decisions in food allergy influence patient risk perception, quality of life, and daily management.

12:00 High-risk allergy: guidelines, gaps, and clinical responsibility

Alexandra Santos (United Kingdom, London)

12:15 Peanut allergy as a high-risk model: precision, discrepancies, and clinical certainty

Ángel L. Brull (Spain, Madrid)

12:35 Living with risk: the consequences of diagnostic decisions

Christina Jones (United Kingdom, University Campus)

Join us at our Symposium



Scoring Against Allergies

New Therapeutic Approaches on the Horizon



Match Analysis

1

**PQ Grass 27600 SU:
Progress in paediatrics
after our goal in adults**

Coach: Mohamed Shamji

Players: Sven Becker,
Janice Layhadi,
Stephanie Dramburg

Match Analysis

2

**Building Future Strikers:
VLP Peanut Lines Up
as a game changer**

Coach: Janice Layhadi

Players: Mohamed Shamji,
Roxanne Oriel,
Alexandra Santos

Friday 12th June 2026

3 - 4pm

Room: London

**Allergy
Therapeutics**

Aluminium
free company



**Bencard
Allergie**



come and visit us on stand G10

Friday 12 June 2026

12:00 - 13:00 SAT1-3 - AstraZeneca - From barrier repair to better outcomes: Epithelial health towards achieving remission
(Room Zurich, Sponsored Sessions)

Chair: **Joaquim Mullol** (Spain, Barcelona)

- 12:00 Welcome**
Joaquim Mullol (Spain, Barcelona)
- 12:02 Introduction**
Oscar Palomares (Spain, Madrid)
- 12:12 Reframing airway disease: the role of the epithelium as a key immune-functioning organ**
Anju Peters (United States of America, Chicago)
- 12:24 From damage to repair: targeting epithelial dysfunction to modify disease trajectory**
Oscar Palomares (Spain, Madrid)
- 12:36 From mechanism to remission: exploring the mechanisms of epithelial dysfunction in airway health**
Stella E Lee (United States of America, Boston)
- 12:48 Faculty-led discussion and audience Q&A**
Joaquim Mullol (Spain, Barcelona), Oscar Palomares (Spain, Madrid),
Anju Peters (United States of America, Chicago), Stella E Lee (United States of America, Boston)
- 12:58 Summary and close**
Joaquim Mullol (Spain, Barcelona)

12:00 - 13:00 SAT1-4 - GSK - Unlocking Sustained Control in Airway Disease: What Will It Take?
(Room London, Sponsored Sessions)

Chair: **E. Heffler** (Milano, Italy)

- 12:00 Not Just Control, but Sustained Control: Raising the Bar in Airway Disease Management**
E. Heffler (Milan, Italy)
- 12:10 Lessons From Success: Pathways to Sustained Control in Other Inflammatory Diseases**
P. Howarth (London, United Kingdom)
- 12:20 Evolving Respiratory Care: Bridging Today's Practice to Tomorrow's Sustained Control**
P. Gevaert (Gent, Belgium), E. Heffler (Milan, Italy)
- 12:40 What Will It Take? Turning the Vision of Sustained Control Into Clinical Reality (Panel discussion)**
E. Heffler (Milan, Italy), P. Gevaert (Gent, Belgium), P. Howarth (London, United Kingdom)
- 12:50 Unlocking the Era of Sustained Control: The Path Forward for Airway Disease**
E. Heffler (Milan, Italy)
- 12:55 Q&A**
P. Gevaert (Gent, Belgium), E. Heffler (Milan, Italy), P. Howarth (London, United Kingdom)

Who Benefits from AIT? Measuring, Predicting and Improving Treatment Response

Saturday, 13 June 2026
13:45 – 14:45 Room Krakow

Satellite
Symposium

Chairs

Prof. Susanne Lau
Germany



**Prof. Magdalena
Zemelka-Wiacek**
Poland



Speakers

**Tracking Patient Progress in AIT:
What the Chamber Reveals**
Prof. Marek Jutel
Poland



**Predicting Patients' Response
to AIT: Myths and Measurements**
Prof. Ludger Klimek
Germany



**Asthma and Allergy: Biomarker
Discovery for Asthma Diagnosis
and Assessment of Severity Using
Machine Learning and AI**
Prof. Adnan Custovic
United Kingdom



**Join this Allergopharma-sponsored
symposium and visit us at our booth!**

allergopharma

Friday 12 June 2026

12:00 - 12:15 PT 1-1 - CSL - Garadacimab in Practice: Real-world experience from the First Year of Use
(Innovation Hub, Product Theatre)

Chair: **P. Li (Hong Kong, Hong Kong)**

12:00 Garadacimab in Practice: Real-world experience from the First Year of Use
Markus Magerl (Germany, Berlin)

12:15 - 12:30 PT 1-2 - CSL - Growing Up Protected: Why Long-Term Prophylaxis Matters in Adolescents with HAE
(Innovation Hub, Product Theatre)

Chair: **P. Li (Hong Kong, Hong Kong)**

12:15 Growing Up Protected: Why Long-Term Prophylaxis Matters in Adolescents with HAE
S. Betschel (Toronto, Canada)

12:45 - 13:00 PT 1-3 - Beckman Coulter - Basophil Activation Test (BAT)
(Innovation Hub, Product Theatre)

Chair: **J.-M. Busnel (Marseille, France)**

Objectives:

BAT is a functional assay for measuring basophil activation in response to specific allergens or other stimuli.

Basophils play a critical role in allergies by releasing histamine and other mediators when activated. During a Basophil Activation Test a sample of blood is exposed to suspected allergens and then analyzed on a flow cytometer to identify the activation of basophils using conjugated antibodies specific to activation markers expressed on the surface of basophils.

However, due to the perceived complexity of the tools, BAT has not been widely adopted so far. Ready-to-use dry reagents can support driving adoption by being straightforward, standardized and easy to use, giving access to BAT insights even to non-expert laboratories.

BAT is minimally invasive and could potentially be complementary to traditional tools used in the study of allergies.

12:45 Next-Gen Basophil Activation Test
J.-M. Busnel (Marseille, France)

13:30 - 14:30 SAT1-6 - Stallergenes Greer - From Nobel-prize discovery to AIT clinical evidence: Shaping pathways to respiratory allergy remission
(Room Utrecht, Sponsored Sessions)

Chair: **M. Akdis (davos wolfgang, Switzerland)**

13:30 Introduction
M. Akdis (davos wolfgang, Switzerland)

13:35 1. Turning off allergy at its source: The potential of AIT
M. Akdis (davos wolfgang, Switzerland)

13:45 2. Birch SLIT: What's New in the Evidence
O. Pfaar (Marburg, Germany)

14:00 3. From consensus to clinical impact: AIT outcomes through the lens of remission
J. C. Virchow (Rostock, Germany)

14:15 Take home messages - Q&A
J. C. Virchow (Rostock, Germany), O. Pfaar (Marburg, Germany), M. Akdis (davos wolfgang, Switzerland)

Friday 12 June 2026

13:30 - 14:30 SAT1-7 - Neopharmed Gentili - Treat-to-Target in HAE: A personalised approach to support patients reach normalisation of life
(Room Krakow, Sponsored Sessions)

Chair: **M. Magerl (Berlin, Germany), M. Magerl (Berlin, Germany)**

Objectives:

- Review the Treat-to-Target approach in HAE published in 2026, and its role in supporting the implementation of guidelines to optimise clinical outcomes
- Understand the psychosocial impact of HAE and how to personalise patients' treatment goals from adolescence through adulthood
- Explore real-world case studies highlighting how treatment decisions can be aligned with what matters most to individual patients

13:30 Welcome, introductions and objectives

M. Magerl (Berlin, Germany)

13:40 Treat-to-Target: A new goal-orientated approach to optimise outcomes in HAE

M. Cancian (Padova, Italy)

13:50 Treat-to-Target in action: Real-world implementation in adolescents and adults

I. Boccon-Gibod (La Tronche, France), M. Cancian (Padova, Italy), M. Campbell (London, United Kingdom), M. Magerl (Berlin, Germany)

14:20 Summary and Q&A

M. Magerl (Berlin, Germany)

15:00 - 16:00 SAT1-8 - Allergy Therapeutics - Scoring Against Allergies: New Therapeutic Approaches on the Horizon
(Room London, Sponsored Sessions)

Chairs: **Janice A Layhadi (United Kingdom, London), Mohamed Shamji (United Kingdom, London)**

15:00 PQ Grass 27600 SU: Progress in paediatrics after our goal in adults

Sven Becker (Germany, Tübingen), Janice A Layhadi (United Kingdom, London), Stephanie Dramburg (Germany, Berlin)

15:30 Building Future Strikers: VLP Peanut Lines Up as a game changer

Mohamed Shamji (United Kingdom, London), Roxanne Oriel (United States of America, New York), Alexandra Santos (United Kingdom, London)

Friday 13 June 2025

15:00 - 16:00 SAT1-9 - Blueprint Medicines - Recognizing and Managing Indolent Systemic Mastocytosis in All Its Forms: An Update for Allergologists on Suspicion, Diagnosis, and Treatment Strategy
(Room Krakow, Sponsored Sessions)

Chairs: V. Sabato (Antwerp, Belgium)

15:00 Welcome and introductions
V. Sabato (Antwerp, Belgium)

15:05 Foundations of clonal mast cell disorders: When to suspect, how they present, and why phenotypes matter
V. Sabato (Antwerp, Belgium)

15:15 Diagnostic work-up of indolent systemic mastocytosis for allergologists: A practical guide
K. Sotlar (Salzburg, Austria)

15:25 Treating indolent systemic mastocytosis: Aligning treatment goals with phenotypes
F. Siebenhaar (Berlin, Germany)

15:35 From clinical studies to real life in indolent systemic mastocytosis: Insights from real-world evidence
C. Gourguechon (Orléans, France)

15:45 Q&A
V. Sabato (Antwerp, Belgium), K. Sotlar (Salzburg, Austria), F. Siebenhaar (Berlin, Germany),
C. Gourguechon (Amiens, France)

16:30 - 17:30 SAT1-10 - Celltrion - Proven by Evidence and Ready for Clinical Practice: Omalizumab Biosimilar Beyond Approval
(Room London, Sponsored Sessions)

Chairs: Torsten Zuberbier (Germany, Berlin)

Objectives:

This symposium aims to provide clinicians with a comprehensive understanding of omalizumab biosimilars, from regulatory approval pathways to real-world clinical evidence in chronic spontaneous urticaria (CSU). Participants will explore pivotal clinical trial data, post-marketing analyses, and patient case studies to evaluate the efficacy and safety of omalizumab biosimilars in practice. The session will also address the evolving role of biosimilars in expanding access to biologic therapy across allergic diseases, supporting sustained and early intervention strategies.

16:30 Opening Remarks
Torsten Zuberbier (Germany, Berlin)

16:35 Decoding Biosimilars : Grasping the Similar-but-not-identical Paradigm
Torsten Zuberbier (Germany, Berlin)

16:45 In-depth Perspectives on Omalizumab Biosimilar: What Pivotal Study Tells us in CSU
Torsten Zuberbier (Germany, Berlin)

16:55 Voices From Real-world Experience: What Omalizumab Biosimilar Means to Patients with CSU
Stefan Cimbollek (Spain, Seville)

17:05 Evolving Roles of Biosimilars Across Allergic Diseases: Expanding Access and Supporting Sustained Care
Enrico Heffler (Italy, Milan)

17:15 Panel Discussion / Q&A
Torsten Zuberbier (Germany, Berlin), Stefan Cimbollek (Spain, Seville), Enrico Heffler (Italy, Milan)

Friday 13 June 2025

16:30 - 17:30 SAT1-11 - Thermo Fisher Scientific - Tree nut anaphylaxis: patient journey and allergy workup
(Room Krakow, Sponsored Sessions)

Chair: **Paul J. Turner (United Kingdom, London)**

16:30 Welcome & Introduction

Paul J. Turner (United Kingdom, London)

16:32 Defining anaphylaxis and predicting future risk - focus on tree nut allergies

Paul J. Turner (United Kingdom, London)

16:42 Enhancing diagnostic precision in tree nut and seed allergies

Alexandra Santos (United Kingdom, London)

16:57 Tree nut allergy after anaphylaxis: Prognosis and management

Helen Brough (United Kingdom, London)

17:12 Interactive case-based discussion

Paul J. Turner (United Kingdom, London), Alexandra Santos (United Kingdom, London),
Helen Brough (United Kingdom, London)

17:27 Summary & Closure

Paul J. Turner (United Kingdom, London), Alexandra Santos (United Kingdom, London),
Helen Brough (United Kingdom, London)

18:00 - 18:30 MSAT 1-1 - Pharvaris - Unmasking BK-Mediated Angioedema: From Biological Mechanisms to Therapeutic Opportunities. (Room London, Sponsored Sessions)

Chair: **T. Caballero (Madrid, Spain)**

18:00 Unmasking Bradykinin-Mediated Angioedema: Uncovering the Biology and Understanding Therapeutic Opportunities

T. Caballero (Madrid, Spain)

18:02 The Converging Pathways to BK: A Unified Mechanistic View

T. Buttgereit (Berlin, Germany)

18:15 Finding A Target That Delivers: The Unmet Needs in Therapeutic Strategies

M. Cancian (Padova, Italy)

18:28 Q&A

T. Caballero (Madrid, Spain)

Friday 13 June 2025

**18:00 - 18:30 MSAT1-2 - Otsuka Pharmaceutical - Shaping the future of HAE prophylaxis:
Insights from real patient stories (Room Krakow, Sponsored Sessions)**

Chair: A. Banerji (Boston, United States of America)

Objectives:

The objectives of this promotional symposium organised and funded by Otsuka are:

- To provide practical, clinically relevant insights to support clinicians in evaluating unmet needs, optimising treatment, and navigating decision-making pathways when considering long-term prophylactic treatment for HAE
- To present and discuss real-world HAE patient cases illustrating clinical scenarios

For Healthcare Professionals or Other Relevant Decision Makers only

OPE-DON-2600030 (v3.0) / May 2026

18:00 Shaping the future of HAE prophylaxis

A. Banerji (Boston, United States of America)

18:05 Managing unmet therapeutic needs: a case-based perspective

18:15 Optimising HAE management: a case for a treatment switch

A. Banerji (Boston, United States of America)

18:25 Audience Q&A and Meeting Close

A. Banerji (Boston, United States of America)

A CSL-sponsored symposium

From Disease Burden to Control in HAE

Aligning Innovation and Personalized Approaches to Improve Patient Outcomes

12:00–13:00 pm TRT | Saturday June 13, 2026

Room Utrecht, Istanbul Congress Center, Istanbul, Türkiye

We are pleased to invite you to this educational symposium, organized and funded by CSL for healthcare professionals only. This symposium will feature an expert panel of speakers, including a physician experienced in HAE who also lives with the condition. In this symposium, the evolving definition of disease control in HAE will be discussed, alongside an overview of the HAE therapeutic landscape within the framework of recently updated international guidelines. We will also explore individualized patient management approaches with interactive case-based discussions. We look forward to welcoming you to this exciting and engaging symposium in Istanbul.

Faculty



Asli Akkor (Chair)

*The Istanbul University
Faculty of Medicine,
Istanbul, Türkiye*



Mauro Cancian

*University Hospital of Padua,
Padua, Italy*



Thomas Buttgereit

*Charité-Universitätsmedizin
Berlin and Fraunhofer Institute
for Translational Medicine and
Pharmacology ITMP, Berlin,
Germany*



Kathrin Schön

*Charité-Universitätsmedizin
Berlin and Fraunhofer Institute
for Translational Medicine and
Pharmacology ITMP, Berlin,
Germany*

Session title	Speaker(s)
Introduction, welcome and learning objectives	Asli Akkor (Türkiye; Chair)
<i>HCP-patient discussion:</i> The Lived Burden of Disease & Redefining Control in HAE	Thomas Buttgereit (Germany) and Kathrin Schön (Germany)
Q&A	All faculty
<i>Presentation:</i> Individualizing Treatment Choices in HAE to Improve Patient Outcomes	Mauro Cancian (Italy)
<i>Panel discussion with integrated Q&A:</i> Connecting Insights to Interventions in HAE: Personalized Long-Term Prophylaxis in Practice	Asli Akkor (Türkiye; Chair), Mauro Cancian (Italy), Thomas Buttgereit (Germany) and Kathrin Schön (Germany)
Meeting close	Asli Akkor (Türkiye; Chair)



Meet us at the CSL booth at EAACI, located at E20 on Level B5-A of the exhibition area, from June 12–14, 2026

This educational symposium, for healthcare professionals only, is initiated, organized, and funded by CSL. Treatments that are not currently approved in Türkiye will be discussed, please refer to regulatory guidance in your country.

EAACI, European Academy of Allergy and Clinical Immunology; HAE, hereditary angioedema; HCP, healthcare professional.

TUR-AND-0003 | May 2026

Saturday 13 June 2026

08:45 - 09:45 SAT2-1 - DBV Technologies - Advances in Peanut Allergy Management and Immunotherapy (Room London, Sponsored Sessions)

Chair: **H. Sampson** (New York, United States of America), **M. Torres** (Malaga, Spain)

08:45 Introduction

H. Sampson (New York, United States of America)

08:50 Immunotherapy for Food Allergy: The Routes of Administration and Their Immune Pathways

A. Santos (London, United Kingdom)

09:10 VIASKIN Peanut: New Clinical Data and Regulatory Pathway

P. Rodríguez del Río (Madrid, Spain)

09:35 Conclusion

M. Torres (Malaga, Spain)

12:00 - 12:15 PT 2-1 - Bilastine, 15 years young! Evidence-based. Lifespan-wide: Optimizing Efficacy Across Generations (Innovation Hub, Product Theatre)

12:00 Optimizing Efficacy Across Generations

P. Rodríguez del Río (Madrid, Spain), P. Kuna (Łódź, Poland)

12:00 - 13:00 SAT2-2 - ALK - 20 years of SQ SLIT-tablet experience: Key learnings and new horizons (Room Paris, Sponsored Sessions)

Chair: **M. Zapata** (San José, Costa Rica)

Objectives:

Title: 20 years of clinical experience with SLIT-tablets

- SLIT-tablets - past, present and future
- What have we learned about the clinical effect on united airway
- Expanding Horizons: SLIT and Peanut Allergy - Insights from the Alliance Trial

12:00 Introduction

M. Calderon (San José, Costa Rica)

12:05 Disease modifying & preventative benefits: The ultimate goal of allergy immunotherapy

S. R. Durham (London, United Kingdom)

12:20 Connecting the airways: Clinical benefits beyond allergic rhinitis

A. V. Bülow (Copenhagen, Denmark)

12:35 Next steps: Peanut SLIT-tablet Phase 2 efficacy & safety outcomes

E. Kim (Chapel Hill, United States of America)

12:50 Panel discussion

M. Calderon (San José, Costa Rica)

From Burden to Breakthrough:

Revolutionising Treatment in CRSwNP and Severe Asthma

GSK

Saturday, 13th June | 12:00 – 13:00 CET
ICC Istanbul | Session Room: Zurich Room

Join our esteemed experts at our Industry Lunchtime Symposium.



Dr Santiago Quirce
Spain



Dr Veronica Seccia
Italy



Prof. Seitze Reitsma
The Netherlands

Objectives:

- Highlight the power of a unified airway approach for optimal disease management
- Explore unmet patient needs and persistent challenges with inconsistent suppression of Type 2 inflammation in CRSwNP
- Redefine long term treatment outcomes with ultra-long acting biologic therapy for CRSwNP and Severe Asthma

Agenda:

The power of the unified airway approach	Dr Santiago Quirce
Navigating patient realities and the burden of CRSwNP	Dr Veronica Seccia
Redefining treatment expectations with ultra-long-acting biologic therapy	Prof. Seitze Reitsma

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website:
<http://www.mhra.gov.uk/yellowcard> or search for MHRA Yellow Card in the Google Play or Apple App

CRSwNP, chronic rhinosinusitis with nasal polyps.

This promotional symposium is organised and funded by GSK. GSK sponsored studies and products being discussed.

▼ This medicine is subject to additional monitoring. Please refer to the Summary of Product Characteristics for more detailed information.

This product has not received marketing authorization in Türkiye. Availability and approved indications may vary by country. Please check the prescription/licence conditions in your country before prescribing.

Full prescribing information is available at the meeting, or the GSK booth.

PM-GBL-DEPE-BROC-260002 | May 2026

Please scan to access the
Exdensur (depemokimab)
prescribing information



EXDENSUR
(depemokimab)
injection 100 mg

Saturday 13 June 2026

12:00 - 13:00 SAT2-3 - CSL - From Disease Burden to Control in HAE: Aligning Innovation and Personalized Approaches to Improve Patient Outcomes (Room Utrecht, Sponsored Sessions)

Chair: A. Akkor (Istanbul, Türkiye)

Objectives:

Explore patient insights on disease control in HAE, including disease burden beyond the attack and the importance of HRQoL

Highlight current and emerging HAE therapies and the latest treatment guideline recommendations supporting informed, individualized treatment decisions

Empower clinicians to tailor prophylaxis strategies to diverse patient needs and preferences via shared decision making

12:00 Introduction, welcome and learning objectives

A. Akkor (Istanbul, Türkiye)

12:05 HCP–patient discussion: The Lived Burden of Disease & Redefining Control in HAE

T. Buttgereit (Berlin, Germany), K. Schön (Berlin, Germany)

12:20 Q&A

A. Akkor (Istanbul, Türkiye), M. Cancian (Padova, Italy), T. Buttgereit (Berlin, Germany), K. Schön (Berlin, Germany)

12:25 Presentation: Individualizing Treatment Choices in HAE to Improve Patient Outcomes

M. Cancian (Padova, Italy)

12:41 Panel discussion with integrated Q&A: Connecting Insights to Interventions in HAE: Personalized Long-Term Prophylaxis in Practice

A. Akkor (Istanbul, Türkiye), M. Cancian (Padova, Italy), T. Buttgereit (Berlin, Germany), K. Schön (Berlin, Germany)

12:59 Meeting close

A. Akkor (Istanbul, Türkiye)

12:00 - 13:00 SAT2-4 - GSK - From Burden to Breakthrough: Revolutionising treatment in CRSwNP and Severe Asthma (Room Zurich, Sponsored Sessions)

Chair: S. Reitsma (Ede, Netherlands)

Objectives:

- Highlight the power of a unified airway approach for optimal airway disease management
- Explore unmet patient needs and persistent challenges with inconsistent suppression of Type 2 inflammation in CRSwNP
- Redefine long-term treatment outcomes with ultra-long acting biologic therapy for CRSwNP and Severe Asthma

12:00 Welcome and Introductions

S. Reitsma (Ede, Netherlands)

12:05 The power of a unified airway approach

S. Quirce (Madrid, Spain)

12:15 Navigating patient realities and the burden of CRSwNP

V. Seccia (Pisa, Italy)

12:30 Redefining treatment expectations with ultra-long-acting biologic therapy

S. Reitsma (Ede, Netherlands)

12:55 Summary and close

S. Reitsma (Ede, Netherlands)

Saturday 13 June - 8.45 to 9.45 am
Room London

Advances in Peanut Allergy Management and Immunotherapy

Co-chairs : Maria Torres and Hugh Sampson



Introduction

Hugh Sampson

Immunotherapy for Food Allergy : The Routes of Administration and Their Immune Pathways

Alexandra Santos

VIASKIN Peanut : New Clinical Data and Regulatory Pathway

Pablo del Rio

Conclusion

Maria Torres

Saturday 13 June 2026

12:00 - 13:00 SAT2-6 - AstraZeneca - Targeting TSLP to address epithelial-driven inflammation: TEZSPIRE® advances patient outcomes in SUA and CRSwNP
(Room Krakow, Sponsored Sessions)

- 12:00 Welcome and Introductions**
Celeste Porsbjerg (Denmark, Copenhagen)
-
- 12:05 Epithelial health in airway disease**
Martin Desrosiers (Canada, Montreal)
-
- 12:15 TSLP as an upstream orchestrator of the inflammatory cascade**
Enrico Heffler (Italy, Milano)
-
- 12:30 Tezepelumab in practice: What does this mean for patients?**
Njira Lugogo (United States of America, Ann Arbor)
-
- 12:45 Expert panel Q&A**
Celeste Porsbjerg (Denmark, Copenhagen), Martin Desrosiers (Canada, Montreal), Enrico Heffler (Italy, Milano)
Njira Lugogo (United States of America, Ann Arbor)
-
- 12:55 Summary and close**
Celeste Porsbjerg (Denmark, Copenhagen)

12:00 - 12:15 PT 2-1 - Faes Farma | Menarini - Bilastine, 15 years young! Evidence-based. Lifespan-wide: Optimizing Efficacy Across Generations
(Innovation Hub, Product Theatre)

Chair: **Emek Kocatürk (Germany, Berlin)**

Objectives:

The objective of this session is to review the robust clinical foundation of bilastine after 15 years of clinical experience, highlighting its solid efficacy and safety profile through an overview of its clinical development.

- 12:00 Optimizing Efficacy Across Generations**
P. Rodríguez del Río (Madrid, Spain), Piotr Kuna (Poland, Łódź)

12:15 - 12:30 PT 2-2 - Faes Farma | Menarini - Bilastine, 15 years young! Evidence-based. Lifespan-wide: Evidence-rooted. Patient-centered.
(Innovation Hub, Product Theatre)

Objectives:

The objective is to present new evidence on bilastine's clinical development in children and of its rapid onset of action, in 15 minutes, supported by recent pharmacodynamic data. This segment will translate the evidence into patient-centered, practical applications, emphasizing bilastine as a fast, effective, and well-tolerated alternative to first-generation antihistamines, with clear benefits in acute symptom management, treatment adherence, and patient satisfaction across both adults and children.

- 12:15 Evidence-rooted. Patient-centered.**
P. Rodríguez del Río (Madrid, Spain), P. Kuna (Łódź, Poland)

Proven by Evidence and Ready for Clinical Practice:

Omalizumab Biosimilar Beyond Approval

 June 12, 2026 | 16:30 - 17:30  London Room (B2 floor)

Chair: Prof. Torsten Zuberbier

Time	Agenda	Speakers
16:30 - 16:35	Opening Remarks	Prof. Torsten Zuberbier (Germany)
16:35 - 16:45	Decoding Biosimilars: Grasping the Similar-but-Not-Identical Paradigm	
16:45 - 16:55	In-Depth Perspectives on Omalizumab Biosimilar: What the Pivotal Study Tells Us in CSU	
16:55 - 17:05	Voices from Real-World Experience: What Omalizumab Biosimilar Means to Patients with CSU	Dr. Stefan Cimbollek (Spain)
17:05 - 17:15	Evolving Roles of Biosimilars Across Allergic Diseases: Expanding Access and Supporting Sustained Care	Prof. Enrico Heffler (Italy)
17:15 - 17:30	Panel Discussion / Q&A	All faculty

© Celltrion, Inc. 2026 HCOML-00 AD-0526/26EACI-03

Company Sponsored Symposia

13:45 - 14:45 SAT2-7 - Novartis - Press Play on Progress for Patients with CSU
(Room Utrecht, Sponsored Sessions)

Chair: T. Zuberbier (Berlin, Germany)

Objectives:

- Recognize the full burden of CSU symptoms and the impact on patients
- Identify antihistamine failure and the need to escalate promptly
- Understand the role of BTK in CSU and the clinical data for remibrutinib
- Be confident in strategies for using remibrutinib in practice

- 13:45** Welcome and Introduction
T. Zuberbier (Berlin, Germany)
- 13:50** CSU Rewind: The Unpredictable Patient Burden
T. Zuberbier (Berlin, Germany)
- 14:00** Just Released: A New Way Forward in CSU Care
P. Li (Hong Kong, China)
- 14:15** Now Playing: From Evidence to Experience with Remibrutinib
G. Mosnaim (Skokie, United States of America)
- 14:28** Press Play on Progress: An Expert Panel Discussion
T. Zuberbier (Berlin, Germany), P. Li (Hong Kong, China)
- 14:43** Close
T. Zuberbier (Berlin, Germany)

Saturday 13 June 2026

13:45 - 14:45 SAT2-8 - SAT2-8 - Allergopharma - Who Benefits from AIT? Measuring, Predicting and Improving Treatment Response
(Room Krakow, Sponsored Sessions)

Chair: **S. Lau** (Berlin, Germany), **M. Zemelka-Wiacek** (Wrocław, Poland)

13:45 Tracking Patient Progress in AIT: What the Chamber Reveals
M. Jutel (Wrocław, Poland)

14:05 Predicting Patients' Response to AIT: Myths and Measurements
L. Klimek (Wiesbaden, Germany)

14:25 Asthma and allergy: Biomarker discovery for asthma diagnosis and assessment of severity using machine learning and AI
A. Custovic (London, United Kingdom)

14:30 - 15:00 MSAT2-1 - HAL Allergy - Life after the German TAO: What Remains, What Can Other Countries Learn? (Room London, Sponsored Sessions)

Chair: **O. Pfaar** (Marburg, Germany)

14:30 Life after the German TAO: regulatory perspective (PEI)
J. Zimmer (Langen (Hessen), Germany)

14:40 Life after the German TAO: PDCO perspective
E. Hamelmann (Bielefeld, Germany)

14:50 Life after the German TAO: practice perspective
H. Wrede (Herford, Germany)

15:30 - 16:30 SAT2-9 - Takeda - One story, many lives: clinical perspectives on sustained disease control in HAE
(Room London, Sponsored Sessions)

Chair: **M. Cancian** (Padova, Italy)

Objectives:

Our multidisciplinary team of physicians, a pediatric nurse, and a psychiatrist will take you on a journey through a life with HAE

15:30 Introduction and opening
M. Cancian (Padova, Italy)

15:35 Growing up with HAE: striving for the zero-attack ambition to help patients reach their full potential
E. Davis (Oxford, United Kingdom)

15:45 HAE in teenage girls: multidisciplinary clinical and psychosocial considerations during adolescence
M. Cancian (Padova, Italy), R. Arnaout (Riyadh, Saudi Arabia), J. Quintero (Madrid, Spain),
E. Davis (Oxford, United Kingdom)

16:05 Entering adulthood with HAE: building a life through sustained disease control
R. Arnaout (Riyadh, Saudi Arabia)

16:15 Lifelong disease control: supporting life into older age
M. Cancian (Padova, Italy)

16:25 Audience Q&A and close
M. Cancian (Padova, Italy), R. Arnaout (Riyadh, Saudi Arabia), J. Quintero (Madrid, Spain),
E. Davis (Oxford, United Kingdom)

Milestones achieved and the road ahead

FRIDAY 13TH June 2025, 12:00-1:00 PM • BOISDALE
Chairperson: Dr. Joan Bartra: Hospital Clinic Barcelona, Spain

Foundations of our journey

Prof. Ralph Mösges.
ClinCompetence, Cologne GmbH, Germany

At the Crossroads: Where today shapes the future

Dr. Stefan Cimbollek.
Hospital U. Virgen del Rocío, Sevilla, Spain

The road ahead: Focus on innovation

Dr. Jerónimo Carnés.
R&D Director, LETI Pharma, Madrid, Spain

Company Sponsored Symposia

15:30 - 16:30 SAT2-10 - Menarini - Personalized Care in Allergic Rhinitis: The Specialists' Clinical Perspectives
(Room Krakow, Sponsored Sessions)

Chair: Maria Torres (Spain, Malaga)

15:30 Introduction: From Guidelines to Patient-Centered Care
Maria Torres (Spain, Malaga)

15:40 Synergistic Approach in Allergic Rhinitis Management. Specialist's Clinical Insights: The Allergist
Giorgio W Canonica (Italy, Milan)

16:00 Synergistic Approach in Allergic Rhinitis Management. Specialist's Clinical Insights: The Otorhinolaryngologist
Philippe Gevaert (Belgium, Gent)

16:20 Q&A

Sunday 14 June 2026

12:15 - 13:15 SAT3-2 - Otsuka Pharmaceutical - Shaping the future of HAE prophylaxis: an evidence-based approach (Room London, Sponsored Sessions)

Chair: **M. Cancian (Padova, Italy)**

Objectives:

The objectives of this promotional symposium organised and funded by Otsuka are:

- Understanding HAE: the scientific rationale for a long-term prophylactic treatment
- A review of clinical evidence
- Evidence-based insights on switching long-term prophylaxis

For Healthcare Professionals or Other Relevant Decision Makers only

OPE-DON-2600031 (v1.0) / May 2026

12:15 Introduction and housekeeping
M. Cancian (Padova, Italy)

12:20 Understanding HAE: the scientific rationale for a long-term prophylactic treatment
M. Magerl (Berlin, Germany)

12:35 A review of clinical evidence
T. Caballero (Madrid, Spain)

12:50 Evidence-based insights on switching long-term prophylaxis
M. Guilarte Clavero (Barcelona, Spain)

13:05 Q&A session
M. Cancian (Padova, Italy)

12:15 - 13:15 SAT3-3 - LEO Pharma - Right treatment, right patient, right time: Personalized care in AD and CHE (Room Krakow, Sponsored Sessions)

Chair: **B. Geng (La Jolla, United States of America)**

12:15 Welcome and introductions
B. Geng (La Jolla, United States of America)

12:17 Why body location matters in inflammatory skin diseases
B. Geng (La Jolla, United States of America)

12:25 Tailoring Atopic Dermatitis management for lesions affecting high-burden areas
F. G. Hougeir (Rochester, United States of America)

12:45 Breaking the cycle: Optimizing the management of Chronic Hand Eczema
L. Ludriksone-Grasser (Jena, Germany)

13:05 Q&A and meeting close
B. Geng (La Jolla, United States of America), F. G. Hougeir (Rochester, United States of America),
L. Ludriksone-Grasser (Jena, Germany)

JOIN OUR COMPANY SPONSORED SYMPOSIUM

"Life After the German TAO: What Remains, What Can Other Countries Learn?"

Saturday, 13 June 2026
14:30 - 15:00, room "London"

Chair:

O. Pfaar, Germany

Speakers:

J. Zimmer, Germany
regulation perspective (PEI)

E. Hamelmann, Germany
PDCO perspective

H. Wrede, Germany
practice perspective

Treat-to-Target in HAE

A personalised approach to support patients reach normalisation of life

**Krakow Room,
Friday 12 June 2026 @13:30-14:30**

Chair



Prof. Markus Magerl
Germany

Faculty



Dr Isabelle Boccon-Gibod
France



Dr Mari Campbell
UK



Prof. Mauro Cancian
Italy



Objectives



Review the **Treat-to-Target approach in HAE published in 2026**, and its role in supporting the implementation of guidelines to optimise clinical outcomes



Understand the **psychosocial impact of HAE** and how to **personalise patients' treatment goals from adolescence through adulthood**



Explore **real-world case studies** highlighting how treatment decisions can be aligned with what matters most to individual patients

Sunday 14 June 2026

13:45 - 14:15 MSAT 3-1 - Novartis | PeerVoice - Can We Protect Our Patients with Severe Food Allergy From Anaphylaxis? Assessing Potential Pathways as Possible Prophylactic Approaches
(Room Krakow, Sponsored Sessions)

Chair: Alexandra Santos (United Kingdom, London)

Objectives:

- Recognise the cellular pathways and pathophysiological mechanisms involved in IgE-mediated anaphylaxis following exposure to a food allergen
- Identify therapeutic approaches under investigation for the prevention of IgE-mediated anaphylaxis following exposure to a food allergen, including investigational agents and their proposed mechanism of action
- Assess available clinical evidence evaluating these investigational therapeutic approaches in the prevention of severe allergic reaction in patients with an IgE-mediated food allergy

13:45 Welcome and Introduction

Alexandra Santos (United Kingdom, London)

13:46 Assessing Pathophysiological Pathways in Food Allergy: Are There Opportunities to Target Drivers of Anaphylaxis?

Alexandra Santos (United Kingdom, London)

13:54 Exploring the Potential for Protective Interventions in IgE-Mediated Food Allergy: Investigational Approaches and their Available Evidence

Stefania Arasi (Italy, Rome)

14:04 "Ask the Faculty" and Take-Home Messages

Alexandra Santos (United Kingdom, London), Stefania Arasi (Italy, Rome)

14:14 Final Remarks

Recognizing and Managing Indolent Systemic Mastocytosis in All Its Forms:

An Update for Allergologists on Suspicion, Diagnosis, and Treatment Strategy

Friday 12th June | 15:00–16:00 (TRT)

Krakow room, Istanbul Congress Center,
Istanbul, Türkiye & the EAACI Digital Platform


Faculty: Vito Sabato (Chair), Karl Sotlar, Frank Siebenhaar,
Clément Gourguechon

Join us for an in-depth, clinically focused symposium exploring the evolving landscape of ISM or visit the Blueprint Medicines booth (G20) to learn more

Avapritinib is approved by the FDA and EMA for the indication of indolent systemic mastocytosis (ISM).
Avapritinib is not an approved product, nor is it commercialized in Türkiye.

TRT, Türkiye Time; ISM, indolent systemic mastocytosis.

INT-BP-MED-AVANASM-26005 | May 2026



blueprint
MEDICINES
a sanofi company



EAACI CONGRESS 2026 - B5 Level





Access to this exhibition is restricted to healthcare professionals and other relevant decision makers. Promotional content within this area may relate to prescription-only medicines and is intended for Türkiye healthcare professionals. Such content may not be consistent with local laws and regulations outside Türkiye.

List of Exhibitors & Sponsors




COMPANY NAME	ONSITE BOOTH
ADARx	J02
ALK	D16
ALK	D20
AllergoEye	H19
Allergopharma	C20
Allergy Therapeutics	G10
American Academy of Allergy, Asthma & Immunology	H04
Asistan Medikal	B40
AstraZeneca	E25
Beckman Coulter	I10
Bedfont Scientific	I03
Beijing Wanliandaxinke Instruments	J03
BioCryst	B25
Bioprojet Pharma	B46
BluePrint Medicines	G20
Burly	B43
BÜHLMANN Laboratories	H20
Celldex Therapeutics	B36
Celltrion Healthcare	D01
Celltrion Healthcare	D10
Cliantha Research	J01
Cogent Biosciences	I23
CSL Behring	E20
DBV Technologies	E35
Diater	C02
Dr. Fooke-Achterrath Laboratorien	H16
e-LinkCare Meditech	I21
EFA	G01
EUROIMMUN	H10
everSens	H18

COMPANY NAME	ONSITE BOOTH
FAES FARMA	B41
GANSHORN Medizin Electronic	H21
GSK	B20
HAL Allergy	F30
Hycor Biomedical	H13
Inbio	H01
Inmunotek	A20
Intellia Therapeutics	H15
LETI Pharma	C10
LoFarma	A28
MacroArray Diagnostics	A21
Menarini	B10
Neilmed Pharmaceuticals	H03
Nestle Purina	C01
Novartis	D30
Otsuka Pharmaceuticals	B38
Pharvaris	I12
Pharvaris	I13
Probelte Pharma	A25
PROTIA Inc.	H23
Reacta Healthcare	I04
ROXALL Medizin	B35
Sanofi Regeneron	F20
Scibase	B47
Siemens Healthineers	F01
Stallergenes Greer	F10
Sugentech, Inc.	H25
Sunvou Medical	H14
Takeda	B30
Thermo Fisher Scientific	B01
World Allergy Organisation	H02
Yilmaz Bio Medikal	H22



NAIS Village Congress 2026 Societies and Map



SOCIETY NAME	COUNTRY	BOOTH ASSIGNMENT
Armenia Association of Allergology and Immunology	Armenia	N 1
Azerbaijan Society of Allergologists and Immunologists	Azerbaijan	N 2
ABEFORCAL	Belgium	N 3
Croatian Society for Allergology and Clinical Immunology	Croatia	N 4
French Society of Allergy	France	N 5
Georgian Association of Allergology and Clinical Immunology	Georgia	N 6
German Society for Allergology and Clinical Immunology (DGAKI)	Germany	N 7
German Society of Allergology	Germany	N 8
EAAKA GREEK SOCIETY OF ALLERGOLOGY & CLINICAL IMMUNOLOGY	Greece	N 9
GREEK PEDIATRIC ALLERGY SOCIETY	Greece	N 10
Hungarian Society of Allergology and Clinical Immunology	Hungary	N 11
Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO)	Italy	N 12
Italian Society of Pediatric Allergy and Immunology (SIAIP)	Italy	N 13
SIAAIC	Italy	N 14
Kazakhstan Association of Allergology and Clinical Immunology	Kazakhstan	N 15
Macedonian Respiratory Society	North Macedonia	N 16
Pediatric Respiratory Society PEDIARES	North Macedonia	N 17
Society of Pulmonologists of the Republic of Macedonia (SPRM)	North Macedonia	N 18
Polish Society of Allergology	Poland	N 19
ROMANIAN SOCIETY OF ALLERGOLOGY AND CLINICAL IMMUNOLOGY	Romania	N 20
SEAIC	Spain	N 21
SEICAP (Spanish Society of Paediatric Clinical Immunology, Allergy and Asthma)	Spain	N 22
Serbian Association of Allergology and Clinical Immunology	Serbia	N 23
Society of Pediatric Allergy Immunology and Asthma (CAIAD)	Türkiye	N 24
Turkish National Society of Allergy and Clinical Immunology	Türkiye	N 25
Turkish Society of Immunology	Türkiye	N 26
Turkish Thoracic Society	Türkiye	N 27
British Society for Allergy & Clinical Immunology (BSACI)	UK	N 28
CIS Society of Allergology and Immunology	CIS	N 29
ISC/Sister Societies		
Algerian Society of Allergy and Clinical immunology (ASACI)	Algeria	N 30
APAAACI	Asia Pacific	N 31
Hong Kong Institute of Allergy	Hong Kong	N 32
Indian Academy of Pediatrics (IAP) Allergy Chapter	India	N 33
JSA	Japan	N 34
KAAACI	Korea	N 35
GA2CI	United Arab Emirates	N 36
POC - Not at the NAIS Village	Türkiye	

ADARx (www.adarx.com/)

ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibition, degradation, and editing disease-causing mRNA. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated diseases and central nervous system diseases.



ALK (www.alk.net)

With 100 years of experience, ALK continuously apply our scientific knowledge and offers a comprehensive range of allergy products and services to help people take control of their allergy and life. ALK has worked with the allergy community and conducted large clinical trials with >23,000 patients demonstrating consistent efficacy and safety of sublingual immunotherapy (SLIT) tablets for respiratory allergies (including house dust mite and pollen from grass, tree, ragweed and Japanese cedar). More than half of ALK's SLIT-tablets is already available to children and adolescents, and we have completed further paediatric clinical trials to ensure evidence-based SLIT-tablets become available.



AllergoEye GmbH & Co. KG (www.allergoeye.com)

AllergoEye GmbH & Co. KG is a medtech company based in Dresden, combining cutting-edge artificial intelligence with clinical and diagnostic expertise. With a multidisciplinary team of AI engineers, clinicians, and researchers, we create innovative solutions designed for use in clinical trials, specialist practices, and everyday care. Our CE-certified platform AllergoEye uses the conjunctival provocation test (CPT) to redefine how allergen immunotherapy is measured, monitored, and understood. The system ensures speed, precision, and standardization in allergy diagnostics. We seek collaboration with leaders in pharma and medtech—to deliver the future of diagnostic precision today!



Allergopharma GmbH & Co. KG (<https://allergopharma.dermapharm.com/en-en/>)

Allergopharma is a German company with a global network. For over 50 years, we have collaborated with physicians and scientists to develop high-quality allergy treatments – from diagnostics to allergen immunotherapy (AIT). We were the first to publish data on major, intermediate, and minor allergens in AIT products for house dust mite-, grass-, tree-, and mugwort-allergic patients. With our expertise and scientific excellence, we provide physicians with treatment options that help allergy sufferers live a full life. Step by step, we are moving closer to realising our vision: curing allergies.



Allergy Therapeutics (www.allergytherapeutics.com)

Allergy Therapeutics is a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments. We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms. Driving convenience; our short-course treatments make life easier. Our adjuvant technologies not only advance the results of allergy immunotherapy but also drive beneficial immune responses in cancer and infectious disease. Our operations deliver growth and transforms the way we think about immunology.



American Academy of Allergy, Asthma & Immunology (AAAAI) (www.aaaai.org/)

The American Academy of Allergy, Asthma and Immunology (AAAAI) is the most prominent membership organization of more than 7,000 allergists / immunologists (in the United States, Canada and 72 other countries) and patients' trusted resource for allergies, asthma and immune deficiency disorders. This membership includes allergist / immunologists, other medical specialists, allied health and related healthcare professionals—all with a special interest in the research and treatment of allergic and immunologic diseases.



AstraZeneca PLC (www.astrazeneca.com/)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.



Beckman Coulter GmbH (www.beckman.com)

Beckman Coulter Life Sciences is dedicated to developing and providing advanced technologies and equipment for research and discovery to explore new treatment methods. Our products are implemented in all major areas of Life Sciences to simplify and automate existing processes in the lab. For more information please visit <http://www.beckman.com> > www.beckman.com



Bedfont Scientific Ltd (www.bedfont.com/)

For 15 years, the NObreath® FeNO device has supported asthma diagnosis and management. It offers quick, easy testing to help distinguish allergic from non-allergic asthma. NObreath® features anti-microbial tech for infection control and includes free patient software, FeNOchart™. For over 35 years, the Gastrolyzer® range has aided detection of GI disorders via hydrogen and methane breath testing. Gastro+™ is portable; GastroCH4ECK® offers remote breath testing. Includes free software, GastroCHART™. Visit Bedfont® at stand IO3 to learn more!



Beijing Wanliandaxinke Instruments Co.,Ltd

Beijing Wanliandaxinke Instruments Co., Ltd., founded in 1996, is focusing on sophisticated gas analysis equipment. The company is based in Beijing, and it has several branches in Shandong, Jiangsu provinces. It is a national high-tech enterprise with complete and independent intellectual property rights in the field of breath detection technology, integrating the R&D, manufacturing, sales and service of professional medical detection devices. The main products include 13C breath analyzer, FeNO analyzer, EtCO2 sensor, multi-gas sensor, hand-held CO2 / AG monitor, and vet related products etc.



Bioprojet Pharma (www.bioprojet.com/en/)

Bioprojet is a pharmaceutical laboratory founded on a commitment to innovation in the service of health. For over 30 years, we have been designing and developing medicines with patient needs at the core of our approach. Our strength lies in combining scientific expertise with a strong human commitment. Founded in 1982 by Jeanne-Marie Lecomte and Jean-Charles Schwartz, Bioprojet was born from a strong ambition: to bridge the gap between fundamental research and pharmaceutical development. Since its inception, the laboratory has pursued an original strategy focused on therapeutic innovation.



Blueprint Medicines (www.blueprintmedicines.com)

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines in two core focus areas: allergy/inflammation and oncology/hematology.



Burly (www.burly.kz)

The company "Burly" LLP was established in 1997. The primary principal activity of the company was manufacture of active pharmaceutical ingredient "Dry and liquid juice of Echinacea purpurea" and medicinal product "Echinal". In 2001, it was decided to release medicinal products and phyto-teas with a complete production cycle, from the medicinal plant growing to substance and finished product release for export to CIS countries and European countries. In 2004-2005, JSC "National Innovation Fund" of the Republic of Kazakhstan was one of the founders of "Burly" LLP supported by the Ministry of Health of the Republic of Kazakhstan.



BÜHLMANN Laboratories (www.buhlmannlabs.ch)

BÜHLMANN is a fully independent, globally active Swiss based company offering Cellular Allergen Stimulation Tests since 1995. CAST are based on in-vitro activation of basophiles with specific allergen determined in flow cytometry by cell surface marker CD63 and CD203c, or secreted leukotrienes via ELISA. They provide functional results and significantly improve detection of drug, venom and food allergies. BÜHLMANN, the only company offering more than 140 standardized allergens for BAT tests, is focused on the continuous development of new allergens to extend this exclusive panel.



Celldex Therapeutics (<https://celldex.com/>)

Celldex Therapeutics is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic and autoimmune and other devastating diseases.



Celltrion Healthcare (<https://www.celltrion.com/en-us>)

We are a fully integrated biopharmaceutical company committed to delivering innovative and affordable medications to improve patients' access to advanced therapies. Our end-to-end capabilities ensure efficiency, quality, and innovation at every stage, bringing life-changing therapies to patients. With a legacy in the biosimilar sector, and now as a leader in antibody discovery and development, we strive to add value to biologics to address unmet medical needs.



Cliantha Research (<https://atcliantha.com/>)

Full-service CRO in Early (FIH/POC/MOA) and Late Phase trials, specializing in allergy. Our integrated services allow efficiency and customization to meet clients' requirements. Our clinics' excellent regulatory track record and large, diverse, participant databases, support trials applicable worldwide. As experts in allergen challenges, both direct instillation and the naturalistic type in our Environmental Exposure Chambers (qualified for perennial/seasonal allergens), we apply 25+ years of experience to plan programs for drug therapies/devices throughout their development lifecycle.



Cogent Biosciences (<https://www.cogentbio.com/>)

Cogent Biosciences is a biotech company focused on developing precision therapies for genetically defined diseases. The lead program, bezuclastinib, is a selective tyrosine kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.



CSL (<https://www.csl.com/>)

CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.



DBV Technologies (www.dbv-technologies.com)

DBV is a biotechnology company committed to helping children with food allergies live safely. We are developing Viaskin®, a non-invasive patch technology based on epicutaneous immunotherapy, that re-educates the immune system through the skin. Our goal is to offer families a safe, effective, and accessible treatment option to help protect them from accidental exposure reactions. *Epicutaneous immunotherapy and Viaskin are under clinical investigation and have not yet been approved by any health or regulatory authority.



Diater (www.diater.com/es)

Diater is an international biotechnology company based in Spain, focused on the development and manufacturing of immunotherapy treatments and diagnosis for allergic patients worldwide. Established in 1999, we work with top quality raw materials, through our partner Allergen Servilab, to deliver the highest quality personalized treatments and diagnostic solutions. We are pioneers in molecular immunotherapy and betalactamic allergy diagnosis and we are committed to delivering innovation and immunoprecision to patients worldwide.



Dr. Fooke-Achterrath Laboratorien GmbH (www.fooke-labs.de)

Dr. Fooke Laboratories offer innovative high-quality assays for allergy and autoimmune diagnostics. Dedicated to fulfilling our customers' needs, we use state of the art technologies for the development of flexible and reliable routine applications.



e-LinkCare Meditech Co., Ltd. (www.e-LinkCare.com)

e-LinkCare Meditech Co., Ltd. is a multinational medical device company specializing in chronic disease management and point-of-care testing. Established through a collaboration between the UK and Hangzhou, China, the company provides integrated hardware and software solutions for respiratory, cardiovascular, and metabolic diseases.



EUROIMMUN Medizinische Labordiagnostika AG (www.euroimmun.de)

EUROIMMUN is an international provider of medical laboratory products with an extensive portfolio for allergy diagnostics. The company's EUROLINE system encompasses more than 500 different allergens and allergen components and provides reliable screening assays for the efficient determination of specific IgE antibodies. A comprehensive spectrum of indication-oriented and country-specific profiles is available, as well as component-resolved profiles (defined partial allergy diagnostics, DPA-Dx) for in-depth characterisation of allergy triggers. Specialised instruments and software provide efficient automation of analyses. EUROIMMUN's allergy range complements its products for autoimmune, infection and molecular genetic diagnostics.



Eversens SL (www.eversens.com ; www.evernoa.com)

everSens is a Limited Company specialized in the design, development and manufacture of solutions for the analysis of human respiration. Our solutions detect, in a non-invasive way, exhaled biomarkers, useful for the diagnosis and monitoring of various diseases. The aspiration of everSens is to design and build "best-in-class" products that help to optimize both the diagnosis and the control and monitoring of human health, thus improving the quality of life of people and achieving a sustainable health system. Contact us for discovering how evernoa contributes to a better asthma care!



FAES FARMA (www.faesfarma.pt/)

FAES FARMA is a leading Spanish pharmaceutical company with international projection, with more than 1.600 employees, between its headquarters in Madrid, R&D center in Bilbao and its subsidiary companies abroad. Bilastine, is the latest novelty. A new 2nd generation, non-sedating antihistamine, for children and adults, present in more than 100 countries, to relieve the symptoms of allergic rhinoconjunctivitis and to treat itchy skin rashes (wheals or urticaria). FAES FARMA continuous investigation plan will bring news in a near future!



GANSHORN Medizin Electronic GmbH (www.ganshorn.de)

With the development of the SpiroScout, a spirometer based on a calibration-free, highly accurate ultrasound flow sensor, GANSHORN has opened up new horizons: simultaneous flow and gas measurements without any noticeable flow resistance for the patient. Based on its SharpFlow® ultrasound flow measurement method, GANSHORN offers its customers state-of-the-art solutions for body plethysmography, diffusion measurement, cardio-pulmonary exercises testing and much more.



GSK (www.gsk.com/)

GSK is a global biopharma company using deep expertise in the immune system and innovative research to advance respiratory medicine and immunology. GSK is pleased to attend the EAACI Annual Congress and host two industry symposia. © 2026 GSK group of companies. All rights reserved. NP-GBL-IM-WCNT-260001 | April 2026



HAL Allergy (<https://www.hal-allergy.com/>)

HAL Allergy is one of the European top players in the development, production and distribution of allergen immunotherapies for the treatment and prevention of allergic diseases. With a highly competitive product portfolio, including subcutaneous and sublingual products, and a future-oriented pipeline portfolio, HAL Allergy strives to provide the best possible medical products and scientific output. HAL Allergy is located in the Bio Science Park in Leiden, The Netherlands.



Hycor Biomedical (www.HYCORbiomedical.com)

HYCOR is a global manufacturer and marketer of in vitro diagnostics products in allergy diagnostics. NOVEOS System requires only 4-µL sample size per test, reduces QNS errors, resampling and patient trauma. Our advanced micro-particle technology is designed to limit interference from: Biotin, IgG / IgG4, and Solid-phase related cross-reactive carbohydrate determinant (CCD). It has high sensitivity and an excellent low-end precision for up to 13 hours of true walk-away capability. Pinpoint your true allergy triggers with NOVEOS.



InBio (<https://inbio.com/>)

Whether you conduct primary research on allergens, develop diagnostic systems, or create products to alleviate environmental and food allergies, you need expertise in action. And that's exactly what InBio delivers, across everything from highly purified allergens and advanced test kits, to environmental and food allergen testing, to contract research for specialized needs. Broad product catalog - *new standardised reagents for BAT/MAT assays* Deep scientific background Ongoing commitment to R&D Well-documented subject-matter expertise Direct contact with our scientific team Flexible, collaborative relationships



Inmunotek (www.inmunotek.com)

Inmunotek is a Spanish biopharmaceutical company founded in 1992, dedicated to the research, development, manufacturing, and commercialization of medicines and medical devices in the field of allergy and immunology, for both human and veterinary use. Our commitment to research and innovation is driven by our mission to improve patient's quality life and deliver meaningful value to healthcare professionals. Through the development of cutting-edge solutions, we strive to address unmet medical needs and contribute to more effective, personalized patient care.



Intellia Therapeutics (<https://www.intelliatax.com/>)

Intellia Therapeutics is a leading clinical-stage genome editing company developing a pipeline of potential therapies leveraging CRISPR-based technology.



LEO Pharma (leo-pharma.com)

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. Together, we reach far beyond the skin.



LETI Pharma

LETI Pharma is an independent and family-owned biopharmaceutical research company. In its different areas of expertise, it seeks to contribute products to society that add value to health care. Its headquarters are in Barcelona and its industrial plant and allergy research laboratory are in Tres Cantos (Madrid). It has subsidiaries in Germany (Ismaning and Witten) and Portugal (Oporto). LETI Pharma operates with exclusive distributors in several countries in Europe, Latin America and Africa.



LOFARMA SPA (www.lofarma.it/)

Lofarma S.p.A. researches, produces and markets specific immunotherapy tablets, drops and injections (AIT) to treat allergic respiratory diseases. For almost 80 years, Lofarma has been committed to significantly improve the health and quality of life of individuals with allergies. Lofarma's manufacturing site works under GMP guidelines and undergoes routine inspections by Health Authorities. Production excellence is a prerequisite for ensuring quality in Lofarma's own processes. The Company, based in Milan, operates globally through its affiliates in Portugal and Spain, as well as distributors in Albania, Austria, Germany, Greece, Hungary, Mexico, Mongolia, South Korea, Turkey, Ukraine and United Kingdom.



Macro Array Diagnostics (www.macroarraydx.com/)

Founded in 2016, MADx has established itself as a leading developer and manufacturer of high-precision allergy and food intolerance tests. The product range serves laboratories, medical practices, hospitals, and allergy centres worldwide. The company's focus is on the development of pioneering, intuitive immunodiagnostic solutions at the molecular level. With a presence in over 80 countries worldwide, the visionary MADx stands for dynamism, quality, and the promise of constantly pushing the boundaries of diagnostics in the field of allergy and food intolerance.



Menarini Group (www.menarini.com)

Menarini Pharmaceutical Group, with headquarters in Florence, is present in 140 countries worldwide to date, with €4,603 million in consolidated turnover and more than 17,000 employees. With strong centres for Research and Development, Menarini's products are present in the most important treatment areas. Pharmaceutical production is carried out in the Group's 18 manufacturing plants, located in Italy and abroad, which produce over 609 million packets of product a year and distribute them to five continents.



NeilMed Pharmaceuticals Ltd (www.neilmed.com)

The NeilMed brand of products help alleviate common nasal and sinus symptoms in a simple, safe, effective and affordable way. The company supplies millions of products to end users through various trade channels. Our headquarters & manufacturing facility is based in Santa Rosa, California, USA. In addition to our USA headquarters, we also supply and have offices in multiple countries, www.neilmed.com/unk/global-locations.



Neopharmed Gentili (<https://neogen.it/en/>)

Neopharmed Gentili's mission is clear: to improve the lives of people living with rare conditions such as hereditary angioedema (HAE). We combine deep expertise in rare diseases with a strong commitment to patient-focused innovation to create solutions that matter in everyday life. We are driven by curiosity. Guided by empathy. Connected to the rare community. Our journey is shaped by what truly matters to rare disease people. Where every improvement can change a life. Alongside patient associations, scientific societies, all stakeholders and colleagues, we work every day to turn scientific promise into outcomes that patients can feel every day. Together, we stand: Connected to Rare, Committed to life. Date of preparation: May 2026 | EU.HAE.00267.



Nestlé Purina PetCare Company

Nestlé Purina PetCare Company is one of the world's leading pet food companies, dedicated to promoting the bond between people and their pets. For over a decade Purina scientists have been investigating a novel approach that can transform the management of cat allergies. The research has led to a discovery that neutralizes the major cat allergen, Fel d 1, at its source in cat's saliva before entering the environment. The Company launched Pro Plan LiveClear, the first and only cat food proven to reduce allergens on cat hair, can be integrated into current care pathways for cat allergies.



Novartis Pharma AG (www.novartis.com)

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Find out more at www.novartis.com



Otsuka Pharmaceutical Europe Limited

At Otsuka Europe we all share the same values and are dedicated to a common purpose. Otsuka-people creating new products for better health worldwide. Every day across Europe, Otsuka-people channel their passion and commitment into aiming to improve the health of our patients. We aim to help people with diseases that range from those affecting millions to those that affect relatively few. UK-based Otsuka Pharmaceutical Europe Ltd. (OPEL) oversees our businesses in Europe working in close collaboration with our European affiliates and global colleagues. OPE-NPR-2400020 v1.0 Date of Preparation: April 2024



Pharvaris GmbH (www.pharvaris.com)

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Pharvaris' aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema.



Probelte Pharma S.L.U. (www.probeltepharma.es/en/)

Probelte Pharma is a Spanish biopharmaceutical laboratory specialized in the research, development, manufacture and commercialization of allergen immunotherapy vaccines and individualized autovaccines for human use since 1995. In Probelte Pharma, we care about people, and that is why we look for solutions to satisfy the needs of the population. We have a state-of-the-art factory, inaugurated in 2006, which allows us to manufacture our vaccines adapting to the needs of patients and clients in an agile and flexible way, maintaining the highest quality standards in our production without depending on an external company. Our commitment is to continue growing and increasing our production both nationally and internationally.



PROTIA Inc. (www.protia.co.kr)

PROTIA is a Korea-based IVD company specializing in allergy diagnostics. With our patented line blot technology, we provide highly reproducible tests that can detect up to 180 allergens in a single panel. Our product lineup includes 50, 64, 96, 128, and 192-line formats to meet diverse clinical needs. We're excited to introduce our latest innovation: PROTIA Allergy-Q 192D, a multiplex panel covering 90 food, 40 pollen, 10 drug, and 48 recombinant (CRD) allergens and more. PROTIA sets a new standard in broad-spectrum allergy testing with innovative technology and novel bio-product.



Reacta Healthcare (www.reactahealthcare.com)

Reacta Healthcare, established in 2013, operates from a pharmaceutical manufacturing facility in Deeside, North Wales. It is licenced to manufacture challenge meals for use in clinical trials. These challenge meals are currently used to diagnose and monitor food allergy in numerous worldwide therapeutic trials. Patents for the challenge meals have been granted in a number of countries. Reacta Healthcare is developing its in-house analytical capability and has plans in place for expansion into niche areas of food allergen development and manufacture. This will include all aspects from sourcing through to manufacture of end product.



ROXALL Medizin GmbH

ROXALL is an international active pharmaceutical company based in Hamburg, Germany. The main focus is the development, production and distribution of products in the field of allergology, immunology and emergency medicine. With innovations in specific immunotherapy (SIT) ROXALL significantly simplified the therapy of allergic diseases. The cluster immunotherapy represents a time-saving injection therapy and with a perlingual spray application patients are able to perform therapy at home. With CLUSTO-Prick® a quick and easy-to-use medical device for in-vivo diagnostic of allergic diseases is available. ROXALL's ambition is to contribute to a better quality of life for patients and their families.



Sanofi Regeneron (<https://www.sanofi.com/>)

Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patient's needs. Regeneron, a leading biopharmaceutical company, discovers, develops, and manufactures, and commercializes biological medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.



Scibase (<https://www.scibase.com/>)

SciBase is a medical technology company that has developed a unique point of care platform for the non-invasive detection of skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assist researcher, dermatologists and others. SciBase's products include Nevisense and Nevisense Go and the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment.



Siemens Healthineers

About Siemens Healthineers: At Siemens Healthineers, our mission is to enable healthcare providers to increase their value by equipping them with our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine as well as digital health and enterprise services. Our portfolio is at the center of clinical decision making across the full healthcare spectrum. Siemens Healthineers offers a broad spectrum of immunoassay, chemistry, hematology, molecular, and urinalysis testing solutions, in conjunction with automation, informatics, and services to serve the needs of laboratories of any size – today and tomorrow.



Stallergenes Greer

Stallergenes Greer is a fully integrated global healthcare company specialising in the research, diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services. Stallergenes Greer boasts a broad global footprint and extensive allergen and finished AIT product manufacturing capabilities. Supported by more than 120 years of expertise and innovation, our products are available for patients in over 40 countries.



Sugentech, Inc. (<https://www.sugentech.com/en/>)

Sugentech is a South Korean in-vitro diagnostics (IVD) company that develops rapid detection and testing systems, integrating bio, nano, and information technologies. Founded in 2011 and headquartered in Daejeon, it provides medical systems for general hospitals and digital self-testing products for consumers worldwide.



Sunvou Medical (<https://www.sunvou-eu.com/>)

SUNVOU, a global leader in breath molecular diagnosis, holds the most patents & registered products, with 500+ peer-reviewed publications, 5,000+ hospital devices, and 25M+ tests. Founded by ex-NASA, Honeywell, Cisco, Huawei scientists & engineers, joined by MIT & UC Berkeley graduates. We offer breath tests for Nitric Oxide (NO), Carbon Monoxide (CO), Hydrogen Sulfide (H₂S), Hydrogen (H₂), and Methane (CH₄) to assess inflammation & dysbiosis in airways and intestines.



Takeda (www.takeda.com)

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline



Thermo Fisher Scientific (www.thermofisher.com/phadia)

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. Our complete blood test systems support the clinical diagnosis of allergy, asthma and autoimmune diseases. With 1,800 employees worldwide, we are a global leader in in-vitro allergy diagnostics and a European leader in autoimmunity diagnostics. The allergy and autoimmunity product lines operate on a common automated instrument platform, which supports both productivity and cost efficiencies in clinical laboratories around the world.



World Allergy Organization (WAO)

World Allergy Organization (WAO) is an international umbrella organization consisting of 115 regional and national allergology and clinical immunology societies. By collaborating with the member societies, WAO provides educational programs, symposia, and lectureships in nearly 100 countries around the globe. Founded in 1951, WAO organizes major congresses, sponsors scientific symposia in developing areas, and jointly sponsors postgraduate programs during professional, non-allergy association congresses. The WAO mission is to be a global resource and advocate for the specialty, advancing awareness and excellence in clinical care through education, research, and training. World Allergy Organization Journal: global, online, open access, 2023 IF: 3.9.



Yilmaz Bio Medikal Sanayi Ve Ticaret Limited Sirketi (www.yilmazmedikal.com)

YILMAZ MEDİKAL Established in 2006, Yilmaz Medikal has been a pioneering manufacturer specialized in skin prick tests and ophthalmology since 2009. As the first domestic exporter in its field since 2014, our company has proven its global standards with FDA certification since 2018. Representing our nation at prestigious congresses such as EAACI, WAC, AAAAI, and AID, we combine advanced technology with our ORYUM and OVEM brands. Committed to ethical values and an innovative vision, we are on our way to becoming an indispensable partner in the global healthcare market.





See you in
Helsinki!

More
information
here

